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Abstract 
Synapse dysfunction is emerging as a major factor in the pathogenesis of 
Alzheimer’s disease (AD).  Key insights into the pathological mechanisms have been 
provided through studies of familial AD (FAD) genes.  Mutations in the PSEN1 gene 
account for the vast majority of FAD cases, which are typified by the formation of 
amyloid plaques, neurofibrillary tangles and neuronal loss.  The PSEN1 gene 
encodes presenilin 1, a polytopic transmembrane protein, which is the catalytic core 
of a proteolytic enzyme complex known as γ-secretase.   γ-secretase mediates the 
generation of amyloid-β (Aβ) peptides, key constituents of amyloid plaques, and 
hence it is central to AD pathology.  γ-secretase has also been implicated in the 
proteolysis of a wide range of transmembrane proteins associated with different 
cellular signalling pathways and functions. However, the precise role that presenilins 
play in regulating synapse function is not clear. The aim of this thesis is to gain an 
understanding of the physiological role of presenilin 1 at hippocampal synapses in 
anticipation that this may provide a greater understanding of the mechanisms that 
underlie synaptic dysfunction during AD.   
 
This study provides evidence that presenilin is implicated in modulating spontaneous 
excitatory synaptic transmission in hippocampal neurons in dissociated and slice 
cultures.  Further experiments have revealed a role for presenilin in modulating 
synapse number but not neurotransmitter release probability, and calcium imaging 
suggests that γ-secretase activity is dispensable for regulation of cellular calcium 
homeostasis.  In addition, experiments using pharmacological inhibitors of Aβ 
precursor protein processing and Aβ peptide generation have uncovered synaptic 
roles for γ-secretase that are potentially distinct from those of β-secretase.  Together 
these findings suggest a role for presenilin in regulating basal glutamatergic synaptic 
transmission and synapse structure of hippocampal neurons. 
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Chapter 1 : Introduction 
 
 
 
Synapses are specialised points of contacts which enable communication and transfer 
of neural information between a presynaptic neuron and postsynaptic neuron.  The 
mechanisms of electrical information transfer across synapses differ depending on 
the type of synapse.  Traditionally, synapses are classified into two groups, electrical 
synapses which enable bidirectional flow of electrical current through gap junction 
connections and chemical synapses where communication occurs through stochastic 
release of neurotransmitter from presynaptic vesicles in axonal boutons which cross 
the synaptic cleft to interact with postsynaptic receptors.  Chemical synapses are 
highly plastic and can exhibit changes in pre and postsynaptic compartments 
including alterations in synaptic strength and structure during development and in 
response to activity.  Understanding the molecular and cellular basis of synaptic 
transmission and function has been a key goal of modern neuroscience in past 
decades.   
 
Recent synaptic studies have also started to focus on the mechanisms underlying 
synapse dysfunction and elimination, processes believed to be key early events 
associated with neurodegenerative diseases such as Alzheimer’s disease (AD) 
(Selkoe, 2002).  Changes in synapse function and neuronal homeostasis may 
potentially trigger processes that lead to synapse degeneration and loss, events which 
precede the pathological neuronal loss that is universally seen in AD patients 
(Dekosky and Scheff, 1990; Masliah et al., 1991; Terry et al., 1991).  Therefore, for 
effective design of therapeutic strategies for AD, it is crucial to identify and 
understand the neuronal changes at the earliest possible stage.  Understanding the 
physiological role of proteins involved in AD at the level of the synapse, may 
provide further insights into the cellular and molecular changes that occur during 
disease.  One of the key molecules involved in AD is presenilin 1 (PS1).  The vast 
majority of familial AD cases arise from missense mutations in the presenilin 1 gene, 
PSEN1, which is inherited in an autosomal dominant manner.  PS1 is highly 
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implicated in the pathobiology of AD as it is believed to be the catalytic subunit of γ-
secretase, a cellular enzyme complex that generates amyloid-beta peptides (Aβ) by 
cleaving amyloid-β precursor protein (APP).  These Aβ peptides are the core 
constituents of one of the characteristic features of AD, the Aβ plaques.  In addition 
to its role in AD, studies have shown that PS1 is strongly implicated in regulating a 
wide range of different cellular functions.  This chapter will provide an overview of 
our current knowledge of presenilin biology, discuss the role of presenilin in 
regulating physiological neuronal functions and provide a summary of the role of 
presenilins in AD pathogenesis.   
 
 
1.1 Alzheimer’s disease (AD) 
 
Recent epidemiological estimates from the Alzheimer’s disease international 
organization predict that in 2010, there will be approximately 35 million AD patients 
worldwide making it the most prevalent neurodegenerative disease (Prince and 
Jackson, 2009).  Forecasts predict the number of cases will increase dramatically 
over the coming decades with 65.7 million estimated cases in 2030 and 115.4 million 
in 2050 (Prince and Jackson, 2009).  AD is a devastatingly debilitating form of 
dementia associated with a progressively severe and irreversible decline in cognitive 
functions such as deterioration in learning and language abilities and gradual loss of 
memory.    Behavioural disturbances such as aggression, agitation and apathy as well 
as psychological impairments like delusions, anxiety and depression have also been 
reported and can aid clinical diagnosis (Almkvist, 1996; Burns and Iliffe, 2009).  
However, clinical diagnosis of AD is often not straightforward as changes in 
cognitive ability or memory loss are also associated with a host of other dementias 
such as vascular dementia, frontotemporal dementia and dementia with Lewy bodies.  
Additionally, these symptomatic signs are often observed at a relatively advanced 
stage of AD and pathological changes to the brain may start to develop years before 
symptoms are fully recognized.  Recent advances in functional imaging using 
compounds such as Pittsburgh compound-B (PIB) which label Aβ plaques has aided 
clinical diagnosis and provided insights into early changes in brain activity (Klunk et 
al., 2004).  However, the aim of current research efforts is to identify the earliest 
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stage when pathogenesis can be detected, ideally prior to the onset of symptoms.  
Targeting synaptic changes at the earliest stage may offer therapeutic strategies the 
greatest chance of success.   
 
 
1.1.1 Sporadic Alzheimer’s disease (SAD) 
 
Current diagnostic procedures divide AD into two forms: sporadic AD (SAD) and 
familial AD (FAD).  The risk factors associated with sporadic AD, which accounts 
for the vast majority of cases (90-95%) are not well understood.  Aetiological studies 
investigating sociodemographic risk factors have shown a positive correlation 
between age and AD.  Most cases of sporadic AD affect patients over the age of 65 
and the age related risk doubles every 5 years over this age (Brouwers et al., 2008; 
LaFerla and Oddo, 2005).  Other proposed secondary risk factors include family 
history, head injury, hypertension, high cholesterol levels, sedentary lifestyles, 
mental inactivity, cerebral vascular disease, gender (with increased risk in females), 
and environmental factors (Azad et al., 2007; Blennow et al., 2006; Burns and Iliffe, 
2009; Prince and Jackson, 2009).  However, follow up studies of these secondary 
factors will be required to assess their overall contribution and significance to SAD.    
 
Recent studies have also identified that certain SAD cases may have a genetic basis.  
Unlike FAD which is primarily caused by genetic missense mutations, SAD is 
associated with an increase in the copy number of a susceptibility gene located on 
chromosome 19, ApoE.  ApoE can be found as three major single nucleotide 
polymorphisms referred to as ApoE 2, 3 and 4, each associated with a different level 
of risk.  The most abundant form in the central nervous system (CNS) is ApoE3 
which is not linked to any change in risk whereas ApoE2 leads to an advantageous 
decrease in risk.  By contrast, the ApoE4 allele leads to a significant increase in risk 
with approximately 70% of SAD patients having at least one copy of this high risk 
isoform (Corder et al., 1993; Corder et al., 1994;Corder et al., 1995; Holtzman, 
2001; Kim et al., 2009a; Kim et al., 2009b; Saunders et al., 1993).  The role of the 
protein encoded by the ApoE gene, Apolipoprotein E (ApoE) in the development of 
SAD is slowly being uncovered.  ApoE is a glycoprotein which is implicated in the 
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receptor-mediated endocytosis of lipoprotein particles and cholesterol metabolism 
(Kim et al., 2009a; Pitas et al., 1987).  Studies have shown that ApoE can sequester 
Aβ peptides and elimination of ApoE can cause a strong reduction in both 
extracellular and intracellular Aβ suggesting a role for ApoE in Aβ clearance 
(Holtzman et al., 2000a; Holtzman et al., 2000b; Jiang et al., 2008; Strittmatter et al., 
1993).  However, overall the molecular mechanisms associated with SAD remain to 
be fully elucidated.      
 
 
1.1.2 Familial Alzheimer’s disease (FAD) 
 
In addition to sporadic forms of AD, there are autosomal dominant forms of early 
onset familial Alzheimer’s disease (FAD) which typically affects individuals that are 
65 years and below (Fraser et al., 2000; Goedert and Spillantini, 2006; Tandon and 
Fraser, 2002).   FAD cases only account for approximately 5-10% of total AD cases 
and apart from an accelerated age of onset and a shorter time period required for 
exhibition of pathological features, the general pathophysiological features of AD 
such as the expression of plaques and tangles are similar between FAD and SAD 
cases (Lantos et al., 1992; Vetrivel et al., 2006).   
 
Studies of families with FAD have provided great insight into the general molecular 
mechanisms involved in AD.  FAD is associated with mutations in three genes: APP 
gene (on chromosome 21) encoding amyloid-beta precursor protein (APP) (Goate et 
al., 1991), PSEN1 (on chromosome 14) encoding presenilin 1 (PS1) (Sherrington et 
al., 1995) and PSEN2 (on chromosome 1) encoding presenilin 2 (PS2) (Levy-Lahad 
et al., 1995).  Currently over 200 mutations have been reported in these genes, with 
the majority being located within PSEN1 (179 for PSEN1, 14 for PSEN2 and 32 for 
APP; see Alzheimer disease and frontotemporal dementia database website or 
www.alzforum.org for up to date reports, Marambaud and Robakis, 2005; Tanzi and 
Bertram, 2001).  Most mutations are missense mutations which lead to single amino 
acid shifts, though deletion, insertion and splice mutations have been reported (De 
Strooper, 2007).  Interestingly, mutations are found distributed throughout the 
presenilin protein rather than being concentrated within a particular domain/ exon 
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(Bergmans and De Strooper, 2010; Fraser et al., 2000).  On the whole, PSEN1 
mutations are considered more aggressive than PSEN2 and APP mutations and 
typically lead to an earlier age of onset (Brouwers et al., 2008; Tandon and Fraser, 
2002).   
 
Studies of FAD patients and transgenic mice models of FAD mutations have 
revealed that most clinical mutations are associated with neuronal loss and an 
overproduction of Aβ within the CNS.  More specifically, most studies have 
indicated that these mutations lead to an elevated production of the neurotoxic 
aggregation prone form of Aβ peptide, Aβ42 (Borchelt et al., 1996; Citron et al., 
1992; Citron et al., 1997; Duff et al., 1996; Haass et al., 1994; Haass and Selkoe, 
2007; Hardy and Selkoe, 2002; Scheuner et al., 1996).  However, an alternative 
theory has been suggested by recent reports which showed using different FAD mice 
models that it is the ratio of Aβ40 to Aβ42 that determines AD pathogenesis rather 
than absolute levels of Aβ42 production (Bentahir et al., 2006; Kumar-Singh et al., 
2006). However, some mutations can lead to reduced Aβ production, which brings 
into question whether clinical mutations lead to a toxic gain-of-function or loss-of-
function of presenilin (Bentahir et al., 2006). Taken together, these mutations 
suggest that Aβ production is a pivotal event in the molecular pathway underlying 
FAD.   
 
 
1.1.3 Histopathological characteristics of AD 
 
The first reported case of AD was made in 1901 by Alois Alzheimer after conducting 
post-mortem examinations on a patient referred to as Auguste D who was suffering 
from senile dementia prior to her death (see Fortini, 2003 for review).  Through 
histological analysis using Bielschowsky silver staining of brain tissue, Alzheimer 
discovered the two hallmark characterstics used to clinically confirm the disease, the 
presence of extracellular Aβ plaques and intracellular neurofibrillary tangles  
(Goedert and Spillantini, 2006).  
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The neurofibrillary tangles observed in AD patients mainly consist of a protein 
called tau.  Tau is a primarily neuronal specific microtubule associated protein which 
under basal physiological conditions aids the stabilisation of microtubules especially 
in axonal processes (Querfurth and LaFerla, 2010).  During AD it has been proposed 
that tau undergoes abnormal proteolytic processing and becomes 
hyperphosphorylated at proline-directed serine/threonine residues which results in 
the generation of non-membrane associated paired helical filamentous structures 
which then aggregate to give rise to neurofibrillary tangles (Buee et al., 2000; 
Grundke-Iqbal et al., 1986a; Grundke-Iqbal et al., 1986b; Kidd, 1963; Paudel et al., 
1993).   Neurofibrillary tangles are often found within the intracellular regions of 
neurons with particularly strong aggregation in the cell soma and apical dendrites.  
However, the abnormal accumulation of tau is not exclusively confined to AD as 
other neurodegenerative diseases including Amylotrophic Lateral Sclerosis (ALS), 
Pick’s disease, corticobasal degeneration, frontal temporal dementia with 
parkinsonism linked to chromosome 17 and tangle only dementia all exhibit tau 
filaments (Skovronsky et al., 2006).  These conditions come under the collective 
umbrella of neurodegenerative tauopathies (for review see Buee et al., 2000; Lee et 
al., 2001).   
 
Extensive light and electron microscopy studies have shown that extracellular 
plaques that accumulate in AD are mainly composed of a peptide known as Aβ 
(Allsop et al., 1983).  Aβ is a product of the proteolytic cleavage of APP.  APP is 
processed by a series of different catalytic reactions to give rise to a range of Aβ 
peptides of multiple lengths.  Aβ peptides can be found in several different states of 
aggregation within the brain.  Aβ peptides are initially formed as single unit 
monomers and progressive self-aggregation leads to formation of dimers, oligomers, 
protofibrils, fibrils and finally Aβ plaques (Figure 1.1, Bitan et al., 2003; Caughey 
and Lansbury, 2003).  Aβ neuritic plaques mainly consist of Aβ fibrils containing the 
longer, more neurotoxic aggregation prone Aβ42 peptide isoform arranged into 
insoluble β-sheet structures (Glenner et al., 1984; Glenner and Wong, 1984a; 
Glenner and Wong, 1984b; Iwatsubo et al., 1994; Selkoe and Wolfe, 2007).  These 
neuritic plaques are often found in close association with the axons and dendrites of 
neurons as well as glia and blood vessels (Georgakopoulos et al., 1999; Glenner et 
al., 1984; Hardy, 1997; Ribaut-Barassin et al., 2000; Selkoe and Schenk, 2003).  
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Furthermore studies have shown that neuronal processes in contact with plaques may 
exhibit dystrophic morphology, hyperactivity, and dysregulation of calcium 
homeostasis suggesting that these extracellular plaques are influencing the structure 
and health of closely associated neurons (Busche et al., 2008; Garcia-Alloza et al., 
2009; Kuchibhotla et al., 2008; Meyer-Luehmann et al., 2008; Spires et al., 2005; 
Spires-Jones et al., 2007; Wu et al., 2010).  However, there is growing evidence that 
suggests that early cellular changes observed during AD are more tightly associated 
with smaller Aβ species, in particularly oligomers, rather than fibrils and plaques 
(Haass and Selkoe, 2007; Walsh et al., 2005; Walsh and Selkoe, 2007).   
 
Since Alzheimer’s original observations, the pathological phenotype of plaques and 
tangles have been reported in many regions of the CNS including the hippocampus, 
entorhinal cortex, amygdala and neocortex, key regions of the brain associated with 
different forms of learning and memory (Braak and Braak, 1991a; Braak and Braak, 
1991b; Gomez-Isla et al., 1996).  The temporal appearance of Aβ plaques and 
neurofibrillary tangle deposition in the AD brain is different.  Studies in transgenic 
mice models carrying mutations in presenilin, APP and tau genes have shown that 
amyloid pathology occurs prior to tau accumulation suggesting that the amyloid 
pathway is engaged before tau dysregulation (McGowan et al., 2006; Oddo et al., 
2003a; Oddo et al., 2003b).  There is also some evidence from transgenic mice that 
Aβ fibrils could stimulate tangle formation (Gotz et al., 2001).  Primary cell culture 
studies also showed that Aβ peptide aggregates could trigger tau 
hyperphosphorylation in somatodendritic compartments of rat septal neurons (Zheng 
et al., 2002). Additionally, neuronal loss is another key characteristic of AD which 
often accompanies the pathohistological appearance of Aβ deposits and tau 
neurofibrillary tangles.  Neuronal loss is typically measured as a decrease in brain 
weight and increase in ventricular areas as a result of temporal lobe atrophy, 
especially in the hippocampus.     
 
However, whilst the presence of Aβ plaques and neurofibrillary tangles are used to 
confirm the presence of AD, there is still great debate over the pathological 
involvement of these protein aggregates.  Indeed past studies have shown that plaque 
and tau accumulations are often poorly correlated with the extent of memory loss.    
Furthermore, these features can be found in elderly patients who do not experience 
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dementia (Arriagada et al., 1992; Delaere et al., 1990; Kazee and Johnson, 1998). 
This suggests that Aβ plaques and neurofibrillary tangles are possibly not the 
pathological species involved in early stages of AD when cognitive defects start to 
occur.  The current consensus is that the best correlate to early memory impairments 
is the extent of synapse loss and neuronal dysregulation which precludes neuronal 
loss (Braak and Braak, 1997; Dekosky and Scheff, 1990; Selkoe, 2002; Terry et al., 
1991; Terry, 2000).  Hence extensive research efforts have concentrated on gaining a 
better understanding of the cellular and molecular events which lead to synapse 
dysfunction and degeneration.   
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Figure 1.1 - Aβ plaque assembly. 
The assembly of Aβ plaques occurs through a series of aggregation steps. The key 
constituent of Aβ plaques are Aβ peptides, which are generated through sequential 
cleavage of APP by β-secretase and γ-secretase.  Newly biosynthesised soluble 
monomeric peptides are mostly released into the extracellular milieu and  can form 
largely unstructured dimers and oligomers.   These steps are reversible.  
Protofibrils are usually generated from Aβ oligomers and dimers that aggregate to 
form β-sheet and α-helical secondary structures.  Maturation and aggregation of 
protofibrils give rise to fibrils which can aggregate to form insoluble Aβ plaques. 
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1.2 Biosynthesis of Aβ: APP processing  
 
 
1.2.1 Amyloid-beta precursor protein (APP) 
 
The APP gene encodes for APP, a type I integral single transmembrane helical 
glycoprotein with a large luminal N-terminus domain containing a signal peptide, 
and a short cytoplasmic tail (Kang et al., 1987; Robakis et al., 1987a; Robakis et al., 
1987b; Sisodia et al., 1993; Turner et al., 2003).  In mammals, APP belongs to the 
same protein family as APP like protein 1 (APLP1)(Wasco et al., 1992) and 2 
(APLP2) (Wasco et al., 1993).  However, APP is the only member of the group that 
can be processed to generate Aβ peptides (Zheng and Koo, 2006).  APP also shares 
homology with APPL in the fruit fly Drosophila (Rosen et al., 1989) and APL-1 in 
the nematode Caenorhabditis elegans (C. elegans) (Daigle and Li, 1993).  APP is 
ubiquitously expressed throughout the CNS and alternative mRNA splicing of exon 
7 and 8 gives rise to three main isoforms composed of either 695 (APP695), 751 
(APP751) or 770 (APP770) amino acids (Suh and Checler, 2002; Thinakaran and 
Koo, 2008; Turner et al., 2003).  APP695 is predominately expressed in neurons 
whilst APP751 and APP770 are found in glia and non-neuronal cells.   
 
Structural studies on APP have revealed different domains that may be important for 
different cellular functions.  The extracellular N-terminus ectodomain of APP 
contains a wide range of sequences that modulate protein-protein interactions.  These 
include the E1 domain which enables interaction with copper and zinc, the E2 
domain which contains the RERMS sequence and interacts with extracellular matrix 
proteins and the kunitz protease inhibitor (KPI) region located on the extracellular N-
terminus ectodomain of APP770 and APP751 (but not APP695) has been shown to 
regulate cell adhesion through the interaction to heparin and collagen (Mattson, 
1997; Turner et al., 2003; Wolfe and Guenette, 2007; Zheng and Koo, 2006).  The 
extracellular domain of APP has also been proposed to act as a cell surface receptor 
for different ligands including Aβ peptides, F-spondin and Nogo-66 (see Zheng and 
Koo, 2006 for review).  Located on the cytoplasmic domain of the C-terminal tail is 
a YENPTY motif which enables internalisation of APP and also interaction with 
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many different intracellular proteins with phosphotyrosine-binding domains 
(Thinakaran and Koo, 2008; Turner et al., 2003; Zheng and Koo, 2006).  One 
example is Fe65, a nuclear adaptor protein which can regulate synapse structure and 
growth cone activity (Sabo et al., 2003).  Recent studies also showed that AICD, the 
intracellular fragment generated from γ-secretase cleavage of β-CTF can form a 
complex with Fe65 to modulate nuclear signalling and transcription regulation by 
binding to Tip60, a histone acetyltransferase (Cao and Sudhof, 2001; Cao and 
Sudhof, 2004).  Other cellular functions of APP or γ-secretase cleavage products 
include cell migration, cell adhesion, synapse remodelling, axonal transport, 
apoptosis and protein phosphorylation (see for review: Thinakaran and Koo, 2008; 
Zheng and Koo, 2006).  Studies conducted on APP knockout mice show that these 
animals were viable and exhibited a mild phenotype which included lower mass, 
decreased locomotion and impaired long-term potentiation (Dawson et al., 1999; 
Zheng et al., 1995). 
 
 
1.2.2 APP processing  
 
The biology of APP is complex as many different cellular roles have been reported 
not only for the full length protein but also for the different fragments (e.g. AICD, 
Aβ) generated from the cleavage of APP by cellular proteases (see for review: 
Marcello et al., 2008; Mattson, 1997; Rowan et al., 2005; Thinakaran and Koo, 
2008; Turner et al., 2003; Venkitaramani et al., 2007; Zheng and Koo, 2006).  Under 
basal conditions, full length APP holoprotein is constitutively trafficked to the 
plasma membrane.  During its journey to the cell surface, APP can be post-
translationally modified by tyrosine sulphation, N and O glycosylation or 
phosphorylation by different kinases including GSK-3β, SAPK1b/ JNK3, Cdc2, and 
Cdk5 (Brouwers et al., 2008; Buxbaum et al., 1990; De Strooper and Annaert, 2000; 
Georgopoulou et al., 2001; Lee et al., 2003).  
 
Once at the cell surface, full length APP can be processed through two separate 
pathways referred to as the amyloidogenic pathway, which ultimately leads to the 
generation of Aβ peptides, and the non-amyloidogenic or constitutive pathway which 
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leads to production of p3, a small peptide not believed to play a role in AD 
pathology  (Brouwers et al., 2008).  Surface antibody feeding assays have shown that 
APP can undergo internalisation and reinsertion back in the plasma membrane (Koo 
et al., 1996; Koo and Squazzo, 1994).  The subcellular site of APP processing and 
cleavage is still widely debated (see for review: Thinakaran and Koo, 2008).   
 
 
The amyloidogenic pathway and generation of Aβ  
 
Firstly it is important to note that the generation of Aβ not only occurs during AD 
pathogenesis but also during normal basal physiological states (Haass et al., 1992; 
Seubert et al., 1992; Shoji et al., 1992).  In order to generate Aβ, APP is sequentially 
cleaved by two enzyme complexes (See Figure 1.2).  The first proteolytic event takes 
place either between residues Met 671 and Asp 672 (known as the +1 site) or 
between residues 682 and 683 (referred to as the +11 site) on the extracellular N-
terminus of APP by β-secretase (BACE-1) which gives rise to two fragments, a 
soluble APP beta peptide (sAPP-β) that gets released into the extracellular space and 
a membrane associated fragment, β-carboxyl C-terminal fragment (β-CTF, also 
known as C99 (which refers to the number of amino acids) or β-stub) (Selkoe, 2001; 
Sisodia and George-Hyslop, 2002).   β-CTF is subsequently cleaved by γ-secretase at 
γ, ε and ζ sites to generate a range of Aβ species ranging from 37-49 amino acids in 
length and APP intracellular domain (AICD) (also known as γ-CTF or C59) 
(Brouwers et al., 2008; Dries and Yu, 2008).  Aβ is predominantly secreted into the 
extracellular space, whilst AICD is released into the intracellular space. 
 
Under basal physiological states, the more soluble Aβ40 peptide accounts for 
approximately 90% of the total Aβ produced, whilst the more fibrillogenic Aβ42 
peptide is produced at less than 10% of the total amount (Brouwers et al., 2008; 
Hardy and Mullan, 1992).  However in AD, this trend is altered with patients and 
FAD transgenic mutant mice models showing a tendency towards an increase in 
Aβ42 production, Aβ aggregation and/or plaque deposition (Iwatsubo et al., 1994; 
Jarrett et al., 1993; Mori et al., 1992; Saido et al., 1995; Scheuner et al., 1996; Selkoe 
and Wolfe, 2007; Steiner et al., 2001).   
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The non-amyloidogenic/ constitutive pathway and generation of p3 fragments 
 
Past studies have revealed that the main product of APP processing is not Aβ 
through the amyloidogenic pathway but p3 through the constitutive pathway 
(Anderson et al., 1991; Esch et al., 1990; Seubert et al., 1993; Sisodia et al., 1990).  
The generation of p3 fragments, like Aβ fragments, requires two subsequent 
cleavage events on APP to occur (see figure 1.2).  The first event involves the 
cleavage of N-terminus APP at resides Lys 687 and Leu 688 by α-secretase to 
generate two peptides, a soluble APP alpha fragment (sAPP-α) and a membrane 
bound, α-carboxyl C-terminal fragment (α-CTF, also known as C83 or α-stub).  α-
secretase processing of APP prevents the formation of Aβ peptides and therefore 
precludes amyloidogenesis.  Cleavage by α-secretase occurs within the Aβ region 
between amino acids lysine 16 and leucine 17 amino acids (with residue numbers 
being relative to the start of Aβ which is designated residue 1)(Dominguez et al., 
2004; Sisodia and George-Hyslop, 2002).  Like sAPP-β, newly generated sAPP-α 
fragments are released into the extracellular space.  α-CTF is then cleaved within the 
transmembrane region by γ-secretase to generate p3 and AICD.  As with Aβ 
fragments, a range of differently sized p3 fragments can be generated depending on 
the precise location of γ-secretase cleavage of α-CTF.  The exact cellular role of p3 
is not clearly understood, but enhancing the production of p3 may be an attractive 
therapeutic option.  It has been proposed that generation of p3 may be 
neuroprotective purely by decreasing the amount of Aβ produced (Esch et al., 1990; 
Skovronsky et al., 2000).  As α-secretase and β-secretase processing of APP are 
mutually exclusive to each other,  increasing the amount of APP that is processed 
through the constitutive (α-secretase) pathway means less APP is made available for 
processing through the amyloidogenic (β-secretase) pathway and therefore less Aβ is 
generated (Skovronsky et al., 2000).  However, other studies have shown that 
increasing α-secretase activity has no effect on decreasing Aβ generation suggesting 
Aβ generation may be tightly controlled by other regulatory processes (Rossner et 
al., 2000).   
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Figure 1.2 - APP processing by cellular secretases.   
(a) APP is a transmembrane protein with a large extracellular N-terminus domain 
and shorter cytoplasmic C-terminal tail.  APP can be processed by two pathways, 
either the amyloidogenic pathway or the non-amyloidogenic pathway.   
(b) The amyloidogenic pathway leads to Aβ generation.  Firstly β-secretase 
cleavage of APP gives rise to soluble β-APP fragments (sAPP-β) and β-CTF (also 
known as C99 or β-stub).  Subsequent cleavage of γ-CTF by γ-secretase, generates 
two further peptide fragments: Aβ and AICD (also known as C59 or γ-CTF).  
Different cleavage sites on β-CTF can give rise to different peptide fragments.  
AICD is generated by γ-secretase cleavage at the ε-site of β-CTF.  
Whilst γ-secretase cleavage at the γ-site of β-CTF leads to Aβ generation.  
(c) The non amyloidogenic pathway leads to p3 generation.  Firstly, α-secretase 
cleavage of APP generates soluble α-APP fragments (sAPP-α) and α-CTF (also 
C89 or α-stub). This pathway precludes Aβ formation as α-secretase cleavage 
occurs within the Aβ peptide.  Subsequent cleavage of α-CTF by γ-secretase, gives 
rise to p3 and also AICD.  
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1.3 Presenilin and γ-secretase  
 
 
As already mentioned, most FAD mutations are associated with an overproduction 
of Aβ peptides and neuronal loss.  Most of these mutations occur within the PSEN1 
gene, identifying PS1 as an important component in the pathogenesis of AD.  
Determining the cellular role of PS1 may provide insights into the mechanisms 
which underlie AD pathology.    PS1 is a protein that acts as part of a larger enzyme 
complex known as the γ-secretase.  γ-secretase is an important protease involved in 
the processing of a range of cellular proteins and regulation of multiple cellular 
processes (see table 1.1).  Early biochemical studies showed that γ-secretase exists as 
a high molecular weight complex but the composition of the enzyme complex has 
been an issue of intense debate.  Current evidence from biochemical purification and 
activity reconstitution studies shows that γ-secretase activity is derived from a multi 
subunit complex composed of four integral components: PS (1 or 2), nicastrin, 
anterior pharynx defective 1 (APH-1), and presenilin enhancer protein 2 (PEN-2) 
(Edbauer et al., 2003; Fraering et al., 2004b; Hebert et al., 2004; Kimberly et al., 
2003; Sato et al., 2007; Takasugi et al., 2003) (see Figure 1.3).   
 
 
1.3.1 Presenilin: The catalytic core of γ-secretase 
 
The presenilins were first isolated through positional cloning and two homologs 
were found, PS1 (Sherrington et al., 1995) and PS2 (Levy-Lahad et al., 1995) which 
share 67% sequence similarity (Kovacs et al., 1996).  Homologs of presenilins have 
been reported in different model systems including Xenopus, Drosophila and C. 
elegans suggesting that presenilin function is evolutionarily conserved (Tandon and 
Fraser, 2002).  The presenilins are polytopic membrane proteins, where PS1 is 467 
amino acids long and PS2 is 448 amino acids (Dries and Yu, 2008).  Despite some 
differences in function (discussed below), the similarities in structure between PS1 
and PS2 have meant that most of the studies investigating presenilin topology have 
focused on PS1.  The following information referring to the structure of presenilin 
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will be based around our current understanding of PS1 data but should also be 
largely applicable to PS2.   
 
Topological modelling studies have proposed many possible arrangements of PS1 
but the current accepted structure indicates 9 transmembrane domains (TM), a large 
hydrophilic intracellular loop between TM 6 and 7, a N-terminus which projects into 
the cytoplasm and a C-terminal tail located within the lumen/ extracellular space 
(Laudon et al., 2005; Oh and Turner, 2005a; Oh and Turner, 2005b; Spasic et al., 
2006) (See Figure 1.3).  Current evidence strongly suggests that PS1 is the catalytic 
subunit of γ-secretase (Fortini, 2002; Nyabi et al., 2003; Sisodia and George-Hyslop, 
2002; De Strooper and Annaert, 2001; Wolfe et al., 1999b).  PS1 is an aspartyl 
protease with two highly conserved catalytic aspartate residues at amino acid 
position 257 (in TM 6) and 385 (in TM7) which are both found within the active site 
of the γ-secretase enzyme complex (Spasic and Annaert, 2008; Wolfe et al., 1999b).  
Additionally two conserved motifs have been identified: a YD motif in TM 6 
(hydrophobic region 6) and a GxGD catalytic motif in TM 7 (hydrophobic region 8) 
(Beel and Sanders, 2008; Haass and Steiner, 2002; Sato et al., 2006; Steiner and 
Haass, 2000).  These motifs are crucial for peptidase function and are also found in 
bacterial type 4 prepilin peptidase (TFPP), signal peptide peptidase (SPP) and SPP-
like (SPPL) proteases (Friedmann et al., 2004; Kaether et al., 2006a; Weihofen et al., 
2002; Weihofen and Martoglio, 2003).  A recent study also indicated that residue 
Tyr389 within the active zone may be important for catalytic action of γ-secretase 
(Tolia et al., 2006).   
 
Convincing evidence that the aspartate residues are essential for γ-secretase activity 
was demonstrated through mutagenesis studies.  Site directed mutagenesis of either 
aspartate residues led to a significant decrease in the production of Aβ from APP, 
indicating that these residues are crucial for γ-secretase activity (Kimberly et al., 
2000; Wolfe et al., 1999b; Yu et al., 2000a).  Additionally, biochemical studies 
showed that application of aspartyl protease transition state analogs designed against 
the active site of γ-secretase could block the formation of Aβ and led to an 
accumulation of α-CTF and β-CTF fragments (substrates for γ-secretase which are 
generated by α and β secretase cleavage of APP), providing further evidence that the 
aspartate residues are necessary for γ-secretase activity (Esler et al., 2000; Li et al., 
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2000).  The aspartate residues also seem to be evolutionarily conserved as 
mutagenesis of an equivalent aspartate residue within PS2 also led to a decrease in γ-
secretase processing of APP and Notch (Kimberly et al., 2000; Steiner et al., 1999a).   
 
Further evidence that presenilin is involved in γ-secretase activity was provided by 
knock-out mice studies.  Cultured cortical neurons from PS1 knock-out animals 
exhibited an accumulation of APP C-terminal fragments and a greatly reduced 
production of Aβ, indicative of a major reduction in γ-secretase activity (De Strooper 
et al., 1998; Naruse et al., 1998).   These results were mirrored by in vivo studies of 
conditional PS1 knock-out mice where the PS1 gene was deleted in the adult animal.  
A near absent production of Aβ40 and Aβ42 peptides was observed in animals 
generated by crossing conditional PS1 mice and APP transgenic mice, a AD model 
which normally develops amyloid pathology (Saura et al., 2005).  The presence of 
amyloid plaques in 6 month old APP transgenic mice was almost completely absent 
in APP transgenic and conditional PS1 knock-out crossed animals, suggesting that γ-
secretase activity of PS1 is also required for plaque deposition (Saura et al., 2005).  
These studies show that Aβ peptide and plaque generation is predominantly 
produced by PS1 containing γ-secretase complexes rather than PS2 containing 
complexes.  Studies from embryonic stem cells lacking both PS1 and PS2 showed 
that Aβ generation was totally abolished (Herreman et al., 2000; Zhang et al., 2000).  
Together these knock-out studies show that the presenilins are essential for γ-
secretase activity associated with APP processing.  
  
In addition to being the catalytic component of γ-secretase, presenilin was also 
shown to undergo endoproteolysis.  PS1 is initially synthesised as an approximately 
43-48 kDa holoprotein but rapidly undergoes regulated endoproteolysis at residues 
292 and 293 within the intracellular loop (between TM 6 and 7) to generate a ~ 27-
30 kDa N-terminus fragment and a ~16-18 kDa C-terminal fragment (Fortini, 2002; 
Marambaud and Robakis, 2005; Podlisny et al., 1997; Thinakaran et al., 1996).  
Once endoproteolysis occurs, the N and C terminal fragments come together to form 
a non-covalently linked heterodimer in a 1:1 conformation (Campbell et al., 2003; 
Thinakaran et al., 1998).  It is now generally accepted that it is the heterodimeric 
form of PS1 rather than the intact holoprotein that provides the enzymatic activity 
for the γ-secretase complex (Levitan et al., 2001; Thinakaran et al., 1996).  Site 
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directed mutagenesis of either of the conserved aspartyl residues was shown to not 
only significantly decrease γ-secretase activity but also prevented generation of the 
PS1 heterodimer, leading to accumulation of the holoprotein form of PS1 (Wolfe et 
al., 1999a; Wolfe et al., 1999b; Yu et al., 2000a).    Together, this data indicate two 
points; that presenilin undergoes auto-endoproteolysis and that endoproteolysis is an 
important process for maturation of the γ-secretase complex and activity.  However, 
PS1 mutants that are unable to undergo endoproteolysis are still able to assemble 
into γ-secretase complexes, suggesting that endoproteolysis is not strictly required 
for γ-secretase function (Steiner et al., 1999b).  Studies also revealed that inhibitors 
of γ-secretase could specifically crosslink the “active” N and C terminal 
heterodimeric fragments of presenilin (Esler et al., 2000; Li et al., 2000; Seiffert et 
al., 2000).  No interaction between the inhibitors and the holoprotein/ full length 
form of PS1 was detected (Li et al., 2000).  This indicates that γ-secretase inhibitors 
could selectively block γ-secretase dependent functions of PS1, whilst leaving the 
PS1 holoprotein function or γ-secretase independent functions of presenilin 
unchanged.  γ-secretase inhibitors were also shown to have a similar effect on γ-
secretase processing as PS1 knock-out manipulations (De Strooper et al., 1999). 
  
 
1.3.2 Nicastrin, APH-1 and PEN-2: The accessory proteins of   
γ-secretase 
 
As discussed in the previous section, presenilin is responsible for providing the 
enzymatic activity of γ-secretase.  However, overexpression studies highlighted that 
presenilin alone may not be sufficient for γ-secretase activity.  Thinakaren and 
colleagues (1997) found that overexpression of human PS1 could replace 
endogenous presenilin in both neuroblastoma cell lines and neuronal cultures and the 
amount of PS1 N and C terminal heterodimeric fragments was not increased despite 
the overexpression of PS1 protein (Thinakaran et al., 1997).  Together these results 
indicate that there are certain limiting elements that prevent excess γ-secretase 
complex generation.  Experimental evidence showed that nicastrin, APH-1 and PEN-
2 could interact with presenilin and the interaction was important for γ-secretase 
processing of substrates, Notch and APP (Edbauer et al., 2002; Francis et al., 2002; 
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Goutte et al., 2002; Yu et al., 2000b).  These results have strongly suggested that 
presenilin, nicastrin, APH-1 and PEN-2 are the core components of γ-secretase.  
Reconstitution experiments in yeast, Saccharomyces cerevisiae, provided 
confirmation of this hypothesis.  Saccharomyces cerevisiae is deficient in 
endogenous γ-secretase activity but overexpression of exogenous presenilin, 
nicastrin, APH-1 and PEN-2 together are sufficient for the generation of γ-secretase 
activity (Edbauer et al., 2003).  This study also confirmed the results of Thinakaren 
and colleagues by showing that γ-secretase activity could not be reconstituted by 
overexpression of wild type presenilin alone.  Indeed, co-expression of any three 
components proved insufficient to generate γ-secretase activity (Edbauer et al., 
2003).  Other studies from Chinese hamster ovary (CHO) cells (Kimberly et al., 
2003) and Drosophila S2 cells (Takasugi et al., 2003) confirmed that overexpression 
of presenilin-1, nicastrin, APH-1 and PEN-2 could reconstitute γ-secretase activity in 
mammalian cells.  This data shows that nicastrin, APH-1 and PEN-2 act as accessory 
proteins to the catalytic core of presenilin and all four components are necessary and 
sufficient to generate cellular γ-secretase activity.   
 
Nicastrin is a 130kDa glycosylated type 1 single transmembrane protein involved in 
the recognition of γ-secretase substrates and maturation of the γ-secretase complex 
(Chavez-Gutierrez et al., 2008; Morais et al., 2003; Shah et al., 2005; Yu et al., 
2000b).  APH-1 is a seven transmembrane domain protein which provides scaffold 
support and stabilisation for the complex and is necessary for transport of nicastrin to 
the cell surface (De Strooper, 2003; Francis et al., 2002; Goutte et al., 2002; Lee et 
al., 2002; Niimura et al., 2005; Takasugi et al., 2003).  There are three isoforms in 
humans; APH-1a-short, APH-1a-long and APH-1b.  An additional isoform is found 
in rodents, APH-1c, which is duplicated from the APH-1b gene (Hebert et al., 2004).  
PEN-2 is a small (approximately 10-12 kDa) hairpin like protein with two 
transmembrane domains and proposed to play a role in the initiation of presenilin 
endoproteolysis and maturation of the enzyme complex (Crystal et al., 2003; Francis 
et al., 2002; Prokop et al., 2005; Steiner et al., 2002; Takasugi et al., 2003).    
 
The identification of the different isoforms of presenilin and APH-1 suggest that 
theoretically there are several possible combinations of γ-secretase complexes that 
can be generated.  Biochemical analysis reveals that different isoforms of presenilin 
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and APH-1 do not co-exist in the same γ-secretase complex suggesting that only one 
presenilin, APH-1, PEN-2 and nicastrin are present in each complex (Sato et al., 
2007; Shirotani et al., 2004b).  Currently it is unclear whether there is a preferential 
formation of complexes with a particular combination of presenilin or APH-1 
subunits.  It is also not known if different complexes are located within different 
subcellular compartments or if they process different substrates.  Furthermore, it 
remains to be established if there are different complexes preferentially involved in 
AD pathology or normal cellular substrate processing.  Interestingly, recent in vitro 
and in vivo studies have shown that γ-secretase complexes consisting of PS2 rather 
than PS1 lead to a decreased processing of APP and reduced generation of Aβ (Lai et 
al., 2003; Mastrangelo et al., 2005).  This suggests that γ-secretase complexes 
containing PS1 may act as more potent cellular proteases than complexes containing 
PS2.  However, most studies investigating the role of different γ-secretase 
components have focused on overexpression analysis in cell lines which may not 
reflect the levels of γ-secretase activity in vivo.     
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1.3.3 Formation and maturation of γ-secretase 
 
Biochemical studies originally identified γ-secretase as components within high 
molecular weight protein complexes, ranging from a few hundred to over 2000 kDa 
(Capell et al., 1998; De Strooper et al., 1997; Gu et al., 2004; Yu et al., 1998).  More 
recent studies from detergent purified γ-secretase complexes have indicated that the 
stoichiometry of the active complex, containing presenilin, nicastrin, APH-1 and 
PEN-2 in a 1:1:1:1 ratio with a molecular weight of 200 – 250 kDa (Li et al., 2009; 
Osenkowski et al., 2009; Sato et al., 2007).  Formation of γ-secretase complex occurs 
in a highly regulated manner within the endoplasmic reticulum (ER).  Current 
models propose that the interaction between nicastrin and APH-1 occurs first, which 
Figure 1.3 - Structure of the γ-secretase complex  
The γ-secretase enzyme complex consists of four integral transmembrane proteins: 
presenilin, nicastrin, APH-1 and PEN-2.  Presenilin (orange) is the catalytic 
component of the complex.  The active site of presenilin is located with 
transmembrane regions 6 and 7 which contain two catalytic asparate residues at 
sites 257 and 385.  A mature (catalytically active) complex is formed upon 
assembly of all four components and the generation of NTF and CTF fragments by 
endoproteolysis of presenilin.  Endoproteolysis occurs within the intracellular loop 
between transmembrane domains 6 and 7.   
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is then followed by the binding of full length presenilin to this dimeric structure 
(Capell et al., 2003; LaVoie et al., 2003; Lee et al., 2002; Niimura et al., 2005; 
Shirotani et al., 2004a; Takasugi et al., 2003). The C-terminal tail of presenilin binds 
directly with nicastrin to form a stable trimeric complex (Kaether et al., 2004).  The 
subsequent binding of PEN-2 to the trimeric complex stimulates endoproteolysis of 
presenilin to generate the active γ-secretase complex (Fraering et al., 2004a; Kim and 
Sisodia, 2005; Luo et al., 2003; Steiner et al., 2002; Takasugi et al., 2003; Watanabe 
et al., 2005).  Once fully assembled, γ-secretase can leave the ER and translocate to 
different subcellular compartments including the endoplasmic reticulum-Golgi 
intermediate compartment (ERGIC), cis-Golgi, trans-Golgi, endosomes and 
lysosomes en route to the plasma membrane.  The interaction between TM4 of 
presenilin (1) and TM1 of PEN-2 masks the ER-retention signals of these proteins 
and enables exit of the complex from the ER (Fassler et al., 2010).  Any presenilin 
that is not incorporated into active γ-secretase complexes (the majority of presenilin 
is not) is eventually degraded by the proteosome (Kim et al., 1997; Kopan and 
Ilagan, 2004; Lai et al., 2003; Thinakaran et al., 1996; Thinakaran et al., 1997).  
Mature γ-secretase complexes have a half life of several days whilst unincorporated 
proteins have a half life of ~1-6 hrs (Dries and Yu, 2008).  Figure 1.4 shows a 
proposed model of the steps involved in γ-secretase assembly.  
  
A recent study has also shown that other cellular proteins are implicated in 
regulating the subcellular location of γ-secretase.  The protein, retention in 
endoplasmic reticulum 1 (Rer1p) was shown to interact with the first domain of 
PEN-2 to maintain ER localisation of γ-secretase complex (Kaether et al., 2007).  
Other reports have also revealed that other factors including transmembrane 
trafficking protein 21 (TMP21), β-adrenergic receptor, CD147, calsenilin, pigment 
epithelial derived factor (PEDF) may act as modulators of γ-secretase cleavage, 
maturation and trafficking (Chen et al., 2006; McCarthy et al., 2009; Pardossi-
Piquard et al., 2009; Spasic et al., 2007; Zhou et al., 2005).  Further studies will be 
required to determine if other regulators of γ-secretase location exist.   
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Figure 1.4 - Assembly of the γ-secretase complex    
Assembly of the γ-secretase enzyme complex occurs in a stepwise manner in the 
ER.  The first step involves APH-1 and nicastrin coming together to form a sub 
complex (1).  Presenilin, in its immature holoprotein form, then interacts with 
the APH-1 and nicastrin subcomplex to generate a trimeric complex (2).  Finally 
PEN-2 binds to the presenilin, nicastrin and APH-1 complex to generate the fully 
assembled γ-secretase complex (3). Endoproteolysis of the large intracellular 
loop (between transmembrane 6 and 7) of presenilin generates the N and C-
terminal fragments of presenilin, which gives rise to the mature, catalytically 
active form of γ-secretase.   
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1.3.4 Subcellular localisation of γ-secretase components 
 
The subcellular localisation of γ-secretase has been under intense study over the last 
two decades.  PS1 and PS2, nicastrin, APH-1, and PEN-2 were all initially reported 
to be predominately located within the ER and Golgi, but also in lysosomes, and 
endosomes (Annaert et al., 1999; Kim et al., 2000; Kovacs et al., 1996; Lah and 
Levey, 2000; Lee et al., 1996; Rechards et al., 2003).  However, other studies using 
surface biotinylation, immunofluorescence and immunoelectron techniques showed 
that small quantities of PS1, nicastrin, APH-1 and PEN-2 could be located near/ at 
the plasma membrane (Chyung et al., 2005; Hansson et al., 2005; Kaether et al., 
2002; Lah et al., 1997; Ray et al., 1999).  These findings are consistent with an 
ultrastructural immunogold electron microscopy study which showed that PS1 could 
be associated to the plasma membrane, ER, endosomes, nuclear membrane, Golgi 
and post-Golgi membranes (Rechards et al., 2003).   
 
These studies indicate that γ-secretase can be found throughout the secretory 
pathway and in many subcellular compartments but with the majority being located 
within the ER.  Zhang et al., (1998) found using subcellular fractionation methods 
that exogenously transfected presenilin holoprotein was localised in the ER whilst 
PS NTF and CTF fragments were localised to the Golgi (Zhang et al., 1998a).  
Annaert et al., (1999) analysed PS1 wild type neurons and showed that endogenous 
uncleaved PS holoproteins were associated with the nuclear envelope whilst PS NTF 
and CTF fragments were associated with post ER membranes and the intermediate 
compartment but not downstream of the cis-Golgi (Annaert et al., 1999).  These 
studies are in line with the notion that export from the ER involves the 
endoproteolysis of presenilin holoprotein, probably at the ER, to generate the 
catalytically active NTF and CTF fragments of presenilin which can then exit the 
ER.  The localisation of γ-secretase can also be altered throughout development.  
The majority of γ-secretase components are found outside lipid rafts during 
embryonic stages which then translocate to lipid raft rich regions during postnatal 
stages (Vetrivel et al., 2005; Vetrivel et al., 2004).  It is not clear if this switch is a 
regulatory mechanism that enables different substrates to be cleaved by γ-secretase 
during different stages in development.    
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PS1 and PS2 are found in CNS neurons and glial cells as well as in other tissue 
including muscle, lung and spleen (Lah et al., 1997; Lee et al., 1996).  Hippocampal 
and cortical pyramidal neurons have particularly high expression levels of PS1 (Page 
et al., 1996).  Recent immunofluorescence study has shown that PS1 exhibits good 
co-localisation to Homer and Bassoon suggesting that it is found at mature synapses 
in rat dissociated culture systems (Inoue et al., 2009).  In mature mouse hippocampal 
neurons immunofluorescence labelling has shown strong co-localisation between 
PS1 and MAP2 indicating its presence in dendritic regions.  Moreover, the PS1 
signal is also strong in the cell body and axons, where the staining pattern is similar 
to presynaptic puncta labelling (Cook et al., 1996; Fraser et al., 2000; Lah et al., 
1997).  A study using immunolabelling methods for electron microscopy showed 
that PS1 is located at the postsynaptic density of spines and also some synaptic 
vesicles in the presynaptic bouton of neurons (Lah et al., 1997).  Other reports have 
also found that PS1 is associated with synaptic vesicles, dense core vesicles, 
somatodendritic clathrin-coated vesicles, synaptic adhesion sites and neuronal 
growth cones (Beher et al., 1999; Efthimiopoulos et al., 1998; Frykman et al., 2010; 
Thinakaran and Parent, 2004).  However, a separate study showed no colocalisation 
between PS1 and the synaptic vesicle marker synaptobrevin, and also a lack of 
punctate staining in hippocampal axons (Annaert et al., 1999).   
 
 
1.3.5 Subcellular location of γ-secretase activity 
 
Despite the high levels of γ-secretase components in the ER, it is not clear if this 
subcellular compartment is the main site of γ-secretase processing in the cell.  
Processing of certain substrates including APP and Notch by γ-secretase is 
understood to take place in compartments located downstream of the ER, most 
probably at or near the cell surface (Cupers et al., 2001; Koo and Squazzo, 1994; 
Sisodia et al., 2001).  However, the majority of the studies examining the location of 
presenilin has focused mainly on the site of protein expression and assume that its 
expression is correlated with γ-secretase activity.  One issue with this assumption is 
that only a limited amount of synthesised PS is incorporated into active γ-secretase 
complexes suggesting that expression may not be a good indicator of activity (Dries 
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and Yu, 2008; Lai et al., 2003; McCarthy et al., 2009).  More recent biochemical 
studies using biotin surface labelling have shown that γ-secretase activity is found on 
the plasma membrane of Hela and CHO cells suggesting that active γ-secretase 
complexes can reside at the cell surface.  Quantitative western blot analysis indicated 
that approximately 6% of γ-secretase protein (PS1 NTF) is found on the cell surface 
(Chyung et al., 2005).  Furthermore, γ-secretase cleavage assays also showed that the 
surface population of γ-secretase accounts for 6.1% of the total cellular γ-secretase 
activity (Chyung et al., 2005).  This study suggests that a small but significant 
amount of active γ-secretase can be isolated from the cell membrane, consistent with 
the role of PS1 in cleaving cell surface proteins such as APP, Notch, and cadherins.  
It is currently unclear which intracellular compartments may provide the majority of 
the cellular γ-secretase activity.   
 
An elegant study by Kaether and colleagues (2006) tried to tackle this question by 
engineering a green fluorescent protein (GFP) tagged version of the γ-secretase 
substrate β-CTF (GFP-β-CTF) (the membrane associated fragment that remains after 
β-secretase cleavage of APP), which upon cleavage by γ-secretase, gives rise to two 
protein fragments, Aβ peptide and GFP tagged AICD (GFP-AICD) (Kaether et al., 
2006a; Kaether et al., 2006b).   GFP-AICD fragments are not membrane associated 
and diffuse within the intracellular milieu upon generation.  Visualisation of diffuse 
cytoplasmic GFP signal is a positive sign of GFP-AICD production by γ-secretase 
cleavage of GFP-β-CTF.  However blocking GFP-β-CTF processing using a specific 
γ-secretase inhibitor, DAPT causes the GFP component to remain associated with 
the intracellular membrane compartment.  Hence the GFP signal between γ-secretase 
processed (diffuse) and γ-secretase unprocessed (membrane associated) β-CTF can 
be readily distinguished.  By inhibiting the traffic of GFP-β-CTF through different 
subcellular compartments in the secretory pathway, the sites of γ-secretase activity 
can be assessed.  If γ-secretase activity is present in a subcellular compartment where 
transport has been blocked, then the GFP signal would be cytoplasmic and diffuse.  
On the other hand if γ-secretase activity is not present at a particular subcellular 
compartment then the GFP signal would be membrane associated and highlight the 
intracellular compartment where γ-secretase cleavage is absent.   Inhibition of 
transport from the ER (using Brefeldin A), Trans Golgi Network (TGN) (using a 
20oC temperature block) and Golgi (using monensin) resulted in membrane 
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associated GFP-β-CTF signal suggesting that there is no γ-secretase activity in these 
subcellular compartments.  The only cellular region where diffuse GFP signal was 
observed was at the plasma membrane. This study shows that the ER, TGN and 
Golgi are not sites of γ-secretase cleavage whereas the plasma membrane is a site of 
γ-secretase activity (Kaether et al., 2006b).  This study highlights the discrepancy 
between subcellular location of γ-secretase components and the site of γ-secretase 
activity.  Other subcellular compartments where γ-secretase activity had been 
previously reported such as endosomes and lysosomes were not tested in this study 
(Chen et al., 2000; Koo and Squazzo, 1994; Vetrivel et al., 2004).  Recent 
subcellular fractionation studies showed that γ-secretase activity can be found in 
synaptic membrane, synaptic vesicle and endosomal fractions (Frykman et al., 2010).  
Further studies will be required to determine if there are other intracellular sites of γ-
secretase activity.  Additionally, it will be important to identify whether different 
substrates are cleaved at different subcellular sites within neurons.    
 
γ-secretase inhibitors have also been shown to influence presenilin localisation.  
Application of cell permeable inhibitors L-685,458 (also known as inhibitor X) or 
compound E, led to an elevation of cell surface PS1 and PEN-2 by enhancing the 
translocation step from the Golgi and TGN to the plasma membrane (Wang et al., 
2004).  This result suggests that inhibition of γ-secretase activity may modulate 
expression of γ-secretase components at the plasma membrane.  Interestingly a cell 
impermeable γ-secretase inhibitor, MRL631, that could block Notch processing 
(presumably at the cell surface) by γ-secretase, did not alter expression of surface 
presenilin 1 suggesting that intracellular but not extracellular γ-secretase activity was 
required for the trafficking of PS1 to the cell surface (Wang et al., 2004). 
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1.3.6 γ-secretase and regulated intramembraneous proteolysis 
of transmembrane substrates 
 
γ-secretase is a unique protease, not only because it is a multi component complex 
but because the proteolytic cleavage occurs within the transmembrane region of its 
substrates, a process termed regulated intramembrane proteolysis (RIP).  Because of 
this property, γ-secretase is classified as a member of the intramembrane cleaving 
protease (I-Clip) family which includes serine protease rhomboid, signal peptide 
peptidase (SPP) and metalloprotease S2P (Beel and Sanders, 2008; Kopan and 
Ilagan, 2004; Steiner and Haass, 2000; Wolfe and Kopan, 2004).  Transition state 
inhibitors have shown that substrates interact with presenilin rather than with other γ-
secretase components (Kornilova et al., 2005), however it has remained unclear how 
presenilin could hydrolyse the peptide-bonds of substrates within the hydrophobic 
lipid environment of membranes.  Annaert and colleagues indicate that presenilin 
maintains a ring like structure that enables substrates to interact with the active zone 
of presenilin (Annaert et al., 2001).  Recent reports using negative stain and cryo 
electron microscopy have revealed greater insights into the structure of presenilin.  
Using protein obtained from cultured cells, presenilin was found to have a spherical 
structure of approximately 10 nm in diameter with an internal compartment which 
enabled water molecules to enter and aid intramembraneous proteolysis (Lazarov et 
al., 2006; Ogura et al., 2006; Osenkowski et al., 2009).  The water cavity was located 
within TM 6 and 7, which contains the active zone region and the aspartate residues 
required for γ-secretase activity (Sato et al., 2006; Tolia et al., 2006).    Hence this 
cavity contains the necessary elements for RIP.   
 
Nearly all substrates of γ-secretase are type 1 transmembrane proteins with an 
extracellular region comprised of less than 300 amino acids (Annaert and De 
Strooper, 2002; Struhl and Adachi, 2000).  The truncated extracellular region is 
generated by pre–processing of the extracellular domain by other cellular proteases 
such as α and β secretase to induce the release of the ectodomain.  Truncated 
substrates initially bind to the γ-secretase complex at a site near the presenilin active 
zone prior to undergoing RIP (Kornilova et al., 2005).  Surprisingly the substrates do 
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not appear to have any shared sequence motif (Annaert and De Strooper, 2002; 
Struhl and Adachi, 2000).   
 
γ-secretase can perform RIP at three different sites within the transmembrane region 
of substrates, known as the γ, ζ and ε-sites.  The ε-site is located closest to the 
intracellular C-terminal region of the membrane.  Cleavage at this site gives rise to 
intracellular fragments such as AICD and NICD from APP and Notch respectively 
(see Ebinu and Yankner, 2002; Gu et al., 2001; McCarthy et al., 2009; Weidemann 
et al., 2002; Wolfe and Guenette, 2007).  The ζ-site is located 3 amino acids closer to 
the N-terminus from the ε-site and the γ site is located 3 amino acids up from the ζ-
site and closest to the N-terminus/ extracellular region (see Steiner et al., 2008).  For 
APP, it is cleavage at the γ-site that is necessary for generating Aβ40 and Aβ42, the 
major Aβ peptides released during physiological conditions and AD pathogenesis, 
respectively (Brouwers et al., 2008).  The presence of three different sites for RIP 
explains the heterogeneity of peptide fragments generated by γ-secretase cleavage, 
and why a range of different Aβ fragment sizes are generated from APP. It is 
currently unclear if all substrates are cleaved at all three sites like in the case of APP 
or if there is preferential cleavage at a particular site (s).   
 
Understanding the mechanisms and components involved in the regulation of γ-
secretase activity will hopefully provide insights and enable the design of effective 
therapeutic strategies for treatment of AD.  One recent report showed that siRNA 
knock down of the accessory cargo protein TMP21 could selectively enhance 
cleavage at γ-sites whilst leaving ε-cleavage sites undisturbed.  This means that 
TMP21 could selectively modulate Aβ production whilst leaving NICD and AICD 
generation (and associated nuclear signalling pathways) from Notch and APP 
respectively intact (Chen et al., 2006).  Further research is required to determine if 
there are other regulators of γ-secretase cleavage at specific sites.   
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1.4 Other cellular secretases 
 
 
In addition to γ-secretase, the roles of two other cellular secretases have also been 
heavily investigated in recent years.  The main reason for the interest in α and β 
secretase, like γ-secretase, comes from their well documented involvement in the 
cleavage of APP and the generation of Aβ (Lammich et al., 1999; Vassar et al., 
1999).  As already discussed, both α and β secretase process APP prior to γ-secretase 
cleavage, to generate APP C-terminal fragments which act as substrates for γ-
secretase.  Cleavage of APP by α and β secretase, gives rise to the N-terminus of p3 
and Aβ, respectively.  The next section provides a brief overview of the properties of 
α and β secretase.   
 
 
1.4.1 α-secretase 
 
The molecular identity of the component(s) which underlies α-secretase cleavage of 
APP remains to be fully resolved.  Studies suggest that the enzymatic activity is 
attributed to several different candidates including members of a disintegrin and 
metalloprotease family (ADAM) such as ADAM 10, ADAM 9, ADAM 19, ADAM 
17 (also known as tumour necrosis factor-α converting enzyme (TACE)) (Allinson et 
al., 2003; Asai et al., 2003; Buxbaum et al., 1998b; Kojro and Fahrenholz, 2005; 
Lammich et al., 1999; Parvathy et al., 1998).  Many members of the ADAM family 
of proteins contain a cysteine-rich disintegrin domain, a pro-domain, a 
transmembrane domain, a cytoplasmic tail, and a metalloproteinase domain which 
contains the HEXGHXXGXXHD consensus sequence (Endres and Fahrenholz, 
2010; Parkin et al., 2004).  The catalytic activity of ADAM proteins derives from the 
metalloproteinase domain whilst the pro-domain is important for maintaining the 
correct structural organisation.  As suggested by the name, the disintegrin domain is 
important for interaction with extracellular matrix proteins, integrins, and the 
cysteine residues may be required for interactions with other substrates (Parkin et al., 
2004). Currently it is not known what contribution each of these proteins provides to 
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total cellular α-secretase activity.  However as multiple proteins are potentially 
implicated, designing specific inhibitors has been particularly challenging.   Studies 
have shown that cleavage of APP by α-secretase takes place at the plasma membrane 
of neurons (Parvathy et al., 1999).  In addition to processing of APP, other α-
secretase substrates have also been identified and include prion protein PrP, ephrins, 
N-cadherin, Notch, tumour necrosis factor-α, transforming growth factor-α and 
APLP2 (see Endres and Fahrenholz, 2010; Pruessmeyer and Ludwig, 2009).  Like 
substrates of γ-secretase, there is also a lack of sequence homology amongst α-
secretase substrates.  The main similarity between different α-secretase substrates is 
the presence of a α-helix structure close to enzymatic cleavage site, which is 
approximately 12-16 amino acids from the plasma membrane (Sahasrabudhe et al., 
1993; Sisodia, 1992).   
 
 
1.4.2 β-secretase 
 
The identity of β-secretase is better understood than that of α-secretase.  Over a 
decade ago, multiple labs independently reported using different techniques the 
cloning of the enzyme underlying β-secretase activity, beta site APP-cleaving 
enzyme 1 (BACE-1) (but also known as aspartyl protease 2 (Asp2) and membrane-
anchored protease of the pepsin family (memapsin 2) (Cai et al., 2001; Hussain et al., 
1999; Lin et al., 2000; Sinha et al., 1999; Vassar et al., 1999; Yan et al., 1999).  
BACE1 is a type 1 transmembrane aspartyl protease of 501 amino acids in length 
and contains a N-terminus signal peptide (amino acids residues (a.a) 1-12), a 
preprotein domain (a.a 22-45), a catalytic domain (a.a 45-459), 2 conserved aspartic 
protease motifs (DTGS at residues 93-96 and DSGT at a.a 289-292) and a C-
terminal extension with a transmembrane domain (a.a. 460-477) and a cytoplasmic 
tail (Selkoe and Schenk, 2003).  BACE1 is predominately expressed in neurons and 
whilst its subcellular localisation is still under debate, reports have shown that 
BACE1 is located in early endosomes and the trans-Golgi network, cellular 
compartments that provide the more acidic environment proposed to be required for 
optimal β-secretase activity (Laird et al., 2005; Vassar, 2004).   Knock-out mice 
studies have shown that β-secretase cleavage is involved in APP processing.  
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Crossing BACE-1 knockout animals with mutant transgenic mice overexpressing 
APP lead to an absence of Aβ generation, providing unequivocal evidence that 
BACE-1 is necessary for Aβ production (Luo et al., 2001).    Unlike γ-secretase 
knock-out mice, BACE1 knock-out mice are viable and exhibit normal behaviour 
(Cai et al., 2001; Luo et al., 2001; Roberds et al., 2001).  BACE-1 is also implicated 
in the cleavage of a wide range of membrane associated proteins including 
neuregulin-1 (NRG-1), neuregulin-3 (NRG-3), voltage-gated sodium channel β2 
subunit (SCNβ2), P-selectin glycoprotein ligand-1 (PSGL-1) and sialyl transferase 
ST6Gal (see for review: De Strooper et al., 2010).  Genetic screens have also 
identified a homologue of BACE-1, BACE-2 which shares 68% sequence similarity 
(Bennett et al., 2000; Solans et al., 2000; Yan et al., 1999).    Expression of BACE-2 
in the CNS is low and may not provide a major contribution to β-secretase activity in 
the brain (Bennett et al., 2000; Solans et al., 2000; Yan et al., 2001).   
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1.5 Cellular functions of γ-secretase 
 
 
In addition to presenilins role in AD, studies have also shown that presenilins and 
associated γ-secretase activity is important for modulating different cellular 
functions.  γ-secretase is a promiscuous cellular protease which can cleave a wide 
range of substrates associated with many different cellular processes including 
trafficking, signal transduction, cell adhesion, calcium homeostasis, apoptosis and 
synapse function (Beel and Sanders, 2008; Hass et al., 2009; McCarthy et al., 2009; 
Parks and Curtis, 2007; Vetrivel et al., 2006; Wakabayashi and De Strooper., 2008).  
Table 1.1 shows a summary of substrates and protein interactors of γ-secretase and 
proposed signalling processes.  Additionally, not only can γ-secretase cleavage of 
substrates directly alter signalling pathways, but intracellular domain fragments such 
as NICD from Notch, AICD from APP and CICD from cadherins may also play a 
role in membrane to nuclear signalling pathways (see McCarthy et al., 2009).  With 
the wide range of substrates and the presence of multiple γ-secretase cleavage sites, 
understanding the biology of presenilin and γ-secretase seems complex.  Many of the 
substrates listed were identified using in vitro biochemical methods and the 
functional physiological significance of most of these interactions in neuronal 
systems remains to be shown.   The following section will discuss the role of a few 
selected γ-secretase substrates and their proposed cellular functions. 
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Table 1.1: γ-secretase interacting proteins or substrates and proposed cellular 
functions of presenilin association 
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APLP-1 + 2 X X   .   X    
ApoER2     X   Lipoprotein receptor 
APP X X  X X X   
β-catenin X X   X X   
Cadherin (E+N) X    X X   
Calsenilin   X      
CD43 + 44 X    X    
CSF-1R  X     X  
DCC  X   X   Netrin-1 receptor 
Delta  X   X   Notch pathway ligand 
Ephrin-B1, B2  X      Eph receptor ligands 
ErbB4     X  X Apoptosis 
γ-protocadherins X    X    
GluA3      X  Glutamate receptor 
subunit 
Insulin receptor     X  X  
Jagged  X   X   Notch pathway ligand 
LAR X X      Receptor protein 
tyrosine phosphatase 
LRP1     X   Endocytosis 
Megalin/ LRP2     X   LDL receptor 
Nectin-1 α X X      Notch pathway ligand 
Notch     X   Notch receptor 
NRADD        Apoptosis 
NRG-1  X   X   CNS development 
p75NTR  X   X   Neurotrophin receptor 
SCNβ2 X       Migration regulator 
SorLA, Sortilin     X X   Sorting receptors 
Sorcin   X      
Syntaxin 1A + 5    X     
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The table was adapted from information from the following reviews: McCarthy et 
al., 2009; Parks and Curtis, 2007; Vetrivel et al., 2006; Wakabayashi and De 
Strooper., 2008.  See reviews for original references. Abbreviations: APLP, amyloid 
precursor-like protein; ApoER2, apolipoprotein E receptor-2; APP, amyloid 
precursor protein; CSF-1R, colony-stimulating factor 1 receptor; DCC, deleted in 
colorectal cancer; GluA3, glutamate receptor subunit 3; LAR, leukocyte-common 
antigen related; LRP, low density lipoprotein receptor-related protein; NRADD, 
neurotrophin receptor alike death domain protein; NRG-1, neuregulin-1; p75NTR, p75 
neurotrophin receptor; SCNβ2, sodium channel subunit β2. 
 
 
 
1.5.1 Nuclear signalling and developmental regulation by 
Notch/NICD and other γ-secretase associated transcriptional 
regulators 
 
Numerous studies have established that PS1 is implicated in the proteolytic cleavage 
of Notch.  Notch is a type 1 integral transmembrane protein with an N-terminus 
domain which contains extracellular calcium binding Notch/ Lin12 regions and 
epidermal growth factor (EGF) repeats.  The C-terminal intracellular tail contains 
tandem ankyrin domains and a PEST domain (Fortini, 2002).   
 
Notch is predominantly located on the cell surface following its initial production in 
the ER and transport to the plasma membrane.  During the passage to the cell 
surface, Notch is processed in the trans-Golgi region by a member of the furin family 
to produce two closely associated fragments, which is the mature form of Notch.  
Once at the cell surface, Notch interacts with Notch ligands, members of the 
Delta/Serrate/Lag-2 family including Delta and Jagged which are located on adjacent 
cells.  Ligand binding to Notch acts as a trigger for two subsequent proteolysis 
reactions.  Firstly, α-secretase cleavage by a disintegrin and metalloprotease domain 
family protein gives rise to an intramembrane and an ectodomain fragment.  
Secondly, whilst the ectodomain fragment gets released extracellularly, the 
intramembrane domain undergoes γ-secretase processing to generate a cytoplasmic 
protein, Notch intracellular domain (NICD).  Upon generation, NICD traffics to the 
nucleus to interact with the Rel-family transcription factor, C-promoter-binding 
factor (CBF1 in mammals; Drosophilia equivalent is Suppressor of hairless (Su-H); 
Chapter 1: Introduction 
 54
C. elegans equivalent is LAG-1) and activate gene transcription (Chan and Jan, 
1999; Louvi and Artavanis-Tsakonas, 2006; Schroeter et al., 1998).  NICD is 
believed to play a role in a range of cell functions including regulating nuclear signal 
transduction, cell fate and development (Bray, 2006; De Strooper et al., 1999; 
Fortini, 2002; Mumm et al., 2000; Mumm and Kopan, 2000; Struhl and Greenwald, 
1999; Ye et al., 1999). 
 
Strong evidence that the presenilins were involved in Notch signalling came from 
knock-out mice studies.  Western blot analysis and pulse chase experiments showed 
that NICD production was essentially absent from PS1 knock-out neurons (De 
Strooper et al., 1999).  Furthermore the lack of NICD production observed in PS1 
knock-out cells could be mimicked by application of several γ-secretase inhibitors to 
wild type cells, indicating that γ-secretase activity of PS1 was specifically required 
for generation of NICD (De Strooper et al., 1999).  Morphological analysis showed 
that constitutive PS1 knock-out mice (on PS2 background) exhibited severe 
developmental defects during late embryonic ages including disturbed somitogenesis 
and segmentation and impairment in axial skeletal development (De Strooper et al., 
1998; Shen et al., 1997; Wong et al., 1997) which was very similar to the phenotype 
observed in Notch knock-out mice (Conlon et al., 1995; Swiatek et al., 1994).  
Interestingly, Wong et al., (1997) also showed that PS1 levels may directly influence 
expression levels of Notch1 and Dll1 (Notch1 ligand) mRNA which were decreased 
in PS1-/- mice compared to control animals (Wong et al., 1997).  This data suggests 
that the defects in embryonic development observed in PS1 mice are due to PS1 
processing of Notch.   
 
Studies in other model systems showed similar findings regarding γ-secretase 
processing of Notch.  In Drosophila, when the presenilin homolog gene was 
inactivated, such mutants exhibited a Notch knock-out phenotype with impaired 
Notch nuclear signalling and morphological defects during development (Selkoe, 
2000).   Studies of mutant Sel-12 in C.elegans, which shares 50% homology with 
human PS1 also has defects in Notch signalling which affects oviposition (Jarriault 
and Greenwald, 2002).  Together, these studies show that the regulation of Notch 
signalling by presenilins is highly conserved.   
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As Notch signalling is involved in regulating nuclear transcription and certain 
signalling cascades, blocking γ-secretase processing of Notch may generate many 
undesired effects and this is the main reason why γ-secretase is deemed an unsuitable 
pharmacological target for AD therapeutics.  However, one study showed that in 
adult PS1 conditional knock-out brain, the expression of Notch effector genes Hes1, 
Hes5, and Dll1 are no different to wild type (Yu et al., 2001).  This is in contrast to 
studies using constitutive PS1 knock-out animals and shows Dll1 levels are reduced 
in the embryo (Wong et al., 1997).  This suggests that potentially different regulatory 
mechanisms may be used in adult and embryonic development with adult Notch 
processing potentially not requiring PS1 activity.  If so then use of γ-secretase 
inhibitors in adult animals may bypass the deleterious developmental effects of 
eliminating PS1/γ-secretase activity in the embryo.  Further studies will be required 
to investigate the cellular effects of differential developmental processing of Notch 
by γ-secretase.   
 
Studies have also shown that ErbB4, a transmembrane receptor tyrosine kinase 
implicated in cell growth, proliferation and differentiation can be sequentially 
processed by α-secretase and γ-secretase to generate B4-ICD which can translocate 
to the nucleus and potentially regulate transcriptional processes (Ni et al., 2001; 
Sisodia and George-Hyslop, 2002; Wong et al., 1997). 
 
 
1.5.2 Cell signalling and cell adhesion through β-catenin and 
cadherins 
β-catenin is implicated in modulating a range of different cellular processes through 
its association with Wnt intracellular signalling cascades (De Ferrari and Inestrosa, 
2000; Fraser et al., 2000).   Wnts are secreted glycoprotein growth factors involved 
in regulating many different neuronal processes including axon guidance and 
regulation of neuronal and synapse morphology (Salinas and Zou, 2008). Upon 
binding its receptor Frizzled at the cell surface, Wnt can activate a signalling cascade 
which blocks glycogen-synthase-kinase-3β (GSK-3β) activity and limits the 
phosphorylation of β-catenin.  This process stabilises cellular β-catenin by 
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preventing its degradation.  Unphosphophorylated β-catenin can translocate to the 
cell nucleus and interact with the LEF/TCF (T cell-specific transcription factor 1) 
transcriptional regulators which trigger activation of cyclin D1, metalloproteases and 
other Wnt target genes.   
However, in the absence of Wnt, a separate signalling cascade is stimulated.  In this 
instance, cytoplasmic β-catenin can be phosphorylated by GSK-3β which promotes 
its interaction with Axin, adenomatous polyposis coli and β-transducing repeat-
containing protein, and initiates the process of β-catenin proteasomal degradation.  
This process prevents β-catenin from activating Wnt target genes and subsequent 
nuclear signalling.   
 
Biochemical studies have revealed that the cytoplasmic loop of presenilins can 
interact with β-catenin as well as other armadillo-repeat proteins including δ-catenin 
(Levesque et al., 1999; Murayama et al., 1998; Yu et al., 1998; Zhou et al., 1997).  
However, different studies have indicated that presenilin can stabilise, destabilise or 
have no effect on β-catenin cellular levels; calling into question the functional 
significance of the interaction between these two proteins on Wnt associated nuclear 
signalling (Hass et al., 2009; Nishimura et al., 1999; Zhang et al., 1998b).  Presenilin 
can also interact with GSK-3β, leading to the phosphorylation of PS1 at amino acid 
residues 353 and 357 which reduces the interaction between PS1 and β-catenin 
(Kirschenbaum et al., 2001).   
 
Another proposed role for β-catenin is in regulating cell-cell interactions by acting as 
a linker molecule between cadherins, cell adhesion molecules located at the cell 
surface and α-catenin, an intracellular protein which interacts with the actin 
cytoskeleton (Goda, 2002; Okuda et al., 2007).   Some evidence suggests that 
presenillins can be found at the plasma membrane in a complex with β-catenin and 
N- (neuronal, in neuronal cells) and E- (epithelial, in non-neuronal cells) cadherins 
(Baki et al., 2001; Georgakopoulos et al., 1999; Marambaud et al., 2002; Marambaud 
et al., 2003; Uemura et al., 2003).  Marambaud and colleagues find that γ-secretase 
cleavage of E-cadherin disrupts cadherin-β-catenin interactions and initiate 
disassembly of the adherens junctions of fibroblasts.  γ-secretase inhibitors could 
prevent the calcium (ionomycin) stimulated disruption of cell-cell adhesion 
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(Marambaud et al., 2002).   This study suggests that γ-secretase may act as a 
negative regulator of cell adhesion through its interactions with cadherins.  However, 
another study proposes that PS1 interaction with N-cadherin causes dissociation of 
p120-catenin and β-catenin from N-cadherin and enhances the interaction between 
N-cadherin and γ-catenin to promote synapse stabilisation and maturation in chick 
cilary neurons (Rubio et al., 2005).  It remains to be determined whether N-cadherin, 
β-catenin and PS1 interactions can modulate central synapse formation and 
stabilisation.   
 
Presenilin is also involved in the processing of SCNβ2, a member of the IgCAM 
superfamily which may act as a cell adhesion molecule.  Block of γ-secretase activity 
using selective γ-secretase inhibitor DAPT resulted in impaired cell-cell adhesion in 
Chinese hamster ovary cells overexpressing SCNβ2.  This result suggests that γ-
secretase processing of SCNβ2 is also important for regulation of cell-cell contacts 
(Kim et al., 2005). 
 
 
1.5.3 γ-secretase independent forms of cellular regulation by 
presenilins 
 
Recent studies have revealed that presenilins can modulate different cellular 
functions in a manner that is independent of its catalytic γ-secretase activity.  Most 
studies tend to associate γ-secretase independent functions of presenilin with the 
“inactive” holoprotein form of presenilin (as opposed to the “active” N and C 
terminal fragments that occur after presenilin endoproteolysis).  It is currently 
unclear what proportion of cellular presenilin may act in this way, but this feature of 
presenilins may provide a function for the population of presenilin proteins that is 
not incorporated in the γ-secretase complex.  The role of presenilins as ER calcium 
leak channels is discussed below.  Other γ-secretase independent actions of 
presenilins are extensively discussed in the following reviews (Hass et al., 2009; 
Selkoe and Wolfe, 2007). 
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1.5.4 Presenilin and regulation of intracellular calcium  
 
Much attention has surrounded the hypothesis that changes in intracellular calcium 
may be an underlying factor for neuronal loss in AD (Bezprozvanny and Mattson, 
2008; Green and LaFerla, 2008; Khachaturian, 1989; LaFerla, 2002; Mattson, 2010).  
Many FAD mutations in PS1 and PS2 have been associated not only with Aβ 
deposition but also dysregulation of intracellular calcium homeostasis (LaFerla, 
2002).  Indeed there are reports that show that these two factors are linked.  Some 
studies indicate that Aβ peptides can elevate intracellular calcium in cultured cells, 
providing experimental evidence that calcium overload may be a potential 
mechanism for AD pathogenesis (Demuro et al., 2005; Guo et al., 1999; Mattson, 
1992; Mattson et al., 1993). However, intracellular calcium is also required for a 
wide range of cellular processes in neurons (see for review: Berridge et al., 1999; 
Berridge et al., 2000; Berridge et al., 2003).  
 
Maintenance of intracellular calcium concentration is achieved by balancing the 
amount of calcium entering and leaving the cell through the plasma membrane and 
the amount being sequestered and released from intracellular ER stores.   Calcium 
from the extracellular milieu can enter the cell through voltage-gated calcium 
channels and voltage-gated ligand channels such as NMDA receptors, GluA2-
lacking AMPA receptors and acetylcholine receptors located on the plasma 
membrane (Berridge et al., 2003; LaFerla, 2002).  Conversely, calcium ATPases 
such as the plasma membrane calcium ATPase and sodium calcium exchanger are 
responsible for transporting calcium from cytoplasmic regions to the extracellular 
space (Strehler and Zacharias, 2001).   Intracellular calcium buffers such as 
calretinin, calbindin and parvalbumin also help maintain basal calcium 
concentrations within a range of a few ten - hundreds nM (Baimbridge et al., 1992).  
Internal ER calcium stores actively transports calcium from the cytoplasm into the 
lumen of the ER through the sarco/endoplasmic reticulum calcium ATPase 
(SERCA) pump.  Conversely, calcium is released from ER stores into the cytoplasm 
through inositol-1,4,5-trisphosphate receptors (IP3R) and ryanodine receptors (RyR) 
located on the ER membrane.  Calcium release from ER stores is important for 
modulating IP3 signalling, calcium-induced calcium release (CICR) and capacitative 
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calcium entry (CCE), which involves opening of plasma membrane store-operated 
calcium channels to enable calcium influx to replenish ER calcium stores (Bojarski 
et al., 2008; Verkhratsky, 2002).   
 
Exisiting evidence has shown that presenilins are implicated in modulating 
intracellular calcium homeostasis under physiological conditions and in AD 
(Bezprozvanny and Mattson, 2008; Bojarski et al., 2008; Green and LaFerla, 2008; 
Thinakaran and Parent, 2004).   Transgenic mice studies have shown that presenilins 
can modulate calcium stores either by regulating the SERCA pump (Green et al., 
2008), IP3R (Cheung et al., 2008; Cheung et al., 2010; Stutzmann et al., 2004), RyR 
(Chakroborty et al., 2009; Chan et al., 2000; Lee et al., 2005; Stutzmann et al., 2007; 
Zhang et al., 2009), sorcin (a ryanodine binding protein) (Pack-Chung et al., 2000), 
calsenilin (a calcium binding protein) (Buxbaum et al., 1998a; Leissring et al., 2000) 
and also by acting as a passive calcium leak channel in the ER (Nelson et al., 2007; 
Tu et al., 2006).   
 
By making single channel recordings from reconstituted bilayers expressing PS1 
proteins, Tu et al., (2006) propose that wild type PS1 holoprotein can act directly as 
a low conductance calcium leak channels in the ER and thus play a role in the 
regulation of intracellular calcium stores (Tu et al., 2006).  Overexpression of a PS1 
D257A mutant lacking both γ-secretase activity and the ability to undergo 
endoproteolysis was still able to form a functional leak channel, providing evidence 
that the holoprotein form of PS1 was specifically involved (Tu et al., 2006).   Leak 
channels could also be formed in APH-1 null cells which are deficient in active γ-
secretase complexes.  This report provides an insight into the role of PS1 in the ER 
but further experiments will be required to determine if endogenous PS1 may play a 
similar role in neuronal systems. Tu and colleagues (2006) also showed that FAD 
mutant presenilin constructs, PS1-M146V and PS2-N141I, did not have the ability to 
form functional leak channels leading to calcium accumulation and overload in the 
ER.  Studies of other PS1 mutants also show similar disruptions in intracellular 
calcium signalling (Green et al., 2008; Lee et al., 2005).  This suggests that either a 
dysregulation of intracellular calcium levels or calcium signalling may be a potential 
pathogenic mechanism in AD (LaFerla, 2002).   
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One recent study showed using live calcium imaging that intracellular calcium was 
reduced in presenilin double knock-out cells (Zhang et al., 2009).  The authors found 
that the effect on calcium signalling could be mimicked by application of ryanodine 
to wild type neurons suggesting that presenilins are involved in modulating calcium 
release from intracellular stores.  Interestingly these double knock-out animals also 
had impaired short and long term plasticity (paired-pulse facilitation and LTP) when 
presenilin 1 and 2 was eliminated from the presynaptic CA3 cell at hippocampal 
CA3-CA1 synapses.  Together this result suggests that presenilins may modulate 
intracellular calcium concentration through interaction with RyR which in turn may 
affect synaptic plasticity.  However, it is unclear whether the mechanism by which 
presenilin regulates intracellular calcium through RyR is dependent or independent 
of γ-secretase activity of presenilins, and this point will need to be addressed.    
 
Presenilins can also regulate CCE.  CCE enables depleted intracellular ER stores to 
be replenished by calcium influx through store-operated channels in the plasma 
membrane (Herms et al., 2003; LaFerla, 2002; Ris et al., 2003; Yoo et al., 2000).  
Studies have shown that CCE is depressed in several FAD mutations and associated 
with an increase in ER calcium (Smith et al., 2002; Yoo et al., 2000).  Presenilin 
associated regulation of CCE was shown to involve both γ-secretase dependent and 
γ-secretase independent actions (Akbari et al., 2004).  These experiments 
demonstrate that presenilin may modulate intracellular calcium through a wide range 
of possible signalling mechanisms and emphasises the need to gain a greater 
understanding the role of presenilin in maintaining calcium homeostasis.   
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1.6 The role of presenilin at the synapse 
 
 
Insights into the potential role of presenilins in modulating synapse dysfunction and 
degeneration during AD may be gained by understanding the role of presenilins in 
modulating normal synapse function.  Although some studies have started to 
investigate the functional role of presenilin during physiological states, currently 
there are still a lot of unknowns.  This section will describe some of the main 
properties of synapses and provide a summary of past studies to date that have 
focussed on the role of presenilins in modulating synapse function. 
 
 
1.6.1 The properties of a synapse 
 
Synapse structure 
 
The term synapse was originally coined by Charles Sherrington in the late 19th 
century (Sherrington, 1897).   This term is used to describe the specialised functional 
intercellular connection from a presynaptic neuron onto a postsynaptic target, which 
in the CNS is usually another neuron.  The synapse is the site at which information 
transfer occurs through a process known as synaptic transmission.   Electron 
microscopy studies from the 1950’s revealed the key properties that define the 
morphology of chemical synapses in the CNS (Cowan et al., 2001; De Robertis and 
Bennett, 1955; Palay, 1956; Palay and Palade, 1955).  The presynaptic axonal 
bouton contains 10-100’s of small (approximately 20-50nm diameter) vesicles 
containing neurotransmitter which accumulate within a region of the bouton referred 
to as the active zone (Harris and Sultan, 1995; Schikorski and Stevens, 1997).   
Studies of single release sites revealed that the number of docked vesicles, which are 
primed and ready for release, are variable.  This typically ranges from 2-16 vesicles 
and is largely correlated to the size of the presynaptic bouton (Harris and Sultan, 
1995).  It is this pool of docked vesicles which is thought to morphologically 
represent the readily releasable pool (Schikorski and Stevens, 2001; Ziv and Garner, 
2004).   
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Opposite the presynaptic bouton is the postsynaptic compartment of a synapse.  The 
postsynaptic compartment of an excitatory synapse is easily recognised by the 
electron dense thickening of membrane which is often associated with an actin rich 
spine-like protrusion (Cowan et al., 2001).  The postsynaptic compartment of an 
inhibitory synapse is located on the dendritic shaft and is less distinctive at the 
ultrastructural level as the postsynaptic thickening is often absent (Sheng and 
Hoogenraad, 2007). The postsynaptic membrane contains postsynaptic receptors 
involved in neurotransmitter reception and signal propagation.  Together the 
intracellular actin cytoskeleton and associated scaffold proteins help maintain the 
structure of the postsynaptic compartment and a host of other proteins such as 
kinases, phosphatases and other molecules are implicated in intracellular signalling 
pathways (Scannevin and Huganir, 2000; Sheng and Hoogenraad, 2007). 
 
Separating the pre and the postsynaptic compartments is the synaptic cleft.  The 
synaptic cleft is approximately 20-24 nm in width and contains a dense matrix of 
proteins such as the extracellular domains of synaptic surface proteins emanating 
from pre and postsynaptic cells and cell adhesion molecules (Lucic et al., 2005; 
Zuber et al., 2005).  Cell adhesion molecules are involved in formation of synapses 
during development and maintenance of synapse structure in mature neuronal 
systems (Garner et al., 2002; Scheiffele, 2003).  Cell adhesion molecules can also 
co-ordinate structural changes in the pre and postsynaptic compartments of the 
synapse in response to different types of neuronal activity, hence playing a key role 
in modulating structural plasticity of the synapse.  The proteins within the cleft also 
help limit the diffusion of neurotransmitter away from the cleft, enabling a higher 
concentration of neurotransmitter to reach the postsynaptic site (Chua et al., 2010). 
 
 
Synaptic transmission 
 
Synaptic transmission is a process that enables information transfer and 
communication between cells in neural networks.  For fast (~100 µs) synaptic 
transmission, a series of co-ordinated events must occur.  Arrival of an action 
potential causes the membrane of the presynaptic bouton to become depolarised, 
leading to an influx of calcium through the opening of voltage gated calcium 
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channels (VGCC) located at the active zone.  There are two main classes of 
pharmacologically definable calcium channels involved in modulating presynaptic 
calcium influx, P/Q (CaV2.1) and N (CaV2.2) type calcium channels relevant to fast 
synaptic transmission.  These channels are closed at resting membrane potentials and 
rapidly activate upon depolarisation of the membrane.  The calcium influx through 
VGCC causes a transient rise in local intracellular calcium in the bouton. The 
calcium binds to synaptotagmin I, the main calcium sensor on synaptic vesicles 
(Geppert et al., 1994; Xu et al., 2009) and initiates the fusion of docked vesicles to 
the presynaptic membrane leading to vesicle exocytosis and neurotransmitter release.  
The neurotransmitter diffuses across the synaptic cleft and binds receptors on the 
postsynaptic neuron.   
 
There are two main classes of postsynaptic receptors; ionotropic and metabotropic 
receptors.  As implied by the name, ionotropic receptors are ion channels.  
Glutamatergic ionotropic receptors are non selective cation channels which enable 
conductance of potassium, sodium, and calcium ions, leading to cell depolarisation.  
GABAergic ionotropic receptors are ion channels that enable the passage of chloride 
ions and causes cell hyperpolarisation.  Metabotropic receptors are ligand activated 
G-protein coupled receptors which can indirectly associate with certain ion channels 
through intracellular second messenger signalling pathways.  It is generally accepted 
that the major excitatory neurotransmitter in the hippocampus is glutamic acid 
(glutamate) and the major inhibitory neurotransmitter is gamma-aminobutyric acid 
(GABA) (Sheng and Hoogenraad, 2007).   
 
Normal synaptic release of glutamate from excitatory boutons typically activates the 
α-amino-3-hydroxy-5-methyl-isoxazole-4-propionic acid (AMPA) and N-methyl-D-
aspartic acid (NMDA) ionotropic glutamate receptors (Andersen et al., 2007).  
Whereas stronger, high frequency stimuli is required for activation of metabotropic 
glutamate (1) receptors which are perisynaptically located (Batchelor and 
Garthwaite, 1997; Baude et al., 1993).  Under certain situations, glutamate can also 
spill-over and activate receptors on adjacent synapses (Kullmann and Asztely, 1998) 
or act on presynaptic autoreceptors. 
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AMPA receptors are homo or hetero oligomers composed of GluA1-4 subunits 
(Hollmann et al., 1989; Hollmann and Heinemann, 1994; Madden, 2002).  GluA1-2 
and GluA2-3 subunit arrangements are believed to be the most common 
combinations of AMPA receptors in the hippocampus (Wenthold et al., 1996).  The 
binding of glutamate to AMPA receptor subunits leads to activation of the ion 
channel and the generation of an inward excitatory postsynaptic current (EPSC).  
The kinetics of channel opening is very quick which gives rise to an EPSC with a 
fast rise time (a few hundred µ sec).  The EPSC depolarises the postsynaptic 
membrane.  An action potential can be generated if a large EPSP is formed or if 
multiple EPSPs summate to depolarise the cell beyond the threshold for action 
potential generation. Synaptic transmission during resting conditions mainly 
involves the AMPA receptor.  However, membrane depolarisation, for example by 
activation of AMPA receptors, can aid activation of the NMDA receptor (Andersen 
et al., 2007).   
 
NMDA receptors are heteromeric complexes consisting of NR1 and NR2A-D 
subunits (Cull-Candy et al., 2001; McBain and Mayer, 1994).  The NMDA receptor 
is unique in that it requires two agonists for ligand associated receptor activation.  
NR2 subunits contain the glutamate binding site and the co-agonist glycine or D-
serine binds to NR1 subunits.  NMDA receptors are activated by a slightly different 
mechanism to AMPA receptors.  For activation not only do both ligand binding sites 
on the NR1 and NR2 subunits need to be occupied but membrane depolarisation is 
also required, meaning these receptors are also voltage activated.  
The pore of NMDA receptors is blocked by a magnesium ion at resting membrane 
potentials (Nowak et al., 1984).  It is this magnesium block that prevents the entry of 
ions through the NMDA receptor ion channel during basal conditions, such that the 
NMDA receptor does not significantly contribute to the postsynaptic current at 
resting membrane potentials.  However, depolarisation of the membrane by either 
activation of AMPA receptors or back propagating actions potentials enables the 
magnesium block to be released from the pore, allowing the influx of calcium ions 
and generation of a cation current.  The current generated through the NMDA 
receptor is much slower than that of AMPA currents, lasting up to a few hundred 
milliseconds.   This is because glutamate dissociates from the NR2 subunit fairly 
slowly and the receptor is therefore in the activated state for a relatively long period 
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of time.   NMDA receptors are also considered coincidence detectors as both 
presynaptic release and postsynaptic membrane depolarisation are needed for their 
activation.  NMDA receptors are highly permeable to calcium and provide a means 
for calcium entry in the cell.  Postsynaptic calcium influx is a necessary step in the 
activation of many different calcium dependent signalling cascades such as 
activation of calcium/calmodulin dependent protein kinase (CaMKII), a serine/ 
threonine protein kinase implicated in the induction of a form of synaptic plasticity 
known as long term potentiation (LTP) (Silva et al., 1992).   Studies showed that it is 
the NR2B containing NMDA receptors that are important for LTP, as this subunit 
binds to α-CaMKII with higher affinity than NR2A subunit (Barria and Malinow, 
2005).  This was further clarified through genetic inhibition of NR2B which led to 
impairment in LTP and contextual fear conditioning (Zhao et al., 2005).   
 
GABAA receptors are heteropentameric assemblies composed of a combination of 
subunits (which include α, β, γ, δ, ε, θ and π) arranged to form a chloride permeable 
ion channel (though some bicarbonate ions can also pass) (Mohler et al., 2005).  In 
the adult hippocampus, GABAA receptors are predominately found postsynaptically.  
Ligand-activation of GABAA receptors leads to an increase in chloride conductance, 
which gives rise to an inhibitory postsynaptic current and contributes to cell 
hyperpolarisation.  Hyperpolarisation of the cell has an inhibitory effect on cell 
excitability by setting the membrane potential further from the action potential 
generation threshold.   
 
Studies from Bernard Katz and colleagues identified the quantal nature of synaptic 
transmission from experiments conducted at the frog neuromuscular junction (NMJ) 
where the presynaptic terminal of a motoneuron contacts a postsynaptic muscle cell.  
Through intracellular recordings from the muscle endplate, Katz and colleagues 
revealed that end plate potentials (EPPs) can be evoked by stimulation of the 
presynaptic motoneuron.  However, a second population of end plate potentials was 
also observed in the absence of stimulation and termed miniature depolarising EPPs 
(mEPPs).  mEPPs were similar in waveform to evoked EPPs but smaller and more 
uniform in amplitude.  These mEPPs corresponded to the postsynaptic response to 
the stochastic release of a single “packet” (vesicle) of neurotransmitter called 
quantum from the presynaptic terminal in an action potential/ stimuli independent 
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manner (Del Castillo and Katz, 1954a; Del Castillo J. and Katz, 1954b; Fatt and 
Katz, 1952).  This result indicates that neurotransmitter release not only occurs in a 
synchronous manner with action potential stimulation but also in a spontaneous 
manner in the absence of action potentials.  Quantal analysis revealed that the size of 
evoked/stimulated postsynaptic responses can vary from trial to trail and these 
fluctuations are associated with the number of quanta released.  This proposes that a 
mEPP is the postsynaptic response to the smallest unit of neurotransmitter release, a 
quantum, and the size of evoked EPP is linked to the number of quanta released 
(Andersen et al., 2007).  Hence it is possible to examine the efficacy of a synaptic 
connection by examining the quantal parameters: the number of active release sites 
(n), the release probability of a connection (pr) and the quantal size (amplitude of the 
postsynaptic response following release of neurotransmitter from a single synaptic 
vesicle) (q) (Branco and Staras, 2009; Cowan et al., 2001; Kerchner and Nicoll, 
2008).  By studying these quantal parameters it may be possible to get an 
understanding of the relative changes in pre and postsynaptic function.  An alteration 
in n and/or pr is associated with a change in presynaptic quantal release and q being 
associated with the number and quality of postsynaptic receptors.  By examining 
these parameters it is possible to locate the pre and/ or postsynaptic factors that 
contribute to the change in synaptic efficacy.    Later studies also found that quantal 
synaptic transmission could also occur in the CNS with largely similar properties to 
the NMJ (Auger and Marty, 2000; Lisman et al., 2007).   
 
 
Synapse number 
 
The number of synaptic contacts on a neuron is controlled by the dynamic formation 
and elimination of synapses.  Both processes can occur not only during development 
but also in mature systems to help refine neural networks.  Synapse structure and 
number can also be regulated by neuronal activity (Goda and Davis, 2003).  CNS 
neurons often extend long axons which make multiple en passant synapses onto 
postsynaptic dendrites.   Molecular components of the presynaptic release machinery 
such as syntaxin and SNAP25 are ideally positioned along the length of the axonal 
process to enable recruitment to synapses during formation of new boutons (Ziv and 
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Garner, 2004).    Current models suggest that the formation of new contacts at 
central synapses can be initiated by the release of secreted factors, including Wnts 
and neurotrophins such as brain-derived neurotrophic factor (BDNF) (Goda and 
Davis, 2003).  Contact between processes/ filopodia from the postsynaptic dendrite 
with the presynaptic axon can lead to establishment of new synapses (Garner et al., 
2002; Goda and Davis, 2003; Ziv and Garner, 2004).  Studies have indicated that pre 
and postsynaptic compartments can assemble simultaneously to form a synaptic 
contact (Okabe et al., 2001).  The presence of low numbers of synaptic vesicles in an 
ill- defined presynaptic bouton which often lacks mitochondria are signs of an early 
or immature synapse (Ziv and Garner, 2004).  Whereas a more established synapse is 
more readily recognised by the presence of docked vesicles, a large reserve pool of 
presynaptic vesicles in a structurally well defined bouton on the presynaptic axon.  
Maturation of the postsynaptic compartment is associated with the presence of 
postsynaptic receptors such as NMDA and AMPA receptors and postsynaptic 
density (PSD)-95 and scaffold proteins.     
 
To decrease synapse number, processes relating to synapse disassembly (where 
single contacts between two neurons are eliminated) and input elimination (where all 
contacts between two neurons are eliminated) are involved (Goda and Davis, 2003).  
The mechanisms regarding synapse elimination are poorly defined but are believed 
to be driven by the postsynaptic cell.  Live imaging studies have revealed that spine 
morphological changes and retraction may indicate early stages of synapse 
elimination.  These morphological changes in postsynaptic structure are associated 
with changes in the actin cytoskeleton which can be regulated by activity and 
different intracellular signalling pathways (see Goda and Davis, 2003 for extensive 
discussion).  Overall, the dynamic regulation of synapse formation and elimination is 
necessary for the maintenance of synapse number.    
 
Recent studies have also indicated that presynaptic vesicles are highly mobile and 
can split from existing mature synapses and traffic in anterograde and retrograde 
directions to other boutons along the same axon.  These mobile vesicles can 
functionally incorporate into existing synapses and undergo stimulated synaptic 
release (Darcy et al., 2006; Staras et al., 2010).  Interestingly, studies have also 
indicated that these mobile vesicles can form orphan release sites where synaptic 
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release occurs in the absence of a postsynaptic target (Krueger et al., 2003; Staras et 
al., 2010).  These studies suggest that mobile vesicles may be involved in 
maintaining the presynaptic vesicle pools of existing synapses but may also be 
implicated in the formation of new synapses in mature neuronal networks.  Though 
not yet tested, the loss of synaptic vesicles from presynaptic terminals could 
potentially be an early marker of synapse elimination.  Therefore, conceptually, 
synapse vesicle movement may be implicated in both synapse formation and 
elimination.   
 
However, the molecular mechanisms that regulate synapse number, including 
synapse stabilisation are still poorly understood.  Also on a technical level, 
establishing the time point when a synapse can be defined as “formed” or “lost” is 
not trivial.  The morphology of an immature/ dissembled synapse is often variable 
and difficult to assess purely by examining still fluorescence images.  Time lapse 
imaging provides a more convincing read out of synapse formation or loss but 
ultimately the connection needs to be assessed on a functional level before it can be 
established as a synapse.   As synapse loss is a key early event in AD pathogenesis 
understanding the mechanisms that regulate synapse number will be important to 
understand the structural changes that occur during AD. 
 
 
Synaptic plasticity and memory – focus on the hippocampus 
 
As already mentioned, memory loss is one of the key symptoms used by clinicians to 
aid the diagnosis of AD and other dementias.  The hippocampus is a key structure 
involved in memory storage and is one of the first and most severely affected regions 
of the brain by Aβ plaque deposits.  The hippocampus (or hippocampal formation) is 
a curved cylindrical structure positioned within the medial lateral ventricle and part 
of the limbic system.   The hippocampal formation is a group of cortical regions 
which can be divided into the dentate gyrus (DG), the hippocampus (proper), the 
subicular complex and the entorhinal cortex (EC).  The subicular complex can be 
further subdivided into the subiculum, presubiculum and parasubiculum.  The 
hippocampus (proper) can be subdivided into three areas termed cornu ammonis 
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(CA) 1, CA2 and CA3.  The main excitatory cells of the hippocampus are the 
pyramidal cells.  Different subsections of the pyramidal cell can occupy different 
anatomically defined layers (or laminae) of the hippocampus.  The stratum oriens 
contains the basal dendrites, stratum pyramidale contains the cell soma, and the 
stratum radiatum and stratum lacunosum moleculare contain the apical dendrites of 
pyramidal cells.   A widely studied excitatory circuit within the hippocampal 
formation is the “trisynaptic circuit” which consists of synapses made from EC to 
DG, DG to CA3 and CA3 to CA1.  This circuit has been extensively used for 
synaptic studies of the hippocampus because the connections and projections are 
well characterised and defined and the gross cytoarchitecture and circuitry is well 
maintained after slice preparation.   
 
Studies from the 1950’s provided the first major source of evidence that the 
hippocampal formation may be important for learning and memory formation.  
Milner and colleagues examined a patient named HM who had lost the ability to 
form new memories following surgical bilateral medial temporal lobe resection 
(Scoville and Milner, 1957).  This work indicated that the medial temporal lobe and 
the hippocampus were important for declarative memory.  In addition, human and 
animal studies have also shown that the hippocampus is also important for spatial 
learning (Eichenbaum, 2000; Maguire et al., 1997; Morris et al., 1982; Squire, 1992).  
These and many other studies have demonstrated that the hippocampus is important 
for different types of learning and memory (Eichenbaum, 2000; Squire, 1992).   
 
However understanding the cellular changes underlying mechanisms of learning and 
memory in the hippocampus has been challenging.  Past studies have shown that 
activity or experience can bidirectionally alter the strength of synaptic connections.  
The plastic nature of synapses has been proposed as a property that enables the brain 
to integrate cognitive information and form new memories (Lynch, 2004; Martin and 
Morris, 2002; Morris et al., 2003).  A form of long term plasticity termed long term 
potentiation (LTP), has been proposed as a potential cellular correlate for learning 
and memory where either chemical or electrical stimulation can lead to an activity-
dependent strengthening of synaptic connections (Bashir and Collingridge, 1992; 
Bliss and Collingridge, 1993; Bliss and Lomo, 1973).  Further studies have shown 
that impairing LTP induction by either genetic or pharmacological methods can lead 
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to defects in the ability of animals to perform hippocampal-dependent spatial 
memory tasks providing strong evidence that LTP and learning and memory may be 
closely associated (Barnes et al., 1994; Bejar et al., 2002; Castro et al., 1989; Giese 
et al., 1998; Jones et al., 2001a; Jones et al., 2001b; McNaughton et al., 1986; Morris 
et al., 1986; Moser et al., 1998).   
 
Studies have also identified several key characteristics that make LTP a good 
candidate mechanism for learning and memory (Bliss and Collingridge, 1993; 
Malenka and Nicoll, 1998; Malenka and Nicoll, 1999).  As memories can often last a 
lifetime, one important consideration for the proposal that LTP is the cellular 
correlate for learning and memory is the fact that it can be persistent and long lasting 
with demonstrations of in vitro and in vivo potentiation lasting from hours to weeks 
to years (Bliss and Collingridge, 1993; Malenka and Nicoll, 1999).  Input specificity 
which refers to the increase in synaptic strength only at active stimulated synapses 
and not at unstimulated cells is another factor (Engert and Bonhoeffer, 1997; Engert 
and Bonhoeffer, 1999).  Studies have also shown that LTP is associative.  This refers 
to the ability of activity at one synapse to influence the plasticity of another nearby 
synapse.  The final property is cooperativity which refers to the temporally matched 
onset of pre and postsynaptic activity.   The properties of input-specificity, 
associativity and cooperativity can be supplied by the known characteristics and 
actions of the NMDA receptor.  The induction of LTP is dependent on NMDA 
receptor activation.  Strong evidence for the involvement of NMDA receptors came 
from pharmacological experiments where blockade of NMDA receptors using 
selective antagonist, D-AP5 could inhibit induction of hippocampal LTP 
(Collingridge et al., 1983).  D-AP5 had no effect on the expression of LTP or on 
basal synaptic transmission, which means NMDA receptors were crucial for LTP 
induction but dispensable for other forms of synaptic activity.   The importance of 
NMDA receptor activation during LTP induction was further highlighted using 
genetic NMDA receptor knock-out animals or site directed mutagenesis of the C-
terminal tail which also showed that LTP could not be induced in the absence of 
functional NMDA receptors (Sprengel et al., 1998; Tsien et al., 1996b).  The ligand 
and voltage dependent activation, high permeability to calcium ions and the 
requirement for temporally associated pre and postsynaptic activity are the major 
molecular properties of the NMDA receptor that make it a key factor in the induction 
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of LTP.   For this reason many AD transgenic models have used LTP paradigms and 
hippocampal-dependent spatial tasks (such as Morris water maze) to assess any 
changes in learning and memory.   
 
 
1.6.2 Presenilin knock-out mice models 
   
Several types of presenilin knockout mice models have been generated.  The first 
series of presenilin transgenic animals were constitutive presenilin 1 knock-out mice 
which identified the key role of PS1 in embryonic development.  As already 
mentioned, PS1 knock-out embryos have severe developmental abnormalities 
including an impaired axial skeletal development, disturbed somitogenesis,  
respiratory problems and cerebral haemorrhaging due to deficiencies in Notch 
signalling (De Strooper et al., 1998; Shen et al., 1997; Wong et al., 1997) (Figure 
1.5).  Like Notch knock-out animals, PS1 constitutive knock-out mice did not 
survive beyond embryonic ages (Conlon et al., 1995; Swiatek et al., 1994).  It was 
found that the developmental impairments in the embryo were associated more with 
PS1 null animals than PS2 null animals.  In fact, PS2 constitutive knock-out animals 
were viable and survived till late postnatal ages (Herreman et al., 1999).    The only 
phenotypic difference between PS2 knock-out and wild type mice was the 
development of mild pulmonary fibrosis and haemorrhages in adult animals at 
approximately 6 months of age (Herreman et al., 1999).  However, a constitutive 
PS1 and PS2 double knock-out mice showed a phenotype that mimicked the Notch 
knock-out mice, with lethality being observed at ~E8.5-11.5 (Donoviel et al., 1999; 
Herreman et al., 1999).  This shows that PS1 and PS2 double knockout mice exhibit 
a more severe phenotype than knocking out PS1 alone, demonstrating that a 
deficiency in PS2 enhances the effect of PS1 elimination on embryonic development 
but elimination of PS2 alone has little effect on embryonic development 
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One major problem with constitutive PS1 knock-out animals was that embryonic 
lethality precluded the study of PS1 during postnatal ages.  To overcome this issue, 
more recent knock-out animals of presenilins have been generated using Cre/LoxP 
mediated deletion methods (Tsien et al., 1996a; Tsien et al., 1996b).  The Cre/LoxP 
system has been extensively used to produce animals where the targeted gene can be 
temporally inactivated by Cre-recombinase, a type I bacterial topoisomerase that 
catalyses site-specific recombination of DNA.  The gene of interest can be 
engineered to have LoxP DNA motifs at both ends of the gene (termed a floxed 
gene) which are then used by Cre-recombinase as excision recognitions sites to 
enable conditional elimination of the floxed gene.  In addition, different promoters 
can be used to generate tissue/ cell type specific knock-out animals.   
 
Dewachter et al., (2002) generated conditional knock-out mice where PS1 expression 
was controlled by a Thy-1 promoter which led to PS1 gene elimination in post 
mitotic cells, and therefore was mainly neuron specific (Dewachter et al., 2008).  
Conditional PS1 knock-out mice were also generated with α-CaMKII promoter 
which led to PS1 gene elimination in forebrain excitatory neurons starting from 
juvenile ages (Feng et al., 2001; Yu et al., 2001).  To eliminate the PS1 gene in mice, 
floxed PS1 mice were crossed with α-CaMKII-Cre mice and progressive knock-out 
was observed from 3-4 weeks after birth (Tsien et al., 1996a; Tsien et al., 1996b; Yu 
et al., 2001).  This approach enables the impact of presenilin elimination to be 
PS1+ PS1- PS1+ PS1-
ai aii
a 
Figure 1.5 - Morphological differences between PS1 wild type (+/+) and constitutive 
PS1 knock-out (-/-) mice 
(ai) Image of PS1 +/+ (left) and PS1 -/- animal (right). (aii) Excised brain from PS1 +/+ 
(left) and PS1 -/- (right) animal.  In general, PS1 -/- are smaller in size than PS1 +/+ .  
Heterozygous (+/-) animals exhibit similar morphology to wild type animals (data not 
shown). PS1 -/- animals also show varying degrees of haemorrhaging in the brain which 
is not commonly observed in PS1 +/+  and PS1 +/- .  
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assessed in adult animals and circumvents the developmental issues observed with 
constitutive knock-out animals.  PS1 could also be eliminated in floxed cultured cells 
by infection or transfection of Cre viruses or cDNA respectively.   
 
The α-CaMKII promoter was also used to generate forebrain specific double PS1 
and PS2 knock-out animals (Saura et al., 2004).  In line with constitutive PS1 knock-
out studies where minimal Aβ production was observed (De Strooper et al., 1998; 
Naruse et al., 1998), adult conditional forebrain specific PS1 and PS2 knock-out 
animals did not exhibit any amyloid plaque deposits indicating that neuronal 
presenilin is required for Aβ and plaque generation in embryonic and adult stages of 
development. PS1 and PS2 conditional double knock-out animals also exhibited 
signs of AD pathobiology at 6 months of age, with the accumulation of glial 
fibrillary acidic protein, neurofibrillary tangles and hyperphosphorylated tau.  
Inflammation and neurodegeneration was observed in the cortex and hippocampus in 
a progressive and age-dependent manner (Saura et al., 2004).  Furthermore, 
functional changes in neurons occurred before noticeable neurodegeneration.  
Neurons also had reduced dendritic complexity and spine loss by 6 months.  This 
suggests a loss of presenilin function can eventually lead to an AD phenotype.  
However, an electron microscopy study which used the same PS1 and PS2 
conditional knock-out animals as Saura and colleagues (2004) showed that at 2 
months of age, a significant increase in spine density of CA1 pyramidal neurons of 
the hippocampus could be observed (Aoki et al., 2009).  Closer examination using 
quantitative HRP DAB labelling revealed a significant (28%) increase in NR2A 
subunits in spines and an increase (31%) in postsynaptic density measurements  
(Aoki et al., 2009).  Together the studies of Saura et al., (2004) and Aoki et al., 
(2009) provide evidence that elimination of presenilin initially leads to an increase in 
spine density which is then followed by a subsequent decrease in spine density with 
age.   
 
An important point to note with presenilin knock-out mice studies is that both γ-
secretase dependent and γ-secretase independent forms of presenilin activity are 
eliminated.  This means that it is not possible to identify whether a change in cell 
function is attributed to a loss of γ-secretase dependent activity of presenilin or loss 
of γ-secretase independent activity of presenilin, or both.  This factor makes the 
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identification of molecular mechanisms potentially more complicated in knock-out 
studies.        
  
 
1.6.3 Presenilins, synaptic plasticity and learning and memory  
 
Conditional presenilin knock-out mice models have been extensively used in 
experiments that have examined aspects of learning and memory.  The following 
studies mainly investigated the role of presenilin in LTP experiments and 
behavioural tests such as the Morris water maze.     
 
LTP is often proposed as a cellular correlate of learning and memory and induced by 
either strong electrical stimulation (e.g application of high frequency trains of 
stimuli, see Bliss et al., 1986) or chemical stimulation (see for example: Otmakhov 
et al., 2004) which leads to a long lasting enhancement of postsynaptic strength.  
Studies from forebrain specific PS1 conditional knock-out animals showed no 
change in LTP induction or expression/ maintenance in the CA1 region (Yu et al., 
2001) or dentate gyrus (Feng et al., 2001).  Additionally knock-out of PS1 in 
forebrain neurons in adult animals did not lead to any impairment in paired-pulse 
facilitation, a form of presynaptic short term plasticity (Yu et al., 2001).  In conflict 
with these reports, a study from PS1 neuronal specific knock-out mice reported 
impairment in the induction/ initial phase of CA1 LTP (Dewachter et al., 2008).  
Interestingly, despite a reduced response during the initial phase of LTP, the 
expression/ maintenance phases of LTP were no different to wild type control 
animals.  It is unclear why only the initial phase is impaired.  The authors also 
observed a corresponding decrease in NMDA receptor field EPSP response and 
reduced expression of activated α-CaMKII, NR1 and NR2B subunits, suggesting that 
PS1 may regulate cellular proteins required for LTP induction.  These PS1 neuronal 
specific knock-out mice also exhibited a smaller number of synaptic vesicles (total 
population and docked vesicles) and a reduction in paired-pulse ratio, suggesting that 
PS1 is involved in regulating presynaptic vesicle pools and release probability 
(Dewachter et al., 2008).   
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The reason for the difference in LTP between the conditional forebrain specific PS1 
knock-out animals and the neuron specific PS1 knock-out mice are currently unclear.  
The main difference between these two knock-out models is the use of different 
promoters.  However, the α-CaMKII promoter used in forebrain specific PS1 knock-
out mice (Feng et al., 2001; Yu et al., 2001) and the thy-1 promoter used in neuronal 
knock-out mutants (Dewachter et al., 2008) should exhibit similar effects as both 
promoters should essentially cause specific elimination of PS1 from neurons, which 
means the differences may arise from other subtle differences between the two mice 
models.    Further studies will be required to understand the reason for the 
discrepancy in LTP between different conditional PS1 knock-out mice. 
  
Studies from forebrain specific (α-CaMKII promoter) conditional presenilin double 
knock-out animals revealed that eliminating both PS1 and PS2 led to a reduction in 
LTP and paired-pulse facilitation (at inter-event intervals of 20-100ms).  
Examination of synaptoneurosomes also revealed a reduction in NR1, NR2A 
subunits and CaMKII suggesting a decrease in certain synaptic proteins (Saura et al., 
2004). Interestingly no change in NR1, NR2A and CaMKII was seen in total lysates.  
The forebrain specific double presenilin knock-out animals (Saura et al., 2004) seem 
to be phenotypically more similar to neuron specific PS1 knock-out animals 
(Dewachter et al., 2008) than forebrain specific PS1 knock-outs (Feng et al., 2001; 
Yu et al., 2001).       
 
A recent study at CA3-CA1 synapses in the hippocampus found that LTP and 
synaptic facilitation were impaired only when PS1 and PS2 were both eliminated 
from the presynaptic cell.  No change in LTP was observed upon PS1 and PS2 
elimination from the postsynaptic neuron (Zhang et al., 2009).  This suggests that 
presynaptic presenilins rather than postsynaptic presenilins are involved in 
modulating LTP (Zhang et al., 2009).  However, this result is at odds with an earlier 
report which showed that presenilin associated impairments in LTP was mainly 
postsynaptically expressed (Saura et al., 2004).  Zhang et al., (2009) also shows that 
short term facilitation is only impaired when both PS1 and PS2 are presynaptically 
eliminated as presynaptic elimination of PS1 on its own does not lead to any 
impairment in paired-pulse ratio.  Taken together, there seems to be a considerable 
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amount of variability in long and short term plasticity between different presenilin 
mice models.  The reasons behind these differences are not entirely clear at present.   
 
Behavioural studies also revealed some discrepancies between different conditional 
presenilin knock-out mice.  Most studies examined the performance of different 
animals on the Morris water maze, a test of spatial memory.  One study showed that 
forebrain specific PS1 knock-out mice which exhibited no changes in hippocampal 
LTP did show a mild behavioural impairment in spatial memory task with an 
extended period of time required to locate the platform and a subsequent decrease in 
the number of crossings (Yu et al., 2001).  This indicates that PS1 is not required for 
long term plasticity but it is for spatial memory.  However, this finding was not 
confirmed by Feng and colleagues who performed virtually identical experiments 
using a forebrain specific PS1 knock-out animal (Feng et al., 2001).  Feng and 
colleagues found normal learning and retention in the Morris water maze and normal 
contextual fear conditioning (Feng et al., 2001).  The differences between these 
studies are currently not well understood.  
 
Dewachter et al., (2008) showed that neuron specific PS1 knock-out animals showed 
no difference in Morris water maze performance (spatial navigation task), no change 
in novel object recognition task, no change in amygdala dependent cued conditioning 
but a decreased freezing in hippocampal and amygdala dependent contextual fear 
conditioning (Dewachter et al., 2008).  This study suggests that neuronal presenilin 
is not required for most hippocampal dependent tasks including spatial navigation 
tasks but is involved in a hippocampal and amygdala dependent behavioural task.    
 
Conditional double knock-out mice also showed an impaired performance on the 
Morris water maze and contextual fear conditioning tasks suggesting elimination of 
both PS1 and PS2 can lead to defects in hippocampal dependent forms of learning 
and memory (Saura et al., 2004).    Presenilin double knock-out animals had 
impaired LTP and spatial and associative memory at 2 months of age but in the 
absence of any changes in neuron number.  By 6 months, an extreme impairment in 
the performance of the Morris water maze was observed together with 
neurodegeneration.  This suggests that functional changes may precede the 
noticeable loss of neurons.  However, the molecular mechanisms underlying the 
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behavioural changes observed in presenilin knock-out mice remains poorly 
understood.  Interestingly, pharmacological intrahippocampal infusion of a γ-
secretase inhibitor after training led to an enhanced spatial memory performance 
suggesting that γ-secretase acts as a negative regulator of long-term memory (Dash 
et al., 2005). This study also indicates that γ-secretase inhibitor treatment may not 
generate the same results as presenilin knock-out mice in behavioural tests.  It is not 
clear if the differences arise from a non-specific action of the inhibitors or if there 
are compensatory mechanisms present in the knock-out animals or another 
unidentified possibility.   
 
 
1.6.4 Presenilins and synaptic transmission   
 
As constitutive PS1 knock-out mice do not survive beyond late embryonic stages, 
the role of PS1 in these animals could not be analysed in postnatal/ adult ages.  Due 
to this developmental defect, all synaptic studies investigating the role of PS1 from 
these animals involved generating neuronal cultures from tissue obtained from 
embryonic mice.  A recent electrophysiological study examines the role of PS1 in 
modulating basal synaptic transmission.  Dissociated cortical neurons from 
constitutive PS1 null mice showed an increase in miniature excitatory postsynaptic 
current (mEPSC) frequency without a change in mEPSC amplitude (Parent et al., 
2005).  One interpretation of this result is that PS1 null neurons exhibit a change in 
presynaptic function, in the absence of a change in postsynaptic activity.  
Intriguingly, immunofluorescence data reports a lack of change in presynaptic active 
zone marker, bassoon, but an increase in postsynaptic density staining, and an 
overall increase in colocalised PSD-95 and bassoon signal.   An increase in spine 
number was also observed.  This result suggests that PS1 may modulate synapse 
number in cortical cultures.  Taken together, these results show that PS1 may play a 
role in modulating synaptic transmission and synapse number in cortical neurons.   
 
Additionally, Parent and colleagues found that the PS1 null phenotype could be 
mimicked by chronic application of a potent γ-secretase inhibitor suggesting that γ-
secretase activity of presenilin was required for regulation of synapse function of 
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cortical cells (Parent et al., 2005).  Separate studies also showed that 
pharmacological inhibition of γ-secretase activity could lead to an increase in 
mEPSC frequency in hippocampal neurons (Kamenetz et al., 2003; Priller et al., 
2006).   
 
Parent and colleagues also showed that a membrane-tethered protein fragment 
named α-deleted in colorectal cancer C-terminal fragment (α-DCC CTF) could 
accumulate within the membrane compartments of PS1 knock-out neurons or after 
block of γ-secretase cleavage in wild type cells (Parent et al., 2005).  The authors 
proposed that accumulation of α-DCC CTF could increase cAMP/ PKA signalling 
and enhanced neurite development in neuroblastoma cells and potentially provide a 
mechanistic explanation for the increase in miniature frequency and number of 
synaptic contacts in cortical neurons (Parent et al., 2005).  Together this study 
proposes that γ-secretase activity is involved in regulating cortical synaptic 
transmission and further studies will be required to determine if cAMP/PKA/ α-DCC 
signalling plays a major role in modulating synaptic transmission at other synapses. 
 
 
1.6.5 Comparison of PS1 and PS2 associated γ-secretase 
functions 
 
Despite the similarities in sequence homology, it is unclear whether PS1 and PS2 
share parallel functional roles.  Intriguingly, the vast majority of FAD mutations 
have been found in PSEN1 gene (>170) with only a handful of cases being reported 
in PSEN2 gene (~10).  Additionally PSEN1 mutations tend to more aggressive than 
mutations in PSEN2, as shown by the onset of symptoms at an earlier age (Bertram 
and Tanzi, 2004; Tandon and Fraser, 2002).  These genetic differences are 
suggestive that PS1 and PS2 may not have the same function in FAD pathology.  
 
Past studies have indicated that PS1 is the major isoform transcribed in the brain 
with PS2 being more highly expressed in peripheral tissues (Beel and Sanders, 2008; 
Tandon and Fraser, 2002).  However other in situ hybridisation experiments have 
shown that both PS1 and PS2 transcripts can be found in the hippocampus, cortex 
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and other CNS regions (Kovacs et al., 1996; Lee et al., 1996).  The subcellular 
localisation of PS1 and PS2 remains to be fully determined.  A study undertaken on 
mammalian cell lines showed using biochemical cell fractionation techniques that 
PS1 and PS2 were found in intermediate buoyant density fractions, which contained 
markers for the ER, Golgi, TGN, endosomal vesicles and lysosomal vesicles (Kim et 
al., 2000).  However PS1 but not PS2 is also found in a low buoyant density fraction, 
which corresponds to non-identified subcellular region(s) that excluded the 
organellar markers associated with the intermediate fraction (Kim et al., 2000).  This 
study suggests a potential difference in PS1 and PS2 subcellular distribution. 
 
Phenotypic differences between PS1 knock-out and PS2 knock-out mice suggest that 
these proteins may potentially play dissimilar roles in Notch signalling.  As already 
mentioned, PS1 constitutive knock-out animals exhibit severe impairments in 
embryonic developments (De Strooper et al., 1998; Shen et al., 1997; Wong et al., 
1997) whilst PS2 knock-out animals do not have any noticeable embryonic defects 
(Herreman et al., 1999).  Only at later stages of adult development did PS2 knock-
out animals display differences to wild type animals, suggesting PS2 activity does 
not seem to be required for Notch signalling in the embryo and that PS1 and PS2 
have differential roles in development.  However a more severe impairment in 
embryonic development was observed in PS 1 and 2 double knock-out animals when 
compared to PS1 animals suggesting that loss of both genes exaggerates the effect of 
loss of PS1 (Donoviel et al., 1999; Herreman et al., 1999).  These results suggest that 
there may be some functional overlap between PS1 and 2 but it seems that PS1 is the 
main homologue implicated in Notch signalling during embryonic development.  
The proposed minor role of PS2 may be compensated for by the presence of PS1 
allele in PS2 knock-out animals (Herreman et al., 1999).  However, the opposite 
situation does not apply, presence of PS2 does not rescue/ compensate for the lack of 
PS1 implying a dominant role for PS1 in embryonic development (De Strooper et al., 
1998; Shen et al., 1997; Wong et al., 1997) 
Analysis of Aβ generation also showed that PS1 and PS2 may have differential roles 
in APP processing.  It was also shown that only very low amounts of Aβ were 
generated in PS1 constitutive knock-out animals (De Strooper et al., 1998; Naruse et 
al., 1998) suggesting that PS1 plays a significant role in Aβ generation. The presence 
of some remaining residual Aβ suggests that a small component of γ-secretase is 
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derived (presumably) from PS2 in cultured neurons.  However, the amount of Aβ 
generated by PS2 knock-out animals is highly comparable to control animals 
providing evidence that APP processing can be completely rescued by PS1 in PS2 
knock-out cells (Herreman et al., 1999).  Another study shows that the amount of 
APP-CTFs found in PS1 wild type mice after treatment with γ-secretase inhibitors is 
comparable to the amount of APP-CTFs found in PS1 knock-out mice suggesting 
that similar deficiencies in APP processing are seen upon either blocking γ-secretase 
activity pharmacologically or eliminating the PS1 gene (Parent et al., 2005).  These 
studies indicate that PS1 is the main presenilin isoform involved in APP processing 
and γ-secretase complexes composed of PS2 may play a limited role in APP 
proteolysis.  This finding has been confirmed with in vivo studies showing that APP 
cleavage is less efficient with PS2 containing complexes than PS1 containing γ-
secretase complexes (Mastrangelo et al., 2005).   
 
γ-secretase inhibitors were also used to determine the relative contributions of PS1 
and PS2 to cellular γ-secretase activity.  Drug binding studies conducted on 
blastocyst cell membranes showed that the Ki values of γ-secretase inhibitors on 
PS1+/+ PS2+/+ membranes were more closely matched to PS1+/- PS2-/- than to 
PS1-/-PS2+/+ cell membranes (Lai et al., 2003).   This result suggests that most 
endogenous γ-secretase activity is supplied by PS1 rather than PS2.  It was also 
shown that PS1 and PS2 are not associated within the same high molecular weight 
protein complex which supports the notion that each γ-secretase complex contains 
only one PS protein (Lai et al., 2003).    
 
However, other studies using blastocyte pluripotent stem cell lines have indicated 
that PS2 can contribute to a greater percentage of the cellular γ-secretase activity 
than originally shown.  PS1-/- blastocytes only showed ~ 40 – 50% reduction in γ-
secretase activity (Herreman et al., 2000; Zhang et al., 2000).  This indicates that the 
contribution of PS1 and PS2 to total γ-secretase activity may vary between cell 
types.  Overall, these studies support the notion that PS1 and PS2 associated γ-
secretase complexes have differential cellular functions with PS1 being the major 
source of cellular γ-secretase activity.   
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1.7 Concluding remarks  
 
Studies of FAD patients have revealed the crucial role of presenilin (1) in AD 
pathogenesis.  In line with this observation, presenilin mutant mice often develop the 
characteristic hallmarks of AD; amyloid plaques, neurofibrillary tangles and 
neuronal loss.  Presenilin knock-out mice studies have also outlined potential roles 
for presenilin in regulating certain forms of plasticity, learning and memory.  
However, whether presenilin plays a major role in regulating synapse function in 
hippocampal neurons remains to be fully determined.   Investigations into the role of 
presenilin in modulating different synaptic functions may provide further insights 
into the pathogenic mechanisms that occur during AD progression.  The subsequent 
chapters of this thesis examine the impact of the loss of γ-secretase activity or 
presenilin 1 expression on different aspects of synaptic function in hippocampal 
neurons.   
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Aims 
 
 
 
The aim of this thesis is to examine the role of presenilin (1) in regulating synaptic 
transmission and neuronal function in hippocampal neurons.  Presenilin function is 
investigated by two separate approaches.  A constitutive PS1 knock-out mouse 
model is used to examine the γ-secretase dependent and γ-secretase independent 
roles of presenilin 1 and specific γ-secretase inhibitors are used to examine the  
synaptic effects of selective block of γ-secretase activity of presenilin.   
 
The roles of presenilin in regulating the following aspects of synapse function are 
investigated: 
 
• Excitatory and inhibitory spontaneous synaptic transmission using whole-cell 
recordings in dissociated and organotypic cultures 
• Release probability using optical (FM styryl dye destaining kinetics) and 
electrophysiological (PPR and rate of MK801 block of NMDA receptor 
current) methods 
• Synapse number using immunocytochemical methods 
• Intracellular calcium concentration using live calcium imaging 
 
The synaptic effects of β-secretase inhibition are also examined.  This series of 
experiments have been performed to further investigate whether loss of Aβ 
production has any effects on synapse function.  These experiments may also 
provide some insight into the potential synaptic effects that may arise with 
therapeutic treatment with γ-secretase and β-secretase inhibitors.
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Chapter 2: Materials and Methods 
 
 
 
The experiments outlined in this thesis were performed on hippocampal primary 
dissociated cultures and organotypic slice cultures.  Both of these well characterised 
model systems have been widely used for the study of synapse function and 
plasticity.   Primary dissociated cultures comprise of simple neuronal networks with 
extensive synaptic connections arranged on a monolayer.  These cultures are well 
adapted for use with a range of techniques including electrophysiology, 
immunocytochemistry and live cell imaging.  Organotypic slice cultures enable the 
study of synapse function in a system whereby the gross cytoarchitecture of a 
hippocampal slice is largely maintained during development in vitro and provide an 
advantageous system for conducting long term whole-cell recordings and 
neuropharmacological characterisations.  All experiments were performed at room 
temperature and with a minimum of three separate culture preparations unless 
otherwise mentioned.  All chemicals and reagents used aside from those listed below 
were purchased from Sigma-Aldrich. 
 
 
2.1 Animals 
 
All animal procedures were carried out in accordance with ‘The Animals (Scientific 
Procedures) Act 1986’. 
 
 
2.1.1 Rat colonies  
 
Sprague-Dawley rats were obtained in-house from UCL Biological Services Unit.  
Animals were collected and used on the day of dissection and preparation.   
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2.1.2 PS1 mice colonies and genotyping 
 
PS1 mice were kindly provided by Professor S. Sisodia (University of Chicago, 
USA).  Detailed descriptions of the method used for generating PS1 -/- mice can be 
found in (Wong et al., 1997).  Briefly, PS1 -/- animals were generated by using a 
PS1 targeting vector to replace the second coding exon (exon 4, amino acids 30-113) 
and neighbouring sequences with a neomycin-resistance gene and HSV thymidine 
gene by homologous recombination.  PS1 +/- animals were backcrossed with 
matched background wild type mice strains (C57Bl/6J) and heterozygote offsprings 
were used for mating. 
 
Analysis of mouse genotype was performed using polymerase chain reaction 
methods (PCR).  DNA was extracted from PS1 tail biopsies and brain tissue samples 
using a QIAGEN ® DNeasy Blood and Tissue kit according to manufacturers’ 
instructions.   For genotyping, three specifically designed primers (sequence supplied 
and designed by Sisodia lab) against the neomycin cassette and the PS1 gene were 
used in a PCR to determine the presence of targeted PS1 null and/or endogenous PS1 
alleles, generating a 370 base pair (bp) and a 500 bp PCR fragment for the respective 
alleles.  The primer sequences are outlined below:  
 
Neomycin  CCA TTG CTC AGC GGT GCTG 
mPS1 forward  AGC CAA GAA CGG CAG CAG CAG CAT GAC AGG 
CAG AG 
mPS1 reverse  CTT CCA TGA GCC ATT TGC TAA GTGC 
 
PCR products were separated by agarose gel electrophoresis (0.7% agarose in 1x 
TAE buffer containing 0.5 µg/ml ethidium bromide), visualised by UV illumination 
and examined for 370 bp and 500 bp bands against a 100 bp DNA molecular weight 
ladder.  Genotyping procedures were performed by D. Elliott.  Only animals that 
yielded duplicate positive genotyping results (obtained from two different tissue 
samples) were included in the final data set.  For PS1 mice experiments, embryonic 
littermates were used for comparison.   
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Table 2.1 shows the components used for PCR amplification of PS1 DNA.  A total 
volume of 25 μL was used for each PCR tube.   
 
Table 2.1: Components for PS1 PCR reaction. 
Compound Concentration Volume Final Conc. 
PCR buffer 10x 2.5 μL 1x 
dNTPs (Contains ATP, 
GTP, CTP, TTP) 
10 mM 1.0 μL 100 μM/ dNTP 
MgCl2 50 mM 0.75 μL 1.5 mM  
Primers: 
Neo 
mPS1 forward 
mPS1 reverse 
50 μM 
 
 
0.25 μL each 0.5 μM/Primer 
Taq Polymerase  
(Add last) 
5 U/μL  0.25 μL 0.05 U/μL 
Mouse DNA  N/A 1.0-2.0 μL (1.0-2.0 μL) 
 
Table 2.2 shows the protocol used for PCR amplification of PS1 mice DNA. 
 
Table 2.2: PS1 PCR reaction protocol. 
Step Temperature (°C) time (min) 
1 94.0 5 
2 94.0 1 
3 60.0 1 
4 72.0 2 
5 Repeat 35 times to Step 2 
6 72.0 10 
7 4.0 24 
8 END 
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2.2 Hippocampal cell culture (rat and mice) 
 
 
2.2.1 Materials  
 
Table 2.3: Chemicals / Reagents / Products used for dissociated cell culture 
Product Company Location 
12 mm glass coverslips Assistent Sondheim, Germany 
Acetic acid Sigma - Aldrich Dorset, UK 
Aztek atomiser Sylmasta Ltd Sussex, UK 
B27 supplement Invitrogen Paisley, UK 
DNase I  Merck chemicals Darmstadt, Germany 
Eagle’s Basal medium (BME) Invitrogen  Paisley, UK 
Fetal calf serum (FCS) 
(batch tested)  
Sigma – Aldrich 
Invitrogen 
Dorset, UK 
Paisley, UK 
Glutamax Invitrogen Paisley, UK 
Hank’s balanced salt solution 
(HBSS) 
Invitrogen Paisley, UK 
MitoTM serum extender BD bioscience  New Jersey, US 
Neurobasal medium Invitrogen  Paisley, UK 
Papain Lorne laboratories Ltd Reading, UK 
Poly-D-lysine (PDL) Sigma - Aldrich Dorset, UK 
Sterile plastic for tissue 
culture  (Nunc) 
VWR international Lutterworth, UK 
Rat tail collagen  (personal stocks 
extracted from Sprague-
Dawley rat tails) 
London, UK 
Trypsin (MRC LMCB in house 
stocks) 
London, UK 
Trypan blue Invitrogen Paisley, UK 
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Table 2.4: Buffers and Solutions, used for used for dissociated cell culture 
Buffer / Solution Contents Storage Sterilisation 
Astrocyte medium BME, 6 mg/ml glucose, 10 mM 
HEPES, 1 mM sodium pyruvate, 
100 units/ml penicillin, 0.1 mg/ml 
streptomycin, 10 mM HEPES, 10% 
FCS 
4oC 0.2 µM filter 
Dissection solution HBSS with 10 mM HEPES 4oC 0.2 µM filter 
Neuronal medium  Neurobasal, 6 mg/ml glucose,  
0.1% MitoTM serum extender,   
2.5% B27 supplement, 100 units/ml 
penicillin, 0.1 mg/ml streptomycin, 
2 mM glutamax  
4oC 0.2 µM filter 
Papain digestion 
solution 
Dissection solution containing  
1.5 µM calcium choride, 2 mg/ml L-
cysteine, 0.1 µm/ml DNase I,  
0.5 mM EDTA, 30 units papain 
4oC 0.2 µM filter 
PDL-collagen 
solution 
Acetic acid (0.025%), 1:7 dilution 
rat tail collagen, 5 µm/ml PDL in 
HPLC grade water 
Room 
temp 
0.2 µM filter 
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Table 2.5: Chemicals / Reagents / Products used for organotypic slice culture 
Product Company Location 
Ceramic blades Campden Instruments Loughborough, UK 
Cyanoacrylate RS components Northants, UK 
Earle’s balanced salt solution 
(EBSS) 
Invitrogen Paisley, UK 
Horse serum Invitrogen Paisley, UK 
Minimum essential medium 
with Glutamax-1(MEM) 
Invitrogen  Paisley, UK 
MillicellTM membrane inserts Millipore Watford, UK 
Sterile 6 well plate for tissue 
culture  (Nunc) 
VWR international Lutterworth, UK 
Vibrating microtome Campden Instruments Loughborough, UK 
 
 
Table 2.6: Buffers and Solutions, used for organotypic cell culture 
Buffer / Solution Contents Storage Sterilisation 
Organotypic 
culture medium 
50% MEM, 25%  horse serum,  
23% EBSS, 36 mM glucose, 100 
units/ml penicillin, 0.1 mg/ml 
streptomycin 
4oC 0.2 µM filter 
Organotypic 
slicing medium 
EBSS with 25 mM HEPES 4oC 0.2 µM filter 
 
 
 
 
2.2.2 Methods 
 
Cell culture procedures were performed under sterile conditions in laminar flow 
cabinets.  Cell culture media was warmed to 37oC and equilibrated within humidified 
5% CO2 incubator prior to use.  All cultures were maintained at 37oC with 
humidified 5% CO2 to maintain pH balance.   
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2.2.2.1 Preparation of glass coverslips 
 
All dissociated cultures were plated on pre-cleaned glass coverslips which have been 
treated for 12-18 hrs with 100% fuming nitric acid, then thoroughly rinsed with 
deionised water for 3-4 hrs and maintained in 100% ethanol till use.  When needed, 
coverslips were placed into a sterile Petri dish inside a flow cabinent and left at room 
temperature for 30-40 min or until the ethanol had fully evaporated.  12 dry 
coverslips were inserted into the middle two rows of a 24 well plate.  (The 
surrounding outer two rows were filled with 700 µl water at the time of glial cell 
plating (see below) to minimise medium evaporation).  A light mist-like layer of 
PDL-collagen mix was applied to the coverslips using a fine atomiser powered by a 
positive pressure pump.   Coated coverslips were left to dry at room temperature 
before sterilisation by UV illumination for 15-18 min.  Plates were then packaged 
and sealed using plastic vacumn wrap and stored for a maximum of 4 weeks.   
 
 
2.2.2.2 Preparation of astrocyte feeder layer 
 
To enhance neuronal survival and development, neurons were grown on top of a 
monolayer of astrocytes.  Astrocytes were obtained by taking excess cells from a 
hippocampal dissection and plating them in T25 sterile flasks in astrocyte growth 
medium.  After 4-6 days incubation, the astrocytes formed a 65-95% confluent 
monolayer and were ready for plating onto glass coverslips.  For this, astrocytes 
were first rinsed twice with 1x PBS (lacking calcium and magnesium ions), followed 
by a rapid application (and subsequent aspiration) of trypsin to aid detachment of the 
cells from the flask.  Once detached, cells were gently triturated with a flame 
polished sterile plugged Pasteur pipette for 5-10 passages to breakdown any clusters 
of astrocytes.  Cells were plated onto poly D-lysine-collagen coated coverslips at 
2,500 – 3,500 cells per well in 500 µl of astrocyte growth medium and maintained in 
a 37oC incubator supplied with 5% CO2 for 3-5 days until 60-80% confluency was 
achieved.   
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2.2.2.3 Preparation of rat hippocampal dissociated neurons 
 
Dissociated neuronal cultures were prepared from hippocampal tissue, containing the 
dentate gyrus and regions CA1-3 of P0-1 rat pups.  Following decapitation, the brain 
was rapidly removed from the animal’s skull by performing a sagittal cut from the 
medial occipital region to the frontal lobe area firstly of the skin followed by that of 
the skull.  Hemispheres were separated down the midline with a sharpened spatula 
and submerged in ice cold dissection solution.   The hippocampus was visible once 
the meninges and midbrain regions were excised using sharp forceps under a 
stereomicroscope. The hippocampus was removed from the brain using a sharpened 
spatula and cut into 3-4 equally sized pieces using a sterile no. 10 blade.  The tissue 
pieces were rinsed once with dissection solution and then transferred into a falcon 
tube containing papain digestion solution and incubated at 37oC for 20-28 min.  
After this time, the papain solution was aspirated and the tissue rinsed 3x with pre-
warmed neuronal culture medium.  To dissociate the digested hippocampal pieces, a 
sterile flame polished plugged Pasteur pipette was used to gently triturate the tissue 3 
times.  In order to estimate the number of viable cells, 5 µl of trypan blue was added 
to 50 µl of the triturated cell mixture and then live cells that excluded the dye were 
counted using a hemacytometer.  Cells were seeded in 500 µl neuronal culture 
medium at 12,500 – 17,500 cells per well.  After 24–48 hrs, 100 µl of neuronal 
culture medium containing the anti-mitotic agent, cytosine arabinoside (4 µM final 
concentration) was added to each well to minimise further astrocyte growth.   An 
example of a dissociated neuron cultured for 12 days in vitro (DIV) is shown in 
Figure 2.1 a. 
 
 
2.2.2.4 Preparation of mouse hippocampal dissociated neurons 
 
Previous characterization of PS1-/- mice (Wong et al., 1997) have shown no 
surviving animals beyond postnatal ages suggesting that knock-out of the PS1 gene 
results in late embryonic (E) lethality.  Consistent with this, genotyping postnatal 
animals after weaning (at P21) did not yield the PS1-/- genotype.   For this reason, 
embryonic pups were used to prepare PS1 mice dissociated cultures.  3-11 month old 
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female PS1 +/- mice were mated with male PS1 +/- mice to generate litters which 
should contain a combination of PS1 +/-, PS1 +/ + and PS1 -/- pups.  E15-17 mice 
were obtained from pregnant female PS1 +/- mice.  All pups from a given litter were 
individually dissected and hippocampi were removed.  Cortical brain samples and 
tail biopsies (approximately 2 mm) were also collected from each pup and placed in 
individual eppendorf tubes for genotyping.  Samples were maintained on ice or 
stored at -20oC until genotyping.  All mice were genotyped by D. Elliott using PCR 
(see section 2.1.2).     
 
Hippocampi from individual pups were digested, triturated, counted and plated 
separately to prevent mixing of different genotypes.  Mice neurons were plated at 
19,000 – 22,500 cells per well onto coverslips with rat astrocyte feeder layer.  Initial 
experiments where mice neurons were plated at the same (low) density as that used 
for rat cultures resulted in poor cell health, assessed by excess cell debris in the 
culture media after plating and morphological abnormalities such as sunken somas.   
 
 
2.2.2.5 Organotypic slice culture preparation 
 
Organotypic slices were cultured using a modified interface method (De Simoni et 
al., 2003; De Simoni and Yu, 2006; Stoppini et al., 1991).  This is a simple and 
adaptable procedure that enables the culture of static slices at the air-medium 
interface, enabling them to be studied over a wide developmental period.  1 ml of 
pre-warmed organotypic culture medium was put into each well of a 6 well plate, 
followed by a semi permeable membrane insert (Millipore).  3 smaller pieces of semi 
permeable membrane, termed confetti, were placed onto the surface of each insert, 
and a hippocampal slice was placed on top of each confetti piece.  From past 
experience, slices in culture flatten and strongly adhere to any membranous material 
over time.  Thus, these smaller pieces of confetti allow for the easy manoeuvre and 
access of organotypic slices whilst minimising stress and damage to the slice when 
transferring from the culture insert to the experimental set up.   Culture plates and 
organotypic culture and slicing media were freshly prepared on the day of slicing.  
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Plates were maintained at 37oC whilst organotypic slicing medium was maintained 
on ice.   
 
Parasaggital hippocampal slices were prepared from P6-8 male Sprague-Dawley rats.  
The brain was removed from the skull using the method outlined in section 2.2.2.3, 
and immersed in ice cold organotypic slicing medium.  A midline cut was made 
using a no. 22 blade to separate the two hemispheres.  A wide ended spatula was 
used to manoeuvre each hemisphere onto the stage of the slicing chamber.  Each 
hemisphere was glued along the midline cut using cyanoacrylate, and 300 µM thick 
slices were cut in ice-cold slicing solution using a vibrating microtome (vibraslice, 
Campden Instruments, Ltd) with either a ceramic blade or a stainless steel blade.  
The cut slices were transferred to a Petri dish containing ice cold slicing solution, 
and the hippocampus was isolated under a dissecting microscope.  Dissected 
hippocampal slices were quickly rinsed in 10 ml ice cold organotypic culture 
medium and carefully plated onto the small confetti pieces using a wide end sterile 
plastic or glass Pasteur pipette.  Excess culture medium was removed from the 
surface of the membrane insert using a flame polished glass Pasteur pipette, and the 
plate was returned to the incubator.  Organotypic culture medium was replaced every 
2-3 days by aspirating 900 µl and replacing with 1 ml pre-warmed medium.  Figure 
2.2 b shows a typical hippocampal slice soon after slicing (top) and after 14 days in 
vitro (bottom). 
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2.3 Drugs and Inhibitors 
 
 
2.3.1 γ-secretase inhibitors 
 
PS1 mice, rat dissociated and organotypic cultures were used for pharmacological 
experiments to examine the effects of γ-secretase inhibitors on synapse function.  
The following two γ-secretase inhibitors were used for most experiments:  
 
 
DIV 14 
DIV 0 
b
Figure 2.1 - Hippocampal dissociated and organotypic slice cultures   
(a) Low magnification DIC image of a rat dissociated neuron grown in 
culture at DIV 12.  These low density cultures are used for most of the 
experiments discussed in this thesis. Scale bar, 20 µm.  
(b) Image of sample organotypic slice cultures made from the hippocampal 
formation at DIV 0 (top) and DIV 14 (bottom).  Note the broadening and 
thinning of the slice with time whilst gross cytoarchitecture and slice shape is 
largely maintained. Scale bar, 1 mm.  Image adapted from De Simoni and Yu, 
2006. 
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N-[N-(3,5-di¯uorophenacetyl)-l-alanyl]-S-phenylglycine t-butyl ester (DAPT) is a 
dipeptidic compound which interacts with the C-terminal fragment of presenilin 
(Morohashi et al., 2006) and shown to reduce Aβ production in human neuronal 
cultures (Dovey et al., 2001) and rat cortical cultures (Hoey et al., 2009). DAPT was 
used at a final concentration of 10 µM (Chyung et al., 2005; Yang et al., 2008).  
Figure 2.2 a (top, red) shows the molecular structure for DAPT. 
 
(1S-Benzyl-4R-[1-(1S-carbamoyl-2-phenylethylcarbamoyl)-1S-3-
methylbutylcarbamoyl]-2R-hydroxy- 5-phenylpentyl)carbamic acid tert-butyl ester 
(L-685,458) is a transition state analogue and shown by previous studies to bind to 
the active zone region of presenilins to inhibit its enzymatic activity (Li et al., 2000; 
Shearman et al., 2000), and blocks Aβ production in a range of APP overexpressing 
cell lines (Shearman et al., 2000).  L-685,458 was used at a final concentration of 1 
µM (Kamenetz et al., 2003). Figure 2.2 a (bottom, blue) shows the molecular 
structure for L-685,458. 
 
 
2.3.2 β-secretase inhibitors 
 
In chapter 7, the effects of β-secretase inhibitor treatment on dissociated and 
organotypic hippocampal cultures were examined.   β-secretase IV  is an inhibitor 
which acts at the active site of β -secretase and was used at a final concentration of 1 
µM (Wen et al., 2008).  Figure 2.2 b (green) shows the molecular structure for β-
secretase IV.   
 
The drugs listed above were purchased from Merck Biosciences, made up in 
dimethyl sulfoxide (DMSO) and stored according to manufacturer’s 
recommendations.  0.1% DMSO was used as a mock vehicle control for all 
experiments (Sigma).   
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DAPT
L685,485 
a 
b 
Β-sec IV 
Figure 2.2 - Molecular structure of γ-secretase and β-secretase inhibitors   
(a) Molecular structure of γ-secretase inhibitors DAPT (red, top) and L-685,458 
(blue, bottom).  These inhibitors are used throughout this thesis to 
pharmacologically block γ-secretase dependent actions of presenilin in both 
dissociated and organotypic slice cultures.  (Adapted from Tomita and Iwatsubo, 
2004). 
(b) Molecular structure of β-secretase inhibitor IV (β-sec IV) (green).  This drug 
was used to inhibit β-secretase activity in dissociated and organotypic slice 
cultures. (Adapted from Stachel et al., 2004). 
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2.4 Electrophysiology 
 
 
2.4.1 Materials 
 
 Table 2.7: Chemicals / Reagents / Products used for electrophysiology 
Product Company Location 
2-chloroadenosine Sigma - Aldrich Dorset, UK 
ATP dipotassium salt Sigma - Aldrich Dorset, UK 
Axon pclamp 10.2 Molecular devices  Berkshire, UK 
Boroscillicate glass 
capillaries (150F- 7.5) 
Harvard Apparatus Edenbridge, UK 
CNQX Tocris Bioscience Bristol, UK 
Creatine phosphate 
dipotassium salt 
Merck chemicals Darmstadt, Germany 
DB2 micropipette holders G23 instruments London, UK 
DL-AP5 Tocris Bioscience Bristol, UK 
GTP sodium salt Sigma - Aldrich Dorset, UK 
MK801 maleate Tocris Bioscience Bristol, UK 
NBQX  Tocris Bioscience Bristol, UK 
Picrotoxin Sigma - Aldrich Dorset, UK 
Tetrodotoxin citrate (TTX) Tocris Bioscience Bristol, UK 
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Table 2.8: Buffers and Solutions, used for electrophysiology 
Buffer / Solution Contents Storage Sterilisation 
External solution 
for dissociated 
cultures 
130 mM NaCl, 2.5 mM KCl, 
2.2 mM CaCl2, 1.5 mM MgCl2,  
10 mM HEPES, 10 mM D-glucose 
4oC 0.2 µM filter 
External solution 
for organotypic 
slice cultures 
120 mM NaCl, 2.5 mM KCl,  
2.2 mM CaCl2, 1.5 mM MgCl2, 
1.25 mM NaH2PO4, 26 mM 
NaHCO3, 11 mM D-glucose 
4oC 0.2 µM filter 
Internal solution 
for dissociated 
cultures and 
organotypic  – 
mEPSC   
100 mM K gluconate, 17 mM 
KCl, 5 mM NaCl, 10 mM 
HEPES–KOH, 0.5 mM EGTA-
KOH, 4 mM MgCl2, 20 mM K2 
creatine phosphate, 4 mM K2-
ATP, 0 .5 mM Na3-GTP. 
-20oC 0.2 µM filter 
Internal solution 
for organotypic  – 
mEPSC and 
mIPSC  (low Cl 
internal) 
105 mM K gluconate, 3 mM KCl, 
2 mM NaCl, 10 mM HEPES–
KOH, 0.5 mM EGTA-KOH,   
20 mM K2 creatine phosphate,  
4 mM K2-ATP, 0 .5 mM Na3-GTP.
-20oC 0.2 µM filter 
Internal solution 
for organotypic 
slices – paired-
pulse and MK801 
experiments 
115 mM Cs methanosulfonate,  
20 mM CsCl, 10 mM Cs-HEPES, 
4 mM NaCl2, 4 mM Mg-ATP,  
0.5 mM Na3-GTP, 10 mM  
K2 creatine phosphate,  
0.5 mM EGTA-Cs.   
-20oC 0.2 µM filter 
 
Abbreviations: mEPSC – miniature excitatory postsynaptic current; mIPSC – 
miniature inhibitory postsynaptic current 
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2.4.2 Methods 
 
Electrophysiology methods were used to study the electrical properties of neurons.  
For this thesis, recordings were made from visualised neurons in whole-cell 
configuration in voltage clamp mode.  PS1 mice dissociated cultures were used 
between 10-16 DIV whilst rat dissociated culture recordings were performed on 10-
17 DIV neurons.  Organotypic slices were used at two different ages, from DIV 6-8 
for paired-pulse ratio and MK801 block experiments and DIV 9-15 for miniature 
EPSC and IPSC recordings.   
 
 
2.4.2.1 Patch clamp recordings from hippocampal dissociated cells 
 
Coverslips were transferred from the incubator to the glass bottomed chamber of an 
Olympus IX70 inverted microscope.  The microscope was fixed on a vibration 
isolation air-table (Technical manufacturing corporation, Massachusetts, US) and all 
connections and wires were grounded to the air table to minimise electrical noise.  
The amplifier was an Axopatch 200B linked to an Intel Celeron CPU (2.53 Hz) via a 
National instruments BNC-2090 board.  Data was acquired using a custom 
programme written in house by Dr. D. Hagler (called Acquire).  An Axon CV203BU 
headstage was attached to a XYZ stainless steel stage with actuators motorized from 
Newport which was securely attached to the microscope and remotely controlled 
using a Soma Instruments touch pad controller (MC300).  Glass pipettes were pulled 
from thick walled filamented borosilicate capillaries (GC150F-7.5) using either a 
Narishige 2 stage vertical puller (Model PP830) or a Sutter Instruments 
Flaming/Brown horizontal puller (Model P97) using a 5 step program.  Pipettes used 
for whole cell recordings were neither fire polished nor coated with sylgard.  Pipettes 
were of 2.5-5.8 MΩ resistance when filled with potassium-gluconate internal 
solution using a plastic/fused silica micropipette (Microfil, World Precision 
Instruments, Florida, USA) attached to a 1ml syringe.  The internal solution was 
filtered through a 0.4 µm syringe filter prior to pipette filling to remove any dust 
(Nalgene, Hereford, UK).  Glass pipettes were placed in a DB2 holder (G23 
instruments, London, UK) which contained an Ag/AgCl wire (AgCl layer generated 
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using electrophoresis) and electrically connected to the headstage via a gold pin.    
An additional ground electrode, made from silver wire either coated with an AgCl 
layer or attached to a small AgCl pellet was submerged in extracellular solution in 
the bath chamber and connected to the headstage using insulated wire.   
 
Positive and negative pressure could be applied to the recording electrode through a 
mouthpiece connected to the pipette holder by a length of silicone tubing to aid in 
achieving a giga-ohm seal.  To obtain a recording, a recording electrode was placed 
in the bath chamber and the pipette offset was adjusted to zero using manual controls 
on the amplifier to eliminate the potential difference between the ground electrode 
and the recording pipette.  The recording electrode was positioned above visually 
selected neurons using a 10x phase contrast objective (0.30 NA) and patched under 
differential interference contrast (DIC) optics with 40x magnification objective (0.85 
NA).  Pipette resistance and seal formation was monitored by applying a 5 mV (100 
ms duration) test pulse in voltage-clamp mode.   Positive pressure was applied to the 
patch pipette during the approach to the soma to prevent blockage of the pipette tip.  
Upon visualisation of a small dimple on the cell soma and an increase in electrode 
resistance, positive pressure was stopped and gentle suction was applied to the 
mouth piece to aid seal formation.  When the seal increased to 100 MΩ, holding 
current was injected (voltage command -40 mV) to promote formation of a high 
resistance seal (>1GΩ (cell-attached)).  When cell-attached configuration was 
obtained, pipette capacitance transients were manually cancelled on the amplifier 
and the cell was set to a holding potential of -70 mV.  To achieve the whole-cell 
configuration, short bursts of negative suction were applied to the pipette until the 
membrane at the tip of the patch pipette broke.  Series resistance was uncompensated 
and input resistance and access resistance were monitored throughout the recording 
and recordings terminated if an increase of over 20% was observed.  Holding current 
and resting membrane potential was also monitored at the start and end of 
recordings.   
 
Dissociated cells were voltage clamped at -70 mV and recordings were filtered 
online at 2 kHz (4 pole Bessel filter) and digitized at 10 kHz using Acquire software.  
mEPSCs were continually recorded in the presence of 0.5 µM TTX and 100 µM 
picrotoxin.  For a subset of neurons, CNQX (20 µM) or NBQX (20 µM) and DL-
Chapter 2: Materials and Methods 
 100
AP5 (50 µM) was applied at the end of the mEPSC recording period to block 
glutamatergic currents to show that the events recorded, corresponded to excitatory 
currents.  Recordings were carried out at room temperature and in external solution 
for dissociated cultures (see Table 2.8).  For γ or β-secretase inhibitors experiments, 
drugs were also included in the bath solution during the recordings and coverslips 
were discarded 30-45 mins after removal from the incubator.   
 
Analysis 
Peak amplitude and frequency values were measured with Analyse software (written 
by D. Hagler) and input resistance, series resistance, cell capacitance, rise time and 
decay time were calculated in Igor 6.0.3.1 using custom scripts written by Dr. L.A. 
Cingolani in the lab.  Cells with an access resistance of <30 MΩ and resting 
membrane potential less than -45 mV were used for analysis.  mEPSCs were 
identified offline using Analyse software.  mEPSCs were scored based on the criteria 
that the decay time was slower than the rise time and amplitudes were at least double 
the baseline noise, using a threshold crossing principle.    Raw traces were visually 
examined and false events were not counted.  Analysis of dissociated cells was 
performed on a 100 sec time window at the beginning of each continuous recording.  
Cells with large baseline fluctuations which did not permit an accurate measure of 
baseline values were not analysed.  
  
To estimate the rise and decay times, the baseline of each single event was taken as 
the average value from -2.5 ms to -12.5 ms before the peak mEPSC amplitude.   The 
time to reach from 10 to 90% of the peak amplitude was taken as the rise time value.   
 
For the decay time, the following formula was used:  
 
 
 
where the area between 10 to 90% of the decay slope (peak amplitude to downstream 
baseline) was divided by the peak amplitude.    
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Series resistance (Rs), input resistance (Rin) and cell capacitance (Cm) was calculated 
from a 5 mV (100ms duration) test pulse from each cell, using the following 
equations: 
  
Rs = Δ V / Ii    
 
where Δ V was 5 mV, and Ii was the instantaneous current; 
 
 
Rin = Δ V / Iss 
 
where Δ V was 5 mV, and Iss was the steady state current; 
 
 
 Cm = τ / Rs 
 
where τ was estimated using a double expontential fit of the decay phase of the 
instantaneous current, and Rs was series resistance.   
 
 
2.4.2.2 Electrophysiology from hippocampal organotypic slice cultures  
 
The procedure for electrophysiological recordings in organotypic slice cultures was 
the same as that outlined for dissociated cultures (see section 2.4.2.1) except for the 
following modifications.  Hippocampal slice cultures were transferred to the glass 
bottomed chamber of an Olympus BX50WI upright microscope and held in place 
using 5 parallel dental floss fibres attached to a U shaped flattened platinum wire.  
An Axopatch 200B amplifier was connected to an Intel Pentium 4 CPU (2.8 Hz) via 
an Axon instuments digidata 1440A.  Slice recordings were made using either 
Acquire software or Clampex 10.2 (Axon instruments).  An Axon CV203BU 
headstage was attached to a Luigs and Neumann motorized micromanipulator which 
was mounted to the vibration isolation table and moved independently from the 
microscope.  The slice was continuously perfused with organotypic extracellular 
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solution (bubbled with 95% O2 and 5% CO2) at a flow rate of 1.0-1.5 ml/min 
delivered using either a gravity flow perfusion system linked to a Capex L2C 
(Charles Austen) vacuum pump or a peristaltic pump (Ismatec) where the inflow rate 
was equalized to the outflow rate.  10x (0.30 NA) and 40x (0.80 NA) water 
immersion objectives were used with DIC optics to visually identify CA1 pyramidal 
cells in the hippocampal slice.   In some slices, a mild positive pressure was applied 
for a short period to the surface of the slice to remove excess debris from the cell 
soma (Edwards et al., 1989).  The pipette was then withdrawn from the bath and 
replaced with a new pipette to attempt to patch cells in the cleaned region. 
 
For mEPSC recordings in organotypic slices, the same conditions as that used for 
dissociated neurons were applied (see section 2.4.2.1).  To record both mEPSCs and 
mIPSCs in organotypic slices, a low Cl internal was used (see Table 2.8).  For these 
experiments cells were either held at -50 mV where both inward mEPSC and 
outward mIPSCs were observed simultaneously or cells were first held at -70 mV to 
detect inward mEPSC currents and then held at 0 mV to record outward mIPSCs.  
For experiments where evoked AMPA and NMDA EPSCs were examined, a cesium 
methanosulfonate based internal solution was used. For evoked current experiments, 
a single cut was also made between the CA3 and CA1 regions of the slice using a no. 
10 blade to minimize recurrent activity.    To evoke EPSCs, the Schaeffer collateral 
axons of the stratum radiatum were stimulated with a concentric bipolar electrode 
placed onto the superficial regions of the slice and at least 200 µM from the cell 
soma to minimize the chances of stimulating the cell directly.  For AMPA currents, 
cells were voltage clamped at -70 mV and Schaffer collaterals were stimulated to 
achieve an amplitude of approximately 30 pA.  For NMDA currents, cells were 
voltage clamped at -40 mV, and stimulation was set to obtain a 50-80 pA current. 
   
Paired-pulse ratio (PPR) and rate of NMDA current block using a non-competitive 
NMDA receptor antagonist, MK801, were used as two separate estimates of release 
probability.  For paired-pulse experiments, neurons were voltage clamped at -70 mV 
and two identical afferent stimuli separated by 50 ms interval were used to evoke 
sequential excitatory postsynaptic currents.  Each pair of stimuli was given at a 
frequency of 0.2 Hz and up to 80 sweeps were recorded.  NBQX (10 µM) was 
applied at the end of PPR experiments and blocked both EPSCs, confirming that the 
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currents were glutamatergic.  NBQX was also perfused continuously to isolate the 
NMDA receptor current for MK801 experiments.  The rate of NMDA current block 
by use-dependent antagonist MK801 was determined at a holding potential of -40 
mV, which relieved the magnesium block of NMDA receptors to generate an inward 
NMDA current upon synaptic stimulation (Huang and Stevens, 1997).  In this 
configuration, the presence of MK801 leads to a progressive reduction in NMDA 
receptor current amplitude due to block of open NMDA receptors (Huang and 
Stevens, 1997).   After obtaining a stable baseline, a single current stimulus was 
applied to the Schaeffer collaterals to get a synaptic NMDA current.  Stimulation 
was then stopped and MK801 (40 µM) was bath applied for 9-10 min to ensure the 
slice was saturated with the inhibitor.  After this period, MK801 was continuously 
perfused, and changes in the EPSC amplitude were monitored in response to 
stimulation at 0.125 Hz.  Recordings were terminated after 150 sweeps.  γ-secretase 
inhibitors,  β-secretase inhibitors or 0.1% DMSO vehicle control was included in the 
perfusate when testing slices that had been chronically treated with these drugs.   
 
Analysis 
For mEPSC recordings made using Acquire, frequency and amplitude were 
determined in Analyse, whereas for data obtained using clampex 10.2, frequency and 
amplitude measurements were made in clampfit 10.2.  Criteria for miniature event 
detection were the same as that described for dissociated cells.    For rise time and 
decay time measurements the same method as that used for dissociated cells was 
applied except the baseline of each single event was taken as the average value from 
-7 to -17 ms before the peak mEPSC amplitude.   Analysis was performed on 5 min 
continuous recordings.  Paired-pulse ratio and MK801 block experiments were 
analysed in Clampfit 10.2.  Initial experiments estimating paired-pulse ratio were 
performed in the presence of 2-chloroadenosine, an agonist of presynaptic A1 
receptors that reduces polysynaptic excitation (Futai et al., 2007)(data not shown).  
Other reports (Scanziani et al., 1992) have shown that 2-chloroadenosine could have 
a strong influence on presynaptic release probability, and thus experiments were 
repeated in the absence of 2-chloroadenosine.  All experiments presented in this 
thesis were from the latter group.  Due to the lack of 2-chloroadenosine, occasional 
bursting activity was observed in a minority of organotypic slices.  Sweeps 
containing bursting activity were eliminated from analysis.  The baseline of each 
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sweep was calculated by taking the average over a 20 ms period up to 3.5 ms before 
the first stimulation. To obtain the paired-pulse ratio of a cell, the mean peak 
amplitude of the 2nd EPSC was divided by the mean peak amplitude of the 1st EPSC 
(A2/A1).  Approximately 68 – 80 sweeps were averaged and analysed.   To measure 
the rate of MK801 block, the peak amplitude of each EPSC was plotted against time 
and a mono-exponential decay curve fit was used to obtain the time constant (τ) of 
MK801 block for each cell.  The NMDA current amplitude generated by the first 
stimuli in the presence of MK801 was set to one and all subsequent NMDA current 
responses were normalised to the amplitude of the first stimuli.   
 
 
 
 
2.5 FM Imaging  
 
 
2.5.1 Materials  
 
Table 2.9: Chemicals / Reagents / Products used for FM imaging experiments 
Product Company Location 
Advasep - 7 Biotium  Hayward, CA, US 
CNQX Tocris biosciences Bristol, UK 
DL – AP5 Tocris biosciences Bristol, UK 
Field stimulation chamber Custom made in house London, UK 
FM 1-43 Invitrogen Paisley, UK 
Metamorph software Molecular devices  Berkshire, UK 
Stimulator Grass technologies Slough, UK 
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Table 2.10: Buffers and Solutions, used for FM imaging experiments 
Buffer / Solution Contents Storage Sterilisation 
External solution 
for dissociated 
cultures  
- 2.2 mM (normal) 
calcium 
130 mM NaCl, 2.5 mM KCl, 2.2 
mM CaCl2, 1.5 mM MgCl2, 10 
mM HEPES, 10 mM D-glucose, 
10 µM CNQX, 50 µM DL-AP5, 
100 µM picrotoxin  
4oC 0.2 µM filter 
External solution 
for dissociated 
cultures  
- 1 mM (low) 
calcium 
130 mM NaCl, 2.5 mM KCl, 1 
mM CaCl2, 2 mM MgCl2, 10 mM 
HEPES, 10 mM D-glucose, 10 µM 
CNQX, 50 µM DL-AP5, 100 µM 
picrotoxin 
4oC 0.2 µM filter 
External solution 
for dissociated 
cultures  
- 5 mM (high) 
calcium 
130 mM NaCl, 2.5 mM KCl, 5 
mM CaCl2, 0.6 mM MgCl2, 10 
mM HEPES, 10 mM D-glucose, 
10 µM CNQX, 50 µM DL-AP5, 
100 µM picrotoxin 
4oC 0.2 µM filter 
External solution 
for dissociated 
cultures  
- 0.5 mM calcium 
(used for washes 
and removal of 
FM dye) 
130 mM NaCl, 2.5 mM KCl, 0.5 
mM CaCl2, 10 mM MgCl2, 10 mM 
HEPES, 10 mM D-glucose, 10 µM 
CNQX, 50 µM DL-AP5, 100 µM 
picrotoxin 
4oC 0.2 µM filter 
 
 
2.5.2 Methods  
 
2.5.2.1 FM Styryl-dye labeling and imaging 
 
FM-dye labelling and visualisation of neurons was conducted on an Olympus 
BX50WI upright epifluorescence microscope setup.  Dissociated cells loaded with 
FM1-43 were viewed through a 40x (0.80 NA) water immersion objective using a 
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475/40 nm excitation filter, 505LP dichroic and a 535/45 nm emission filter with 
light supplied by a Prior Lumen 200 illumination system.  Metamorph 7.1.0.0 
imaging software running on an Intel Celeron CPU (2.53 GHz) was used to control a 
Princeton Instruments 1392 x 1040 cooled-CCD camera and a Uniblitz VMM-D1 
shutter driver to enable time lapse acquisition of 12-bit images.  A gravity flow 
perfusion system (1-2 ml/min) with suction supplied by a Capex vacuum pump was 
used for washing away excess extracellular dye.   
 
A glass bottomed, custom built slotted field stimulation chamber assembled with two 
parallel platinum wires set 1 cm apart, was used to induce stimulated uptake of styryl 
dye, FM1-43 dye into synaptic vesicles.  Extracellular field stimulation consisted of 
a 2 ms 22 V square pulses applied via a stimulator (Grass, Astro-Med, USA) 
connected to the platinum wires.  To selectively load the recycling vesicle pool, 600 
stimuli at 10 Hz was applied to the cells in the presence of FM1-43 (10 µM) in the 
extracellular solution for dissociated neurons.  After stimulation, neurons remained 
in solution containing the dye for a further 30 sec for vesicle endocytosis to complete 
(Murthy et al., 1997; Tokuoka and Goda, 2008).  Cells were then rinsed 1x for 30 
sec using 0.5 mM calcium solution, followed by a 1 min wash with a fluorescent 
quenching agent Advasep-7 (1 mM, Biotium) in 0.5 mM calcium solution.  
Advasep-7 was then removed from the solution and a 7-8 min wash in low calcium 
solution was applied to remove excess dye from the extracellular space and plasma 
membranes.  Low 0.5 mM calcium solution also helped to reduce unloading of the 
dye by spontaneous spikes.     
An estimate of release probability at single synapses was obtained by examining the 
rate of vesicle exocytosis (destaining) of the recycling pool (Branco et al., 2008).  
For this, neurons were returned to normal calcium (2.2 mM) dissociated solution and 
stimulated using 900 stimuli at 5 Hz (Murthy et al., 1997) to cause vesicle release 
which can be visualized by a gradual decrease in FM fluorescence intensity at 
presynaptic puncta.  Field stimulation applied to induce synaptic vesicle exocytosis 
also helped differentiate actively recycling vesicles (which lost fluorescence when 
stimulated) from non-specific tissue staining or unhealthy neurons (which did not 
respond to stimulation).   For all exocytosis stimulations, timelapse images were 
acquired every 10 sec for 5 mins (700 ms exposure time), and a 60 sec baseline (zero 
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stimulation) period was made prior to initiating stimulation to monitor any possible 
photobleaching.   
An estimate of the readily releasable pool size (RRP) at presynaptic terminals was 
performed by stimulating FM dye uptake using 30 stimuli at 1 Hz field stimulation 
(Tokuoka and Goda, 2008; Waters and Smith, 2000).  Following an 8 min wash 
period in 0.5 mM calcium, cells were stimulated using 600 stimuli at 20 Hz repeated 
3 times with a 15 sec interval between each train to induce destaining of dye from 
the RRP.  Dissociated cells of DIV 13-17 were used for FM experiments.  All FM 
imaging experiments were performed at room temperature in the presence of 10 µM 
CNQX and 50 µM DL-AP5 to prevent recurrent activity, and 100 µM picrotoxin to 
block GABAA currents.  n refers to the number of coverslips used and an average of 
50 boutons were imaged for each coverslip. 
 
Analysis  
Image analysis of FM experiments was performed in metamorph 7.1.0.0.  For both 
recycling pool and RRP experiments, FM loaded puncta were selected by placing a 
size 5 ellipse around fluorescent regions located along a neuronal process.  For 
estimates of local background levels in recycling pool destaining experiments, a size 
5 ellipse was placed on non fluorescent (and non neuronal) regions located adjacent 
to the FM loaded bouton.  For each frame, background region measurements were 
averaged and this value was subtracted from each FM loaded region at the same time 
point.   All data points were normalized to the fluorescence of the first frame and 
fluorescence pixel measurements were plotted against time.  A plateau followed by a 
monotonic decay curve (least squares fit) was fitted to estimate the decay constant 
for FM destaining in Prism (version 5.0.1, Graphpad).   
Background subtraction for the readily releasable pool experiments was obtained by 
taking the remaining fluorescence at the end of the destaining protocol from the 
fluorescence obtained prior to destaining.  Fluorescence values (post background 
subtraction) for the RRP were determined by taking an average of the first five 
frames prior to destaining.  The fluorescence values of γ-secretase inhibitor treated 
cells were normalized to the fluorescence values of DMSO control cells from the 
same preparation.   
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2.6 Calcium imaging 
 
2.6.1 Materials  
 
Table 2.11: Chemicals / Reagents / Products used for calcium imaging 
Product Company Location 
EGTA AM  Invitrogen Paisley, UK 
Fluorescein Sigma Dorset, UK 
Fura-2 AM Invitrogen Paisley, UK 
Image pro plus Media cybernetics  Bethesda, MD, US 
Ionomycin Sigma Dorset, UK 
Ryanodine Tocris Bioscience Bristol, UK 
Thapsigargin Tocris Bioscience Bristol, UK 
 
 
Table 2.12: Buffers and Solutions, used for calcium imaging 
Buffer / solution Contents Storage  Sterilisation 
External solution for 
basal calcium 
measurements 
130 mM NaCl, 2.5 mM KCl, 
2.2 mM CaCl2, 1.5 mM 
MgCl2, 10 mM HEPES, 10 
mM D-glucose, 100 µM 
picrotoxin  
4oC 0.2 µM filter 
External solution for 
KCl based 
depolarisation  
72.5 mM NaCl, 60 mM KCl, 
2.2 mM CaCl2, 1.5 mM 
MgCl2, 10 mM HEPES, 10 
mM D-glucose, 100 µM 
picrotoxin  
4oC 0.2 µM filter 
External solution for 
measurement of R min  
(zero CaCl2) 
130 mM NaCl, 2.5 mM KCl, , 
1.5 mM MgCl2, 10 mM 
HEPES, 10 mM D-glucose, 
4oC 0.2 µM filter 
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100 µM picrotoxin, 4 mM 
EGTA-AM 
External solution for 
KCl induced 
depolarisation during 
measurement of R min 
(zero CaCl2) 
72.5 mM NaCl, 60 mM KCl, 
1.5 mM MgCl2, 10 mM 
HEPES, 10 mM D-glucose, 
100 µM picrotoxin, 4 mM 
EGTA-AM 
4oC 0.2 µM filter 
 
 
2.6.2 Methods  
 
2.6.2.1 Live calcium imaging with Fura-2 
 
Fura-2 is a polyamino carboxylic acid which is capable of binding free calcium ions 
in cells.  Upon binding calcium, the fluorescence excitation wavelength maximum 
shifts from 363 nm (calcium free) to 335 nm (calcium bound) (Figure 2.3 a).  This 
property of Fura-2 enables ratiometric estimates of intracellular calcium 
concentrations by monitoring the fluorescence at wavelengths of 340 nm (increases 
in signal upon binding calcium) and 380 nm (decreases in signal upon binding 
calcium).  Such ratiometric dyes were preferred over single wavelength dyes as 
measurements should be independent of variations in dye loading, intracellular dye 
concentration and differences in neuronal structure.  A non-fluorescent, membrane 
permeable (uncharged) form of Fura-2, Fura-2-acetoxymethyl ester (Fura-2-AM) 
was used to deliver the dye into cells.  When applied to the bath, Fura-2-AM can 
pass from the extracellular space into the intracellular compartment of cells where 
endogenous intracellular esterases can cleave the AM groups to generate the 
charged, less membrane permeable, and fluorescent molecule known as Fura-2 
(Figure 2.3 b).   
 
Fura-2 imaging of neurons was conducted on a Zeiss Axiovert 135 TV inverted 
microscope setup.  This microscope set up was kindly provided by Professor John 
Garthwaite and Dr Andrew Batchelor at UCL.  Dissociated cells containing Fura-2 
were viewed through a 10x fluar (0.5 NA) air objective using a 340/15 nm and 
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380/15 nm excitation filter, 430 LP dichroic and a 510/40 nm emission filter with 
light supplied by a Prior Lumen 200 illumination system.  Image Pro 6.3 Software 
(Media cybernetics Inc, Bethesda, USA) was used to control a Qimaging Rolera XR 
Camera and paired 340 and 380 nm wavelengths 12 bit monochrome images were 
acquired using a filter wheel switching mechanism inside the Prior Lumen 200 lamp 
housing.   Cells were continuously perfused with extracellular dissociated solution 
containing picrotoxin (100 µM) at 1.5- 2 ml/min using a peristaltic pump (Ismatec).  
Tetrodotoxin (TTX, 0.5 µM) was used to block calcium signals resulting from 
spontaneous network activity. DMSO mock, γ-secretase inhibitors or intracellular 
store drugs (ryanodine or thapsigargin) were also maintained in the extracellular 
solution following a chronic drug treatment.  Dissociated cultures from DIV 13-15 
were used.   
 
Cells were loaded by preincubating coverslips in Fura-2 AM (1 µM) dissolved in 
dissociated culture media for 25 min at 37oC/ 5% CO2 incubator.  After this period, 
coverslips were briefly rinsed in extracellular dissociated cell solution and placed 
onto the microscope chamber.  A DIC image was taken to aid neuronal 
identification.  For background subtraction, 340 nm and 380 nm fluorescence images 
were acquired from a region within the microscope chamber that was not associated 
with the coverslip i.e. a non cellular region.  For data collection, a region of the 
coverslip containing small networks of healthy neurons was selected and paired 
timelapse images were captured by rapid sequential switching from 340 nm (600 ms 
exposure) to 380 nm (60 ms exposure) wavelengths.  Paired 340 and 380 nm images 
were captured every 2.18 sec and the ratio for each frame was obtained by dividing 
fluorescence values excited by 340 nm and 380 nm wavelengths.   
 
Initial experiments were performed to determine the overall spontaneous network 
activity of dissociated neuronal cultures.  Preliminary observations showed that the 
number of spontaneous calcium transients was variable from preparation to 
preparation but also from coverslip to coverslip (see Figure 2.4 for examples).  
Spontaneous calcium transients were usually highly temporally synchronized across 
cells (as shown in Figure 2.4) and could be blocked with sodium channel inhibitor, 
TTX (Figure 2.4 b).  For all experiments presented in chapter 6, TTX was present 
throughout the course of the experiment.  The maintenance of cells in TTX for the 
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duration of the experiment provided conditions similar to those used during mEPSC 
recordings.   
 
 
Figure 2.3 - Properties of Fura-2 (AM)   
(a) Ratiometric properties of Fura-2 are displayed. Binding of calcium to Fura-2 
causes a spectral shift of the fluorescence excitation maximum from 363 nm 
(calcium free) to 335 nm (calcium bound). By imaging at 340 and 380 
wavelengths, the intracellular calcium ratio and concentrations can be estimated. 
Adapted from www.bphys.uni-linz.ac.at 
(b) Fura-2 AM contains acetoxymethyl (AM) ester groups which generate an 
uncharged molecule which can permeate plasma membranes.  Once inside the 
cell, intracellular endogenous esterases cleave the AM ester groups to give rise to 
a Fura-2, a charged and less membrane permeable form of the calcium dye.  
Fura-2 form is fluorescent and binds intracellular free calcium.  Adapted from 
www.biotek.com 
b 
a 
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Figure 2.4 - Spontaneous calcium transients in hippocampal dissociated 
neurons    
(a) The presence of highly temporally synchronised calcium transients in 3 
different neurons in a hippocampal dissociated culture at DIV 14. Calcium 
transients were measured using 380 nm wavelength and are represented as 
downward deflections (see arrows) from baseline basal calcium.     
(b) Spontaneous calcium transients are presented as the ratio between 340 nm 
and 380 nm wavelengths and seen as upward deflections.  Application of 500 nM 
TTX at time 0 eliminates all calcium transients suggesting these calcium signals 
result purely from spontaneous action potential generation within the neuronal 
network.    
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2.6.2.2 Basal and KCl-stimulated calcium induced calcium release (KCl-
stimulated CICR).   
 
Basal and KCl-stimulated CICR calcium was measured in the same cells.  Basal 
calcium was taken as the calcium measurements in the absence of exogenous 
stimulation.  KCl-stimulated CICR was stimulated using 30 sec bath application of 
60 mM KCl in extracellular bath solution.  KCl equiosmolarly replaced NaCl to 
maintain osmotic balance at 285-290 mOsm. 
 
To examine the period that KCl remains in the bath and evaluate the time taken for 
solutions to enter and exchange in the microscope chamber, the same protocol used 
for KCl application during CICR experiments was re-run after data had been 
collected but with KCl being replaced with a fluorescein solution (50-200 µM).   
Figure 2.5 shows the fluorescence signal from a cell loaded with Fura-2 and excited 
using 340 nm wavelengths.  The fluorescence of the cell before, during and after KCl 
application (application shown by black and white checkered bar) is represented as a 
solid red line.  Note how the cellular fluorescence signal increases in response to 
KCl application and then decays back to baseline levels.  This same protocol was 
administered once again but with 30 sec fluorescein application instead of KCl.  The 
timecourse for fluorescein application is represented by a dashed red line and is 
superimposed onto the timecourse of KCl application.  The fluorescence signal 
observed during fluorescein application is much stronger than the signal seen during 
KCl application (and effectively saturates the pixels of the camera) but provides an 
estimate of the time taken for solutions to exchange in the microscope chamber.  The 
superimposed KCl and fluorescein applications also show that the cellular change in 
fluorescence in response to KCl is temporally matched to the amount of time KCl is 
in the microscope chamber.     
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Figure 2.5 - Estimation of bath exchange rate during calcium imaging 
experiments    
(a) The solid red line shows the 340 nm wavelength fluorescence response of a 
neuron loaded with fura-2 before, during and after 60 mM KCl application.  KCl 
was applied at time 0 for 30 sec, indicated by checked box.  KCl application is 
represented by the black and white checked box.  Note the modest increase in 
fluorescence values during KCl application. 
The dotted red line shows a subsequent fluorescein (100 µM) application (using 
the same protocol as that used for KCl, but with KCl being replaced by 
fluorescein) onto the same cell.  Note the rapid and dramatic increase in 
fluorescence values upon fluorescein application (application represented by 
black and white checked box).  The plateau phase represents saturation of the 
camera.  Note how the fluorescence values come back to baseline by ~ 100-120 
sec after application.  This suggests that the bath exchange time is approximately 
100-120 sec.   
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2.6.2.3 Estimating calcium concentration in hippocampal dissociated cultures  
 
In addition to the direct comparison of ratio values, these values can also be used to 
estimate intracellular calcium concentrations ([Ca2+]i) according to standard 
procedures first described by Grynkiewicz et al., (1985) using the following 
equation:  
 
[Ca2+] i = Kd (Sf2/Sb2) (R-Rmin/ Rmax-R) 
 
In this equation, Kd is the dissociation constant of fura-2 for calcium at room 
temperature, and it is set at 135 nM (Grynkiewicz et al., 1985; Koch and Barish, 
1994).  Sf2, Sb2, Rmin and Rmax values were calculated in situ from hippocampal 
neuronal cultures.  Sf2 refers to the amount of free calcium and Sb2 is the amount of 
bound calcium measured using 380 nm excitation wavelength.  Sf2 was determined 
by taking the 380 nm fluorescence in zero calcium and Sb2 was taken as the 380 nm 
fluorescence in 2.2 mM external calcium.  The Sf2/Sb2 ratio was calculated to be 7.7 
by taking the mean 340/380 nm values from 4 separate coverslips.     
 
Rmin is the estimated 340/380 fluorescence ratio obtained in the absence of calcium.  
To obtain in situ measurements of this ratio value, the ionophore, ionomycin (10-20 
µM) (Erdahl et al., 1995; Wang et al., 1998) with 4 mM EGTA and 0 mM 
extracellular calcium was bath applied to hippocampal cultures to reduce free 
calcium as much as possible (Brenowitz and Regehr, 2003) (Figure 2.6, solid red bar 
shows ionomycin, EGTA, 0mM calcium extracellular solution application).  After 
several minutes upon application, a minor but stable drop in ratio values (Figure 2.6, 
red line) was observed, relative to the baseline ratio measured in 2.2 mM calcium 
extracellular solution (Figure 2.6 green line represents cellular response at 2.2 mM 
calcium).  Rmin was taken as the minimum value during the plateau in the presence 
of ionomycin and EGTA in 0 mM calcium and was 0.68 (n=4 coverslips).  
Rmax is the estimated 340/380 fluorescence ratio obtained in the presence of 
saturating concentrations of calcium.  For this, ionomycin (10-20 µM) was bath 
applied in 2.2 mM calcium extracellular solution (Figure 2.7, solid blue bar shows 
ionomycin application).  After several minutes of application, ratio values gradually 
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increased, indicating an increase in intracellular calcium, which was followed by a 
plateau phase corresponding to the saturation of fura-2 (Figure 2.7, blue line).  The 
plateau value gave an Rmax value of 14.05 (n=4 coverslips).  
 
As Rmin and Rmax values were applied to all subsequent ratio values to estimate 
intracellular calcium levels, it was important to show that the range of fluorescence 
observed during basal conditions and high KCl-stimulated CICR (discussed later) is 
within the range set by in situ measurements of Rmin and Rmax.  To test this, ratio 
values for both basal and KCl-stimulated CICR conditions were obtained prior to 
measurement of Rmin or Rmax in hippocampal cells.  The green line on Figure 2.6 
and Figure 2.7 shows ratio values for basal calcium and during KCl application 
(black and white checked bar).  This result shows that basal and peak CICR ratio 
values obtained in the same cells as that used to measure Rmin and Rmax were 
within the range of Rmin and Rmax measurements.  Additionally basal and CICR 
ratio values obtained in cells where either Rmin or Rmax measurements were also 
measured were similar to the ratio values obtained for subsequent experiments where 
Rmin and Rmax were not calculated (see chapter 6).  Due to this outcome, I justified 
that Rmin and Rmax values could be applied to all ratio measurements.   
 
As a further control to show that the increase in ratio obtained during KCl-stimulated 
CICR was associated in part with extracellular calcium concentration, KCl was 
applied in the presence of 0 mM calcium extracellular solution during the plateau 
phase of Rmin measurements where cellular calcium concentrations was assumed to 
be at its lowest point.  The purple line on Figure 2.6 shows the basal and CICR ratio 
values in 0 mM calcium and KCl application is indicated by the checked box.  As 
expected, no changes in fluorescence ratio were observed during KCl application in 
the absence of calcium; this strongly indicated that KCl-stimulated CICR requires 
calcium influx from the extracellular solution (Figure 2.6.).   
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Analysis 
Fura-2 images were analysed in Image J (NIH, US).  To make results comparable to 
an earlier published study (Zhang et al., 2009), analysis was performed on somatic 
regions (see also Basarsky et al., 1994; Koch and Barish, 1994).  Neuronal somas 
were traced on DIC images and the template was overlaid onto 340 nm and 380 nm 
fluorescence images.  Fluorescence values for each frame were noted for both 
wavelengths and the ratio for each frame was calculated by dividing 340 nm values 
by 380 nm values (340/380).  Regions of interest were also superimposed onto 
background images and the mean fluorescence from these regions was subtracted 
from both 340 and 380 nm images at matched timepoints.   
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Figure 2.6 - Calculation of Rmin in hippocampal neurons in situ  
(a) The cellular response of a neuron during basal conditions and during KCl-
stimulated CICR in the presence of 2.2 mM calcium extracellular solution (light 
green line). The black and white checked bar shows KCl application period (30 
sec). This pattern reflects a typical cellular response to KCl application.  To 
calculate Rmin in hippocampal cells, ionomycin (20 µM) and 4 mM EGTA in 0 
mM calcium extracellular solution was applied to the bath.  The red line shows the 
cellular response and the solid red bar represents ionomycin/EGTA application 
period.  Note the drop in ratio values approximately 2 min into application of 
ionomycin solution, indicated by black arrow.  The plateau phase following the 
ratio drop is considered the time point where Fura-2 is minimally bound by 
calcium (calcium free) and represents Rmin.  The purple line shows the cellular 
response to a further application of KCl (second black and white checked bar) 
whilst in the presence of 0 mM extracellular calcium.  Note how there is no 
increase in ratio values during this second KCl application, in the absence of 
extracellular calcium.  This result shows that KCl-stimulated CICR occurs only in
the presence of calcium.     
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Figure 2.7 - Calculation of Rmax in hippocampal neurons in situ  
(a) The cellular response of a neuron during basal conditions and during KCL-
stimulated CICR in the presence of 2.2 mM calcium extracellular solution (light 
green line). The black and white checked bar shows KCl application period (30 
sec). This pattern reflects a typical cellular response to KCl application.   
To calculate Rmax in hippocampal cells, ionomycin (20 µM) in 2.2 mM calcium 
extracellular solution was applied to the bath. The blue line shows the cellular 
response and the solid blue bar represents ionomycin application period.  Note 
the increase in ratio values approximately 2-3 min into the application of 
ionomycin.  The plateau phase following the increase in ratio is considered the 
time point where Fura-2 is maximally bound by calcium (dye is saturated) and 
represents Rmax. Note that Rmax ratio values are higher than values obtained 
during KCl application suggesting that calcium influx upon KCl application does 
not saturate the calcium dye.   
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2.7 Immunocytochemical fluorescence imaging 
 
 
2.7.1 Materials 
 
Table 2.13: Buffers and Solutions, used for immunocytochemistry 
Buffer/solution  Contents Storage 
Phosphate buffered 
saline (PBS) 1x 
137 mM NaCl, 27 mM KCl, 10 mM 
Na2HPO4, 1.8 mM KH2PO4, pH 7.3-4 
Room 
temperature 
Fixative solution  4% (v/v) paraformaldehyde (PFA), 4% 
(w/v) sucrose in 1x PBS.  pH 7.3-4 
Room 
temperature 
Permeabilisation 
solution 
0.3% (v/v) Triton X-100, 10% (v/v) goat 
serum in 1x PBS 
Room 
temperature 
Blocking solution 10% (v/v) goat serum in 1x PBS Room 
temperature 
 
 
2.7.2 Methods 
 
2.7.2.1 Immunocytochemical examination of pre and postsynaptic 
proteins  
 
Antibody labelling of dissociated cultures   
Immunofluorescence labeling against synaptic proteins is an established method for 
identifying synaptic connections in primary culture systems.  Primary neuronal 
cultures are an ideal system for this technique as the extracellular matrix is fairly low 
compared to brain tissue and thus background staining is minimal, which aids 
reliable identification of synapses.  To identify synapses, primary antibodies against 
presynaptic vesicle markers, synapsin (1:800 dilution, anti-mouse or rabbit, synaptic 
systems, Germany) or synaptophysin (1:300, anti-rabbit, synaptic systems) and 
postsynaptic markers, Homer (1:1500, anti-rabbit, synaptic systems) or glutamate 
receptor subunit GluA1 (1:20 dilution, anti-rabbit, Calbiochem) were used.   
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Additionally, an antibody against microtubule associated protein 2 (MAP2, 1:800, 
anti-chicken, Abcam) was applied to all coverslips to label neuronal processes.    
For rat dissociated neurons treated with γ-secretase inhibitors and β-secretase 
inhibitor IV, both postsynaptic GluA1 and Homer staining was performed with 
synapsin as a presynaptic marker.  For PS1 mice cultures, only synaptophysin 
staining was performed.   
 
As the epitope for the GluA1 antibody was located on the N-terminus extracellular 
domain, labelling was performed on live cultures.  Thus, with a restricted period of 
incubation (16 min), this antibody should presumably label a large proportion of the 
surface population of GluA1 receptors and a minimal amount of the intracellular 
pool due to the slow rate of endocytosis (Adesnik et al., 2005; Cingolani et al., 2008; 
Passafaro et al., 2001).   For Homer, synapsin and synaptophysin where the protein 
is largely located within the intracellular compartment, antibodies were applied after 
fixation.    
 
The procedure below outlines the steps for double pre and postsynaptic marker 
labelling.  For cells where GluA1 was co-labelled with synapsin, all points in the 
procedure apply.  For cells that were either co-labelled with synapsin and Homer or 
labelled with synaptophysin alone all steps prior to fixation were omitted.  GluA1 
primary antibodies were applied directly to culture media.  All other primary and 
secondary antibodies were applied in PBS solution containing 10% (v/v) goat serum.     
 
GluA1 antibody was diluted in conditioned culture medium (1:20 dilution) and 
applied to coverslips.  Coverslips were maintained in a 5% CO2 incubator at 37oC for 
16 min.  After this period, cells were rinsed with 37oC PBS 3-4 times and then fixed 
with 4% PFA/4% sucrose fixative solution (pH 7.25-7.35) at room temperature for 
15 min.  This fixative makes covalent cross-links between proteins to enable good 
preservation of cell structure (Cingolani et al., 2008; Passafaro et al., 2001; St-
Laurent et al., 2006).   
 
After fixation, cells were rinsed 3 times with PBS and subsequently permeabilised 
with 0.3% (v/v) Triton X-100 for 10 min.  Coverslips were rinsed 2x with PBS and 
then incubated in a solution containing 10% (v/v) goat serum for 0.5-1 hr to block 
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non-specific sites.   Next, primary antibodies (against Homer, synapsin, 
synaptophysin or MAP2) were applied for 1 hr at room temperature.  After this 
period, cells were washed 4x with PBS, with each wash lasting 10 minutes.  Cy-2 or 
Cy-3 conjugated secondary antibodies (1:300 dilution, anti-rabbit or mouse, Jackson 
Immunoresearch) were applied to label either pre or postsynaptic proteins.  
Secondary antibodies were species matched with primary antibodies, for example, 
presynaptic synapsin was labelled with an anti-mouse monoclonal primary antibody 
and a mouse secondary antibody was used to fluorescently conjugate the primary 
antibody.  In this case, the postsynaptic marker was labelled with an antibody from a 
different species to the presynaptic antibody, for example, a polyclonal rabbit 
primary antibody would be used to label GluA1 and an anti-rabbit secondary 
antibody of a different colour to the presynaptic antibody was used.  An AMCA 
secondary antibody (1:200 dilution, anti-chicken, Jackson Immunoresearch) was 
used to label MAP2.  All secondary antibodies were applied for 1 hour at room 
temperature.  Cells were washed 4x with PBS, with each wash lasting 10 mins to 
remove excess unbound secondary antibody.  One final wash in 0.1% PBS was made 
prior to mounting using antifade solution (Sigma) onto glass slides.  Coverslips were 
left overnight at room temperature and then sealed with nail varnish before acquiring 
images on a confocal microscope. 
 
 
Confocal imaging 
Confocal images were obtained using a Leica SPE confocal microscope, mounted on 
a Leica DM2500 inverted microscope using a 40x oil objective (1.15 NA).  AMCA 
fluorophore was excited with a 405 nm solid state laser and emission fluorescence 
between 412-469 nm wavelengths was collected with a spectrophotometer detector.  
The 405 nm excitation laser was used with a 405/532 nm dichroic mirror.  Cy2 
fluorophore was excited with a 488 nm solid state laser and emission fluorescence 
between 500-530 nm wavelengths was collected.  The 488 nm solid state laser was 
used with a 488/635 nm dichroic mirror.  Cy3 fluorophore was excited by a 532 
solid state laser; with a 405/532 nm dichroic mirror and emission fluorescence 
between 570-723 nm wavlengths was collected.  Confocal Z-stacks were acquired 
using a sequential line-scan mode, with 3x scan averaging, 1x accumulation, and 0.3 
µm between optical planes.  The pinhole diameter was set to 1 Airy units, and 1024 
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x 1024 pixel, 8 bit images were captured using Leica LASAF software.  Images for 
test and control groups were acquired within the same imaging session where the 
same laser power, gain and offset settings were used for all groups. 
 
Analysis of pre and postsynaptic marker number 
All drug treatment groups were processed, imaged and analysed together with 
DMSO mock control groups.  Images were either acquired or analysed (or both) 
blind to treatment.   Analysis was performed on z-series projections made from all 
images that were in focus.  All images were processed with a smoothing function 
prior to generating of the z-series projection.  For synapse density measurements, 
somatic regions were excluded from analysis.  For this, the perimeter of the soma 
was manually traced and a zero value was applied to all pixels within the traced 
region.  Only presynaptic (synapsin and synaptophysin) and postsynaptic (GluA1 
and Homer) markers that co-localised with MAP2 signal were used for analysis in 
order to exclude background staining with synaptic markers.  Practically, a MAP2 
mask was generated by thresholding the MAP2 signal to the sum of the mode and 
standard deviation of the signal in the MAP2 channel.  This mask was then applied 
to both pre and post synaptic marker images to create a template for synaptic marker 
analysis.  All synaptic marker counts were processed using semi-automated non-
subjective procedures in Image J to eliminate any potential bias.  A rolling ball 
radius was applied to all masked images to subtract and level dendritic shaft 
background fluorescence.  Images were subsequently thresholded to 10x the standard 
deviation of the image to isolate distinct puncta.  A watershed procedure was applied 
to images to bisect any closely overlapping structures into individual components.  
Individual puncta was then automatically counted for each marker.  To fulfill the 
criteria of a synapse, pre and postsynaptic markers were overlaid and co-localisation 
was automatically assessed and counted.  Neurite length measurements were made 
using Neuron J (Meijering et al., 2004) or neurite tracer (Pool et al., 2008) plugin 
modules within Image J.   
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Figure 2.8 - Immunofluorescence analysis of synaptic marker puncta 
Sample image of a typical neuron immunolabelled against MAP2 (a) and 
synaptic marker Homer (b).  Panel (c) shows the same synaptic marker image as 
in (b) after processing with a MAP2 mask (extracted from a) and with somatic 
regions subtracted.   Panel (d) shows the same image as in (c) but after rolling 
ball subtraction, thresholding and watershed processing.  Panel (c.i) and (d.i) 
show magnified images of the red region shown in panel (3) and (4) respectively.  
Scale bar for panels a – d is 20 µm.  Scale bar for panels c.i and d.i is 40 µm.   
a b
c d
c.i d.i
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2.8   Organotypic spine analysis 
 
 
2.8.1 Materials  
 
Table 2.14: Chemicals / Reagents / Products used for visualization of spines in 
organotypic slices 
Product Company Location 
Alexa 488 hydrazide Invitrogen Paisley, UK 
Antifade Sigma - Aldrich Dorset, UK 
Coverglass Assistent Sondheim, Germany 
Glass slides Fisher - scientific Loughborough, UK 
 
 
2.8.2 Methods  
 
2.8.2.1 Fluorescence labeling of spines of CA1 pyramidal cells in 
organotypic slices 
 
The number of spines on a dendritic process can provide an estimate of synapse 
number in organotypic slice cultures.  For this, CA1 pyramidal cells were visualized 
by addition of a green shifted fluorescently conjugated hydrazide, Alexa 488 (100-
300 µM) to the intracellular solution and filled by patching cells in whole-cell 
configuration.  Cells were filled for 15-20 mins before slow withdrawal of the patch 
pipette from the soma.  Cells where the somatic membranes resealed quickly with 
minimal dye loss were retained for confocal imaging and analysis.  Slices were 
rinsed twice using PBS and then fixed with 4% PFA/ 4% sucrose in PBS overnight.  
Following this, slices were mounted and sealed with antifade solution onto glass 
slides and maintained at 4oC until imaging.   
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Confocal imaging of spines of CA1 pyramidal cells in organotypic slices 
Alexa Fluor – 488 hydrazide was excited with a 488 nm laser, 488/635 nm dichroic 
mirror and fluorescence collected between 500-530 nm wavelengths.  Low 
magnification organotypic spine Z-stacks were acquired using a 40x oil objective 
with the same settings as that used for dissociated cultures but with 0.5 µm step 
between planes.  High magnification Z-stack images of secondary or tertiary 
branches from basal and apical dendrites were acquired as low magnification images 
but with the following adjustments: 63x oil objective, 5x zoom and 0.4 µm step 
between optical sections.  Images were acquired at 512 x 512 pixels at 8 bit. 
Images for drug treated test and control groups were acquired within the same 
imaging session where the same laser power, gain and offset settings were used for 
all groups. 
 
Analysis 
Spine analysis was performed on Z-stack projections of Alexa-488 filled apical and 
basal dendrites.  Spine number was estimated by manually counting the number of 
spine-like protrusions emanating from the dendritic shaft.  Protrusions were counted 
if they fit any of the following criteria (As De Simoni et al., 2003, based on Harris et 
al., 1992; Peters and Kaiserman-Abramof, 1969):- 
 
-Mushroom spine: head diameter > 2-fold greater than neck diameter 
-Stubby spine: neck length is similar to neck diameter 
-Thin spine: head and neck diameter is similar but length is greater than neck 
diameter 
-Filopodial process: as thin spine but head diameter can be smaller than neck 
diameter.   
 
Process length was measured by tracing a line along the dendritic shaft using either 
Leica LASAF software or Neuron J plugin within Image J processing suite. 
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2.9 Statistics 
 
Data was assessed with unpaired two-tailed Student’s t-test for comparison of 
control and drug treatment groups.   Non-parametric Mann-Whitney test was 
performed for data that was not normally distributed.  For comparison of three or 
more groups, a one-way analysis of variance (ANOVA) test followed with a Tukeys 
post hoc test was used.  Power calculations were also performed for data sets where 
low samples sizes were obtained to help determine the statistical power of the 
results.  Statistical significance in figures is represented by p < 0.05*, p < 0.01**, 
and p < 0.001***.  All data values are presented as mean ± standard error of the 
mean (s.e.m). 
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Chapter 3: The role of presenilin in 
modulating spontaneous synaptic 
currents in hippocampal neurons 
 
 
 
3.1 Introduction 
 
 
The key role of presenilin in the generation of Aβ peptides has prompted many 
studies to try and gain a better understanding of the biology of presenilin. Studies 
have primarily focused on the hippocampus as it is a region of the CNS that is 
heavily afflicted with amyloid accumulations during AD.  Additionally, impairments 
in neuronal and synaptic activity in the hippocampus have been widely associated 
with the learning and memory deficits commonly observed in AD patients.   
Moreover, the progressive impairment in cognitive functions observed during AD is 
highly associated with the extent of synapse loss (Dekosky and Scheff, 1990; Scheff 
and Price, 2003; Sze et al., 1997; Terry et al., 1991).   Hence understanding the role 
of presenilins in modulating synaptic activity and function may provide valuable 
insights into the mechanisms that may contribute to the synapse loss, 
neurodegeneration and memory deficits associated with AD.   
 
Studies investigating the role of presenilin in spatial learning paradigms and long 
term synaptic plasticity such as LTP have been extensively examined in a wide range 
of transgenic mice models (see introduction).  However the role of presenilins in 
regulating basal synaptic transmission remains to be fully elucidated.  A recent study 
performed on dissociated cortical cultures reported that PS1-/- cells exhibit a higher 
mEPSC frequency rate than PS1+/+ and PS1+/- cells but with no change in mEPSC 
amplitude (Parent et al., 2005).  This effect on mEPSC frequency of PS1-/- mice 
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could be mimicked by γ-secretase treatment of PS1+/+ cells indicating that γ-
secretase activity is required for modulation of spontaneous synaptic transmission in 
cortical cultures.  Additionally, PS1-/- cells showed an increase in spine density and 
synapse number when compared to PS1+/+ cells which may be correlated with the 
increase in mEPSC frequency.  Other studies revealed that γ-secretase inhibitor 
treatment of hippocampal neurons also showed similar enhancements in mEPSC 
frequency in the absence of a change in mEPSC amplitude, suggesting that γ-
secretase activity is important for modulation of hippocampal synaptic transmission 
(Kamenetz et al., 2003; Priller et al., 2006).   At the start of this project, no reports 
had examined spontaneous currents in hippocampal neurons from PS1 -/- mice.  The 
role that presenilins and γ-secretase activity plays in modulating synaptic function in 
the hippocampus remains to be fully understood.   
 
The aim of this chapter was to perform an extensive investigation into the role of 
presenilin in modulating basal synaptic spontaneous currents in two different model 
systems of the hippocampus: dissociated cultured neurons and organotypic slice 
cultures.   These currents represent the random spontaneous stochastic release of 
neurotransmitter from the presynaptic terminal and subsequent activation of 
postsynaptic ionotropic receptors in an action potential independent manner (Cowan 
et al., 2001; Frerking et al., 1997; Wall and Usowicz, 1998).  These events can be 
detected by performing patch clamp recordings from the postsynaptic neuron.  
Whole-cell recordings provide information about the total activity of synaptic 
connections made onto the postsynaptic cell.  Examining release events can provide 
insights into the loci of modulation with presynaptic changes being often associated 
with an alteration in frequency and postsynaptic modifications being linked with a 
change in amplitude (Cowan et al., 2001; Del Castillo and Katz, 1954b; Kerchner 
and Nicoll, 2008; Prange and Murphy, 1999).  As mentioned in the introduction, the 
two main factors which influence the frequency of spontaneous events are the 
number of functionally active synaptic connections being made onto a neuron (n) 
and the release probability (Pr) of a synapse, whereas spontaneous synaptic current 
amplitude on the other hand is linked with changes in the postsynaptic receptor 
number and conductance (q) (Cowan et al., 2001; Kerchner and Nicoll, 2008).  By 
examining spontaneous synaptic currents, one can start to determine if there may be 
any alterations in presynaptic and/or postsynaptic function.  The electrophysiology 
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experiments presented in this chapter mainly focus on spontaneous excitatory 
synaptic currents and were performed in the presence of GABAA receptor blocker, 
picrotoxin to enable selective examination of excitatory responses (Figure 3.1 – 3.9).  
However preliminary recordings were also made in organotypic slices to examine 
inhibitory synaptic currents (Figure 3.10 – 3.11).  For recordings of inhibitory 
currents, picrotoxin was omitted from the extracellular solution and AMPA and 
NMDA receptor antagonist, NBQX and DL-AP5 were used to inhibit glutamatergic 
currents.  All spontaneous events were recorded in the presence of TTX (0.5 µM) to 
block sodium channels and the generation of action potentials and will be referred to 
as miniature excitatory or inhibitory postsynaptic currents (mEPSC, mIPSC) from 
hereon.   
 
 
 
3.2 Examination of the effect of γ-secretase 
activity inhibition on mEPSC properties in 
dissociated hippocampal neurons.   
 
The first experiment of this chapter examined the effects of γ-secretase inhibitor 
treatment on mEPSC properties in hippocampal rat dissociated neuronal cultures.  
Whilst the effects of γ-secretase inhibition on Aβ production in rat dissociated 
neuron has been studied before (Hoey et al., 2009), the impact of γ-secretase 
inhibition on mEPSCs have not been investigated in rat dissociated cultures prior to 
this study.  γ-secretase inhibitors have been extensively used to show that γ-secretase 
activity is required for regulated intramembraneous proteolysis of APP to generate 
Aβ (De Strooper et al., 1998).  To examine whether γ-secretase activity is required 
for the regulation of mEPSC in hippocampal cultures, two structurally different, cell 
permeable and potent γ-secretase inhibitors, DAPT and L-685,458 were chosen.   
 
Previous studies have used DAPT and L-685,458 in many different cell preparations, 
at a wide range of concentrations and for an assortment of treatment times (from 
hours to weeks) (see for example, Kamenetz et al., 2003; Parent et al., 2005; Priller 
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et al., 2006).  Due to the lack of consensus in treatment times, initial studies were 
performed in dissociated neurons to determine whether there were any differences in 
mEPSC frequency and amplitude following different application periods.  Neurons 
were pre-incubated with either DAPT (10 µM) or L-685,458 (1 µM) for 1 hr, 3 hrs, 
24 hrs and 48 hrs.   
 
A significant increase in mEPSC frequency was observed following 48 hr pre-
treatment of hippocampal dissociated cells with either DAPT or L-685,458 when 
compared to DMSO mock control cells (Figure 3.1 left; DMSO: n = 21, 2.50 ± 0.45 
Hz; DAPT: n = 15, 9.35 ± 1.97 Hz;  L-685,458: n = 14,  7.56 ± 1.70 Hz.  Student’s t-
test: DMSO versus DAPT, p = 0.0004 ***; DMSO versus L-685,458, p = 0.0017 
**).  However, no significant changes in amplitude were observed after 48 hr 
treatment with DMSO mock, DAPT or L-685,458 (Figure 3.1 right; DMSO: 26.86 ± 
3.33 pA; DAPT: 27.62 ± 2.73 pA; L-685,458: 23.60 ± 2.11 pA.  Student’s t-test: 
DMSO versus DAPT, p = 0.87; DMSO versus L-685,458, p = 0.47).  Figure 3.2 
summarises the mEPSC frequency and amplitude results for the other treatment 
times.  Treatment with DAPT for 24 hr showed a significant increase in mEPSC 
frequency but not with L-685,458 for the same duration, relative to DMSO mock 
control (Figure: 3.2a iii left; DMSO: n = 10, 2.63 ± 0.68 Hz; DAPT: n = 7, 9.39 ± 
1.39 Hz;  L-685,458: n = 6, 6.89 ± 2.44 Hz .  Student’s t-test: DMSO versus DAPT, 
p = 0.0002 ***; DMSO versus L-685,458, p = 0.056).   No significant differences in 
mEPSC amplitude were observed following 24 hr treatment with DAPT or L-
685,458 when compared to DMSO control (Figure 3.2 a iii right; DMSO: 22.57 ± 
4.07 pA; DAPT: 22.41 ± 2.27 pA; L-685,458: 23.47 ± 5.04 pA.  Student’s t-test: 
DMSO versus DAPT, p = 0.98; DMSO versus L-685,458, p = 0.89).  Treatment with 
DAPT or L-685,458 for 3 hrs did not show any differences in mEPSC frequency 
when compared to DMSO control (Figure 3.2 a ii left; DMSO: n = 6, 4.85 ± 1.64 Hz; 
DAPT: n = 6, 11.51 ± 3.08 Hz; L-685,458: n = 6,   5.93 ± 1.74 Hz.  Student’s t-test: 
DMSO versus DAPT, p = 0.08; DMSO versus L-685,458, p = 0.66).  This same 
treatment also did not show any differences in mEPSC amplitude (Figure 3.2 a ii 
right, DMSO: 37.19 ± 8.99 pA; DAPT: 32.70 ± 2.85 pA, L-685,458: 31.14 ± 4.91 
pA, Student’s t-test: DMSO versus DAPT, p = 0.64; DMSO versus L-685,458, p = 
0.57).  Treatment of cells for 1 hr with DAPT, L-685,458 or DMSO did not show 
any significant differences in mEPSC frequency (Figure 3.2 a i left; DMSO: n = 6, 
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4.38 ± 1.64 Hz; DAPT: n = 9, 4.23 ± 0.88 Hz; L-685,458: n = 6,   6.31 ± 2.09 Hz.  
Student’s t-test: DMSO versus DAPT, p = 0.91; DMSO versus L-685,458, p = 0.47) 
or amplitude (Figure 3.2 a i right; DMSO: 23.59 ± 3.75pA; DAPT: 28.23 ± 2.37pA; 
L-685,458: 32.61 ± 5.47pA.  Student’s t-test: DMSO versus DAPT, p = 0.29; DMSO 
versus L-685,458, p = 0.23).   
 
Together these results suggest that 48 hr treatment with DAPT or L-685,458 is 
sufficient for a significant effect on mEPSC frequency.  However mEPSC amplitude 
does not seem to change with acute or chronic γ-secretase inhibition as there were no 
significant changes in event size with 1 hr, 3 hr or 24 hr DAPT or L-685,458 pre-
incubation when compared to DMSO mock control of the equivalent time point.  
This result shows γ-secretase activity is involved in the modulation of mEPSC 
frequency but not mEPSC amplitude at hippocampal synapses.  Additionally, this 
result also shows that chronic treatment rather than acute treatment with γ-secretase 
inhibitors is required for an effect on mEPSC frequency.  For this reason, all 
subsequent drug treatments were performed with chronic pre-incubation for 36-48 
hrs and in line with other studies in neuronal culture systems where chronic 
pharmacological treatments were used (Kamenetz et al., 2003; Priller et al., 2007).   
 
Further kinetic analysis of mEPSC waveform was also conducted on data obtained 
from dissociated cultures.  Figure 3.3a shows that 10-90% rise time (left) and decay 
time (right) of mEPSCs following DAPT or L-685,458 treatments were not 
significantly different to DMSO mock control cells.  There were also no significant 
differences in resting membrane potential, input resistance and cell capacitance 
between rat cultures treated with DMSO, DAPT or L-685,458 cells, suggesting that 
passive membrane properties are not altered upon chronic inhibition of γ-secretase 
activity (Figure 3.3b).  In summary, chronic treatment of rat dissociated neurons with 
γ-secretase inhibitors results in a higher mean mEPSC frequency rate when 
compared to DMSO mock control cells.  This indicates that γ-secretase activity is 
involved in the modulation of mEPSC frequency in wild type rat hippocampal 
dissociated cultures.   
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Figure 3.1 - mEPSC frequency is modulated by chronic treatment with γ-
secretase inhibitors   
(a) Sample traces of mEPSC recordings from hippocampal rat dissociated neurons 
chronically treated for 48 hr with DMSO mock control (black) or γ-secretase 
inhibitor DAPT (red) or L-685,458 (blue). Scale bar, 25 pA, 200 ms. (b) Summary 
of mEPSC frequency (left) and amplitude (right) for DMSO (grey, n = 21, 
frequency mean: 2.50 ± 0.45 Hz, amplitude mean: 26.86 ± 3.33 pA), DAPT (red, n 
= 15, frequency mean: 9.35 ± 1.97 Hz, amplitude mean: 27.62 ± 2.73 pA), and L-
685,458 (blue, n = 14, frequency mean 7.56 ± 1.70 Hz, amplitude mean: 23.60 ± 
2.11 pA). Statistical analysis was performed using student’s t-test (bar graphs; p < 
0.01 **, p < 0.001 ***).  Chronic treatment with γ-secretase inhibitors 
significantly increased mean mEPSC frequency compared to DMSO mock control 
but did not change mEPSC amplitude.  (c) Cumulative distribution plots of inter-
event interval time (left) and mEPSC amplitude (right) for data shown in (b).   
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Figure 3.2 - Establishing timecourse of γ-secretase inhibitor treatment for mEPSC 
recordings.   
(a) mEPSC frequency and amplitude in rat dissociated cultures was analysed following 1 hr (i), 
3 hr(ii) and 24 hr (iii) pretreatment with γ-secretase inhibitor, DAPT (red) or L-685,458 (blue) 
or with DMSO mock control (grey).     Statistical analysis was performed using student’s t-test.  
Treatment with DAPT (10 µM) for 24 hrs (and 48 hrs – see Figure 3.1) lead to a significant 
increase in mEPSC frequency compared to DMSO mock control cells.  L-685,458 application 
(1 µM) for 24 hrs also exhibited a higher mEPSC rate but not at a statisically significant level 
(24 hr; DMSO: 2.63 ± 0.68 Hz [n = 10]; DAPT: 9.39 ± 1.39 Hz [n = 7], L-685,458:  6.89 ± 2.44 
Hz [n = 6], student’s t-test: DMSO versus DAPT: p = 0.0002 ***, DMSO versus L-685,458, p 
= 0.056).  24 hr treatment with either DAPT or L-685,458 did not significantly influence 
mEPSC amplitude (24 hr; DMSO: 22.57 ± 4.07 pA [n = 10]; DAPT, 22.41 ± 2.27 pA [n = 7], 
L-685,458, 23.47 ± 5.04 pA [n = 6]).  Treatment with DAPT or L-685,458 for 3hrs did not 
significantly alter mEPSC frequency (3 hr; DMSO: 4.85 ± 1.64 Hz [n = 6]; DAPT: 11.51 ± 3.08 
Hz [n = 6]; L-685,458: 5.93 ± 1.74 Hz [n = 6]). Treatment with DAPT or L-685,458 for 3 hr 
also had no effect on mEPSC amplitude (3 hr; DMSO: 37.19 ± 8.99pA [n = 6]; DAPT, 32.70 ± 
2.85 pA[n = 6], L-685,458, 31.14 ± 4.91 pA [n = 6]).  Treatment with DAPT or L-685,458 for 1 
hr did not significantly alter mEPSC frequency compared to DMSO control (1 hr; DMSO: 4.38 
± 1.64 Hz [n = 6]; DAPT, 4.23 ± 0.88 Hz [n = 9], L-685,458, 6.31 ± 2.09, [n = 8]).  mEPSC 
amplitude was also not significantly altered following 1 hr treatment with DAPT or L-685,458 
(DMSO: 23.59 ± 3.75 pA [n = 6]; DAPT, 28.23 ± 2.37 pA [n = 9], L-685,458, 32.61 ± 5.47 pA 
[n = 8]).  No changes in mEPSC amplitude were observed between DAPT or L-685,458 
treatments relative to mock control DMSO at any of the tested timepoints.  This data suggests 
mEPSC frequency, but not amplitude can be modulated by chronic but not acute block of γ-
secretase activity using inhibitors, DAPT and L-685, 458.   
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Figure 3.3 - Electrophysiological properties of rat dissociated neurons treated 
with γ-secretase inhibitors, DAPT and L-685,458. 
(a)  Measurements of 10-90% rise time (left) and decay time constant (right) of 
mEPSCs from rat dissociated neurons chronically treated with either DMSO control 
(grey, n = 21) or γ-secretase inhibitors; DAPT (red, n = 15), or L-685,458 (blue, n = 
14). Statistical analysis was performed using student’s t-test.  Neither rise time nor 
decay time were significantly altered between γ-secretase inhibitors DAPT and L-
685, 458 when compared to DMSO mock control. 
(b) Table featuring resting membrane potential (Vm), input resistance (Rin) and 
membrane capacitance (Cm) of cells chronically treated with DMSO mock control, 
DAPT and L-685,458.  
300.89 ± 29408.3 ± 48-54.8 ± 1.3L-685,458 
238.62 ± 31411.5 ± 50-53.3 ± 1.8DAPT 
273.2 ± 30451.3 ± 55 -52.6 ± 1.2DMSO 
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3.3 Examinination of mEPSC properties of 
hippocampal neurons from PS1 transgenic mice 
 
 
The role of PS1 in modulating hippocampal mEPSC frequency and amplitude had 
not been examined in PS1 mutant mice prior to this study.  The next experiment in 
this chapter was to investigate whether there were any differences in mEPSC 
properties between PS1+/+, PS1+/- and PS1-/- hippocampal neurons.  In addition, 
the effects of γ-secretase inhibitor treatment on PS1+/+, PS1+/- and PS1-/- 
hippocampal neurons was also examined.  The PS1 -/- mice were generated on a PS2 
+/+ background (Wong et al., 1997).  However the role of PS1 and PS2 in regulating 
hippocampal mEPSC properties was unknown.  The examination of PS1 -/- animals 
where PSEN1 gene function had been eliminated should lack all PS1 associated γ-
secretase activity in addition to the loss of PS1 γ-secretase independent functions.  
The use of γ-secretase inhibitors on the other hand should block both PS1 and PS2 
associated γ-secretase complexes but should not influence γ-secretase independent 
functions of presenilins (see introduction).  Examining the effects of γ-secretase 
inhibition on PS1-/- cells will provide a way to examine whether there is a major 
contribution of PS2 associated γ-secretase complexes in the regulation of mEPSC 
properties.     
 
Recordings showed that PS1-/- neurons exhibit a higher mean mEPSC frequency 
than PS1+/+ and PS1+/- mice (Figure 3.4 b left; PS1 -/-: 6.18 ± 1.14 Hz; PS1 +/+ 
mean: 3.04 ± 0.53 Hz; PS1 +/- mean: 2.81 ± 0.44 Hz.  One-way ANOVA followed 
by a Tukey’s post hoc test: PS1 +/+ versus PS1 +/-: p > 0.05, PS1 +/+ versus PS1 -/- 
: p < 0.05 *; PS1 +/- versus PS1 -/- : p < 0.05 *).  No significant differences in 
mEPSC amplitude were observed between PS1 +/+, PS1 +/- or PS1 -/- mice (Figure 
3.4 b right; PS1 +/+: 21.46 ± 1.92 pA, PS1 +/- mean: 20.84 ± 2.97 pA, PS1 -/-: 20.41 
± 1.68 pA.  One-way ANOVA: p = 0.94).  This result suggests that the PS1 gene is 
required for modulating mEPSC frequency but not mEPSC amplitude.  This result is 
consistent with the study by Parent et al., (2005) which showed that PS1-/- cortical 
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cells also exhibit a higher mEPSC frequency rate than PS1+/+ cells.  Figure 3.5 
shows the 10-90% rise time and decay time of mEPSC from PS1+/+, PS1 +/- and 
PS1 -/- cells.  There were no significant differences between the three genotypes.  
There were also no significant differences in resting membrane potential, input 
resistance and cell capacitance between PS1+/+ and PS1 +/- compared to PS1-/- 
cells (Figure 3.5 b).   
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Figure 3.4 - mEPSC frequency is increased in presenilin-1 (PS1) knock-out 
mice.     
(a)  Sample traces of mEPSC recordings from hippocampal PS1 +/+ (top), PS1 +/- 
(middle) and PS1 -/- (bottom) mice neurons. Scale bar, 20 pA, 200 ms. (b) 
Summary of mEPSC frequency (left) and amplitude (right) for PS1 +/+ (light 
grey, n = 22), PS1 +/- (mid grey, n = 18) and PS1 -/- (dark grey, n = 21) neurons. 
Statistical analysis was performed using ANOVA followed by a Tukey post test 
(bar graphs; p < 0.05 *). PS1 -/- animals exhibit a significantly higher mEPSC 
frequency (mean: 6.18 ± 1.14 Hz) than PS1 +/+ (mean: 3.04 ± 0.53 Hz) or PS1 +/- 
(mean: 2.81 ± 0.44Hz) animals.  mEPSC amplitude is not significantly altered 
across genotypes (PS1 +/+: 21.46 ± 1.92 pA, PS1 +/-: 20.84 ± 2.97 pA, PS1 -/-: 
20.41 ± 1.68 pA). There was no significant differences between PS1 +/+ and PS1 
+/- animals in mEPSC frequency or amplitude.  This data shows that elimination 
of PS1 leads to an increase in mEPSC frequency.    
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Next, I examined whether γ-secretase inhibitors had any effect on PS1+/+, PS1 +/- 
and PS1 -/- cells (Figure 3.6).  Chronic treatment of PS1+/+ cells with DAPT or L-
685,458, led to a significant increase in mean mEPSC frequency when compared to 
PS1+/+ cells treated with DMSO mock control (Figure 3.6 a i middle; PS1 +/+ 
DMSO, n = 12, 3.75 ± 0.82 Hz; PS1 +/+ DAPT, n = 7, 10.43 ± 3.47 Hz; PS1 +/+ L-
685,458, n = 5, 6.95 ± 1.05 Hz.  Student’s t-test: DMSO versus DAPT, p = 0.03*; 
DMSO versus L-685,458, p = 0.04*).  There were no significant effects on mean 
mEPSC amplitude following γ-secretase inhibitor treatment of PS1 +/+ cells (Figure 
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Figure 3.5 - Electrophysiological properties of dissociated neurons from PS1 
+/+, PS1 +/- and PS1 -/- mice. 
(a)  Measurements of 10-90% rise time (left) and decay time constant (right) of 
mEPSCs from PS1 +/+ (light grey, n = 22), PS1 +/- (mid grey, n = 18) and PS1 -/- 
(dark grey, n = 21) neurons.  Statistical analysis was performed using ANOVA 
followed by a Tukey post test.  Rise time and decay time was not significantly 
different between the genotypes. (b) Table featuring resting membrane potential 
(Vm), input resistance (Rin) and membrane capacitance (Cm) of hippocampal 
dissociated cells from PS1 +/+, PS1 +/- and PS1 -/- mice.   
248.5 ± 26383.0 ± 35-53.6 ± 0.9PS1-/- 
235.9 ± 29371.7 ± 43-53.1 ± 0.8PS1+/- 
231.6 ± 29373.4 ± 25 -53.8 ± 0.7PS1+/+ 
Cm (pF)Rin (MΩ)Vm (mV) 
a 
b 
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3.6 a i right; PS1 +/+ DMSO, 23.44 ± 3.27 pA; PS1 +/+ DAPT, 28.26 ± 6.36 pA; 
PS1 +/+ L-685,458, 22.26 ± 3.95 pA.  Student’s t-test: DMSO versus DAPT, p = 
0.46; DMSO versus L-685,458, p = 0.84).  PS1 +/- cells treated with γ-secretase 
inhibitors DAPT and L-685,458 both led to  significant increases in mean mEPSC 
frequency (Figure 3.6 a ii middle; PS1 +/- DMSO, n = 12, 3.51 ± 0.50 Hz; PS1 +/- 
DAPT, n = 9, 9.84 ± 1.74 Hz; PS1 +/- L-685,458, n = 6, 11.6 ± 2.20 Hz.  Student’s t-
test: DMSO versus DAPT, p = 0.0009***; DMSO versus L-685,458, p = 
0.0002***).  There were no significant effects on mEPSC amplitude following γ-
secretase inhibitor treatment of PS1 +/- cells (Figure 3.6 a ii right; PS1 +/- DMSO, 
23.04 ± 4.31 pA; PS1 +/- DAPT, 32.01 ± 4.95 pA; PS1 +/- L-685,458, 31.70 ± 5.78 
pA.  Student’s t-test: DMSO versus DAPT, p = 0.19; DMSO versus L-685,458, p = 
0.26).  Finally the effects of γ-secretase inhibitors on PS1 -/- cells were examined.  
PS1 -/- showed an increase in mEPSC frequency when compared to PS1 +/- and PS1 
+/+ cells under basal conditions (without drugs, Figure 3.4 b, left).  Treatment of 
PS1-/- cells for 48 hr with DAPT and L-685,458 did not lead to any significant 
changes in mEPSC frequency when compared to PS1-/- cells treated with DMSO 
mock control (Figure 3.6a iii middle; PS1 -/- DMSO, n = 12, : 8.16 ± 1.58 Hz; PS1 -
/- DAPT, n = 14, 6.98 ± 1.29 Hz; PS1 -/- L-685,458, n = 11, 7.57 ± 1.22 Hz.  
Student’s t-test: DMSO versus DAPT, p = 0.57; DMSO versus L-685,458, p = 0.77).  
There were also no significant effects on mEPSC amplitude following γ-secretase 
inhibitor treatment of PS1 -/- cells (Figure 3.6 a iii right; PS1 -/- DMSO, 22.66 ± 
2.55 pA; PS1 -/- DAPT, 21.79 ± 1.77 pA; PS1 -/- L-685,458, 19.78 ± 1.74 pA.  
Student’s t-test: DMSO versus DAPT, p = 0.78; DMSO versus L-685,458, p = 0.37).   
 
Overall this data suggests that PS1 -/- mice exhibit a higher mEPSC frequency rate 
under basal conditions and treatment of PS1+/+ and PS1 +/- cells with γ-secretase 
inhibitors leads to an elevation in mEPSC frequency rate that is comparable to that 
observed with PS1-/- cells.  The lack of effect of γ-secretase inhibitors on PS1 -/- 
animals suggests that most γ-secretase activity that is associated with modulating 
mEPSC frequency in hippocampal neurons occurs through PS1 rather than PS2.  
Examination of mEPSC amplitude showed that there were no significant differences 
between drug treated neurons and DMSO mock controls in all three genotypes 
suggesting neither γ-secretase dependent or independent activity of presenilins is 
required for regulation of mEPSC size.  As both γ-secretase dependent and γ-
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secretase independent forms of PS1 activity are eliminated in PS1-/- mice, it is not 
possible to determine which is more important for modulating mEPSC frequency 
using this single approach.  However taking this result and the finding that increased 
mEPSC frequency rate is observed upon γ-secretase treatment of PS1 +/+ and PS1 
+/- mice suggests that PS1 associated γ-secretase dependent activity rather than PS1 
γ-secretase independent activity is required for modulation of mEPSC.  This result 
provides evidence that PS1 plays a role in modulating mEPSC frequency in mice 
hippocampal cultures and is consistent with observations of PS1 activity on cortical 
neurons (Parent et al., 2005).   
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Figure 3.6 – Examination of chronic γ-secretase treatment on miniature excitatory 
postsynaptic currents from PS1 +/+, PS1 +/- and PS1 -/- hippocampal cells.     
(a) Left, Sample traces from PS1 +/+ (light grey, i),  PS1 +/- (mid grey, ii) and PS1 -/- (dark 
grey, iii) mice, treated with DMSO mock control (black), or γ-secretase inhibitor; DAPT 
(red) or L-685,458 (blue). Scale bar, 20 pA, 200 ms.  Middle and right, Summary of mEPSC 
frequency and amplitude data for PS1 +/+ (i), PS1 +/- (ii) and PS1 -/- (iii) neurons, 
respectively. For each genotype, γ-secretase inhibitor (DAPT (red) or L-685,458 (blue)) 
treatment was compared to DMSO mock control (grey).  Statistical analysis was performed 
using student’s t-test (bar graphs; p < 0.05 *, p < 0.01 **, p < 0.001 ***). (i) Application of 
γ-secretase inhibitor, DAPT to PS1 +/+ cells (red, n = 7, frequency mean: 10.43 ± 3.47 Hz, 
amplitude mean: 28.26 ± 6.36 pA) increased mEPSC frequency significantly when compared 
to DMSO control (grey, n = 12, frequency mean: 3.75 ± 0.82 Hz, amplitude mean: 23.44 ± 
3.27 pA) (DMSO versus DAPT, p = 0.03*).  Application of L-685,458 to PS1 +/+ cells (blue, 
n = 5, frequency mean: 6.95 ± 1.05 Hz, amplitude mean: 22.26 ± 3.95 pA) also caused an 
increase in mean frequency relative to DMSO control (DMSO versus L-685,458, p = 0.04 *). 
(ii) Application of DAPT (red, n = 9, frequency mean: 9.844 ± 1.74 Hz, amplitude mean: 
32.01 ± 4.95 pA) or L-685,458 (blue, n = 6, frequency mean: 11.6 ± 2.20 Hz, amplitude 
mean: 31.70 ± 5.78 pA) to PS1 +/- cells significantly raised mEPSC frequency with respect 
to DMSO mock (grey, n = 12, frequency mean: 3.51 ± 0.50 Hz, amplitude mean: 23.04 ± 
4.31 pA).  (mEPSC frequency DMSO versus DAPT; p = 0.0009 ***; DMSO versus L-658, 
458; p = 0.0002 ***). mEPSC amplitude was not significantly altered in PS1 +/- cells treated 
with DAPT or L-685,458.  (iii) PS1 -/- cells were treated with DMSO mock control (grey, n 
= 12, frequency mean: 8.16 ± 1.58 Hz, amplitude mean: 22.66 ± 2.55 pA), DAPT (red, n = 
14, frequency mean: 6.98 ± 1.29 Hz, amplitude mean: 21.79 ± 1.77 pA), or L-685,458 (blue, 
n = 11, frequency mean: 7.57 ± 1.22 Hz, amplitude mean: 19.78 ± 1.74 pA).  No changes in 
mEPSC frequency were observed in PS1 -/- animals following treatment with DAPT or L-
685,458.  There were no significant changes in mean mEPSC amplitude following drug 
treatment in PS1+/+, PS1 +/- or PS1 -/- mice.  Together this data suggests inhibition of γ-
secretase activity in PS1 +/+ or PS1 +/- animals leads to an increase in mEPSC frequency but 
not in PS1-/- animals.   
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3.4 Examination of the effect of γ-secretase 
activity inhibition on mEPSC properties in 
hippocampal organotypic slice cultures.   
 
 
The experiments discussed so far, examined either the impact of γ-secretase activity 
block or PS1 gene elimination (or both) on mEPSC properties in hippocampal 
dissociated cultures made from rat and mice.  Next, to understand whether the 
increase in mEPSC frequency following γ-secretase activity inhibition can also occur 
in a more intact hippocampal model, organotypic hippocampal parasagittal slices 
were treated with DAPT or L-685,458 and mEPSC recordings were made.  
Organotypic cultures were selected over acute slices as prolonged (48 hr) treatment 
of γ-secretase inhibitors was required for a robust effect on mEPSC rate in 
dissociated cultures (Figure 3.1).  One key benefit of this well characterised system 
over primary dissociated culture is that the extracellular environment is more similar 
to that found in vivo and the gross cytoarchitecture and connectivity is largely 
maintained.  Unfortunately due to the propensity for PS1-/- animals to die during late 
embryonic developmental stages, the production of slices from these mice was not 
an available option.  The main problem being embryonic hippocampal tissue tended 
to be much softer and smaller than postnatal tissue which made generation of a 
suitable number of consistent slices much more challenging.  A general observation 
about organotypic slice cultures is that the mean mEPSC frequency was much lower 
than dissociated cultures.  This warranted longer recording times to get a more 
comparable estimate of the mEPSC population.   
 
As observed in dissociated cultures, γ-secretase treatment of organotypic slices also 
led to an increase in mean mEPSC frequency in slices (Figure 3.7) with DAPT 
showing a highly significant increase and L-685,458 a lesser yet still significant 
increase compared to DMSO control (Figure 3.7 b left, DMSO: n = 20, 0.36 ± 0.06 
Hz; DAPT: n = 17, 1.35 ± 0.27 Hz; L-685,458: n = 16, 0.75 ± 0.18 Hz.  Student’s t-
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test: DMSO versus DAPT, p = 0.0004 ***; DMSO versus L-685,458, p = 0.032 *).  
In common with dissociated neurons, there was no significant difference in mean 
mEPSC amplitude in organotypic slices treated with DMSO (mock), DAPT or L-
685,458 (Figure 3.7 b right; DMSO: 17.40 ± 0.60 pA; DAPT: 18.23 ± 2.31 pA; L-
685,458: 19.43 ± 1.08 pA.  Student’s t-test: DMSO versus DAPT, p = 0.71; DMSO 
versus L-685,458, p = 0.09). 
 
This result is largely in agreement with a previous report which showed that 24 hr 
pre-treatment with 1 µM L-685,458 could lead to an increase in mEPSC frequency 
but not amplitude in hippocampal rat organotypic cultures (Kamenetz et al., 2003).  
Figure 3.8 a shows the 10-90% rise time (left) and decay time (right) of mEPSC 
from organotypic slices treated with DMSO (mock control), DAPT or L-685,458.  
There was no significant difference in rise time or decay time between the three 
conditions.  There were also no significant differences in resting membrane 
potential, input resistance and cell capacitance between DMSO, DAPT and L-
685,458 treated slices (Figure 3.8 b).  Together these results show that γ-secretase 
activity block can influence the presynaptic function of neurons in intact slice 
preparations as well as in dissociated cells.   
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Figure 3.7 – Examination of mEPSC in rat hippocampal slice cultures 
treated with γ-secretase inhibitors, DAPT and L-685,458.   
(a) Sample traces of mEPSC recordings from hippocampal rat organotypic slices 
treated for 48 hr with DMSO mock control (black) or γ-secretase inhibitors, 
DAPT (red) or L-685,458 (blue). Scale bar, 20 pA, 1000 ms. (b) Summary of 
mEPSC frequency (left) and amplitude (right) for DMSO (grey, n = 20, frequency 
mean: 0.36 ± 0.06 Hz, amplitude mean: 17.40 ± 0.60 pA), DAPT (red, n = 17, 
frequency mean: 1.35 ± 0.27 Hz, amplitude mean: 18.23 ± 2.31 pA) and L-
685,458 (blue, n = 16, frequency mean: 0.75 ± 0.18 Hz, amplitude mean: 19.43 ± 
1.08 pA) recordings.  Slices treated with γ-secretase inhibitor; DAPT or L-685, 
458 were compared to DMSO mock control slices.  Statistical analysis was 
performed using student’s t-test.  Slices chronically treated with γ-secretase 
inhibitor DAPT or L-685, 458 exhibited a significant increase in mean mEPSC 
frequency when compared to DMSO mock control (DMSO versus DAPT, p = 
0.0004 ***; DMSO versus L-685, 458, p = 0.032 *). mEPSC amplitude was not 
significantly altered between DMSO and γ-secretase inhibitor treated slices.  
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Figure 3.8 – Electrophysiological properties of rat hippocampal organotypic 
slice neurons treated with DMSO mock control or γ-secretase inhibitor 
DAPT. 
(a)  Measurements of 10-90% rise time (left) and decay time constant (right) of 
mEPSCs from neurons of rat organotypic slices chronically treated with either 
DMSO (mock control) or γ-secretase inhibitor, DAPT or L-685,458. Slices treated 
with DAPT or L-685,458 were compared to DMSO mock control slices. 
Statistical analysis was performed using student’s t-test.  Neither rise time or 
decay time were significantly altered between the DAPT nor L-685,458 treated 
slices and DMSO mock control slices. 
(b) Table featuring resting membrane potential (Vm), input resistance (Rin) and 
membrane capacitance (Cm) of organotypic slice neurons chronically treated with 
DMSO (mock control), DAPT and L-685,458.  
a 
b 
208.0 ± 24248.0 ± 21 -57.5 ± 1.1DMSO 
220.0 ± 25273.2 ± 23-56.8 ± 0.7DAPT 
222.66 ± 24219.5 ± 27-56.8 ± 1.1L-685,458 
Cm (pF) Rin (MΩ)Vm (mV) 
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3.5 Examinination of the effect of γ-secretase 
activity inhibition on mIPSC properties in 
hippocampal organotypic slice cultures.   
 
 
As already demonstrated above, pharmacological blockade of γ-secretase activity 
using DAPT and L-685,458 in rat and mice dissociated cultures and rat organotypic 
slice cultures, led to an increase in mEPSC frequency when compared to DMSO 
mock control cells.  Next, I wanted to investigate whether there was any effect of γ-
secretase inhibition on mIPSCs.  This experiment was conducted in organotypic slice 
cultures using a low chloride based internal, in the absence of picrotoxin and 
measured using two configurations.  Configuration 1 involved holding the cell at -50 
mV and recording both mEPSC and mIPSC simultaneously.  Configuration 2 
involved firstly holding the cell at -70 mV to record mEPSC and then holding the 
cell at 0 mV (close to the reversal for cations) to measure mIPSCs.  For the latter, 
NBQX (20 µM) and DL-AP5 (50 µM) were applied to specifically isolate inhibitory 
currents when holding the cell at 0 mV. 
 
Recordings where mEPSC and mIPSCs were recorded simultaneously (Figure 3.9), 
showed an increase in mean mEPSC frequency in cells treated with γ-secretase 
inhibitor DAPT when compared to DMSO controls, consistent with previous 
observations (see Figure 3.1) (Figure 3.9 b i left, DMSO: n = 7, 0.18 ± 0.03 Hz; 
DAPT: n = 6, 0.56 ± 0.14 Hz. Student’s t-test: DMSO versus DAPT frequency, p = 
0.016 *).  No significant effects on mean mEPSC amplitude was observed between 
DMSO mock and DAPT treated slices (Figure 3.9 b i right, DMSO: n = 7, 17.56 ± 
1.15 pA; DAPT: n = 6, 17.77 ± 1.399 pA. Student’s t-test: DMSO versus DAPT 
amplitude, p = 0.91).  Examination of mIPSC showed no significant effects on mean 
frequency or mean amplitude between DMSO mock and DAPT treated slices (Figure 
3.9 b ii, DMSO: 0.25 ± 0.07 Hz, 15.21 ± 1.00 pA; DAPT: 0.24 ± 0.07 Hz, 14.21 ± 
0.54 pA.  Student’s t-test: DMSO versus DAPT frequency, p = 0.94; DMSO versus 
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DAPT amplitude, p = 0.42).  This result suggests that γ-secretase blockade 
selectively increases excitatory transmission whilst leaving inhibitory currents 
unaltered.  However as the number of mIPSC observed under this configuration was 
relatively low, an alternative approach was used to determine if this effect was still 
seen.  For this configuration 2 was used.  Recording mEPSC at -70 mV showed 
similar effects to previous observations, with an increase in mEPSC frequency but 
not amplitude in slices treated with DAPT when compared to DMSO control slices 
(Figure 3.10 b i, DMSO: n = 7, 0.27 ± 0.03 Hz, 15.65 ± 0.50 pA; DAPT: n = 5, 0.84 
± 0.27 Hz, 15.03 ± 1.05 pA.  DMSO versus DAPT frequency, p = 0.033 *, DMSO 
versus DAPT amplitude, p = 0.57).  For recordings of mIPSC at 0 mV, no difference 
was seen in mIPSC frequency or amplitude between DMSO and DAPT treated 
samples (Figure 3.10 b ii, DMSO: n = 7, 1.52 ± 0.30 Hz, 27.07 ± 1.08 pA; DAPT: n 
= 5, 1.61 ± 0.28 Hz, 29.41 ± 1.31 pA.  DMSO versus DAPT mIPSC frequency, p = 
0.83; DMSO versus DAPT mIPSC amplitude, p = 0.20).  Together these results 
indicate that γ-secretase activity is involved in the modulation of miniature 
excitatory currents but not inhibitory currents.   
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Figure 3.9 – mEPSC frequency but not mIPSC frequency is modulated by chronic 
treatment with γ-secretase inhibitor, DAPT. (Configuration 1). 
(a) Sample traces of mEPSC and mIPSC recordings from hippocampal organotypic slices 
treated with DAPT (red) or DMSO mock (grey).  Cells were patched using a low Cl 
Kgluconate based internal and voltage clamped at -50 mV.  mEPSC were visualised as 
fast inward currents whilst mIPSC were seen as slower outward currents.  mEPSC and 
mIPSC were recorded simultaneously from the same cell. Scale bar, 20 pA, 1000 ms. (b i) 
Summary of mEPSC frequency (left) and mEPSC amplitude (right). Statistical analysis 
was performed using student’s t-test. Slices treated with DAPT (red, n = 6, frequency 
mean: 0.56 ± 0.14 Hz, amplitude mean: 17.77 ± 1.399 pA) displayed an significant 
increase in mEPSC frequency when compared to DMSO mock control slices (grey, n = 7, 
frequency mean: 0.18 ± 0.03 Hz, amplitude mean: 17.56 ± 1.15 pA).  (DMSO versus 
DAPT frequency, p =  0.016 *).  mEPSC amplitude was not significantly altered between 
DMSO and DAPT groups.  (b ii) Summary of mIPSC frequency (left, checked) and 
mIPSC amplitude (right, checked). Slices treated with DAPT (red, n = 6, frequency mean: 
0.24 ± 0.07 Hz, amplitude mean: 14.21 ± 0.54 pA) displayed no difference in mIPSC 
frequency or amplitude when compared to DMSO mock control slices (grey, n = 7, 
frequency mean: 0.25 ± 0.07 Hz, amplitude mean: 15.21 ± 1.00 pA).  This result indicates 
that treatment with γ-secretase inhibitor, DAPT leads to an increase in mEPSC frequency 
but with no significant change in mIPSC frequency.  Neither mEPSC or mIPSC amplitude 
is altered been DMSO or DAPT treated slices.   
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Figure 3.10 – mEPSC frequency but not mIPSC frequency is modulated by chronic 
treatment with γ-secretase inhibitor, DAPT.  (Configuration 2). 
(a) Sample traces of mEPSC and mIPSC recordings from hippocampal organotypic 
slices treated with DAPT (red) or DMSO mock (grey).  Cells were patched using a low 
Cl Kgluconate based internal solution and firstly voltage clamped at -70 mV to 
visualised fast inward mEPSCs and then 0 mV to visualise slower outward mIPSCs. 
Scale bar, 20 pA, 1000 ms. (b i) Summary of mEPSC frequency (left) and mEPSC 
amplitude (right). Statistical analysis was performed using student’s t-test. Slices treated 
with DAPT (red, n = 5, frequency mean: 0.84 ± 0.27 Hz, amplitude mean: 15.03 ± 1.05 
pA) displayed an significant increase in mEPSC frequency when compared to DMSO 
mock control slices (grey, n = 7, frequency mean: 0.27 ± 0.03 Hz, amplitude mean: 
15.65 ± 0.50 pA).  (DMSO versus DAPT frequency, p =  0.033 *).  mEPSC amplitude 
was not significantly altered between DMSO and DAPT groups.  (b ii) Summary of 
mIPSC frequency (left, checked) and mIPSC amplitude (right, checked). Slices treated 
with DAPT (red, n = 5, frequency mean: 1.61 ± 0.28 Hz, amplitude mean: 29.41 ± 1.31 
pA) displayed no difference in mIPSC frequency or amplitude when compared to 
DMSO mock control slices (grey, n = 7, frequency mean: 1.52 ± 0.30 Hz, amplitude 
mean: 27.07 ± 1.08 pA).  This result indicates that treatment with γ-secretase inhibitor, 
DAPT leads to an increase in mEPSC frequency but with no significant change in 
mIPSC frequency. As with mEPSC, mIPSC amplitude is not altered between DMSO or 
DAPT treated slices.   This result complements the result obtained in Fig 3.10. 
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3.6 Discussion 
 
The aim of this chapter was to gain a general understanding of the role of presenilins 
in modulating mEPSC and mIPSC in hippocampal neurons.  The results presented 
outline a role for the γ-secretase associated activity of presenilins in regulating 
mEPSC frequency but not amplitude.  The effect on mEPSC frequency was robustly 
observed following 48 hr pre-incubation with either DAPT or L-685,458 in 
dissociated rat and mice wild type neurons as well as organotypic slices.  
Interestingly, γ-secretase inhibitor application for shorter durations did not reveal 
statistically significant results.  However the results obtained for shorter treatments 
also seemed to be more variable which may be linked with the smaller sample sizes 
currently obtained for certain experiments (see Figure 3.2).  One example where a 
large but statistically insignificant result was observed is with 3 hr pre-treatment with 
DAPT when compared to DMSO mock control cells (Figure 3.2 ii).  For this 
experiment, a sample size of 6 was acquired for both control and test treatments with 
an average frequency standard deviation of 5.78 Hz.  Application of this value to 
power calculations showed that a sample size of 14-16 cells may generate a 
statistically significant result with a power of 80%.  Therefore, the low sample size 
obtained for this experiment may not be adequate to detect a statistically significant 
outcome and further experiments are warranted to provide a better estimate of the 
effect of 3 hr DAPT treatment on mEPSC frequency.  Power calculations for cells 
treated with L-685,458 for 24 hrs also suggests that a larger sample size (n = 16-18 
as opposed to n = 6-10) may provide a more reliable estimate of statistical 
significance.  However, current interpretations of the results obtained in this chapter 
generally suggest that presenilin function may target synaptic processes that occur 
over a longer (rather than shorter) time frame.    
 
This effect on mEPSC frequency is in agreement with previous studies reporting of 
the impact of pharmacological block of γ-secretase activity on mEPSC properties.  
Parent et al., (2005) showed using cortical dissociated neurons that PS1-/- mice 
exhibited a higher mEPSC frequency rate than PS1 +/+ mice.  4-24 hr treatment of 
PS1+/+ cells with γ-secretase inhibitors L-685,458 (1 µM) or compound E (10 nM) 
also led to an increase in mEPSC frequency.  Kamenetz et al., (2003) showed that 24 
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hr treatment with L-685,458 (1 µM) elevated mEPSC frequency rate in rat 
hippocampal organotypic slice cultures.  In agreement with experiments presented in 
Figure 3.2, Kamenetz et al., (2003) also showed that 1 hr pre-treatment of L-685,458 
did not cause any changes in mEPSC frequency or amplitude.  Priller et al., (2006) 
showed that with extended (18-20 day) treatment with DAPT (1 µM), mEPSC 
frequency was increased in hippocampal autaptic culture preparations.  Taken 
together with the observations reported in this chapter, there is good evidence that γ-
secretase activity is implicated in modulating mEPSC frequency in cortical and 
hippocampal cultured mice and rat neurons.   
 
Results from PS1-/- mice also indicated that the γ-secretase activity involved in 
modulating mEPSC frequency is associated with PS1 rather than PS2.  Application 
of γ-secretase inhibitors to PS1-/- neurons showed no major additional effects on 
mEPSC frequency or amplitude (Figure 3.6), suggesting that PS2 does not contribute 
to γ-secretase activity modulation of mEPSC frequency in hippocampal neurons.  
This conclusion is in line with previous studies showing that γ-secretase activity in 
neuronal cultures is primarily derived from PS1 (De Strooper et al., 1998; Naruse et 
al., 1998; Parent et al., 2005).  However, from the experiments performed so far, one 
cannot rule out any other possible effects of PS2 associated γ-secretase activity on 
cellular functions that are independent of presenilin 1 associated γ-secretase activity 
modulation of mEPSC.  Whilst the levels of PS2 expression were not directly tested 
in our hippocampal culture system, an earlier study using a conditional PS1-/- mouse 
model showed that elimination of PS1 does not alter PS2 protein expression, 
suggesting that PS2 levels are not up or down regulated in PS1 -/- animals (Yu et al., 
2001).  One important point to note is that immunolabelling or examining protein 
expression of PS1 and PS2 may not provide the most reliable correlate for cellular γ-
secretase activity and could be potentially misleading as only a small proportion of 
cellular presenilins (in “active” N and C terminal derivative form) is incorporated 
into active γ-secretase complexes through a tightly regulated albeit not entirely 
understood process (Dries and Yu, 2008; Lai et al., 2003; Thinakaran et al., 1997).  
In light of this, investigating the γ-secretase activity of PS2 and PS1 complexes 
separately in hippocampal synapses may provide insights into potential differential 
roles in modulating unique synaptic functions.  One possible approach is to 
selectively knock-down endogenous PS1 or PS2 using siRNA techniques and 
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determine if there are any differential changes in miniature current properties.  
Alternatively, constitutive PS2 knock-out animals (Herreman et al., 1999) may 
provide insights into the role of PS2 in synaptic transmission.     
 
One recent report has indicated that mEPSC frequency and amplitude recorded in 
hippocampal CA1 neurons are not significantly altered in acute slices from 
conditional CA3 region-specific PS1 and PS2 double knockout mice (Zhang et al., 
2009).  The reason for the discrepancy between the findings of Zhang et al., (2009), 
which utilised presenilin double knock-out animals, and others using constitutive 
PS1-/- mice (Parent et al., 2005 and Figure 3.5 -3.7) and γ-secretase inhibitor treated 
cells (Kamenetz et al., 2003; Parent et al., 2005; Priller et al., 2006) and Figure 3.1-3, 
3.6-10) is currently not fully understood.  Potentially the difference may be related to 
the preparation (acute slices versus dissociated and organotypic slices) or the 
selective presynaptic knockout of presenilin (as opposed to global effects of 
interfering with PS, as is the situation in PS1 -/- cells and γ-secretase inhibitors).   
The effect of γ-secretase activity inhibition on spontaneous inhibitory currents had 
not been investigated prior to this study. Interestingly, preliminary experiments 
indicate that block of γ-secretase does not alter mIPSC properties suggesting a 
selective effect on excitatory synapses.  It is currently unknown if γ-secretase 
selectively translocates to excitatory synapses or if the effect on mEPSC frequency is 
linked with selective processing of a substrate that modulates spontaneous currents at 
excitatory synapses but not at inhibitory synapses.  It has recently been shown that 
overexpression of APP can lead to a reduction in excitatory AMPA and NMDA 
current amplitude but with no change in inhibitory GABA current amplitude 
(Kamenetz et al., 2003).  This may indicate that γ-secretase processing of APP may 
lead to changes in excitatory but not inhibitory synaptic transmission.  Further 
studies will be required to determine how the loss of γ-secretase activity and APP 
processing alters excitatory synapse function.  Interestingly, a study showed that 
mEPSC frequency is increased in APP knock-out mice suggesting loss of APP (and 
loss of γ-secretase processing of APP) can lead to the opposite effect of APP 
overexpression.  This provides an interesting mechanism where γ-secretase 
processing of APP may act to bidirectionally regulate synaptic transmission (Priller 
et al., 2006).  mIPSC properties are yet to be determined in APP knock-out mice.   
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3.7 Conclusion 
 
This chapter showed that γ-secretase activity of presenilin (1) is implicated in 
regulation of mEPSC frequency at hippocampal excitatory synapses.  This result 
suggests that presenilins are potentially involved in regulating presynaptic properties.   
However, it is currently unclear how γ-secretase activity may lead to a change in 
presynaptic function.  As changes in presynaptic function are commonly associated 
with either an alteration in release probability or synapse number, the next two 
chapters will address these two points in turn. 
Chapter 4: Presenilin modulation of release probability 
 154
Chapter 4: The role of presenilin in 
modulating release probability in 
hippocampal neurons 
 
 
 
4.1 Introduction 
 
The data presented in chapter 3 provides evidence that pharmacological inhibition of 
γ-secretase activity and PS1 deficiency can lead to an increase in mEPSC frequency 
suggestive of a change in presynaptic function.  One factor that may contribute to a 
change in presynaptic function is a change in release probability.  The release 
probability (Pr) at synapses in the CNS can be highly variable (Allen and Stevens, 
1994; Branco et al., 2008; Branco and Staras, 2009; Dobrunz and Stevens, 1997; 
Murthy et al., 1997).  This variability is observed at multiple levels, from synapses 
between different brain regions, synapses being made between different classes of 
neurons, synapses from different axons onto the same postsynaptic cell and synapses 
from the same axon onto the same postsynaptic cell (Branco et al., 2008; Branco and 
Staras, 2009; Dobrunz, 2002; Dobrunz and Stevens, 1997).  Release probability has 
also been shown to be closely associated with the size of the readily releasable pool 
(RRP) at single synapses (Branco et al., 2009; Dobrunz, 2002; Rosenmund and 
Stevens, 1996).  To examine if release probability was altered following γ-secretase 
activity inhibition using pharmacological agents or elimination of PS1 gene, an 
electrophysiological estimate was used in organotypic slice cultures whilst live cell 
imaging of single synapses was adopted for dissociated cultures.   
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4.2 Estimating release probability using optical 
measurements of FM-dye destaining 
 
 
An estimate of release probability of a synapse can be measured directly by 
examining the rate of FM dye de-staining from single presynaptic terminals as a 
measure of synaptic vesicle exocytosis (Figure 4.1).  The expectation is that synapses 
with a high release probability will display a faster rate of de-staining and synapses 
with lower release probabilities will exhibit a slower rate of de-staining upon 
successive stimulation (Branco et al., 2008; Zakharenko et al., 2001).  FM dye de-
staining was measured by applying 900 stimuli at 5 Hz and the rate of fluorescence 
loss was observed by acquiring images at 0.1 Hz.   Experiments were performed in 
the presence of CNQX (20 µM) and DL-AP5 (50 µM) to block postsynaptic 
glutamatergic receptors and recurrent activity and picrotoxin (100 µM) to block 
postsynaptic GABAA receptors. 
 
Figure 4.1 – Stimulated FM dye uptake and destaining of hippocampal 
neurons   
(a) (i) 40x magnification DIC image of a rat dissociated neuron at DIV 14.  (ii) A 
fluorescent image of the same neuron as in (i) but after stimulated uptake (and 
subsequent exchange of the extracellular solution) of FM 1-43 dye using 600 
stimuli at 10 Hz field stimulation.  Note the dotted pattern along neuronal 
processes.  This fluorescent signal mostly corresponds to FM dye loading into 
active presynaptic terminals.  Applying a further field stimulation of 900 stimuli 
at 5 Hz leads to exocytosis and subsequent destaining of the FM dye from the 
presynaptic boutons (iii).  Note how most of the FM signal disappears following 
this stimulation.  The remaining regions stained with FM-dye most likely 
correlate with non-specific signal where dye has associated with the membrane of 
the cell or presynaptic boutons that have not destained. Scale bar, 20 µm 
a i ii iii
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4.2.1 Examination of release probability of PS1 +/+ and PS1 -/- 
neurons using FM dyes 
 
The rate of FM dye destaining from PS1 +/+ and PS1 -/- dissociated neurons was 
performed in low (1 mM calcium, Figure 4.2 a i), normal (2.2 mM calcium, Figure 
4.2 a ii) and high calcium concentrations (5 mM calcium, Figure 4.2 a iii).  Analysis 
revealed that the rate of dye destaining in PS1 +/+ and PS1 -/- cultures at a given 
calcium concentration did not show any significant differences, thus suggesting a 
lack of change in release probability between these genotypes (Figure 4.2 b i-iii).  
The rate of destaining for both genotypes increased with increasing concentrations of 
calcium as expected of calcium dependence of neurotransmitter release (Dodge, Jr. 
and Rahamimoff, 1967).  This result shows that the release machinery in both 
genotypes can respond adequately to changes in calcium.  This result indicates that 
the difference in mEPSC frequency observed between PS1 +/+ and PS1 -/- neurons 
may not be associated with a change in release probability.  To further investigate 
this point, both genotypes were treated with γ-secretase inhibitor DAPT to determine 
if γ-secretase inhibition causes any alteration of Pr at single synapses.  Quantification 
of destaining kinetics in normal calcium concentrations showed that chronic pre-
treatment with DAPT did not alter the rate of destaining of either PS1 +/+ or PS1 -/- 
cells (Figure 4.3).  This result provides further evidence that release probability in 
mice is not altered by the loss of PS1 gene or presenilin associated γ-secretase 
activity and the difference in mEPSC frequency is not related to changes in release 
probability.   
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Figure 4.2 – Destaining kinetics of PS1 mice in different concentrations of 
extracellular calcium.   
(a) Average destaining timecourse of PS1 +/+ mice (black triangle) and PS1 -/- 
mice (open circle) in low (1 mM) calcium (i), normal (2.2 mM) calcium (ii) and 
high (5 mM) calcium (iii) in extracellular bath solution.  Orange bar shows 
timecourse of field stimulation (900 stimuli at 5 Hz) used to elicit FM dye 
destaining from neuronal boutons.  (b)  Summary of decay constants (τ) obtained 
from experiments shown in (a).  PS1 +/+ (light grey) and PS1 -/- (checked grey) 
respond similarly at a given extracellular calcium concentrations.  However, note 
that the decay constant of FM dye destaining is altered in response to changing 
extracellular calcium concentrations irrespective of PS1 genotype.  (b, i) Mean 
response in 1 mM calcium extracellular calcium shows PS1 +/+ (τ = 75.39 ± 2.30, 
n = 3) and PS1 -/- (τ = 70.56 ± 5.48, n = 5) destaining kinetics are similar 
(student’s t-tests, PS1+/+ versus PS1-/-, p = 0.54).  (b, ii) A similar lack of 
significant difference is observed in 2.2 mM extracellular solution between PS1 
+/+ (τ = 54.67 ± 6.13, n = 5) and PS1 -/- (τ = 51.24 ± 1.77, n = 5) (student’s t-tests, 
PS1+/+ versus PS1-/-, p = 0.60).  (b, iii) With 5 mM extracellular calcium the 
decay constant between PS1 +/+ (τ = 48.26 ± 5.11, n = 5) and PS1 -/- (τ = 39.71 ± 
2.08) is also not significantly altered (Student’s t-tests, PS1+/+ versus PS1-/-, p = 
0.11).   This data suggests that elimination of PS1 gene does not lead to a change 
in synaptic vesicle destaining dynamics from hippocampal boutons.  n corresponds 
to the number of coverslips. 
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Figure 4.3 – Destaining kinetics of PS1 mice cells following γ-secretase 
inhibitor treatment.   
(a) Average destaining timecourse of PS1 +/+ mice (i, triangles) and PS1 -/- 
mice (ii, open circles) in normal (2.2 mM) calcium concentrations.  Cells for 
each genotype were treated with either DMSO mock control (grey) or γ-
secretase inhibitor, DAPT (red).  Orange bar shows timecourse of field 
stimulation (900 stimuli at 5 Hz) used to elicit FM dye destaining from neuronal 
boutons.  (b)  Summary of decay constants (τ) obtained from experiments 
shown in (a).  PS1 +/+ cells treated with DMSO or DAPT destained with 
similar kinetics (b i, PS1 +/+ DMSO, (light grey), n = 5, τ = 54.67 ± 6.13; PS1 
+/+ DAPT (red), n =7, τ = 51.78 ± 4.44.  Student’s t-test: PS1 +/+ DMSO 
versus DAPT, p = 0.70).  PS1 -/- cells treated with DMSO or DAPT also 
destained with similar kinetics (b ii, PS1 -/- DMSO (light grey checked 
squares), n = 5, τ = 51.24 ± 1.77; PS1 -/- DAPT (red checked squares), n =7, τ = 
53.61 ± 4.26.  Student’s t-test: PS1 -/- DMSO versus DAPT, p = 0.67).  This 
data indicates that γ-secretase inhibition does not alter synaptic vesicle 
destaining kinetics in either PS1 +/+ or PS1 -/- cells.   
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4.2.2 Examination of release probability of γ-secretase inhibitor 
treated rat dissociated neurons using FM dyes 
 
As shown in chapter 3, block of γ-secretase activity in rat dissociated hippocampal 
cultures using two specific inhibitors, DAPT and L-685,458 was sufficient to cause 
an increase in mEPSC frequency.  To determine whether this electrophysiological 
change was due to a change in release probability, FM dye destaining properties 
were examined in rat dissociated cultures treated with DAPT and L-685,458.  As 
performed for electrophysiological recordings, rat cells were treated with DAPT or 
L-685,458 for 48 hrs prior to experiments to block γ-secretase activity.  Analysis of 
drug treated and DMSO mock control cells showed no significant effect on synaptic 
vesicle exocytosis (Figure 4.4).   This data is in line with observations made in 
dissociated PS1 mice neurons where no differences between PS +/+ and PS1 -/- was 
seen (Figure 4.2 and 4.3).  Together this data suggests that γ-secretase activity of 
presenilins is not essential for regulating release probability at single synapses of 
dissociated neurons.   
 
I next examined the readily releasable pool (RRP), which correlates to the population 
of vesicles that are primed and ready to undergo release and hence influence release 
probability (Tokuoka and Goda, 2008; Waters and Smith, 2000).  To estimate RRP, 
30 action potentials were applied at 1 Hz in the presence of FM dye in the 
extracellular solution.  Cells treated with DMSO mock or γ-secretase inhibitors, 
DAPT and L-685,458 did not reveal any significant differences in fluorescence 
following loading of the RRP (Figure 4.5).  This result suggests γ-secretase activity 
in not involved in the regulation of presynaptic RRP size.   
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Figure 4.4 – Destaining kinetics of rat dissociated neurons treated with γ-
secretase inhibitors in different concentrations of extracellular calcium.   
(a) Average destaining timecourse of neurons treated with DMSO mock (grey), 
DAPT (red) and L-685,458 (blue) in 1 mM calcium (i), 2.2 mM calcium (ii) and 5 
mM calcium (iii) in extracellular bath solution.  Orange bar shows timecourse of 
field stimulation (900 stimuli at 5 Hz) used to elicit FM dye destaining from 
neuronal boutons.  (b)  Summary of decay constants (τ) obtained from experiments 
shown in (a).  There was no significant differences in destaining kinetics between 
DAPT and L-685,458 treated cells compared to DMSO mock control cells in (low) 
1 mM calcium (b i, DMSO: n = 6, τ = 59.13 ± 9.77; DAPT: n = 6, τ = 72.07 ± 
10.29; L-685,458: n = 5, τ = 51.02 ± 9.20.  Student’s t-test, DMSO versus DAPT, p 
= 0.38; DMSO versus L-685,458, p = 0.50). There was also no significant 
differences in destaining kinetics between DAPT and L-685,458 treated cells 
compared to DMSO mock control cells in (normal) 2.2 mM calcium (b ii, DMSO: n 
= 19, τ = 60.63 ± 5.33; DAPT: n = 16, τ = 54.72 ± 2.30; L-685,458: n = 18, τ = 
55.06 ± 2.70.  Student’s t-test, DMSO versus DAPT, p = 0.35; DMSO versus L-
685,458, p = 0.37). This same pattern was also seen between DAPT and L-685,458 
treated cells compared to DMSO mock control cells in (high) 5 mM calcium (b iii, 
DMSO: n = 7, τ = 34.30 ± 2.86; DAPT: n = 5, τ = 40.74 ± 4.96; L-685,458: n = 7, τ 
= 36.61 ± 2.13.  Student’s t-test, DMSO versus DAPT, p = 0.26; DMSO versus L-
685,458, p = 0.53).  This result shows that γ-secretase inhibition has minimal effect 
on FM dye destaining kinetics in rat dissociated neuronal cultures.  This suggests 
that γ-secretase activity is not involved in the modulation of synaptic vesicle 
dynamics.   
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Figure 4.5 – Estimation of readily releasable pool size in cells treated with γ-
secretase inhibitors DAPT and L-685,458 and DMSO control.  
(a) Quantification of readily releasable pool size of cells treated with DMSO mock 
(grey), DAPT (red) and L-685,458 (blue).  Values for γ-secretase treated cells 
were normalised to DMSO controls for a given culture.  There was no significant 
changes in readily releasable pool size (measured as fluorescence obtained with 30 
action potentials (and after background subtraction) – see methods) between 
DMSO mock, DAPT and L-685,458 treated cells.  (DMSO: n = 15, τ = 1.00 ± 
0.06; DAPT: n = 13, τ = 1.14 ± 0.13; L-685,458: n = 8, τ = 0.98 ± 0.14.  Student’s 
t-test, DMSO versus DAPT, p = 0.33; DMSO versus L-685,458, p = 0.90).  This 
results shows γ-secretase activity is not involved in the regulation of readily 
releasable pool size.   
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4.3 Examination of release probability of γ-
secretase inhibitor treated organotypic slices by 
measuring paired-pulse ratio and the rate of 
MK801 blockade 
 
FM-destaining experiments outlined above show that Pr was not altered at single 
synapses in dissociated neurons treated with γ-secretase inhibitors suggesting that the 
increase in mEPSC frequency observed following γ-secretase inhibition is not due to 
changes in Pr.  To examine whether this conclusion is also applicable to organotypic 
slices which have been treated with γ-secretase inhibitors, an electrophysiological 
approach was used.  A widely used method for measuring release probability in 
slices is examination of the paired-pulse ratio (PPR).  Paired-pulse facilitation is a 
form of presynaptic plasticity that has been linked with low release probability 
synapses and can be largely explained by the presence of residual calcium in 
presynaptic terminals (Katz and Miledi, 1968).  Arrival of an action potential at a 
synapse leads to a transient elevation of local calcium in the presynaptic terminal.  If 
a second action potential arrives within a few ten - hundreds of milliseconds, the 
residual calcium leads to a greater increase in the neurotransmitter released due to an 
increase in release probability and/or number of docked presynaptic vesicles (Cowan 
et al., 2001; Wu and Saggau, 1994; Zucker and Regehr, 2002).  Conversely if a 
synaptic connection has a high release probability, the number of vesicles being 
exocytosed is higher during the first pulse that then depletes the number of vesicles 
available for release during the second pulse.  Therefore, PPR is generally 
considered to be inversely correlated to release probability, with low probability 
synapses showing high PPR and high probability synapses exhibiting low PPR 
(Dobrunz and Stevens, 1997).  Analysis of PPR showed that there were no 
significant differences between slices treated with γ-secretase inhibitor DAPT and 
DMSO mock control slices (Figure 4.6).   
 
To further characterise release probability in organotypic slice cultures, another 
popular method was utilised, the rate of NMDA receptor mediated blockade by open 
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channel blocker MK801.  MK801 was first used to estimate release probabilities in 
hippocampal acute brain slices by Hessler and colleagues (Hessler et al., 1993) and 
by Rosenmund and colleagues in autaptic dissociated hippocampal cultures 
(Rosenmund et al., 1993).     More recently, MK801 was also used to characterise 
release probability in organotypic slice cultures (Futai et al., 2007).  MK801 is a 
specific blocker of active (open state) NMDA receptors and the rate of progressive 
irreversible block of synaptic NMDA receptor currents is directly correlated with 
release probability, with an increased rate of block reflecting an increase in 
presynaptic release probability.   
 
These experiments were conducted in slices with CA3-CA1 cut to prevent recurrent 
excitation and continuously maintained in extracellular bath solution (EBS) with 
picrotoxin.  Additionally NBQX (20 µm) was added to the EBS to block AMPA 
receptors and enable isolation of NMDA currents.  Cells were held at -40 mV to 
depolarise cells and aid relief of the voltage dependent magnesium block of the 
NMDA receptor.   Slices were perfused with MK801 for approximately 10 mins in 
the absence of stimulation to enable complete exchange of the recording chamber 
(Huang and Stevens, 1997).  Following this, the Schaeffer collaterals were 
stimulated at 0.125 Hz and rate of NMDA receptor current block with MK801 was 
measured.  No differences in the rate of synaptic NMDA current block were 
observed in slices treated with DAPT or L-685,458 when compared to DMSO mock 
control slices (Figure 4.7).  This result shows that γ-secretase activity is dispensable 
for the regulation of release probability in hippocampal organotypic slices.   
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Figure 4.6 – Examining the effect of γ-secretase inhibition on paired pulse 
ratio.   
(a)  Sample averaged traces from a cell treated with DMSO mock (grey, top) and 
γ-secretase inhibitor, DAPT (red, bottom).  (b)  Quantification of paired pulse 
ratio (PPR) of DMSO control (grey) and DAPT drug (red).  No significant 
changes in PPR were observed between DMSO and DAPT treated slices  (DMSO: 
n = 8, mean PPR: 1.419 ± 0.07; DAPT: n = 12, mean PPR = 1.30 ± 0.37.  
Student’s t-test, DMSO versus DAPT, p = 0.41).  This results indicates that γ-
secretase activity is not involved in the regulation of PPR, suggesting that γ-
secretase activity is not required for regulating release probability.   
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Figure 4.7 – Examining the effect of γ-secretase inhibition on rate of MK801 
NMDA receptor block.   
(a)  Sample traces showing the gradual decrease in NMDA receptor current 
amplitude with continuous application of MK801 and extracellular stimulation at 
0.125 Hz.  Grey numbers represent trace number.  (b)  Graph shows evoked 
NMDA current response in the absence (black points) and presence of MK801 (red 
points).   Points were normalised to the amplitude of the first evoked NMDA 
current obtained in the presence of MK801.  (c) Quantification of rate of MK801 
block.  Timecourse of averaged responses to MK801 block (c i) and quantification 
of decay time constant (c ii) for DMSO (grey), DAPT (red) and L-685,458 (blue).  
There was no significant difference in the rate of MK801 block between γ-
secretase inhibitor treated slices and DMSO control (Figure cii, DMSO: n = 11, τ: 
13.76 ± 1.83; DAPT: n = 13, τ = 16.51 ± 1.68; L-685,458: n = 8, τ: 16.30 ± 2.69.  
Student’s t-test, DMSO versus DAPT, p = 0.28; DMSO versus L-685,458, p = 
0.43).  This results indicates that γ-secretase activity inhibition does not affect rate 
of MK801 block, suggesting that γ-secretase activity is not required for the 
regulation of release probability.   
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4.4 Discussion  
 
As discussed in chapter 3, this and other studies have provided evidence that 
presenilin and γ-secretase activity is implicated in modulating mEPSC frequency.  
This chapter set out to examine whether presenilin and γ-secretase activity is 
implicated in regulating Pr at hippocampal synapses and to determine if a change in 
Pr is associated with the change in mEPSC frequency.  The role of presenilin and γ-
secretase activity in modulating release probability has not been extensively studied.  
This study showed using FM styryl dye imaging at single synapses of PS1 -/- mice 
and γ-secretase inhibitors treated cells that release probability is not altered upon 
presenilin manipulation in dissociated hippocampal cultures.  Estimating the rate of 
MK801 block and PPR in organotypic slices treated with γ-secretase inhibitors, 
corrobated our results obtained from optical methods and revealed no alteration in 
release probability when compared to control conditions.  Together these findings 
suggest that presenilin associated γ-secretase activity is not required for the 
regulation of Pr.    
 
Despite the lack of effect on measures of Pr, the effectiveness of γ-secretase 
inhibitors in modulating mEPSC frequency is robust. However, in order to confirm 
that γ-secretase inhibitors are active and modulating APP processing, our 
collaborators from the University of Chicago led by Professor Sangram Sisodia 
performed western blot analysis on rat dissociated cultures treated with the same 
batches of γ-secretase inhibitors as used in this chapter.  Full length APP and APP C-
terminal fragments (CTF) expression was probed using an antibody recognising the 
C-terminal fragments of APP.  The results showed that treatment of rat cultures with 
γ-secretase inhibitors DAPT and L-685,458, led to a strong accumulation of APP 
CTFs in the lysate, which was expected from previous reports (see for example, 
Parent et al., 2005) and strongly implied that γ-secretase inhibitors were effective at 
blocking γ-secretase proteolysis of endogenous APP (see Appendix I).  This result 
provides further evidence that the lack of effect on release probability is not due to a 
lack of γ-secretase activity inhibition using DAPT and L-685,458.   
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A recent study suggests a role for neprilysin, one of several enzymes implicated in 
the degradation of endogenous Aβ, in regulating presynaptic release (Abramov et al., 
2009).  Abramov and colleagues found that acute block of neprilysin activity using a 
selective inhibitor, thiorphan, and an antibody that neutralises neprilysin activity, 
increased FM dye uptake into presynaptic terminals and proposed that neprilysin 
activity negatively modulated basal presynaptic vesicle endocytosis.  The thiorphan 
induced increase in vesicle endocytosis was abolished by treatment with γ-secretase 
inhibitor, L-685,458, suggesting that γ-secretase activity inhibitor prevents the 
thiorphan induced increase in release probability.  However, it was also shown that 
treatment with L-685,458, did not lead to a change in synaptic vesicle endocytosis, 
with the amount of FM dye taken up into synaptic vesicles in γ-secretase treated cells 
and control cells being comparable. This result suggests that γ-secretase activity does 
not regulate vesicle endocytosis under basal conditions and by extension; loss of γ-
secretase activity does not seem to alter release probability relative to control cells.  
This conclusion is consistent with the findings presented in this chapter.   The 
authors also provide evidence that Aβ acts as a positive regulator of release 
probability, as the thiorphan induced elevation of release probability was abolished 
by other manipulations which decreased Aβ production including treatment with β-
secretase, antibodies that sequester extracellular Aβ and upon loss of APP in knock-
out cells.        
 
However, another study that was published during the course of this work showed 
that PPR and neurotransmitter release was altered in a conditional double knock-out 
of presenilin 1 and 2 (Zhang et al., 2009).  Using acute slices obtained from a mouse 
model where both presenilin genes were specifically eliminated from presynaptic 
neurons (double knockout in CA3 pyramidal neurons and recording from wild type 
postsynaptic CA1 neurons of the hippocampus), Zhang and colleagues showed a 
decrease in PPR and a slower rate of MK801 block.  This effect on decreasing 
release probability upon presenilin elimination was seen in low (0.5-2.6 mM) 
calcium but not high (5-7.5 mM) calcium concentrations and not observed when 
presenilin was eliminated from the postsynaptic cell in acute slices. In the same 
study, PPR was also examined in hippocampal dissociated cultures prepared from 
presenilin double knock-out.  In this preparation, knock-out of presenilin was 
induced by infection of Cre-GFP lentivirus for 72 hrs and western blot analysis 
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confirmed the complete absence of PS1 CTF in mature neuronal cultures, 
presumably from both pre and postsynaptic sites.  Examination of PPR was also 
found to be reduced in these neuronal cultures.  The general conclusions from this 
study suggest that presenilins is implicated in regulating Pr.  The reason for the 
discrepancy between the study by Zhang et al., (2009) and the data presented in this 
chapter and Abramov et al., (2009) is unclear.  The double presenilin knock-out 
strategy used by Zhang et al., (2009) is potentially different to pharmacological 
inhibition of γ-secretase activity used in this chapter.  One key point that is not clear 
from the double presenilin knockout animals is whether the effect is dependent or 
independent of γ-secretase activity of presenilins as both are effectively eliminated 
upon deletion of the gene.  If the effect on Pr is operating through a γ-secretase 
independent manner then pharmacological inhibition of γ-secretase activity (as 
presented in this chapter) may not lead to a decrease in release probability.  
Examining release probability in nicastrin knock-out mice (Tabuchi et al., 2009) 
which should lack functional γ-secretase complexes but should express presenilin 
would provide further insight into whether γ-secretase activity is specifically 
required for regulation of presynaptic function.   
 
 
4.5 Conclusion 
 
This chapter showed that expression or γ-secretase activity of presenilin (1) 
dispensable for regulation of release probability.  This result suggest that the 
elevation in mEPSC frequency observed in PS1 knock-out and γ-secretase inhibitor 
treated cells is not associated with alterations in presynaptic release properties.
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Chapter 5: The role of presenilin in 
modulating synapse number in 
hippocampal neurons 
 
 
5.1 Introduction  
As discussed in chapter 3, a robust increase in mEPSC frequency was observed upon 
pharmacological inhibition of γ-secretase activity or elimination of PS1-/- gene.  
Release probability was thoroughly explored in chapter 4 and no significant 
differences between presenilin manipulated and control cells were observed, 
suggesting a change in Pr is not responsible for the change in mEPSC frequency.  In 
this current chapter, the number of synaptic contacts was extensively examined to 
determine if presenilin may play a role in modulating synapse structure and function 
of hippocampal neurons. 
 
Synapse number was assessed using either immunocytochemical methods which 
involved antibody labelling of pre and postsynaptically localised proteins in primary 
dissociated cultures or estimations of spine number from neurons of organotypic 
slices by filling cells with Alexa 488 hydrazide (made up in internal solution) to 
enable visualisation.   A previous report from Parent el al (2005) showed that wild 
type PS1 cortical neurons treated with γ-secretase inhibitors showed an increase in 
the number of postsynaptic spines when compared to untreated PS1 wild type cells 
in cortical cultures (Parent et al., 2005).  Additionally, PS1 knock-out neurons and 
PS1 wild type cells treated with γ-secretase inhibitors showed an increase in 
postsynaptic density marker PSD-95 that overlapped with presynaptic active zone 
marker bassoon when compared to untreated wild type cells.    Analysis of individual 
PSD-95 and bassoon clusters revealed that the increase in colocalised PSD-95 and 
bassoon clusters may be due to a postsynaptic increase in PSD-95 signal following γ-
secretase activity inhibition or PS1 elimination without an alteration in bassoon 
signal.  One drawback of this study was that the synapse density or number was not 
Chapter 5: Presenilin modulation of synapse number 
 170
specifically investigated; purely the percentage difference in PSD-95 and bassoon 
clusters between cells with and without presenilin manipulations was examined.  
Despite this limited method of analysis, the results suggested that PS1 associated γ-
secretase activity could play a role in regulating synapse formation in cortical 
cultures.  In this chapter, I set out to examine the association of synaptic proteins and 
spine number in greater detail in hippocampal dissociated cultures and slice cultures.   
 
 
5.2 Examination of synapse number in rat 
dissociated neurons treated with γ-secretase 
inhibitors  
 
Synapses are defined as the functional connection between a presynaptic and a 
postsynaptic cell.  Whilst immunofluorescence labelling does not directly assess 
functionality (only inferred), past studies have suggested that pre and postsynaptic 
colocalised clusters can display elements of synaptic function such as synaptic 
vesicle release (see for example: Branco et al., 2008; Darcy et al., 2006).  For this 
reason, synapses were identified as puncta/ regions which contained colocalised 
presynaptic and postsynaptic markers.  To be extra careful that only neuronal 
markers were analysed, only puncta that co-localised with neuronal marker, MAP2 
were assessed.  Additionally, the number of pre and postsynaptic puncta were 
separately examined to determine if there were any differences in the non-
colocalised population, which may potentially correspond to extrasynaptic receptors 
(see for review, Triller and Choquet, 2005) or presynaptic orphan synapses (Krueger 
et al., 2003; Staras et al., 2010).  Antibodies recognising presynaptic vesicle proteins 
synapsin and synaptophysin were used to identify presynaptic compartments (Lu et 
al., 1992; Lu et al., 1996; Tarsa and Goda, 2002) that associate with synaptic vesicles 
at both excitatory and inhibitory terminals.  To specifically target excitatory 
connections, antibodies recognising two postsynaptic excitatory synapse markers 
were used.  Homer is an excitatory postsynaptic density scaffold protein (see Sheng 
and Hoogenraad, 2007) and GluA1 is an AMPA receptor subunit found 
predominately at excitatory synapses (see Scannevin and Huganir, 2000).  For 
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GluA1 labelling, antibodies were applied to live cells to aid labelling of the surface 
population of receptors, as opposed to the internal pool (Cingolani et al., 2008; 
Passafaro et al., 2001).   For most experiments, images were acquired by placing the 
neuron of interest into the centre of the field of view which essentially enabled an 
estimate of the majority of synaptic markers to be analysed.  However the total 
synapse number could not be readily assessed as some dendritic branches often 
extended beyond the boundaries of the image acquisition window and hence could 
not be analysed. 
 
Firstly, co-localisation of presynaptic vesicle marker synapsin and excitatory 
postsynaptic density scaffold protein Homer was examined (Figure 5.1).  Analysis 
showed that there was an increase in co-localised Homer and synapsin puncta 
following γ-secretase inhibitor treatment with DAPT and L-685,458  (Figure 5.1 b i; 
DMSO: n = 55, 1.07 ± 0.40 co-localised puncta per 10 µm; DAPT: n = 50, 1.51 ± 
0.07 co-localised puncta per 10 µm;  L-685,458: n = 51, 1.35 ± 0.08 co-localised 
puncta per 10 µm.  Student’s t-test: DMSO versus DAPT, p = < 0.0001 ***; DMSO 
versus L-685,458, p = 0.0038 **).  This result was complimented by a significant 
increase in both presynaptic synapsin density (Figure 5.1 b iii) and postsynaptic 
Homer density (Figure 5.1 b iii).  Together these results implicate a role for γ-
secretase activity inhibition in increasing excitatory synapse density.  However, 
further analysis of synapsin and GluA1 co-localised puncta did not reveal a 
significant difference following γ-secretase inhibitor treatment (Figure 5.2 b; DMSO: 
n = 56, 1.29 ± 0.06 co-localised puncta per 10 µm; DAPT: n = 57, 1.47 ± 0.07 co-
localised puncta per 10 µm; L-685,458: n = 40, 1.36 ± 0.07 co-localised puncta per 
10 µm.  Student’s t-test: DMSO versus DAPT, p = 0.053; DMSO versus L-685,458, 
p = 0.486).  In the same cells, analysis of synapsin puncta revealed a modest yet 
significant increase in density following L-685,458 treatment but only a small but 
non significant increase in synapsin density was observed in DAPT treated cells 
when compared to DMSO mock control cells (Figure 5.2 b ii).  Analysis of GluA1 
density alone showed an increase in both DAPT and L-685,458 treated cells with 
respect to DMSO mock controls, potentially indicating an increase in extrasynaptic 
rather than synaptic surface GluA1 (Figure 5.2 b iii).  The reasons for the observed 
differences in the densities of Homer and synapsin co-localised puncta and GluA1 
and synapsin co-localised puncta are currently not fully understood.      
Chapter 5: Presenilin modulation of synapse number 
 172
 
MAP2 Synapsin Homer
DMSO 
DAPT 
Mergea 
DMSO DAPT L-685 458
0.0
0.5
1.0
1.5
2.0 ***
**
C
o-
lo
ca
lis
ed
 s
yn
ap
si
n 
an
d
H
om
er
 p
un
ct
a 
pe
r 
10
μm
DMSO DAPT L-685 458
0.0
0.5
1.0
1.5
2.0
2.5
**
**
Sy
na
ps
in
 d
en
si
ty
 p
er
 1
0 μ
m
DMSO DAPT L-685 458
0.0
0.5
1.0
1.5
2.0
2.5
***
*
H
om
er
 d
en
si
ty
 p
er
 1
0 μ
m
b i ii iii 
 
 
 
 
 
 
Figure 5.1 – Immunofluorescence analysis of presynaptic synapsin and postsynaptic Homer markers of cells 
treated with γ-secretase inhibitors, DAPT or L-685,458. 
(a) Sample images of neurons treated for 48 hrs with DMSO mock (top, grey) or γ-secretase inhibitor, DAPT (middle, 
red) or L-685,458 (bottom, blue).  Antibody labelling was performed against MAP2 (neuronal marker, blue), Homer 
(postsynaptic marker, green) and synapsin (presynaptic marker, red). Scale bar: low magnification images 20 µm, inset 
images 6 µm. (b) Summary of immunofluorescence quantification of co-localised Homer and synapsin puncta (i), 
synapsin puncta (ii) and Homer puncta (iii) of cells treated with DMSO (grey), DAPT (red) or L-685,458 (blue).  All 
puncta were expressed as density per 10 µm.  A significant increase in colocalised synapsin and Homer puncta density 
(i) was observed in DAPT treated cells and L-685,458 treated cells when compared to DMSO control (student’s t-test: 
DMSO versus DAPT, p = < 0.0001 ***; DMSO versus L-685,458, p = 0.004 **). There was also a significant 
difference in synapsin puncta density (ii) between DMSO and DAPT (t-test: p = 0.001 **) and DMSO and L-685,458 (t-
test: p = 0.003 **).  Analysis of Homer density also revealed a significant increase following γ-secretase inhibitor  
treatment when compared to DMSO control (t-test: DMSO versus DAPT, p = 0.0001***; DMSO versus L-685,458, p = 
0.03 *). n = 55 cells were analysed for DMSO mock, n = 50 for DAPT and n = 51 for L-685,458, pooled from 3 separate 
cultures. Analysis to compare statistical significant between γ-secretase inhibitor treated and DMSO mock treated cells 
was performed using student’s t-test 
L685,458 
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Figure 5.2 – Immunofluorescence analysis of presynaptic synapsin and postsynaptic GluA1 of cells treated with γ-
secretase inhibitors, DAPT or L-685,458. 
(a) Sample images of neurons treated for 48 hrs with DMSO mock (top, grey) or γ-secretase inhibitor, DAPT (middle, 
red) or L-685,458 (bottom, blue).  Antibody labelling was performed against MAP2 (neuronal marker, blue), GluA1 
(postsynaptic marker, green) and synapsin (presynaptic marker, red). Scale bar: low magnification images 20 µm, inset 
images 6 µm. (b) Summary of immunofluorescence quantification of co-localised Homer and synapsin puncta (i), 
synapsin puncta (ii) and Homer puncta (iii) of cells treated with DMSO (grey), DAPT (red) or L-685,458 (blue).  All 
puncta were expressed as density per 10 µm.  No significant increase in colocalised synapsin and Homer puncta density 
(i) was observed in DAPT treated cells and L-685,458 treated cells when compared to DMSO control.  There was a small 
but significant increase in synapsin puncta density (ii) between DMSO and L-685,458 treated cells (t-test: p = 0.005 **).  
No significant difference in synapsin density was observed between DMSO and DAPT.  Analysis of GluA1 density 
revealed a significant increase following γ-secretase inhibitor treatment when compared to DMSO control (t-test: DMSO 
versus DAPT, p = 0.005**; DMSO versus L-685, 458, p = 0.008 **). n = 56 cells were analysed for DMSO mock, n = 57 
for DAPT and n = 40 for L-685,458, pooled from 3 separate cultures. Analysis to compare statistical significant between 
γ-secretase inhibitor treated and DMSO mock treated cells was performed using student’s t-test. 
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5.3 Examination of synapse number in PS1+/+ 
and PS1-/- mice neurons 
 
To further examine whether presenilin is involved in regulation of synapse number, 
immunofluorescence labelling was performed on PS1+/+ and PS1-/- mice cultures.  
The effect of γ-secretase inhibition on mEPSC frequency was mimicked by PS1-/- 
phenotype, and thus the similarities in mEPSC properties could reflect a shared 
mechanism in regulating synapse number.  To test this, both PS1+/+ and PS1-/- 
littermate cultures were labelled in parallel with presynaptic vesicle marker, 
synaptophysin.  Experiments and analysis was performed using the same procedures 
as that used for rat cultures (see above and methods).  Quantification showed that the 
mean density of synaptophysin puncta in PS1-/- neurons was higher than PS1+/+ 
neurons but not at a statistically significant level (Figure: 5.3, Student’s t-test; p = 
0.09).   
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Figure 5.3 – Immunofluorescence analysis of synaptophysin in PS1 +/+ and PS1 -/- 
cells 
(a) Sample images of PS1 +/+ (top) and PS1 -/- (bottom) neurons.  Antibody labelling 
was performed against MAP2 (neuronal marker, left) and synaptophysin (presynaptic 
marker, right). Scale bars: low magnification images 20 µm, inset images 6 µm.  
(b) Summary of immunofluorescence quantification of synaptophysin density in PS1 +/+ 
and PS1 -/- cells.  Synaptophysin puncta were expressed as density per 10 µm.  Analysis 
of synaptophysin puncta showed no significant difference between PS1 +/+ and PS1 -/- 
cells. n = 19 cells were analysed for PS1 +/+ cells and n = 27 cells were analysed for PS1 
-/- cells, pooled from 2 separate cultures.  Statistical analysis was performed using 
student’s t-test (bar graphs; p = 0.09).  
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5.4 Examination of spine number in rat 
organotypic slice cultures treated with γ-
secretase inhibitors 
 
 
Antibody labelling experiments in rat dissociated cultures suggest that γ-secretase 
activity may play a role in regulating colocalised Homer and synapsin positive 
puncta number and thus may provide an explanation for the increase in mEPSC 
frequency.  As with rat dissociated cultures, an increase in mEPSC frequency was 
also observed in the more intact organotypic slice system upon treatment with γ-
secretase inhibitor DAPT and L-685,458.  To determine if an increase in synapse 
number is also observed in organotypic neurons and to test if γ-secretase activity is 
able to regulate synapse number across different experimental systems, further 
analysis was performed on CA1 pyramidal cells.  Earlier studies have shown that 
most spines of CA1 pyramidal cell receive one excitatory synaptic input in vivo and 
hence spine number could be assumed to be a fairly good measure of glutamatergic 
synapse number in slices (Harris and Stevens, 1989; Megias et al., 2001; Schikorski 
and Stevens, 1997).  In order to visualise CA1 pyramidal neurons in organotypic 
slices, cells were filled with Alexa 488 hydrazide through the patch pipette, fixed 
and imaged using confocal microscopy.  High magnification sections of apical and 
basal dendrites from secondary proximal branches were used for analysis.   
 
Low magnification images of filled cells showed that there were no gross 
morphological changes in cells chronically treated with γ-secretase inhibitors DAPT 
or L-685,458 and DMSO mock controls (Figure 5.4).  Analysis of apical and basal 
dendritic processes also did not show any statistically significant changes in mean 
spine density (Figure 5.4 b).  This result suggests that γ-secretase activity inhibition 
does not lead to changes in the number of postsynaptic spines in organotypic slice 
cultures.   
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Figure 5.4 – Spine analysis of organotypic slices treated with γ-secretase 
inhibitors 
(a) Sample image a neuron treated for 48 hrs with DMSO mock (left), DAPT 
(middle) and L-685,458 (right) at low magnification (top) Scale bar, 30 µm.  
High magnification images of typical neurons from slices treated with DMSO 
(left, bottom), DAPT (middle, bottom) and L-685,458 (right, bottom).  Scale bar, 
5 µm. (b) Quantification of spine density of apical dendrites (left) and basal 
dendrites (right).  No significant differences were observed in either apical or 
basal spine density in cells treated with DMSO mock (n: 7 cells), DAPT (n: 6 
cells), or L-685,458 (n; 6 cells).   
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5.5 Discussion 
 
 
The aim of the experiments outlined in this chapter was to investigate whether 
disruption of γ-secretase activity leads to any changes in synapse number in 
dissociated and organotypic hippocampal cultures.  The results show that cells 
treated with DAPT and L-685,458 displayed a tendency for an increase in synapsin, 
Homer and GluA1 density, suggesting γ-secretase activity inhibition modulates both 
pre and postsynaptic marker density.  Moreover, a significant increase in synapsin 
and Homer co-localised puncta was observed, in accordance with a previous study 
by Parent et al., (2005) where an increase in synaptic marker co-localisation was also 
found.  Overall the data from these two studies suggests that γ-secretase activity acts 
as a negative regulator of synapse number and the increase in synapse number may 
provide a structural correlate to the functional increase in mEPSC frequency 
following presenilin manipulations.  This is in line with previous studies which show 
that increases in synapse density are correlated with changes in mEPSC frequency 
(see for example, El-Husseini et al., 2000; Flavell et al., 2006; Levinson et al., 2005).   
 
However, analysis of the density of co-localised GluA1 and synapsin did not reveal 
any significant differences between γ-secretase inhibitor treated and DMSO mock 
control neurons.  This result suggests that an increase in synapse number (observed 
as an increase in synapsin and Homer co-localisation) does not necessarily 
accompany an increase in synaptically located GluA1 receptors.  This is not totally 
unexpected as a study on cultured spinal neurons found that GluA1 AMPA subunits 
are not always expressed at all excitatory synapses (O'Brien et al., 1997).  This result 
suggests that the increase in mEPSC frequency observed in PS1-/- neurons and in γ-
secretase inhibitor treated cells is potentially not due to unsilencing of postsynaptic 
silent synapses as no change in synaptic GluA1 receptors was observed.  This is in 
agreement with the lack of change in postsynaptic mEPSC amplitude.  However, it is 
currently unclear from this study whether there is any change in the synaptic surface 
expression of other glutamate receptor subtypes, such as GluA-2, and further 
experiments will be required to examine this question in more detail.  The increase in 
total GluA1 density (presumably extrasynaptic receptors) however may suggest that 
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more GluA1 receptors are in a mobile state which may potentially be implicated in 
synapse formation.   
 
 
5.5.1 Limitations and points of further investigation  
 
An assessment of synapse number in PS1-/- cells was made.  Analysis of PS1 -/- 
neurons did not reveal a significant increase in presynaptic synaptophysin density 
relative to PS1 +/+ neurons.  Postsynaptic Homer or GluA1 marker labeling was not 
performed for mice neurons as these cells were also used for PS1 antibody labeling 
(data not shown, see chapter 8: overall summary).  As Homer, GluA1 and PS1 
antibodies were all derived from rabbit, this meant only one antibody could be used 
for a given experiment.  As PS1 was always used, this meant that only presynaptic 
labeling was assessed.  One limitation of sole pre or postsynaptic labeling is that the 
signal may not always correlate with the expression of a functional synapse.  This 
was emphasised by a recent study that showed individual assessment of pre or 
postsynaptic markers may not reflect the analysis of pre and postsynaptic co-
localised synaptic labelling.  Parent et al., (2006) showed that PS1-/- cells exhibit an 
increase in synaptic PSD-95 and bassoon co-localised signal when compared to wild 
type cells, suggestive of an increase in synapse number.  This result was in line with 
the observed increase of PSD-95 signal in PS1-/- cells.  However separate analysis of 
bassoon labeling did not reveal an increase in signal in PS1-/- cells when compared 
to control cells.  This study highlights a case where the co-localised synaptic labeling 
should be used for assessment of synapse number.  Thus, future experiments 
examining co-staining between pre and postsynaptic markers may provide a more 
accurate estimate of synapse number in PS1-/- and PS1+/+ cells.   
 
A recent study by Zhang et al., (2009) also showed no changes in synaptophysin 
labelling in conditional presenilin double knockout mice suggesting that 
synaptophysin levels are not altered upon complete elimination of presenilins (Zhang 
et al., 2009).  However, postsynaptic markers were also not assessed in this study.  
Additionally, as synaptophysin is a universal presynaptic vesicle protein found at 
both inhibitory and excitatory synapses, the effect on excitatory synapses may 
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potentially be masked if there is a particularly high ratio of inhibitory to excitatory 
synapses in the regions being analysed.  To test this possibility, excitatory (Homer, 
PSD-95, GluA1 or GluA2) and inhibitory (GABAA or gephyrin) postsynaptic 
markers should be examined for co-localisation with presynaptic markers.  
Additionally, presynaptic excitatory (VGluT) and inhibitory (VGAD) markers can be 
analysed for co-localisation with postsynaptic markers.   
 
Morphological changes and spine loss have been reported in different AD mice 
models (see for example, Moolman et al., 2004).  In line with this, studies have 
shown that Aβ peptides can cause reversible spine loss (Calabrese et al., 2007; 
Shankar et al., 2007; Shrestha et al., 2006).  However, it was not clear if loss of γ-
secretase activity could lead to changes in postsynaptic spine density in intact slice 
preparations.  Analysis of postsynaptic spine number also did not reveal any 
significant differences between γ-secretase inhibitor treated and DMSO mock 
control cells.  The lack of spine changes observed in organotypic slices is contrary to 
the observations by Parent et al., (2005) which report an increase in spine number 
following γ-secretase inhibitor treatment (and also in PS1-/- cells) in dissociated 
cortical cultures.  The lack of change in spine number also diverges from the 
synaptic (Homer and synapsin colocalised puncta) marker results obtained from γ-
secretase treated dissociated cultures (Figure 5.1).  Potentially the differences may be 
due to the differences in the preparation (such as drug penetration) but this is 
unlikely as mEPSC recordings showed an increase in frequency in both dissociated 
cultures and organotypic slice cultures following γ-secretase inhibitor treatment.   
 
A couple of recent studies investigating the density of spines within different regions 
of the dendritic tree of hippocampal CA1 pyramidal cells reported that spines are not 
homogenously distributed.  Extensive electron microscopy analysis on 3-D 
reconstructed dendritic branches revealed that spines were denser at regions closer to 
the dendritic branch points and also spine density was higher in distal compared to 
more proximal regions of the dendritic tree (Katz et al., 2009, but also see Megias et 
al., 2001).  For the organotypic CA1 spine analysis experiments described in this 
chapter, only a small section of the secondary dendrites was assessed, which 
represents a minor proportion of the total dendritic spine population.  Additionally, a 
change in synapse number can arise not just from a change in synapse density but 
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also an increase in dendritic length and increased complexity of dendritic branching.  
To gain more information on synapse distribution, Sholl analysis can also be used to 
assess dendritic branching and complexity.  In light of the reports by Katz et al., 
(2009), assessment of spine number should be revisited and a more in depth analysis 
covering a greater proportion of dendritic spines should be performed (ideally along 
the total dendritic length) in order to get a more reliable assessment of the synapse 
number in organotypic slices in the presence or absence of γ-secretase inhibitors.  
Notably, a study investigating the morphological and functional differences between 
acute and organotypic slices concluded that cells from organotypic slices displayed a 
much greater level of complexity and variability than cells from acute slices at an 
equivalent stage in development (De Simoni et al., 2003).  This study indicates that 
analysis of a greater number of cells is warranted to ensure a more accurate 
assessment of spine number in organotypic slices. Separation of spines into different 
classes may also provide information about whether γ-secretase activity of 
presenilins is involved in regulating spine morphology and maturation.  However, 
this method ultimately relies on being able to completely fill the spine head with dye 
and being able to accurately resolve the spine shape with no loss of signal 
(photobleaching) during image capture.  The limitations of this approach have been 
extensively debated in reports by De Simoni et al., (2004) and Svoboda (2004).   
 
Two recent studies have also investigated the impact of γ-secretase inhibitor 
treatment on postsynaptic changes.  One study by Inoue et al., (2009) reported that 
treatment of mature rat hippocampal dissociated cultures with γ-secretase inhibitor, 
compound E for 1 week led to a modest but significant decrease in GluA1 receptor 
staining when compared to DMSO control (Inoue et al., 2009).  This result is 
potentially in disagreement with the results of GluA1 receptor staining presented in 
this chapter.  However, differences in methodology may explain the divergent 
results.  In the study by Inoue et al., (2009), primary antibodies were applied after 
cell fixation and permeabilisation which would effectively sample the total 
population (surface and internal pools) of GluA1.  This is different to the live 
labeling procedure used in this chapter, which identifies predominantly the surface 
population.  This means the results from the two studies are not necessary 
comparable as different GluA1 populations are examined.  Additionally, Inoue et al., 
(2009) reported no significant changes in presynaptic synaptophysin or postsynaptic 
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PSD-95 density following γ-secretase inhibitor treatment.  Surprisingly, the co-
localisation between pre and postsynaptic markers was not reported in this study, 
despite the double labelling of presynaptic (synaptophysin) and postsynaptic (PSD-
95) markers.   Intriguingly, Inoue and colleagues report a decrease in spine density in 
the absence of a change in PSD-95 puncta (Inoue et al., 2009).  The lack of effect on 
PSD-95 labelling is also inconsistent with reports by Parent et al., (2005) which 
showed that PSD-95 marker staining increases following γ-secretase inhibitor 
treatment with compound E.  The reason for the difference is not entirely clear but 
differences in drug incubation time may be a possibility, as Inoue et al., (2009) treat 
for 7 days whilst Parent et al., (2005) treat for a maximum of 24 hrs.  If these studies 
are correct, together the results proposes a model where synapse number is 
temporally altered depending on the duration of γ-secretase inhibitor exposure with 
synapse number initially increasing (approximately 4-48 hrs preincubation) followed 
by a subsequent decrease in synaptic components (after 7 days).  Prolonged time 
lapse imaging would provide a valuable way to examine this case. 
 
The long term effect of γ-secretase inhibition in vivo has recently been studied by 
Bittner et al., (2009).  Using live two photon imaging of wild type mice neocortical 
neurons, this study reported a decrease in dendritic spine density in vivo following 
systemic administration of γ-secretase inhibitor DAPT (100 mg/ kg) (Bittner et al., 
2009).  Timelapse imaging revealed a significant decrease in mature (persistent) 
spines, 8 days after the administration of DAPT.  The density became progressively 
lower with extended periods of imaging.  No significant changes in spine density 
were observed after 48 hrs treatment, which suggests that the decrease in spine 
density requires long γ-secretase treatment periods in vivo.  Additionally, no effect 
was observed on the number of transient spines suggesting that γ-secretase 
specifically targets a specific population of spines.  Interestingly, when spine 
morphology was examined, no differences between the proportion of thin, stubby 
and mushroom shaped spines was observed following γ-secretase inhibition, 
suggesting block of γ-secretase activity affects all spine types equally.  Presynaptic 
changes were not examined.  The in vivo results obtained by Bittner and colleagues 
are generally in agreement with the spine density results reported by Inoue et al., 
(2009) in dissociated cultures, but in disagreement with the study by Parent et al., 
(2005) where an increase in spine density is observed following 24 hr treatment with 
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γ-secretase inhibitors and the results obtained in γ-secretase treated organotypic 
slices where no change was observed (Figure 5.4).   Further examination of synapse 
number is warranted to investigate the reasons underlying the reported differential 
effects.    
 
Due to limitations in time and resources further analysis could not be undertaken 
during the course of this project.  Immunofluorescence analysis of synaptic markers 
has provided much useful information with regards to understanding relative changes 
in synaptic proteins.  However this technique does not exclude labelling of 
immature/ nascent synapses in addition to mature synapses.  For this, electron 
microscopy examination should also be pursued to clarify the change in synapse 
number using ultrastructural methods.  Electron microscopy may potentially provide 
more accurate estimates of synapse number than immunofluorescence methods as 
the resolution is greater.  For example, electron microscopy may reveal two closely 
associated synapses which may potentially appear as one using immunofluorescence 
labeling techniques.  However one potential drawback with this approach is that only 
a sub section of synapses can be assessed in practice which precludes the assessment 
of total synapse number.  As synapse distribution on neurons is not homogenously 
distributed, there is potential for some biase introduced by synapse selection.  
Furthermore an estimate of functional synapse number should also be examined to 
enable better correlations to be made between mEPSC frequency and synapse 
number.  This could be achieved through a combination of paired recordings, quantal 
analysis and identification of synapses by filling the cells with horseradish 
peroxidase or biocytin as proposed by Branco and Staras, (2009) amongst many 
others.  Co-immunolabelling for voltage gated calcium channels required for 
neurotransmitter release and synapsin, a synaptic vesicle protein associated with 
synapse maturation can also aid identification of functionally mature synapses (Coco 
et al., 1998; Lu et al., 1992; Scholz and Miller, 1995).   
 
One aim of this experiment was to determine if γ-secretase inhibition alters synapse 
number as a possible explanation for the elevated mEPSC frequency observed in 
chapter 3.  Ideally function and synapse number should be assessed in the same cell 
to determine if there is direct correlation.  However this was not possible due to 
technical difficulties in re-identifying neurons that had been previously used for 
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recordings after immunofluorescence labeling.  This meant that estimates of synapse 
number were performed on neurons that were separate to the neurons that were used 
for spontaneous recordings.  As the effect of γ-secretase inhibition on spontaneous 
currents seemed to be restricted to excitatory synapses, immunofluorescence labeling 
was only performed on excitatory synapse markers; Homer and GluA1.  The effect 
of γ-secretase treatment on inhibitory synapse number was not investigated during 
these experiments but future studies should examine if there is any alterations in 
inhibitory synapse number.   
 
 
5.5.2 Potential mechanisms for γ-secretase associated regulation 
of synapse number 
 
Currently, the mechanisms that modulate changes in synapse number are poorly 
understood.  Conceivably, there are possibly many different mechanisms that a 
neuron can use to dynamically and homeostatically regulate synapse formation and 
elimination throughout its lifetime (see Garner et al., 2002; Goda and Davis, 2003; 
Ziv and Garner, 2004).   Investigating how γ-secretase activity is involved in 
regulating signaling pathways implicated in synapse formation and elimination will 
be important to aid our understanding of the role of presenilin in regulating synapse 
number.  As different reports have indicated differential effects of γ-secretase 
inhibition on synapse density, there is a possibility that more than one mechanism is 
involved in regulating synapse number.     
 
Parent and colleagues (2005) reported that elimination of PS1-/- gene or inhibition of 
γ-secretase activity in cortical neurons led to an increase in neurite outgrowth and 
synaptogenesis.  Loss of presenilin expression/activity was also strongly associated 
with the accumulation of membrane-bound DCC C-terminal fragments and enhanced 
cAMP/ PKA signaling and phosphorylation of PKA substrates.  Previous studies 
have shown that cAMP/ PKA signaling is involved in regulation of synaptic 
plasticity including LTP (see Malenka and Nicoll, 1999; Malinow and Malenka, 
2002).  In line with this observation, studies have also shown that enhanced cAMP 
signaling can increase mEPSC frequency (see for example, Bie and Pan, 2005; 
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Bouron, 1999).   cAMP/ PKA signaling has also been linked with regulation of 
synapse morphology (see for example, Ma et al., 1999).  Therefore inhibition of γ-
secretase processing of DCC can cause accumulation of DCC CTF and enhanced 
cAMP/ PKA signaling which could lead to an increase in synapse number and 
mEPSC frequency.  This provides evidence that γ-secretase inhibition or knock-out 
of presenilin can alter structure and function of cortical synapses.  It remains to be 
determined whether changes in cAMP/PKA signaling also occur in hippocampal 
neurons following inhibition of γ-secretase activity.   
 
Inoue and colleagues showed that γ-secretase activity could enhance formation and 
maintenance of dendritic spines through an EphA4 dependent mechanism (Inoue et 
al., 2009).  The authors proposed that γ-secretase processing of EphA4 can generate 
EphA4 intracellular domain fragments which could activate Rac signaling.  Rac 
signaling is implicated in the regulation of the actin cytoskeleton and provides a 
mechanism for the up-regulation of dendritic spines.   Pharmacological block of γ-
secretase activity was shown to have the opposite effect, with a decrease in dendritic 
spines and total GluA1 expression, possibly due to down-regulation of Rac 
signalling.  The authors report that γ-secretase processing of EphA4 can be blocked 
by NMDA and AMPA receptor antagonists, AP5 and CNQX, suggesting that γ-
secretase associated regulation of synapse number is dependent on synaptic activity. 
 
These examples highlight separate mechanisms by which γ-secretase activity is 
potentially involved in modulating synapse number.  There are possibly other γ-
secretase modulated signaling pathways which could play a role in regulating 
synapse number that are yet to be determined.  Other γ-secretase substrates or 
cleavage products such as cadherins (Baki et al., 2001; Marambaud et al., 2002), 
ErbB4 (Garcia et al., 2000), and Aβ (Kamenetz et al., 2003) may potentially play a 
role in synapse regulation in the hippocampus.  Determining how, when and where 
γ-secretase may process potential substrates involved in synaptogenesis and synapse 
maintenance will be important to further our understanding of the role of presenilin 
in regulating synapse number.   
Another important point to note is that different γ-secretase dependent signaling 
pathways may be temporally activated/ regulated depending on the developmental 
expression of the substrates.  As mentioned above, γ-secretase activity inhibition was 
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shown to cause an increase in synapse number with treatment times of 24-48 hrs 
(Parent et al., 2005 and current chapter) whilst longer treatments (e.g. a week, see 
Inoue et al., 2009), could cause a decrease in synapse number.  The reason for the 
difference in synapse number at different time points is not known but we can 
speculate that different signalling pathways may be engaged at different time points 
which may be associated with the temporally differential effects on synapse number.  
Interestingly other transgenic mice studies have revealed that synapse number may 
be bidirectionally altered.  In certain AD transgenic mice models, cholinergic 
synapse density was shown to be initially elevated in younger animals, but with age 
a progressive decrease in synapse number was observed (see for review: Bell and 
Cuello, 2006).  Developmental differences in synapse number were also identified in 
presenilin double knock-out animals which showed an increase in synapse number 
during juvenile-early adult ages (Aoki et al., 2009) and then a decrease in synapse 
number in later adult ages (Saura et al., 2004).  Understanding how these different 
variables and factors are incorporated may eventually provide an explanation for the 
difference in synapse number observed with different treatment times.   
 
 
 
5.6 Conclusion 
 
This chapter showed that γ-secretase activity of presenilin (1) is involved in 
regulation of synapse density in hippocampal dissociated neurons.  This result 
suggests that presenilin is potentially involved in modulating pre and postsynaptic 
structure.  Together with the results reported in chapter 3, these findings indicate a 
role for presenilin in regulating hippocampal synapse structure and function.  
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Chapter 6: The role of presenilin in 
modulating intracellular calcium in 
hippocampal neurons 
 
 
 
6.1 Introduction 
 
As discussed in chapter 3, inhibition of γ-secretase activity in neurons was shown to 
increase mEPSC frequency in both hippocampal dissociated cultures and 
organotypic slice cultures.  Results from chapters 4 and 5 indicate that the increase in 
mEPSC frequency may be associated more closely with an increase in synapse 
number, rather an alteration in release probability.   The rate of FM-dye destaining, 
PPR and rate of NMDA current block by MK801 was not significantly altered 
between γ-secretase inhibitor treated and control groups suggesting release 
probability is not impaired.  However, another possible factor that may influence 
mEPSC frequency is changes in basal intracellular calcium and release of calcium 
from presynaptic calcium stores (see Bardo et al., 2006; Collin et al., 2005).   
 
 
6.1.1 Evidence for calcium regulation of miniature frequency 
 
The view that action potentials can cause depolarisation of the nerve terminal that 
leads to opening of presynaptic voltage gated calcium channels and subsequent 
neurotransmitter release is well established (Cowan et al., 2001).  However, the 
involvement of calcium in mediating release of spontaneous miniature currents has 
been debated.  Initial studies at the NMJ showed that miniature end-plate potentials 
can occur in the absence of action potentials suggesting that these spontaneous 
fusion events can occur independently of calcium influx (Fatt and Katz, 1952). 
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Additionally, studies by Scanziani et al., (1992) showed that cadmium; a non-
selective calcium channel antagonist can reduce the amplitude of evoked responses 
but does not alter the amplitude or frequency of excitatory or inhibitory miniature 
postsynaptic currents in hippocampal organotypic slices suggesting that voltage 
gated calcium channels are not involved in modulating spontaneous release 
(Scanziani et al., 1992).  However there are several studies that report that 
spontaneous postsynaptic currents are modulated by calcium in the presynaptic 
terminals.  Whole-cell recordings from dissociated cortical neurons showed that the 
frequency of miniature inhibitory postsynaptic currents was reduced when immersed 
in a solution containing 0 mM calcium in the extracellular solution, and further 
decreases in frequency were observed upon addition of BAPTA-AM, a high affinity 
calcium chelator (Xu et al., 2009).  Together these findings suggest that mIPSCs are 
sensitive to global changes in basal calcium levels.    Furthermore, it has been shown 
that changing extracellular calcium concentration can influence both mIPSC and 
mEPSC frequency suggesting that spontaneous currents are sensitive to changes in 
extracellular calcium (Xu et al., 2009).   
Several studies have shown that internal ER calcium stores may be involved in 
modulating calcium at presynaptic boutons.  Reports published several years ago 
provided evidence that presynaptic terminals exhibited spontaneous calcium signals 
in both hippocampal CA3 pyramidal cells (Emptage et al., 2001) and cerebellar 
interneurons (Llano et al., 2000).  Additionally it was found that intracellular 
calcium may modulate the frequency of miniature currents in the cerebellum (Bardo 
et al., 2002; Llano et al., 2000), hippocampus (Emptage et al., 2001) and cortex 
(Simkus and Stricker, 2002), via RyR to regulate calcium release from intracellular 
ER stores.   
 
Exogenous application of the plant alkaloid ryanodine is often used to affect RyR 
calcium release from ER stores.  Interestingly, ryanodine can alter the channel 
properties of RyR in a concentration dependent manner with concentrations under 10 
µM causing channels to be held in a sub-conductive state and enabling calcium 
release, whilst concentrations above 10 µM led to blockade of the channel and 
inhibition of calcium release from ER stores (Bardo et al., 2006; Bouchard et al., 
2003).    Indeed, reports have shown that ryanodine application at 10 µM lead to an 
increase in the frequency of miniature events (Llano et al., 2000) whilst 20 – 100 µM 
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concentrations decrease miniature current frequency (Emptage et al., 2001; Llano et 
al., 2000).  Together this data suggests that intracellular calcium stores play an 
important role in regulating miniature events.   
 
Finally, some miniature currents (~5%) still remain in 0 mM calcium solution 
supplemented with calcium chelator BAPTA-AM and thapsigargin, an inhibitor of 
calcium uptake into the ER, indicating that a small population of miniature 
postsynaptic currents are generated in the absence of a calcium related trigger (Xu et 
al., 2009).   
 
 
6.1.2 The role of presenilins in regulating intracellular calcium 
 
A recent study proposes a role for presenilins in regulating neurotransmitter release 
at CA3-CA1 synapses in the hippocampus (Zhang et al., 2009).  PS1 and 2 
homozygous floxed mice were crossed with either α-CaMKII-Cre or Grik4-Cre mice 
to generate CA1 region (postsynaptic) or CA3 region (presynaptic) specific 
conditional presenilin double knockout mice respectively.  Interestingly, this study 
reports that CA3 region-specific conditional presenilin double knock-out animals 
show a multitude of different synaptic changes including impairment in long term 
potentiation, a decrease in paired-pulse facilitation and a decrease in the rate of 
MK801 block. These parameters were not affected in CA1 region-specific knock-
outs.  The authors provide evidence that the synaptic changes observed in CA3 
presenilin double knock-out mice were linked to impairments in intracellular ER 
calcium signalling in CA3 neurons.   
 
ER calcium release can occur from two separate ER resident channels, the RyR or 
the IP3R.  The mechanisms underlying release from these channels differ.  IP3Rs are 
stimulated by IP3 which is a product of an intracellular second messenger cascade.  
Activation of G-protein coupled receptors on the plasma membrane leads to 
stimulation of a G-protein and subsequent induction of phospholipase C (PLC)-
dependent cleavage of phosphatidylinoinositol-4, 5,-bisphosphate to produce IP3. In 
contrast, RyR are activated by agonist induced elevations in intracellular calcium, for 
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example through voltage-gated calcium channels (VGCC), by a process know as 
calcium induced calcium release (CICR).  Activation of RyR located on the ER 
membrane occurs when calcium ions bind to the cytoplasmic domain of RyR, which 
then open to allow release of calcium from the ER (Mattson, 2010). 
 
In the study by Zhang et al., (1999), cellular depolarisation was achieved using acute 
extracellular application (5 or 30 sec bath application) of high KCl (80 mM) solution 
to cells.  Fura-2 imaging showed that KCl-stimulated CICR from intracellular stores 
is decreased upon treatment of control neurons with 100 µM ryanodine in control 
neurons.  This reduction in calcium release was mimicked and occluded in PS double 
knock-out cultured cells, suggesting presenilins can modulate presynaptic facilitation 
by regulating CICR.  A role for IP3Rs was discounted as block of IP3Rs using 
Xestospongin C did not produce a decrease in KCl-stimulated CICR response.    
 
Interestingly, the reported differences in facilitation and PPR were only observed in 
conditional double presenilin knockouts of presynaptic neurons and analysis of either 
PS1 or PS2 single knock-outs showed normal synaptic responses (Yu et al., 2001; 
Zhang et al., 2009).  This intriguing result suggests that there is a difference to 
knocking out both PS as opposed to eliminating either one and there may be 
processes in place to compensate when only one is eliminated to maintain synaptic 
plasticity.  However there is no change in PS2 protein expression in the PS1 
conditional knockout mice as shown by western blot analysis suggesting that if 
compensation is present, it is likely to be associated with a change in functionality 
rather than changes in protein levels (Yu et al., 2001). 
 
One potential limitation of this presynaptic presenilin double knock-out model is that 
it is not clear how presenilin is modulating calcium release through the ryanodine 
receptors.  It is not known whether the attenuation in synaptic facilitation, short-term 
plasticity and intracellular calcium is directly due to eliminating presenilin proteins 
or just the loss of the γ-secretase activity of presenilins.  Essentially, this study does 
not distinguish between γ-secretase dependent presenilin activities from the γ-
secretase independent effects of presenilin, as both are abolished.  It is also not clear 
how presenilins may modulate ER release through RyR. 
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Recent findings have shown that presenilins can act in a γ-secretase independent 
manner to regulate intracellular calcium dynamics.  A study performed in planer 
lipid bilayer membranes and murine embryonic fibroblasts (MEFs) has shown that 
presenilin in its holoprotein form can act as a passive calcium leak channel (Tu et al., 
2006).  This effect does not require γ-secretase activity as the PS1-D257A mutant 
which lacks γ-secretase activity is also capable of forming calcium leak channels.  
Furthermore, overexpression of this presenilin mutant can rescue the decrease in 
calcium signalling in presenilin double knock-out MEFs indicating that γ-secretase 
activity of presenilins is dispensable for its function as a passive calcium leak 
channel.  At present, it is not known whether presenilin holoproteins also form leak 
channels in neurons.  But if they do, then this would provide another explanation for 
the reduced intracellular calcium signalling observed in the presenilin double knock-
out mice.  The decrease in synaptic transmitter release reported by Zhang et al., 
(2009), therefore may be due to a lack of presenilin holoprotein and/ or reduced 
activation of the ryanodine receptor which then causes a decrease in intracellular 
calcium by minimising release from ER stores.  If this hypothesis is true then γ-
secretase activity of presenilins is not necessarily required. 
 
The first aim of this section was to investigate whether pharmacological inhibition of 
γ-secretase activity leads to any changes in basal intracellular calcium concentration 
which may contribute to the changes in hippocampal mEPSC frequency, through 
live calcium imaging of Fura-2.  The second part of this chapter will address whether 
γ-secretase activity blockade alters intracellular calcium concentrations during 
calcium induced calcium release (CICR).  In order to test the potential involvement 
of γ-secretase activity in modulating KCl-induced CICR from stores, 
pharmacological inhibition using γ-secretase inhibitors DAPT and L-685, 458 was 
used.  This approach enables blockade of total γ-secretase (PS1 and PS2 complexes) 
enzymatic activity, whilst presumably leaving other γ-secretase independent 
functions of presenilins intact (Li et al., 2000). 
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6.2 Investigating the effect of γ-secretase 
inhibition on basal intracellular calcium levels  
 
Fura-2 is a widely used and well characterised ratiometric dye which enables the 
quantitative measurement of intracellular calcium concentration whilst eliminating 
experimental inconsistencies including variations in dye loading, excitation intensity, 
detector deficiency and optical pathlength (Grynkiewicz et al., 1985; Maravall et al., 
2000).  Rat hippocampal dissociated cultures chronically treated (48 hr) with either 
DMSO (mock control) or γ-secretase inhibitors, DAPT or L-685,458 were loaded 
with Fura-2 calcium dye by adding Fura-2 AM, a non-fluorescent membrane 
permeable form of Fura-2 (1 µM) to the culture medium and incubating at 37oC for 
25 mins.  Upon entering cells endogenous cellular esterases cleave the ester groups 
of Fura-2 AM to generate fluorescent Fura-2 which remains intracellular.  Healthy 
hippocampal cells loaded with Fura-2 were excited using 340 and 380 nm UV 
wavelengths.  To measure basal calcium concentration, paired 340 and 380 nm 
images were captured in the presence of TTX (1 µM) and picrotoxin (10 µM), to 
parallel conditions used for mEPSC recordings.  A ratio value for each frame was 
obtained by dividing fluorescence values excited by 340 nm and 380 nm 
wavelengths.  In addition to the direct comparison of ratio values, these values were 
also used to estimate intracellular calcium concentrations according to standard 
procedures first described by Grynkiewicz et al., (1985) (see methods).  Figure 
6.1.shows a representative region of a coverslip taken under DIC optics (Figure 
6.1.a) and with 340 nm (Figure 6.1.b i) and 380 nm wavelength excitation (Figure 
6.1.b ii).   
 
Cells treated with DAPT or L-685,458 showed no significant differences in 340/380 
nm ratio values when compared with DMSO mock control cells under basal 
conditions (Figure 6.1.c.i, DMSO, n = 12, mean: 1.00 ± 0.03; DAPT, n = 12, mean: 
1.04 ± 0.03; L-685,458, n = 14, mean: 1.023 ± 0.03.  Mann-Whitney test, DMSO 
versus DAPT: p = 0.54; DMSO versus L-685,458: p = 0.82).  Calcium concentration 
measurements for DMSO, DAPT or L-685,458 cells were also not significantly 
different under basal conditions (Figure 6.1.c.ii, DMSO, mean: 25.76 ± 2.29 nM; 
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DAPT, mean: 28.56 ± 2.64 nM; L-685,458, mean: 27.44 ± 2.50 nM.  Mann-Whitney 
test, DMSO versus DAPT, p = 0.54; DMSO versus L-685,458, p = 0.82).  These 
resting calcium concentration values are in good agreement with an earlier study 
conducted on hippocampal CA1 pyramidal cells where Fura-2 was administered into 
the cell through the patch pipette and calcium concentration was estimated to be 
between 25 - 50 nM (Lancaster and Batchelor, 2000).   This experiment suggests that 
γ-secretase inhibition does not alter basal calcium concentration, and that the 
increase in mEPSC frequency observed following γ-secretase inhibitor treatment 
may not be linked to a change in intracellular calcium concentration.   
 
Figure 6.1 - Measurement of basal calcium in hippocampal neurons  
Low magnification image of dissociated hippocampal rat neurons viewed with DIC optics 
(a).  The same cells loaded with Fura-2 can be examined using excitation wavelengths of 340 
nm (b i) and 380 nm (b ii).  Cells were imaged during basal conditions (i.e. in the absence of 
exogenous stimulation).  Scale bar is 50 µm.  (c) Quantification of basal Fura fluorescence 
signal ratio of 340/380 nm (c i) and respective basal calcium concentration estimates (c ii) for 
cells treated with DMSO mock (grey) or γ-secretase inhibitors DAPT (red) and L-685,458 
(blue).  There was no significant differences in the 340/380 nm ratio between γ-secretase 
inhibitor treated cells and DMSO controls during basal conditions  (DMSO, n = 12, mean: 
1.00 ± 0.03; DAPT, n = 12, mean: 1.04 ± 0.03; L-685,458, n = 14, mean: 1.023 ± 0.03.  
Mann-Whitney test, DMSO versus DAPT, p = 0.54; DMSO versus L-685,458, p = 0.82).  
Analysis of calcium concentration also revealed no significant differences between DMSO 
and DAPT or L-685,458 treated cells (DMSO, mean: 25.76 ± 2.29 nM; DAPT, mean: 28.56 
± 2.64 nM; L-685,458, mean: 27.44 ± 2.50 nM.  Mann-Whitney test, DMSO versus DAPT, p 
= 0.54; DMSO versus L-685,458, p = 0.82). n corresponds to the number of coverslips used. 
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6.3 Investigating the effect of γ-secretase 
inhibition on intracellular calcium levels during 
KCl-induced CICR  
 
The same approach as that used to image intracellular calcium concentrations during 
basal conditions (Figure 6.1) was applied to KCl-induced CICR.  Somatic regions 
were examined in a way that was closely related to the methodology applied by 
Zhang et al., (2009) but with some slight modifications.  The KCl concentration used 
to stimulate CICR was dropped from 80 mM to 60 mM, images were acquired using 
a 10x objective rather than a 40x lens and Fura-2-AM was applied at a concentration 
of 1 µM for 25 min at 37oC rather than 5 µM for 45 min at 37oC.  The high KCl 
extracellular solution used to stimulate CICR was a modified version of normal 
dissociated extracellular solution where NaCl was partly replaced by 60 mM KCl 
and osmotic balance was maintained at around 290 mOsm.  Experiments were 
performed sequentially, switching between DMSO mock control, DAPT and L-
685,458.  All results were presented as 340/380 nm ratio values and calcium 
concentrations (see methods).   
Fura-2 fluorescence is dynamically altered upon bath application (30 sec) of high 
KCl extracellular solution.   Representative images of a cell loaded with Fura-2 are 
shown in Figure 6.2 a.  Acute application of KCl (green bar) causes an increase in 
340 nm wavelength fluorescence (Figure 6.2 a, top row and i) and a decrease in 380 
nm wavelength fluorescence (Figure 6.2 a, bottom row and ii).  Ratio values were 
obtained by dividing 340 by 380 nM fluorescent values and an increase in ratio 
values temporally coincided with KCl application (Figure 6.2 b), indicating an 
elevation of intracellular calcium, presumably from both calcium influx from 
extracellular regions and release from internal calcium stores during CICR.  Calcium 
signal from glial cells was also assessed and judged to have a minimal effect on 
calcium measurements from the soma of neurons (Figure 6.2 c) 
 
Analysis of 340/380 nm wavelength ratio values did not reveal any significant 
differences between mock DMSO and γ-secretase inhibitors DAPT or L-685,458 
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during KCl stimulated CICR (Figure 6.3.b.i, peak ratio: DMSO, n = 12, 6.94 ± 0.32; 
DAPT, n = 12, 6.44 ± 0.24; L-685,458, n = 14, 6.90 ± 0.38.  Student’s t-test: DMSO 
versus DAPT, p = 0.232; DMSO versus L-685,458, p = 0.94).  Analysis of peak 
calcium concentration during KCl-stimulated CICR also showed no differences 
between control and γ-secretase inhibitor treated cells (Figure 6.3.b.i, peak calcium 
concentration: DMSO, n = 12, 958.5 ± 87 nM; DAPT, n = 12, 808.1 ± 59 nM; L-
685,458, n = 14, 999.4 ± 140.9 nM.  Student’s t-test: DMSO versus DAPT, p = 0.17; 
DMSO versus L-685,458, p = 0.82).  This result suggests that γ-secretase activity is 
dispensable for calcium release from internal stores during KCl-stimulated CICR and 
the reduced calcium signals seen in presenilin double knock-out mice (Zhang et al., 
2009) may be a result of loss of γ-secretase-independent activity, rather than loss of 
γ-secretase-dependent activity.    
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Figure 6.2 - Characterisation of KCl-stimulated calcium induced calcium release 
(CICR) in rat hippocampal dissociated neurons.  
(a) Sample images of a neuron loaded with fura-2 and excited with 340 nm 
wavelength (top row and i) and 380 nm wavelength (bottom row and ii).  The time 0 
corresponds to the time when 60 mM KCl was applied to the bath (30 sec duration).  
KCl application is represented by the green bar.  Note, how the (somatic) 
fluorescence intensity decreases in 380 nm wavelength images and (modestly) 
increases in 340 nm wavelength images during KCl application to indicate KCl-
stimulated CICR, presumably from internal stores.  The ratio of 340 and 380 nm 
wavelength responses is shown in (b).  Astrocytes surrounding and beneath neurons 
can also take up Fura-2.  To investigate the contribution of KCl-stimulated CICR 
from glia, a region of interest was drawn around an astrocyte devoid of neurons.  The 
340 nm and 380 nm wavelength responses from an astrocyte is shown in (c i).  Note 
the small effect on 340 and 380 nm fluorescence during KCl application, suggesting 
a minor KCl-induced CICR event in glial cells.  (c ii) shows the 340/380 nm Fura 
fluorescence ratio from the glial cell (green line) superimposed onto the neuronal 
ratio obtained from (b).  This result suggests that the change in fluorescence values 
observed during KCl application is mainly attributed to calcium changes from 
neuronal rather than glial cells.   
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Figure 6.3 - Measurement of peak calcium during KCl-stimulated CICR in 
hippocampal neurons.    
(a) Graphs showing the averaged timecourse of KCl-stimulated CICR for DMSO (i, 
grey, n = 12), DAPT (ii, red, n =12) and L-685,458 (iii. blue, n = 14).  An overlay of 
the three treatments is shown in (iv). Green bar represents KCl bath application  
(60 mM, 30 s)  
(b) Summary of peak 340/380 nm wavelength fluorescence ratio (i) and peak 
calcium concentration (ii) of cells shown in (a).  Peak responses correspond to 
maximum measured calcium increase during KCl-stimulated CICR.  There was no 
significant differences in the peak ratio measured between DMSO mock control and 
γ-secretase inhibitor treated cells  (DMSO, n = 12, 6.94 ± 0.32; DAPT, n = 12, 6.44 ± 
0.24; L-685,458, n = 14, 6.90 ± 0.38.  Student’s t-test: DMSO versus DAPT, p = 
0.232; DMSO versus L-685,458, p = 0.94).  There was also no significant change in 
peak calcium concentration (DMSO, n = 12, 958.5 ± 87 nM; DAPT, n = 12, 808.1 ± 
59 nM; L-685,458, n = 14, 999.4 ± 140.9 nM.  Student’s t-test: DMSO versus DAPT, 
p = 0.17; DMSO versus L-685,458, p = 0.82). Together this result indicates that γ-
secretase activity block does not alter somatic peak calcium responses during KCl-
stimulated CICR.   
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6.4 Investigating the effects of ryanodine 
receptor and SERCA blockade in γ-secretase 
inhibitor treated hippocampal neurons 
 
 
In separate experiments to test the involvement of calcium stores in regulating 
intracellular calcium, cells were pre-incubated with ryanodine (20-30 µM (Emptage 
et al., 2001) for 1 hr at 37 oC) or Thapsigargin (3.8 µM (Emptage et al., 2001) for 1 
hr at 37 oC) to reduce calcium release from intracellular stores.  Cells were 
maintained in solutions reflecting the respective treatments (e.g for ryanodine 
samples, cells were pre-treated and maintained in ryanodine) for the duration of 
calcium imaging experiments.   
 
Firstly, hippocampal neurons pre-treated with ryanodine to block RyRs were 
examined for any differences in basal calcium and peak calcium responses during 
KCl-stimulated CICR in γ-secretase treated cells and DMSO mock cells.   
Ryanodine did not have a significant effect on the calcium concentration estimates 
under basal conditions in control or γ-secretase treated cells (Figure 6.4).  This result 
is consistent with a previous study which showed that ryanodine (30 µM) does not 
influence basal calcium levels in presynaptic terminals (Emptage et al., 2001) though 
the results presented in this chapter examines calcium levels in the soma rather than 
axonal boutons.  Additionally, the peak response to KCl-stimulated CICR in 
ryanodine pre-treated cells was also not significantly altered (Figure 6.5).  Two 
conclusions can be made from our result.  Firstly, block of RyR does not reduce the 
peak calcium response during KCl-stimulated CICR in cells.  Secondly, there is no 
significant difference between the peak calcium concentrations between cells treated 
with γ-secretase inhibitors and control cells with or without ryanodine receptor 
blockade.  However this latter result deviates from observations reported by Zhang et 
al., (2009) who have shown that ryanodine could reduce KCl-stimulated CICR in 
control neurons.  Currently, the reasons for this difference are not entirely clear. 
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Next, Thapsigargin, an irreversible inhibitor of the SERCA pump was tested.   The 
SERCA pump is located on the ER membrane and is responsible for maintaining the 
intracellular calcium homeostasis by actively transporting calcium ions from the 
cytoplasm into the ER lumen.  The hypothesis is that inhibition of the SERCA pump 
by thapsigargin leads to a reduction of calcium in the ER and therefore decreases the 
amount of intracellular calcium rise during KCl-induced CICR.  Hence, this 
experiment should effectively act as a control for KCl-induced CICR, whereby 
depletion of the ER calcium store by thapsigargin would lead to a decrease in 
intracellular calcium levels upon cell depolarisation.   
 
Assessment of basal calcium concentrations in DMSO mock and γ-secretase treated 
cells, with or without thapsigargin application, revealed no significant differences 
between any groups (Figure 6.6).  This result suggests that depletion of ER stores by 
thapsigargin does not significantly influence measurements of basal somatic calcium 
concentration.  However, examination of peak calcium responses during KCl-
stimulated CICR did reveal a difference following thapsigargin treatment in DMSO 
mock and also γ-secretase treated cells (Figure 6.7).  A significant decrease in KCl 
stimulated CICR peak 340/ 380 nm wavelength ratio values and calcium 
concentration measurements was observed in DMSO mock and γ-secretase inhibitor, 
DAPT and L-685,458 treated cells following thapsigargin treatment (Figure 6.7). 
However the magnitude of the reduction between control cells and γ-secretase 
treated cells was not significantly different.  These results highlight several points.  
Firstly, calcium release from ER stores makes a strong contribution to intracellular 
calcium levels during KCl-stimulated CICR as depletion of stores by thapsigargin 
leads to a decrease in peak calcium responses.  Secondly, γ-secretase activity block 
does not significantly alter the cellular response to thapsigargin, suggesting that the 
decrease in peak calcium levels following thapsigargin treatment is independent of γ-
secretase activity.  This finding provides evidence that γ-secretase activity is not 
required for modulation of intracellular calcium during KCl-stimulated CICR.   
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Figure 6.4 - The effects of ryanodine receptor inhibition on basal calcium levels in 
hippocampal neurons. 
(a) Graphs showing 340/380 nm wavelength fluorescence ratio values for DMSO (i), 
DAPT (ii) and L-685,458 (iii) treated cells, in the absence (plain columns) or presence 
(checked columns) of ryanodine (20-30 µM) during basal conditions. There was no 
significant differences in basal calcium ratio values between cells with or without 
ryanodine treatment in DMSO (Fig 6.4 a i, without ryanodine: n = 12, mean: 1.00 ± 0.03; 
with ryanodine: n = 9, mean: 1.09 ± 0.06.  Student’s t-test, DMSO with ryanodine versus 
without ryanodine, p = 0.18), DAPT (Fig 6.4 a ii, without ryanodine: n = 12, mean: 1.04 
± 0.03; with ryanodine: n = 10, mean: 1.11 ± 0.06.  Student’s t-test, DAPT with 
ryanodine versus without ryanodine, p = 0.30), or L-685,458 (Fig 6.4 a iii, without 
ryanodine: n = 14, mean: 1.02 ± 0.03; with ryanodine: n = 9, mean: 1.06 ± 0.03.  
Student’s t-test, L-685,458 with ryanodine versus without ryanodine, p = 0.48) groups.  
(b) Summary of basal calcium concentration estimates from cells shown in (a).  As with 
ratio measurements, no significant differences were observed in calcium concentration 
measurements between cells treated or untreated with ryanodine in DMSO (Fig 6.4 b i, 
without ryanodine: n = 12, mean: 25.76 ± 2.29 nM; with ryanodine: n = 9, mean: 33.39 ± 
5.44 nM.  Student’s t-test, DMSO with ryanodine versus without ryanodine, p = 0.17), 
DAPT (Fig 6.4 b ii, without ryanodine: n = 12, mean: 28.56 ± 2.64; with ryanodine: n = 
10, mean: 34.96 ± 5.71.  Student’s t-test, DAPT with ryanodine versus without 
ryanodine, p = 0.29), or L-685,458 (Fig 6.4 b iii, without ryanodine: n = 14, mean: 27.44 
± 2.50; with ryanodine: n = 9, mean: 30.17 ± 2.82.  Student’s t-test, L-685, 458 with 
ryanodine versus without ryanodine, p = 0.49) groups.  
This data suggests that ryanodine does not significantly alter intracellular calcium 
concentration during basal conditions.  Additionally there were no differences in basal 
calcium concentration in DMSO mock cells or in cells treated with γ-secretase inhibitors 
DAPT and L-685,458, implying that γ-secretase activity is not required for regulating 
basal calcium in the presence or absence of ryanodine. 
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Figure 6.5 - The effects of ryanodine receptor inhibition on peak calcium during KCl-
stimulated CICR in hippocampal neurons. 
(a) Graphs showing the averaged timecourse of Fura-2 ratio measurements during KCl-stimulated 
CICR in cells treated with DMSO (grey (i)), DAPT (red (ii)) or L-685,458 (blue (iii)) in the absence 
(light lines) or presence (dark lines) of ryanodine. Green bar  represents KCl bath application (60 
mM).   
(b) Graphs showing 340/380 nm wavelength Fura-2 fluorescence ratio values for DMSO (i), DAPT 
(ii) and L-685,458 (iii) treated cells, in the absence (plain columns) or presence (checked columns) 
of ryanodine (20-30 µM) during KCl-stimulated CICR. There was no significant differences in peak 
calcium ratio values between cells with or without ryanodine treatment in DMSO (Fig 6.5 b i, 
without ryanodine: n = 12, mean: 6.94 ± 0.32; with ryanodine: n = 9, mean: 7.50 ± 0.36.  Student’s 
t-test, DMSO with ryanodine versus without ryanodine, p = 0.27), DAPT (Fig 6.5 b a ii, without 
ryanodine: n = 12, mean: 6.44 ± 0.24; with ryanodine: n = 10, mean: 6.57 ± 0.36.  Student’s t-test, 
DAPT with ryanodine versus without ryanodine, p = 0.77), or L-685,458 (Fig 6.5 b iii, without 
ryanodine: n = 14, mean: 6.90 ± 0.38; with ryanodine: n = 9, mean: 7.40 ± 0.49.  Student’s t-test, L-
685,458 with ryanodine versus without ryanodine, p = 0.42) groups.  
(b) Summary of peak calcium concentration estimates from cells shown in (b).  As with ratio 
measurements, no significant differences were observed in calcium concentration measurements 
between cells treated or untreated with ryanodine in DMSO (Fig 6.5 c i, without ryanodine: n = 12, 
mean: 958.5 ± 86.88 nM; with ryanodine: n = 9, mean: 1154 ± 163.6 nM.  Student’s t-test, DMSO 
with ryanodine versus without ryanodine, p = 0.27), DAPT (Fig 6.5 c ii, without ryanodine: n = 12, 
mean: 808.1 ± 58.66; with ryanodine: n = 10, mean: 854.8 ± 84.02.  Student’s t-test, DAPT with 
ryanodine versus without ryanodine, p = 0.65), or L-685,458 (Fig 6.5 c iii, without ryanodine: n = 
14, mean: 999.4 ± 140.9; with ryanodine: n = 9, mean: 1149 ± 170.7.  Student’s t-test, L-685,458 
with ryanodine versus without ryanodine, p = 0.51) groups.  
This data suggests that ryanodine does not significantly alter intracellular calcium concentration 
during KCl-stimulated CICR.  Additionally there is no differences in basal calcium concentration in 
DMSO mock cells or in cells treated with γ-secretase inhibitors DAPT and L-685,458, implying that 
γ-secretase activity is not required for regulating peak calcium in the presence or absence of 
ryanodine. 
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Figure 6.6 - The effects of thapsigargin on basal calcium levels in hippocampal 
neurons  
(a) Graphs showing 340/380 nm wavelength ratio values for DMSO (i, grey), DAPT 
(ii, red) and L-685,458 (iii, blue) treated cells, in the absence (plain columns) or 
presence (checked columns) of thapsigargin (3.8 µM) during basal conditions. There 
was no significant differences in basal calcium ratio values between cells treated or 
untreated with thapsigargin in DMSO (Fig 6.6 a i, without thapsigargin: n = 12, mean: 
1.00 ± 0.03; with thapsigargin: n = 5, mean: 0.94 ± 0.03.  Student’s t-test, DMSO with 
thapsigargin versus without thapsigargin, p = 0.19), DAPT (Fig 6.6 a ii, without 
thapsigargin: n = 12, mean: 1.04 ± 0.03; with thapsigargin: n = 5, mean: 0.99 ± 0.05. 
Student’s t-test, DAPT with thapsigargin versus without thapsigargin, p = 0.44), or L-
685,458 (Fig 6.6 a iii, without thapsigargin: n = 14, mean: 1.02 ± 0.03; with 
thapsigargin: n = 5, mean: 1.096 ± 0.06.  Student’s t-test, L-685,458 with thapsigargin 
versus without thapsigargin, p = 0.25) groups.  
(b) Summary of basal calcium concentration estimates from cells shown in (a).  As 
with ratio measurements, no significant differences were observed in calcium 
concentration measurements between cells treated or untreated with thapsigargin in 
DMSO (Fig 6.6 b i, without thapsigargin: n = 12, mean: 25.76 ± 2.29 nM; with 
thapsigargin: n = 5, mean: 20.31 ± 2.62 nM.  Student’s t-test, DMSO with thapsigargin 
versus without thapsigargin, p = 0.19), DAPT (Fig 6.6 b ii, without thapsigargin: n = 
12, mean: 28.56 ± 2.64; with thapsigargin: n = 5, mean: 24.66 ± 4.51.  Student’s t-test, 
DAPT with thapsigargin versus without thapsigargin, p = 0.45), or L-685,458 (Fig 6.6 
b iii, without thapsigargin: n = 14, mean: 27.44 ± 2.50; with thapsigargin: n = 5, mean: 
33.45 ± 4.86.  Student’s t-test, L-685,458 with thapsigargin versus without 
thapsigargin, p = 0.25) groups.  
This data indicate that thapsigargin does not significantly alter intracellular calcium 
concentration during basal conditions.  Additionally there is no difference in basal 
calcium concentration in DMSO mock cells or in cells treated with γ-secretase 
inhibitors DAPT and L-685,458, implying that γ-secretase activity is not required for 
regulating basal calcium in the presence or absence of thapsigargin.  
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Figure 6.7 - The effects of thapsigargin receptor inhibition on peak calcium during KCl-
stimulated CICR in hippocampal neurons  
(a) Graphs showing the averaged timecourse of Fura-2 ratio measurements during KCl-stimulated 
CICR in cells treated with DMSO (grey (i)), DAPT (red (ii)) or L-685,458 (blue (iii)) in the absence 
(light lines) or presence (dark lines) of thapsigargin. Green bar  represents KCl bath application (60 
mM).   
(b) Graphs showing 340/380 nm wavelength fluorescence ratio values for DMSO (i), DAPT (ii) and L-
685,458 (iii) treated cells, in the absence (plain columns) or presence (checked columns) of 
thapsigargin (3.8 µM) during KCl-stimulated CICR. There was a significant difference in peak calcium 
ratio values between cells with or without thapsigargin treatment in DMSO (Fig 6.7 b i, without 
thapsigargin: n = 12, mean: 6.94 ± 0.32; with thapsigargin: n = 5, mean: 5.04 ± 0.14.  Student’s t-test, 
DMSO with thapsigargin versus without thapsigargin, p = 0.002 **), DAPT (Fig 6.7 a ii, without 
thapsigargin: n = 12, mean: 6.44 ± 0.24; with thapsigargin: n = 5, mean: 4.89 ± 0.49.  Student’s t-test, 
DAPT with thapsigargin versus without thapsigargin, p = 0.006**), or L-685,458 (Fig 6.7 b iii, without 
thapsigargin : n = 14, mean: 6.90 ± 0.38; with thapsigargin : n = 5, mean: 4.14 ± 0.63.  Student’s t-test, 
L-685, 458 with thapsigargin versus without thapsigargin, p = 0.002**) groups.  
(b) Summary of peak calcium concentration estimates from cells shown in (b).  As with ratio 
measurements, a significant difference was observed in calcium concentration measurements between 
cells treated or untreated with thapsigargin in DMSO (Fig 6.7 c i, without thapsigargin : n = 12, mean: 
958.5 ± 86.88 nM; with thapsigargin : n = 5, mean: 504.4 ± 24.62 nM.  Student’s t-test, DMSO with 
thapsigargin versus without thapsigargin, p = 0.005 **), DAPT (Fig 6.7 c ii, without thapsigargin : n = 
12, mean: 808.1 ± 58.66; with thapsigargin : n = 5, mean: 497.8 ± 90.87.  Student’s t-test, DAPT with 
thapsigargin versus without thapsigargin, p = 0.012*), or L-685,458 (Fig 6.7 c iii, without thapsigargin 
: n = 14, mean: 999.4 ± 140.9; with thapsigargin : n = 5, mean: 386.3 ± 93.00.  Student’s t-test, L-685, 
458 with thapsigargin versus without thapsigargin, p = 0.023*) groups.  
This data provides evidence that thapsigargin reduces intracellular calcium concentration during KCl-
stimulated CICR, presumably by depleting ER calcium stores.  However, there was no differences in 
the response between DMSO, DAPT or L-685,458 treated cells suggesting that γ-secretase activity is 
not required for the thapsigargin action on ER serca pump and internal calcium stores. 
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6.5 Discussion 
 
 
Previous studies have shown that the frequency of miniature currents is sensitive to 
changes in intracellular and extracellular calcium (Emptage et al., 2001; Llano et al., 
2000; Xu et al., 2009).   To determine if alterations in intracellular calcium could 
contribute to the increase in mEPSC frequency observed in cells treated with γ-
secretase inhibitors, Fura-2 fluorescence was imaged and calcium measurements 
were obtained during basal conditions in the presence of TTX.    The results outlined 
in this chapter, show that there are no major changes in basal neuronal calcium 
concentrations between DMSO mock and γ-secretase inhibitor treated cells, 
suggesting that the increase in mEPSC frequency is potentially not associated with a 
change in intracellular calcium concentration.  However, only somatic calcium 
concentration has been assessed and a more focused examination of axonal boutons 
is warranted to get a better estimate of synaptic calcium in presynaptic terminals 
under basal conditions.  Additionally further experiments will be required to directly 
examine whether the increase in mEPSC frequency observed in γ-secretase inhibitor 
treated cells is due to alterations in ER calcium release.  One approach would be to 
treat γ-secretase inhibitor treated cells with ryanodine or thapsigargin and determine 
if there is any reduction in mEPSC frequency.    
 
Calcium imaging techniques were also used to probe the involvement of γ-secretase 
activity in the modulation of KCl-stimulated CICR from internal ER stores.  As 
discussed above, one study showed that presenilin double knock-out cells exhibited a 
reduced elevation in intracellular calcium during KCl-stimulated CICR compared to 
control cells (Zhang et al., 2009).  This reduction was mimicked by control cells 
treated with ryanodine, whereas it was occluded in knockout cells treated with 
ryanodine.  The presynaptic knockout of presenilins also led to changes in synaptic 
plasticity including an impairment of LTP, a decrease in PPF and a slower rate of 
MK801 block.  Zhang and colleagues (2009) propose that the changes in presynaptic 
function are associated with a reduction in intracellular calcium concentration due to 
defective calcium signalling involving RyRs located on the ER membrane.  
However, one key question remains: is the decrease in intracellular calcium 
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concentration observed during KCl-stimulated CICR in presenilin double knock-out 
cells due to γ-secretase dependent or γ-secretase independent mechanisms?   
 
To test this, KCl-stimulated CICR was induced in wild type rat hippocampal cells 
where γ-secretase activity was pharmacologically blocked with specific inhibitors, 
DAPT and L-685,458.  Estimations of peak calcium during KCl-stimulated CICR 
were not altered between DMSO mock and γ-secretase inhibitor treated cells.  This 
result argues against a role for γ-secretase activity in the modulation of calcium 
release from stores during KCl-stimulated CICR.  This result implies that the 
reduced calcium responses observed during KCl-stimulated CICR in conditional 
presenilin double knock-out neurons is potentially due to γ-secretase-independent 
modulation of ER stores rather than a mechanism that is dependent on γ-secretase 
activity. 
 
This result parallels findings from human salivary gland epithelial (HSG) cells where 
potent γ-secretase inhibitors, DAPT (10 µM, 18-20 hrs pretreatment) or compound E 
(25 µM, 4 hrs pretreatment) do not alter agonist (carbachol) mediated calcium 
release from internal stores (Oh and Turner, 2006).  In this previous study, an 
additional check to show that γ-secretase activity was inhibited following DAPT 
treatment was carried out by western blot analysis for APP-CTF.  Oh and Turner 
(2006) found a band which corresponded to APP-CTF in cells treated with DAPT, 
which strongly indicated that DAPT could block γ-secretase activity and inhibited 
processing of APP-CTF.  Furthermore, this band was absent in control HSG cells 
indicating γ-secretase activity was present in untreated cells.  This indicated that the 
lack of effect on agonist-mediated intracellular calcium release was not due to a lack 
of γ-secretase inhibition.   
 
However, other studies have suggested otherwise, and that γ-secretase activity may 
be required for regulation of intracellular calcium release.  Leissring et al., (2002) 
showed using N2a neuroblastoma cells that application of peptide aldehydes YIL 
and CIL, compounds that were previously thought to act as γ-secretase inhibitors 
could lead to a reduction in agonist (bradykinin)-induced calcium release from 
intracellular stores.  These aldehyde peptides have a fairly low potency and have 
been used prior to the discovery of small molecule inhibitors such as DAPT (Dovey 
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et al., 2001), which are now more commonly used. Leissring and colleagues propose 
that the decrease in calcium release from stores is associated with AICD nuclear 
signalling and transcription with the reduction in calcium being mimicked by APP 
knock-out and presenilin double knock-out fibroblasts (Leissring et al., 2002).  
However further experiments by Oh and Turner (2006) revealed that YIL may be 
reducing calcium release from stores through a secondary mechanism independently 
of γ-secretase activity.  Application of YIL was found to elevate basal IP3 levels 
(two-fold higher than control cells), which led to a reduced sensitivity of IP3R to IP3 
and caused a subsequent reduction in agonist-induced calcium release from ER 
stores.   Oh and Turner (2006) also provided evidence that AICD does not modulate 
intracellular calcium release in HSG cells.  When AICD production was blocked by 
APP siRNA knock-down, calcium release from stores was not decreased, contrary to 
the findings made by Leissring et al., (2002).  The reason for the discrepancy 
between these two studies is not clear.  One possibility may be cell type specific 
differences in calcium store proteins and regulatory mechanisms, but further studies 
are warranted to understand the nature of these differences.   Hence the results 
presented in this chapter, where γ-secretase activity blockade is found to have no 
effect on KCl-stimulated CICR in hippocampal neurons is in agreement with the 
observations presented by Oh and Turner (2006) in HSG cells. 
 
In this chapter, I also found that inhibition of SERCA pump activity by thapsigargin 
but not RyR by ryanodine leads to a decrease in intracellular calcium concentration 
during KCl-stimulated CICR in hippocampal neurons.  This result suggests that 
calcium load in the ER plays a larger role in regulating intracellular calcium 
concentration during KCl-stimulated CICR than calcium release through the RyR.  
However, comparing γ-secretase inhibitor treated cells to control cells revealed no 
differences in calcium responses following preincubation with thapsigargin or 
ryanodine under basal conditions or during KCl-stimulated CICR.  This result 
provides further evidence that γ-secretase activity is not involved in the modulation 
of intracellular calcium.   
 
The lack of effect of ryanodine treatment on peak calcium responses during KCl-
stimulated CICR was surprising as the study by Zhang et al., (2009) showed that 
block of RyR in wild type cells led to a decrease in intracellular calcium presumably 
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due to a decrease in calcium release through RyR from ER stores.  It is currently 
unclear why there is a difference in the results.  Past studies have indicated that 
ryanodine receptor composition may differ between culture systems or cell types 
(Collin et al., 2005).  Alternatively, the result may be due to a difference in the 
ryanodine concentrations used. Low concentrations of ryanodine (less than 10 µM) 
can maintain the RyR  in a sub-conductance state which enables calcium release 
from ER stores, however ryanodine at high concentrations will block RyR and 
decreases calcium release through RyR (Bardo et al., 2006; Bouchard et al., 2003; 
Collin et al., 2005).    The ryanodine concentration used by Zhang et al., (2009) was 
100 µM whilst a concentration of 20-30 µM was used for the experiments in this 
chapter.  Importantly, ryanodine concentration of 20-30 µM was used in previous 
studies and shown to inhibit RyR and decrease mEPSC frequency in cultured slice 
preparations (Emptage et al., 2001).  In line with this observation, an earlier study 
showed that 4 µM ryanodine could block reconstituted RyR in lipid bilayers 
(McPherson et al., 1991).   Therefore, 20-30 µM ryanodine (like 100 µM ryanodine) 
should be a sufficient concentration that can block RyR in dissociated neurons.    
Further investigations will be required to determine the reason for the difference 
between the results of this chapter and Zhang et al., (2009).   
  
A recent study proposes another mechanism for presenilins to regulate intracellular 
calcium.  Green et al., (2008) showed that presenilins could interact directly with the 
SERCA pump in the ER.  Experiments performed on presenilin double knock-out 
fibroblasts demonstrated that SERCA pump function was reduced (despite an 
increased expression of SERCA) leading to an elevation in cytoplasmic calcium and 
reduction in ER calcium concentration suggesting that presenilin was important for 
cellular calcium homeostasis (Green et al., 2008).  Interestingly the authors found 
that a decrease in SERCA activity led to a diminished Aβ production and vice versa 
suggesting that the SERCA pump could regulate APP processing presumably 
through γ-secretase activity. However this study using presenilin double knock-out 
animals did not examine whether direct inhibition of γ-secretase activity could alter 
SERCA pump activity, so whether calcium homeostasis was regulated by γ-secretase 
dependent or independent mechanisms remained unclear.   
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In summary the results in this chapter show that inhibition of γ-secretase activity of 
presenilins does not alter basal somatic calcium or calcium changes in response to 
KCl-stimulated CICR.  This indicates that the reduced intracellular calcium observed 
in presenilin double knock-out neurons may arise as a result of loss of γ-secretase 
independent actions of presenilins rather than loss of γ-secretase dependent actions 
of presenilins.  An alternative method to show that γ-secretase activity is dispensable 
for the reduction in KCl-stimulated CICR is to transfect a γ-secretase inactive mutant 
presenilin construct (e.g. D257A) into presenilin double knock-out neurons.   This 
construct lacks γ-secretase activity but should enable the study of γ-secretase 
independent functions of presenilin.  If γ-secretase activity is not required (i.e. a γ-
secretase independent action of presenilin is involved) then expression of this mutant 
construct should be sufficient to rescue the deficit in intracellular calcium seen in 
presenilin double knock-out cells.  An alternative strategy would be to perform 
calcium imaging experiments in a nicastrin knock-out mouse (Tabuchi et al., 2009) 
which is also deficient in γ-secretase activity but should exhibit some degree of γ-
secretase independent actions of presenilin.  However one possible drawback with 
the nicastrin knock-out animals is that PS1 (NTF and CTF) expression was also 
reduced when compared to wild type control animals suggesting that nicastrin may 
regulate the expression of presenilin to a certain degree.  However not all 
components of the γ-secretase complex were equally affected in nicastrin knock-out 
cells.  Whilst PEN-2, like PS1 also showed a decreased expression, APH-1 was not 
reduced (Tabuchi et al., 2009) suggesting that different mechanisms are implicated 
in the regulation of different components of the γ-secretase complex in nicastrin 
knock-out animals.  This suggests that nicastrin knock-out animals may not generate 
the same phenotype as wild type neurons treated with γ-secretase inhibitors. 
 
One technical point to note is that intracellular calcium concentrations have been 
estimated using an AM ester form of Fura-2.  This dye is well characterised and 
commonly used for intracellular calcium concentration measurements.  However, as 
it can readily pass through the cell membrane the possibility of the dye entering 
intracellular organelles and even the ER cannot be excluded (Scott and Rusakov, 
2008).  However as the experiments presented here were designed to reflect the 
conditions used in an early study by Zhang and colleagues (2009), the studies should 
still be comparable to each other.     
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6.5.1 Calcium regulation and Familial Alzheimer’s disease 
 
In addition to the amyloid cascade and tau neuropathology hypotheses, many reports 
suggest that dysregulation of intracellular calcium homeostasis is a leading cause of 
AD pathology (See for review: Mattson, 2004).  Studies from FAD patients 
(Etcheberrigaray et al., 1998; Hirashima et al., 1996; Ito et al., 1994), cell culture 
experiments (Cedazo-Minguez et al., 2002; Guo et al., 1996; Smith et al., 2002) and 
transgenic animals expressing mutant presenilins (Stutzmann et al., 2004; Stutzmann 
et al., 2006) show that many of the presenilin mutations associated with FAD lead to 
abberant intracellular ER calcium release due to overload of calcium in ER stores.  
However, several studies report an opposite effect where FAD presenilin mutations 
lead to decreased ER calcium levels (Giacomello et al., 2005; Zatti et al., 2004; Zatti 
et al., 2006) which suggest different FAD mutations may lead to dysregulation of 
calcium through different molecular mechanisms.  Overall, greater research efforts 
will be required to understand how calcium homeostasis is altered in FAD patients.   
 
 
  
6.6 Conclusion 
 
This chapter showed that γ-secretase activity of presenilin (1) is not required for 
modulation of intracellular calcium concentration in hippocampal dissociated 
neurons.  By extention this finding proposes that changes in mEPSC frequency upon 
elimination of presenilin activity or expression cannot be explained by changes in 
somatic calcium. 
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Chapter 7: The role of β-secretase in 
modulating synapse function in 
hippocampal neurons. 
 
 
7.1: Introduction 
 
The data presented in previous chapters have shown that presenilin and associated γ-
secretase activity is implicated in regulating aspects of synapse function in 
hippocampal dissociated and organotypic slice cultures.  The results outlined in 
chapters 3 and 5 provide evidence for a role for γ-secretase activity in modulating 
spontaneous synaptic transmission and synapse number.  However experiments 
discussed in chapters 4 and 6 suggest that γ-secretase activity is potentially not 
involved in the regulation of release probability or intracellular calcium 
concentration.  The next question to address is the mechanisms underlying this 
phenomenon: how does pharmacological blockade of γ-secretase increase synapse 
density and mEPSC frequency?   
 
γ-secretase is a promiscuous enzyme complex capable of cleaving many 
transmembrane proteins (see Table 1.1) that are implicated in a wide range of 
cellular functions from cell-cell adhesion and intracellular signalling pathways to 
gene transcription.  It is conceivable that inhibiting its activity and thereby 
decreasing proteolysis of its targets may have some lasting impact on neuronal 
function.  One way to approach this question is to identify which substrate or 
cleavage product(s) of γ-secretase is implicated in the modulation of mEPSC 
frequency.  A suitable candidate is APP.  Several studies over the past few years 
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have investigated the role of APP and its cleavage products, most notably Aβ, in 
modulating synaptic function using a variety of different methods and manipulations.   
 
One breakthrough study performed on organotypic slice cultures showed that 
mEPSC frequency was significantly decreased whilst mEPSC amplitude was not 
changed upon overexpressing wild type APP in CA1 pyramidal cells using a sindbis 
viral vector (Kamenetz et al., 2003).  AMPA and NMDA evoked responses were 
also decreased in cells infected with APP when compared to uninfected controls.  
Transfection of β-CTF, the membrane fragment that is generated from β-secretase 
cleavage of APP, also reduced evoked responses (Kamenetz et al., 2003).  This 
suggests that soluble APP-β fragment is not required for EPSC amplitude 
depression.  However β-CTF and APP overexpressing cells chronically treated with 
γ-secretase inhibitor, L-685,458 (1 µM for 24 hrs) did not exhibit any changes in 
AMPA and NMDA evoked currents when compared to untreated cells, suggesting γ-
secretase activity is necessary for the decrease in current amplitude.  Additionally, a 
mutant APP construct which was unable to undergo β-secretase cleavage, and 
accumulated α-CTF (the membrane fragment made after α-secretase cleavage of 
APP), did not exhibit changes in synaptic transmission, indicating that α-CTF and 
AICD (intracellular fragment generated after γ-secretase cleavage of  α-CTF) were 
not likely involved (Kamenetz et al., 2003).  Taken together these observations 
suggest that γ-secretase processing of APP and possibly Aβ is required and sufficient 
for the electrophysiological changes in synaptic transmission.  Evidence for a direct 
involvement of Aβ in modulating evoked AMPA responses was provided by 
application of exogenous Aβ40 and Aβ42 peptides which led to a dose-dependent 
decrease in field potential responses in control non-infected slices.  Altogether this 
study provides convincing evidence that increases in Aβ peptide causes depression 
of postsynaptic current amplitude in organotypic slices.  Interestingly no alteration in 
PPR was observed in cells overexpressing WT APP suggesting, that elevated Aβ 
production is not involved in regulating presynaptic release probability (Kamenetz et 
al., 2003).  A follow up study showed that the decreased evoked amplitude response 
seen in APP overexpressing cells was due to AMPA receptor removal from spines 
and a decrease in spine density (Hsieh et al., 2006).  Exogenous application of Aβ42 
also induced spine loss in APP overexpressing cells.  However, overexpression of a 
point mutant of APP which prevents β-secretase cleavage and hence prevents Aβ 
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generation prevented the loss of spines (Hsieh et al., 2006).  A recent study also 
indicated that Aβ released from axons and dendrites of neurons can reduce spine 
density at nearby dendritic processes (Wei et al., 2010).  Timelapse imaging also 
revealed that pre and postsynaptic changes can simultaneously occur upon treatment 
with Aβ to cause synapse uncoupling and loss (Calabrese et al., 2007).  This suggests 
that Aβ may be released from both pre and postsynaptic compartments to influence 
both structure and function of the synapse in hippocampal neurons.   
 
Another study using semliki forest virus to overexpress human WT APP (APP695) 
in hippocampal autaptic cultures corroborated the observations seen in organotypic 
slice cultures.  This study showed that upon APP overexpression mEPSC amplitude 
was not affected but mEPSC frequency was decreased compared to uninfected 
control cells (Ting et al., 2007).  The authors also demonstrated that overexpression 
of APP decreased evoked EPSC size whilst a mutant version of APP (M596V), 
which was defective in BACE-mediated APP processing and (could not generate 
Aβ) did not exhibit changes in current amplitude.  There were no significant 
differences in PPR, rate of refilling of the RRP or RRP size in control, WT APP and 
BACE mutant infected cells, suggesting that Aβ was not required for regulation of 
these specific presynaptic parameters.    However a small decrease in the rate of 
stimulated FM vesicle destaining in WT APP overexpressing neurons was observed.  
This suggests that Aβ may be involved in modulating vesicle exocytosis (Ting et al., 
2007).  Overall these reports provide strong evidence that APP overexpression and 
elevated Aβ production that could potentially result from it can cause a reduction in 
synaptic responses in hippocampal dissociated cultures.   
 
A study using a converse approach showed that mEPSC frequency is increased 
whilst mEPSC amplitude is not altered in APP knock-out animals compared to wild 
type controls (Priller et al., 2006).  When release properties were examined, APP 
knock-out cells revealed no significant differences in the rate of NMDA current 
block during MK801 application or in the rate of readily releasable pool (RRP) 
refilling.  An alternative protocol to assess RRP size was also used.  Repetitive 
stimulation at 10 Hz and 50 Hz, where cumulative amplitude response is correlated 
to pool size (Schneggenburger et al., 1999), was used to show that there were no 
significant differences in presynaptic vesicle pool size between wild type and APP 
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knock-out neurons.  Immunostaining of APP knock-out autaptic cultures revealed 
both an increase in dendritic length and the number of synaptophysin positive 
puncta.  Furthermore, immunolabelling of hippocampal sections from juvenile 
knock-out animals showed an increase in synaptophysin staining in the stratum 
radiatum and moleculare layers when compared to wild type control sections (Priller 
et al., 2006).  This data suggests that loss of APP leads to both functional and 
structural changes at hippocampal synapses and in the opposite direction to that 
observed with APP overexpression studies.  It is thus tempting to speculate that Aβ 
may play a role in balancing and maintaining the number of synaptic contacts under 
normal physiological conditions. 
 
The results from APP knock-out animals share many similarities with the data 
obtained from hippocampal neurons after γ-secretase inhibitor treatment or from 
PS1-/- mice (Chapters 3-5).  Hence the effects may potentially arise from a common 
mechanism. As both APP and γ-secretase activity are required for the generation of 
Aβ, there is a possibility that the similarities in alterations of synapse structure and 
function observed in APP knock-out and PS1 knock-out cells may arise from a 
decrease in Aβ.  This suggests that loss of Aβ generation may have a positive effect 
in regulating synapses.  To examine this possibility, Priller et al., (2006) sought to 
rescue the wild type phenotype in APP knock-out cells by preincubating 
hippocampal cells with exogenous Aβ42 or with culture media obtained from cell 
lines that secrete Aβ peptides.  Recordings showed that chronic treatment with Aβ 
peptides resulted in a reduced mEPSC frequency that did not quite reach the 
frequency observed in wild type neurons.  Reasons why a full rescue has not been 
observed are not known but there could be a variety of explanations including 
problems with getting Aβ to synaptic sites.  However, the identity of the specific 
form of Aβ peptide that is involved in regulating synapse function under 
physiological conditions is currently unknown.  It is also unknown if extracellular 
Aβ or intracellular Aβ is involved in modulating this effect on synapse function.  
Together, these studies provide evidence that Aβ may act as a bidirectional regulator 
of mEPSC frequency in the hippocampus by influencing the number of functional 
synapses rather than changes in presynaptic release properties.   
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As outlined in the introduction, Aβ production arises from the sequential cleavage of 
APP by two enzymatic processes.  The latter step which involves γ-secretase and its 
unique ability to intramembraneously cleave β-CTF fragments to generate AICD and 
Aβ has already been extensively explored in this thesis.  However the contribution of 
the initial cleavage of APP to generate β-CTF (and soluble APP-β) by β-secretase 
has not been addressed.    
 
The aim of this chapter was to determine if β-secretase inhibition has any effects on 
hippocampal synapse function.  This would also indirectly test whether Aβ may act 
as a bidirectional regulator of synapse structure and function in hippocampal 
neurons.   
 
 
7.2: Investigating the effects of β-secretase 
activity inhibition on mEPSC properties 
 
To pharmacologically block β-secretase activity in neurons, a selective β-secretase 
inhibitor IV was used (1 µM (Wen et al., 2008)).  Experiments using β-secretase 
inhibitor IV were performed in the same way as γ-secretase inhibitor treated cells.  
mEPSC recordings from rat dissociated cells treated with β-secretase inhibitor IV 
exhibited a significant increase in mean mEPSC frequency when compared to 
DMSO mock treated cells (Figure 7.1 b left, DMSO: n =  8, mean: 1.84 ± 0.65 Hz; 
β-secretase inhibitor IV: n = 17, mean 5.59 ± 0.86 Hz.  Student’s t-test: p = 0.01*).  
Analysis of mEPSC amplitude showed no significant changes between β-secretase 
treated and control cells (Figure 7.1 b right, DMSO: mean: 21.0 ± 3.30 pA; β-
secretase inhibitor IV: mean: 26.04 ± 2.57 pA.  Student’s t-test: p = 0.26).   
 
mEPSC recordings were also performed on organotypic slices treated with β-
secretase inhibitor IV.  As observed in dissociated cells, slices treated with β-
secretase inhibitors also exhibited an increase in mean mEPSC frequency when 
compared to DMSO mock treated cells, however the difference was not statistically 
significant (Figure 7.2 b left, DMSO: n =  7, mean: 0.36 ± 0.06 Hz; β-secretase 
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inhibitor IV: n = 9, mean: 0.65 ± 0.16 Hz.  Student’s t-test: p = 0.14).  No significant 
effects were observed in mean mEPSC amplitude between β-secretase inhibitor IV 
treated and mock control slices (DMSO: mean: 18.30 ± 1.29 pA; β-secretase 
inhibitor IV: mean: 20.81 ± 1.15 pA.  Student’s t-test: p = 0.17).  These results 
indicate that neurons from dissociated and organotypic hippocampal cultures exhibit 
a tendency towards an increase in mEPSC frequency upon chronic β-secretase 
inhibitor treatment.  This finding partially mimics the effects of γ-secretase inhibitor 
treatment.  Whilst the overall effect of β-secretase inhibition on mEPSC properties is 
similar to that observed with γ-secretase inhibition, the magnitude of the effect is 
generally lower in β-secretase inhibitor treated cells than γ-secretase treated cells 
when compared to matched DMSO controls.  The reasons for this are not entirely 
clear, but suggest that β-secretase and γ-secretase modulation of mEPSC frequency 
likely occur through the same pathway, potentially involving an alteration in APP 
processing and/ or decreased Aβ production.   
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Figure 7.1 – mEPSC frequency is modulated by chronic treatment with β-
secretase inhibitor in rat dissociated hippocampal neurons.   
(a) Sample traces of mEPSC recordings from rat hippocampal dissociated 
neurons chronically treated for 48 hr with mock DMSO control (black) or β-
secretase inhibitor (green). Scale bar, 25 pA, 200 ms. (b) Summary of mEPSC 
frequency (left) and amplitude (right) for DMSO (grey, n = 8, frequency mean: 
1.84 ± 0.65 Hz, amplitude mean: 21.0 ± 3.30 pA) and β-secretase inhibitor 
(green, n = 17, frequency mean 5.59 ± 0.86 Hz, amplitude mean: 26.04 ± 2.57 
pA). Statistical analysis was performed using student’s t-test (p = 0.01*).  
Chronic treatment with β-secretase inhibitor significantly increased mean 
mEPSC frequency compared to mock DMSO control but did not change mEPSC 
amplitude.  (c) Cumulative distribution plots of mEPSC inter-event interval (left) 
and mEPSC amplitude (right) for data shown in (b).   
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Figure 7.2 – mEPSC recordings of rat hippocampal organotypic slice cultures 
chronically treated with β-secretase inhibitor.    
(a) Sample traces of mEPSC recordings from hippocampal rat organotypic slices 
treated for 48 hr with mock DMSO control (black) or β-secretase inhibitor IV 
(green). Scale bar, 20pA, 1 sec. (b) Summary of mEPSC frequency (left) and 
amplitude (right) for DMSO (grey, n =  7, frequency mean: 0.36 ± 0.06 Hz, 
amplitude mean: 18.30 ± 1.29 pA) and β-secretase inhibitor (green, n = 9, 
frequency mean: 0.65 ± 0.16 Hz, amplitude mean: 20.81 ± 1.15 pA) recordings.  
Statistical analysis was performed using student’s t-test.  When compared to 
DMSO control cells, chronic treatment with β-secretase inhibitor elevated mEPSC 
frequency but this effect did not reach statistical significance (p = 0.14).  
Differences in mEPSC amplitude between cells treated with mock DMSO and β-
secretase inhibitor were not statistically different (p = 0.17). 
a 
b 
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7.3: Estimating release probability with styryl 
dyes in rat dissociated cells treated with β-
secretase inhibitor 
 
To investigate whether β-secretase inhibition had any effect on release probability, 
FM-dye destaining from synaptic vesicles was examined in hippocampal dissociated 
cultures.  The same protocol as that used for γ-secretase inhibitors was applied to 
cells treated with β-secretase inhibitors.  Destaining of synaptic vesicles was 
performed in low (1 mM), normal (2.2 mM) and high (5 mM) extracellular calcium 
concentrations (Figure 7.3).  The decay time constant of DMSO control cells and β-
secretase treated cells were compared to determine if there are any relative 
differences in release probability estimates.  Analysis showed that there were no 
significant differences in the rate of fluorescence loss from presynaptic terminals 
during evoked vesicle exocytosis between β-secretase inhibitor IV treated and 
DMSO treated cells at any calcium concentration suggesting block of β-secretase 
activity does not lead to a significant change in the rate of vesicle destaining (Figure 
7.3).  Overall this experiment shows that blocking β-secretase activity does not 
influence release probability at single synapses.  Together with the lack of effect of 
γ-secretase treatment on release probability, our data suggests that lack of Aβ 
generation/ decreased APP processing is not a necessary factor involved in the 
regulation of presynaptic release.   
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Figure 7.3 – Destaining kinetics of β-secretase treated rat dissociated cultured 
neurons in different concentrations of extracellular calcium.   
(a) Average destaining timecourse of mock DMSO cells (grey circle) and β-
secretase inhibitor IV treated cells (green square) in 1 mM calcium (left), 2.2 mM 
calcium (middle) and 5 mM calcium (right) in extracellular bath solution.  Orange 
bar shows timecourse of field stimulation (900 stimuli at 5 Hz) used to elicit FM 
dye destaining from neuronal boutons.  (b)  Summary of decay time constants (τ) 
obtained from experiments shown in (a).  DMSO (grey) and β-secretase inhibitor 
IV (green) treated cells respond similarly at a given extracellular calcium 
concentration. (b)(i) Mean response to 1 mM extracellular calcium shows DMSO (τ 
= 59.13 ± 9.76, n = 6) and β-secretase inhibitor IV cells  (τ = 68.16 ± 12.56, n = 6) 
are similar.  (b)(ii) The same lack of significant difference is observed in 2.2 mM 
extracellular solution (DMSO, τ = 60.63 ± 5.33, n = 19; β-secretase inhibitor IV, τ = 
56.96 ± 6.55, n = 11).  (b)(iii) Also at 5 mM extracellular calcium the decay time 
constant between DMSO (τ = 34.30 ± 2.86, n = 7) and β-secretase inhibitor IV (τ = 
42.27 ± 3.32, n = 5) is not significantly altered.  Note the increase in the rate of 
destaining from 2.2 mM to 5 mM extracellular calcium. 
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7.4: Investigating synapse number of rat 
dissociated cells treated with β-secretase 
inhibitor 
 
Rat dissociated cells treated with β-secretase inhibitor IV was imaged and analysed 
in the same way as cells treated with γ-secretase inhibitors.  Estimates of synapse 
number were obtained by analysing the density of Homer and synapsin co-localised 
puncta and was found to be not significantly different between DMSO control and β-
secretase inhibitor IV treated cells (Figure 7.4).  Analysis of individual signals 
revealed that β-secretase inhibitor treatment did not alter the density of Homer 
puncta; however, analysis of synapsin density in the same cells did reveal a 
significant increase in density when compared to DMSO control cells (Figure 7.4 b).  
In separate hippocampal cultures, the density of co-localised synapsin and GluA1 
puncta was also analysed.  No significant differences was observed in synapsin and 
GluA1 co-localised puncta between cells treated with β-secretase inhibitor IV and 
DMSO control cells (Figure 7.5).  Intriguingly, examination of synapsin density did 
not reveal any differences between drug treated and mock control treated cells, 
which is different to the results observed in Figure 7.4.  Additional analysis of 
GluA1 puncta showed that cells treated with β-secretase inhibitor IV had a 
significantly greater number of GluA1 positive puncta than DMSO mock control 
cells (Figure 7.5 b iii) 
 
Due to the differences in the results obtained from these two sets of 
immunofluorescent labelling experiments, it is currently not possible to make strong 
conclusions with regards to the role of β-secretase in modulating synapse number.  
In general, the results suggest that β-secretase inhibition does not greatly alter the 
density of presynaptic synapsin and postsynaptic Homer and GluA1 puncta.  This 
result is different to the observations made with γ-secretase inhibitor treatment, 
where a fairly robust effect on synapse formation was seen.  Taken together, the 
greater number of synapses in APP knock-out mice (Priller et al., 2006) and γ-
secretase inhibitor treated cells (Parent et al., 2005 and chapter 5), potentially arises 
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from a mechanism that does not involve loss of Aβ production as inhibition of β-
secretase does not lead to a strong change in synapse number.   
 
Analysis of dendritic spines in organotypic slices treated with either DMSO (mock 
control) or β-secretase inhibitor IV also revealed no significant differences in spine 
density in apical or basal dendritic branches (Figure 7.6).  This result indicates that 
blockade of β-secretase activity does not alter spine density. 
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Figure 7.4 – Immunofluorescence analysis of presynaptic synapsin and 
postsynaptic Homer markers of cells treated with β-secretase inhibitor IV 
(a) Sample images of neurons treated for 48 hrs with DMSO (top) or β-secretase 
inhibitor IV (bottom).  Antibody labelling was performed against MAP2 (neuronal 
marker, blue), Homer (postsynaptic marker, green) and synapsin (presynaptic 
marker, red). Scale bar: low magnification images 20 µm, inset images 6 µm.  
(b) Summary of co-localised Homer and synapsin puncta (i), synapsin puncta (ii) 
and Homer puncta (iii) of cells treated with DMSO (grey) or β-secretase inhibitor 
(green).  All puncta were expressed as density per 10 µm.  Analysis of synapsin and 
Homer colocalised puncta showed no significant differences between DMSO control 
(density mean: 0.922 ± 0.06 Hz) and β-secretase inhibitor IV treated cells (density 
mean: 1.106 ± 0.07 Hz).  There was also no significant difference in Homer puncta 
density between DMSO (density mean: 1.742 ± 0.07 Hz) and β-secretase treatment 
(density mean: 1.846 ± 0.09 Hz).  However, a small but significant increase in 
synapsin density was observed upon treatment with β-secretase inhibitor IV (density 
mean: 2.064 ± 0.08 Hz) when compared to DMSO control (density mean: 1.819 ± 
0.07 Hz) (DMSO versus β-secretase inhibitor, p = 0.02 *).  n = 39 cells were 
analysed for mock DMSO and n = 33 for β-secretase IV, pooled from 2 separate 
cultures. Statistical analysis was performed using student’s t-test (bar graphs; p < 
0.05*).  
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Figure 7.5 – Immunofluorescence analysis of presynaptic synapsin and postsynaptic GluA1 
markers of cells treated with β-secretase inhibitor IV 
(a) Sample images of neurons treated for 48 hrs with DMSO (top) or β-secretase inhibitor IV 
(bottom).  Antibody labelling was performed against MAP2 (neuronal marker, blue), GluA1 
(postsynaptic marker, green) and synapsin (presynaptic marker, red). Scale bar: low magnification 
images 20 µm, inset images 6 µm. (b) Summary of immunofluorescence quantification of co-
localised Homer and GluA1 puncta (i), synapsin puncta (ii) and GluA1 puncta (iii) of cells treated 
with DMSO (grey) or β-secretase inhibitor (green).  All puncta were expressed as density per 10 µm.  
Analysis of synapsin and Homer colocalised puncta showed no significant differences between 
DMSO mock control (density mean: 1.289 ± 0.07 Hz) and β-secretase inhibitor IV treated cells 
(density mean: 1.436 ± 0.09 Hz).  There was also no significant difference in synapsin puncta density 
between DMSO (density mean: 2.218 ± 0.09 Hz) and β-secretase treatment (density mean: 2.340 ± 
0.09 Hz).  However, a small but significant increase in GluA1 density was observed upon treatment 
with β-secretase inhibitor IV (density mean: 3.174 ± 0.15 Hz) when compared to DMSO control 
(density mean: 2.73 ± 0.12 Hz) (DMSO versus β-secretase inhibitor, p = 0.02 *).  n = 46 cells were 
analysed for DMSO mock and n = 42 for β-secretase inhibitor IV, pooled from 2 separate cultures. 
Statistical analysis was performed using student’s t-test (bar graphs; p < 0.05*).  
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Figure 7.6 – Spine analysis of organotypic slices treated with β-secretase 
inhibitor IV 
(a) Sample image a neuron treated for 48hrs with DMSO (left) or β-secretase 
inhibitor IV (right) at low magnification (top) Scale bar, 30 µm.  High 
magnification images of typical neurons from DMSO treated slice (left, bottom) 
and β-secretase inhibitor IV treated slice (right, bottom).  Scale bar, 5 µm. (b) 
Quantification of spine density of apical dendrites (left) and basal dendrites 
(right).  No significant differences were observed in either apical or basal spine 
density in cells treated with DMSO (n: 7 cells) or β-secretase inhibitor IV (n: 5 
cells).   
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7.5: Discussion 
 
The experiments presented in this chapter examined the effects of pharmacological 
inhibition of β-secretase activity on mEPSC properties, release probability and 
synapse number.   In previous chapters, it was shown that blockade of γ-secretase 
activity by specific inhibitors or elimination of PS1 gene led to an increase in 
mEPSC frequency and synapse number but not in release probability.  Intrigingly, an 
earlier study by Priller et al., (2006) showed very similar observations in synaptic 
properties in APP knock-out mice.  Putting these two sets of results together, where 
both APP knock-out and γ-secretase inhibitor treated cells exhibited an increase in 
mEPSC frequency and synapse number, I wanted to test the hypothesis that loss of 
APP processing, or more specifically, loss of Aβ generation could have a positive 
effect on regulating synapse function.  This was achieved by pharmacologically 
targeting β-secretase activity to prevent Aβ generation. 
 
Initial experiments implicated β-secretase activity in regulating mEPSC properties as 
chronic treatment with inhibitor IV led to an increase in mEPSC frequency when 
compared to DMSO control cells.  A statistically significant increase in mEPSC 
frequency was observed upon prolonged treatment with β-secretase inhibitor IV in 
dissociated hippocampal neurons (Figure 7.1).  However, when the same treatment 
was applied to organotypic slice cultures, a large but statistically insignificant result 
was obtained (Figure 7.2).  Power analysis predicts that a sample size of 16-18 may 
provide a statistically significant result suggesting that further experiments are 
required to improve the current sample size (DMSO, n = 7; b-secretase inhibitor IV, 
n = 9).  
 
Next, FM dye destaining experiments were performed to examine the role of β-
secretase in regulating release probability.  No significant effects were observed in 
vesicle destaining kinetics between β-secretase treated and DMSO control cells 
suggesting that block of β-secretase activity does not alter release probability.  These 
results are in line with observations made with γ-secretase inhibitor treated cells 
(Parent et al., 2005, chapters 3 and 4) and APP knock-out cells (Priller et al., 2006), 
which potentially suggests that elimination of Aβ production could modulate 
Chapter 7: β-secretase modulation of synapse function 
 226
mEPSC frequency but not release probability.  However, β-secretase inhibition had 
no significant effect on synapse density when compared to DMSO controls.  This 
result suggests that lack of Aβ production is potentially not associated with the 
increase in synapse number observed in APP knock-out and γ-secretase inhibitor 
treated cells.  The differential effects of γ-secretase inhibition and β-secretase 
inhibition on synaptic marker expression suggests that the cellular effects of these 
two pharmacological manipulations may be separable and occur independently of 
loss of Aβ production.   
 
This result also indicates that the increase in mEPSC frequency in cells treated with 
β-secretase inhibitor IV is potentially not correlated with a change in synapse 
number.  However, further morphological analysis is warranted to determine if other 
synaptic markers are altered upon treatment with β-secretase inhibitors.  Ideally a 
measure of functional synapses should also be investigated as immunofluorescence 
labelling does not distinguish between functional and non functional synapses e.g. 
orphan synapses.   
 
 
BACE-1 knock-out mice 
 
Another approach to test the involvement of β-secretase action on synapse function 
is to examine BACE-1 knock-out mice.  As expected, studies have shown that 
BACE-1 knock-out mice do not produce Aβ peptides or plaques (Cai et al., 2001; 
Luo et al., 2001; Roberds et al., 2001).  BACE-1 knock-out animals are viable, fertile 
and do not exhibit any major developmental defects.  However, past reports have 
revealed that certain aspects of synapse function and memory are impaired in BACE-
1 knock-out mice (Laird et al., 2005; Ohno et al., 2004).  BACE-1 knock-out mice of 
16 months of age (but not at 3 months) exhibit impaired performance in spatial 
reference memory tests, such as the hidden platform and probe trial tests of the 
Morris water maze when compared to non-trangenic control animals (Laird et al., 
2005).  BACE-1 animals also show impaired performance on the radial water maze 
and Y-maze task, tests of spatial working memory (Laird et al., 2005).  Overall, 
these behavioural tests demonstrate that hippocampal spatial memory is impaired in 
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BACE-1 knock-out mice.  Examination of synaptic responses through input-output 
curves for AMPA and NMDA field potentials do not reveal any differences between 
BACE-1 knock-out and control mice.  Intriguingly, a significant difference in PPR 
between BACE-1 knock-out and control mice is observed with an inter-stimulus 
interval of 50ms but not at lower (~30 ms) or higher (~100 ms, 300 ms, 500 ms) 
inter stimulus intervals.  This suggests that under certain conditions BACE-1 may 
modulate presynaptic function.  This effect on PPR is potentially in conflict with the 
lack of change in presynaptic function measured through synaptic vesicle exocytosis 
upon treatment with β-secretase inhibitors (Figure 7.3).  However the two 
experiments are not entirely comparable as the former measures the short term 
plasticity changes in population responses from brain slices, whilst the latter 
measures presynaptic vesicle dynamics from single synapses in cultured neurons.  
Due to time constraints, PPR was not examined in β-secretase inhibitor treated 
organotypic slices in this present study but future investigations may help determine 
whether the effect on PPR persists across different β-secretase manipulations.   
 
BACE-1 knock-out mice also exhibited no differences in the induction or 
maintenance of LTP or long term depression (LTD) when compared to wild type 
animals.  However applying theta burst stimulation to slices that have already 
undergone LTD to induce de-depression revealed that BACE-1 cells underwent 
greater de-depression than wild type cells.  These slice experiments indicate that 
BACE-1 may be important in regulating certain aspects of synaptic plasticity (Laird 
et al., 2005).  Currently there are no studies on BACE-1 knock-out mice that have 
examined either excitatory or inhibitory spontaneous synaptic currents.  Analysis of 
synapse number in the hippocampus also remains to be performed in BACE-1 
knock-out animals.  Altogether, further experiments are required to obtain a greater 
understanding of the potential pre and postsynaptic roles of β-secretase / BACE-1 at 
hippocampal synapses.    
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Differences between γ-secretase and β-secretase inhibition on 
synapse function  
 
The potential differential effects of β-secretase and γ-secretase inhibitors on the 
regulation of synapse number suggest that Aβ may not act as a negative regulator of 
synapse number.  Parent et al., (2005) provide some evidence for an alternative 
mechanism that regulates the increase in synapse number observed in γ-secretase 
inhibitor treated cells and PS1 knock-out cells. They propose that the increase in 
neurite outgrowth and synapse formation in γ-secretase inhibitor treated cells and 
PS1 knock-out cortical neurons may arise as a result of enhanced PKA/cAMP 
signalling through accumulation of unprocessed DCC fragments.  It is conceivable 
that this mechanism may also be implicated in hippocampal neurons, though this has 
not been directly tested during the course of this project.   
 
The results presented in this thesis suggest that blocking γ-secretase and β-secretase 
share some common outcomes but also some divergent results.  The increase in 
mEPSC frequency observed upon treatment with either inhibitor suggests a common, 
but as yet undefined mechanism in regulating spontaneous currents.  However from 
the approach taken in this current study, it is not possible to determine if the two 
inhibitors act along the same pathway or if separate pathways that both generate an 
increase in mEPSC frequency are implicated.  One possible experiment to examine 
this would be to apply both γ-secretase and β-secretase inhibitors to the same cell 
and determine if there is a greater/lesser change in frequency compared to treatment 
with either inhibitor alone.  Ideally such an experiment should be performed with 
acute pharmacological application so that the effects of drug application could be 
compared to a control time period in the same cell.  However this approach was not 
possible with the γ-secretase inhibitors as the increase in mEPSC frequency occurred 
progressively over time (Figure 3.1 and 3.2).  A time course for β-secretase action 
was not performed for this study so the minimum treatment time required to elicit an 
effect on mEPSC frequency is yet to be determined.  Notably other studies where β-
secretase inhibitor IV was used also adopted a fairly chronic application (Abramov et 
al., 2009; Wen et al., 2008).   
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In addition, the results from chapter 3 and 5 indicate that γ-secretase inhibitor 
treatment leads to an increase in synapse number and mEPSC frequency.  Studies of 
quantal parameters (see for review, Kerchner and Nicoll, 2008) suggest that synapse 
number and mEPSC frequency are correlated and that an increase in mEPSC 
frequency may arise from an increase in the number of functional synaptic sites.   
However the results in this chapter do not fully examine this association and further 
studies will be required to determine if this is the case.  For example, if both mEPSC 
frequency and synapse number of PS1 knock-out neurons drop to the same level as 
wild type animals following re-introduction of active γ-secretase complexes (i.e. 
through transfection/ infection), then this would provide greater evidence that 
synapse number and mEPSC frequency are highly associated.  However, there may 
be technical problems associated with this approach.  Whilst γ-secretase has been 
reconstituted by transfection of all 4 components of γ-secretase into certain cell types 
such as yeast and CHO cells (Edbauer et al., 2003; Kimberly et al., 2003), there are 
currently no published reports showing reconstituted γ-secretase activity in PS1 
knock-out neurons.   
 
However if mEPSC frequency and synapse number are not correlated and act 
through separate mechanisms, then this may affect our interpretation of the β-
secretase inhibitor experiments.  In APP overexpression studies (Kamenetz et al., 
2003), it was shown that both mEPSC frequency and synapse number were 
decreased and no change in PPR was observed.  This suggests that overproduction of 
Aβ may lead to a decrease in synapse number and mEPSC frequency.  In APP 
knock-out animals (and PS1 knock-out mice) the opposite was observed, with an 
increase in synapse number and mEPSC frequency, indicating a positive regulation 
of synapse function by a lack of Aβ.  However β-secretase inhibitor application 
which should also diminish Aβ generation, only leads to an increase in mEPSC 
frequency with no significant change in synapse density.  If mEPSC frequency and 
synapse number are linked then this would suggest that Aβ does not regulate these 
two synaptic parameters.  However if mEPSC frequency and synapse number are 
dissociable then Aβ may be involved in regulating mEPSC frequency but not in 
regulating synapse number.  Indeed, from the experiments performed so far, we 
cannot rule out that a loss of Aβ may still be a possible mechanism that causes the 
elevation of excitatory synaptic transmission following γ-secretase and β-secretase 
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inhibition.  In line with this notion, other studies have shown that soluble Aβ 
oligomers predominantly bind to glutamatergic synapses (Calabrese et al., 2007; 
Koffie et al., 2009; Renner et al., 2010).   However the role of Aβ was not directly 
tested in this project.  To examine this possibility a rescue experiment where 
application of Aβ to γ-secretase or β-secretase treated cells could be attempted.  
However, this experiment is not trivial for two main reasons; the Aβ species 
potentially involved in regulating mEPSC frequency is still currently unknown and 
the mechanism by which Aβ may be potentially regulating mEPSC properties 
remains undetermined.  A previous study (Priller et al., 2006) had attempted this 
rescue experiment with Aβ42 peptides (on APP knock-out mice) and found only a 
partial rescue of the mEPSC frequency rate when compared to control cells.  One 
possibility for the lack of a full rescue is that the Aβ isoform endogenously released 
from neurons under normal physiological conditions is more likely to be Aβ40 rather 
than Aβ42 (Hoey et al., 2009).  Therefore a more successful rescue may be achieved 
with application of Aβ40 peptides.  Further studies are required to discriminate 
between these possibilities.   
 
In studies where Aβ production was either elevated (through APP overexpression – 
see Kamenetz et al., 2003; Ting et al., 2007) or eliminated (in APP knock-out mice – 
see Priller et al., 2006), PS1 knock-out mice (Chapter 4), γ-secretase inhibitor 
treatment (Chapter 4) and β-secretase inhibitor treatment (current chapter), no 
change in PPR, rate of MK801 block or the rate of synaptic vesicle destaining was 
observed when compared to control cells.  These results indicate that Aβ is 
potentially not involved in regulating release probability. 
 
However a recent paper suggests that Aβ may act as a positive regulator of release 
probability (Abramov et al., 2009).  Abramov and colleagues made use of thiorphan, 
a neutral endopeptidase (NEP) inhibitor.  Thiorphan can inhibit the activity of 
neprilysin, a member of the M13 zinc-dependent metallopeptidase family and one of 
the enzymes implicated in degrading Aβ from the synapse.   They showed that 
application of thiorphan to neuronal cultures led to an elevation in endogenous Aβ40 
and Aβ42 levels, in line with previous in vivo studies (Newell et al., 2003).  They also 
found that application of thiorphan led to an increase in FM dye uptake into 
presynaptic vesicles during endocytosis, suggestive of an increase in release 
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probability.  It was also shown that thiorphan could also increase the rate of vesicle 
exocytosis.  AF1126, an antibody that neutralises neprilysin activity also led to an 
increase in FM dye uptake into presynaptic terminals.  Together this data indicates 
that neprilysin activity negatively modulates basal presynaptic vesicle endocytosis 
and exocytosis to regulate release probability. The effect of neprilysin inhibition on 
elevating release probability was shown to be mediated by Aβ, as HJ5.1 and 4G8, 
antibodies that chelate extracellular Aβ peptides prevented the thiorphan-induced 
elevation of presynaptic activity.  γ-secretase and β-secretase inhibitors also blocked 
the effect of thiorphan on endocytosis.  APP knock-out cells also did not exhibit the 
thiorphan-induced enhancement of presynaptic endocytosis whilst transfection of 
APP into APP knock-out cells could rescue the thiorphan associated presynaptic 
enhancement.  This suggested that APP processing / Aβ production was required for 
the thiorphan associated effect. Together this data presents a convincing argument 
that elevations in endogenous Aβ may regulate the thiorphan induced in presynaptic 
enhancement of release probability.   
 
However block of extracellular Aβ using HJ5.1 and 4G8 antibodies or blocking Aβ 
production using chronic γ-secretase and β-secretase inhibitor treatment did not 
show any differences in synaptic vesicle endocytosis when compared to control 
neurons.  This result suggests that eliminating Aβ alone does not have any impact on 
release probability and in line with experiments presented in chapter 4 (PS1 knock-
out mice and γ-secretase inhibitor treatment), this current chapter (β-secretase 
inhibitor treatment) and the study by Priller and colleagues (APP knock-out 
mice)(Priller et al., 2006).  These results suggest that Aβ does not regulate release 
probability in a bidirectional manner.   Whilst elevating endogenous Aβ may 
enhance synaptic vesicle endocytosis (Abramov et al., 2009), blocking Aβ 
production has no positive or negative effect on vesicle recycling.  This result is 
potentially in disagreement with a recent study using presenilin double knock-out 
mice.  Zhang and colleagues (2009) showed that the rate of MK801-mediated 
NMDA current block and PPR was decreased in presenilin double knock-out cells 
relative to control cells suggesting that loss of Aβ generation leads to a decrease in 
release probability (Zhang et al., 2009).  Further studies are required to determine the 
differences between these studies.   
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Intriguingly, inhibition of Aβ degradation by thiorphan also led to an increase in 
mEPSC frequency, suggesting that elevating Aβ may increase the rate of 
spontaneous currents.  This is potentially in conflict with previous studies where 
APP overexpression (and enhanced Aβ production) (Kamenetz et al., 2003; Ting et 
al., 2007) led to a decrease in mEPSC frequency.  The reason for the discrepancy is 
not clear but may be explained by differences in the methods used to generate excess 
Aβ.  For example, the studies by Kamenetz et al., (2003) and Ting et al., (2007) 
examined the effects of overproduction of exogenous human Aβ (Kamenetz et al., 
2003; Ting et al., 2007) whilst Abramov et al., (2009) investigated the effects of 
elevated levels of endogenous rat Aβ by inhibition of its degradation (Abramov et 
al., 2009).  Additionally synapse associated side effects of thiorphan treatment 
cannot be excluded as this compound has also been shown to act on other cellular 
neutral endopeptidases including enkephalinase. 
Understanding the role of Aβ in modulating different aspects of synapse function not 
only requires an idea of the mechanisms involved but also an understanding of the 
amount of Aβ required to cause these effects.  The concentration of Aβ in samples is 
often not known in most overexpression or neprilysin inhibition studies.  Potentially 
the amount of Aβ produced by neurons can also vary as several studies have 
indicated that Aβ release can be regulated by synaptic activity (Cirrito et al., 2005; 
Cirrito et al., 2008; Kamenetz et al., 2003).  One recent study examines this question 
in greater detail using exogenous application of defined amounts of Aβ peptides.  
Recordings of spontaneous currents revealed that only 50 nM of Aβ was required for 
a significant decrease in mEPSC frequency, whilst no significant effect on mEPSC 
amplitude was observed until application of 1 µM of Aβ peptides, suggesting that 
different concentrations of Aβ have differential effects on mEPSC frequency and 
amplitude (Parodi et al., 2010).  It is therefore possible that Aβ within the 
concentration range of 50 - 500 nM   may correspond to the amount of Aβ produced 
in APP overexpressing cells which were previously shown to have similar decreases 
in mEPSC frequency with no changes in mEPSC amplitude (Kamenetz et al., 2003; 
Ting et al., 2007).  Both mEPSC frequency and amplitude progressively decreased 
upon treatment with increasing concentrations of Aβ.  
   
Furthermore, it was shown that both monomeric and fibrillar forms of Aβ did not 
alter mEPSC properties suggesting that dimers or oligomers of Aβ may be involved.   
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Examination of mIPSCs following treatment with Aβ (500 nM, 24 hr) revealed no 
differences in mIPSC frequency or amplitude indicating that Aβ acts selectively at 
glutamatergic synapses (Parodi et al., 2010).  Interestingly, exogenous Aβ treatment 
(500 nM, 24 hrs) also influenced synaptic vesicle release; where a decrease in the 
rate of exocytosis was observed, suggesting that release probability was decreased.  
This is potentially the opposite effect to the observations of Abramov and colleagues 
who have reported that elevating Aβ levels using inhibitors that block Aβ 
degradation increases the rate of vesicle exocytosis.  The reason for the discrepancy 
is currently unknown.  In the Parodi study, electron microscopy also revealed a 
decrease in the presynaptic vesicle pool size suggesting that the decrease in mEPSC 
frequency could be correlated with a structural change in preynaptic vesicle pool.  
Interestingly Aβ was also shown to alter mEPSC frequency in a temporally defined 
manner, with significant decreases in mEPSC frequency being observed following 
12-24 hrs treatment whereas treatment for 0.5–2 hrs caused a significant increase in 
mEPSC frequency.  Furthermore it was shown that this transient increase in mEPSC 
frequency was associated with an elevation in intracellular calcium.  Interestingly, 
this elevation in intracellular calcium could not be blocked by a cocktail of calcium 
channel antagonists including ω-conotoxin, agatoxinVI or nifedipine or glutamate 
receptor antagonists D-AP5 and CNQX, excluding the likely involvement of voltage 
gated calcium channels and postsynaptic glutamate receptors.  Intriguingly, 
treatment with Na7, a small peptide that has been shown to block ion flux through 
channels formed by Aβ, could block the increase in mEPSC frequency and 
intracellular calcium, suggesting that Aβ forms pores in the neuronal membrane 
which allows influx of calcium into the cell (see Arispe et al., 1993a; Arispe et al., 
1993b).  This study proposes that the decrease in mEPSC frequency observed 
following 24 hr treatment with Aβ arises as a consequence of enhanced synaptic 
vesicle release causing vesicle pool depletion during the first two hours of Aβ 
treatment.     
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7.6 Conclusion 
 
This chapter showed that β-secretase inhibition, like γ-secretase inhibition can cause 
changes in mEPSC frequency but not release probability, suggesting BACE1 may 
regulate spontaneous synaptic currents but not presynaptic release.  However a 
difference in synaptic function was observed following treatment with β-secretase 
inhibition or γ-secretese treatment, with no significant up or down regulation in 
synapse number being observed with the former and an increase being observed with 
the latter.  This finding implies that β-secretase is not required for regulation of 
synapse density and highlights disparate roles for β-secretase and γ-secretase in 
modulation of synapse function in hippocampal neurons. 
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Chapter 8: Overall summary and 
general discussions 
 
 
 
8.1 Research summary 
 
Genetic and biochemical studies have emphasised the key role of PS1 in the 
pathogenesis of AD.  However, more recent studies have also shown that PS1 is able 
to interact and process a wide range of cellular proteins (see Table 1.1).  Whilst the 
functional significance of these reported interactions remain to be fully examined, 
they indicate that presenilin could affect a range of signalling pathways also in 
neurons.  Understanding the biology of PS1 may provide insights into the possible 
physiological functions that are disrupted in neurons during AD.  The aim of this 
current project has been to gain a better understanding of the role of presenilin (1) at 
hippocampal synapses.  My findings implicate presenilin in modulating certain 
aspects of hippocampal synapse function.    
 
Whole-cell recordings have revealed that presenilin is involved in regulating 
spontaneous synaptic transmission at excitatory but not inhibitory synapses in 
dissociated and organotypic cultures (Chapter 3).  These results are consistent with 
previous studies that have indicated a role for presenilin in regulating glutamatergic 
synaptic currents (Kamenetz et al., 2003; Parent et al., 2005; Priller et al., 2006).  
Further experiments provide evidence that alterations in miniature frequency are 
associated with changes in synapse number rather than release probability.  
Specifically, live imaging and electrophysiological experiments indicate that 
presenilin activity and expression is dispensable for the regulation of release 
probability (Chapter 4).  In contrast, immunocytochemical analysis reveals an 
increase in the number of co-apposed pre and postsynaptic markers of excitatory 
synapses (Chapter 5).  One interpretation of this outcome is that γ-secretase activity 
may play a role in regulating structural components of synapses and hence act as a 
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modulator of synapse number.  This increase in excitatory synapse number may 
potentially provide an explanation for the increase in mEPSC frequency and 
implicates presenilin in regulating both structural and functional properties of 
hippocampal synapses.   
 
The role of γ-secretase activity of presenilin in regulating intracellular calcium levels 
has also been examined in the soma of hippocampal neurons.  Inhibition of γ-
secretase activity does not alter measurements of intracellular calcium under basal 
conditions or following KCl-stimulated CICR (Chapter 6).  This result indicates that 
γ-secretase activity is not involved in modulating intracellular somatic calcium levels 
at rest or after cell depolarisation.  This finding also suggests that the reported 
reduction in intracellular calcium in PS1 and PS2 double knock-out neurons upon 
KCl stimulated CICR (Zhang et al., 2009) occurs through a mechanism involving a 
γ-secretase independent activity of presenilin rather than a γ-secretase dependent 
action of presenilin.  However, the underlying mechanism remains to be fully 
understood.  My result also proposes that the elevation in mEPSC frequency 
observed in PS1 knock-out and γ-secretase inhibitor treated cells is potentially not 
associated with alterations in intracellular calcium.  However only somatic calcium 
has been examined in this present study and further calcium imaging of axonal 
boutons will provide a more accurate insight into the role of presenilin in modulating 
intracellular calcium at the synapse.   
 
The last part of this study has addressed the role of β-secretase activity in the 
regulation of synapse function (Chapter 7).  The aim has been to gain insights into 
the mechanisms underlying the synaptic effects observed in presenilin 1 knock-out 
and γ-secretase inhibitor treated hippocampal neurons.  The observed synaptic 
changes could occur through a direct loss of presenilin activity or an indirect effect 
of the loss of a γ-secretase cleavage product.  One possible candidate cleavage 
product that is greatly reduced with both presenilin manipulations is Aβ.  APP 
overexpression studies (Hsieh et al., 2006; Kamenetz et al., 2003; Ting et al., 2007; 
Wei et al., 2010) and APP knock out studies (Priller et al., 2006)  provide evidence 
that Aβ may play a bidirectional role in modulating synapse structure and function.  
Interestingly, the synaptic characteristics of APP knock-out animals are very similar 
to the synaptic properties observed in PS1 knock-out animals (Chapter 3, 4 and 5, 
Chapter 8: Overall summary and general discussions 
 237
Parent et al., 2005; Priller et al., 2006).  As both APP and PS1 are required for APP 
processing and Aβ generation, it is possible that the alterations in synaptic 
parameters that are observed in both knock-out studies may arise from the common 
loss of Aβ production.  To this end, I have examined whether blocking Aβ 
generation using β-secretase inhibitors would lead to any changes in synapse 
function.   
 
Similarly to γ-secretase inhibitor treatment, chronic treatment of hippocampal 
neurons with β-secretase inhibitor increases mEPSC frequency but does not alter 
synaptic vesicle exocytosis, suggesting that β-secretase activity is required for 
regulation of synaptic transmission but not for regulation of release probability 
(Chapter 7).  However, β-secretase inhibition has no significant effect on synapse 
number, as estimated through a lack of change in Homer and synapsin co-localised 
synaptic puncta (Chapter 7).  This result diverges from the observations made from 
neurons treated with γ-secretase inhibitors where an increase in co-localised synaptic 
puncta is seen.  The simplest interpretation of these results is that Aβ does not act as 
a bidirectional regulator of synaptic transmission and synapse number.  However 
such a conclusion assumes that the effects on spontaneous synaptic currents and 
synapse number are correlated.  If synaptic currents and synapse number are 
independently regulated, then the increase in mEPSC frequency observed in PS1 
knock-out animals, APP knock-out animals and γ-secretase and β-secretase inhibitor 
treated cells may potentially still be regulated by Aβ, whilst the change in synapse 
number probably not requiring Aβ.   
 
PS1 overpression studies have also been attempted during the course of this project 
as an alternative way to analyse presenilin associated regulation of synaptic function.  
The utility of this approach was illustrated in an earlier study from Kaether et al., 
(2002), where PS1-EGFP constructs were expressed in stably transfected HEK cells 
and found to traffic to different subcellular compartments including the ER and the 
plasma membrane (Kaether et al., 2002).  The study found that exogenously 
expressed constructs could replace endogenous PS1 and PS2 despite the limited level 
of overexpression due to tight regulation of cellular γ-secretase levels (Thinakaran et 
al., 1997).    Functionality of wild type PS1 constructs was confirmed through the 
production of Aβ peptides.  The expression of the PS1 D385N-EGFP mutant 
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construct which did not possess γ-secretase activity, however, led to accumulation of 
APP CTF in cell lysate preparations (Kaether et al., 2002). 
 
My aim was to overexpress either wild type PS1-EGFP or PS1 D385N-EGFP mutant 
constructs in mature dissociated cultured neurons and evaluate the effects on 
different synaptic and neuronal properties.  With regards to mEPSC recordings, the 
plan was to determine if transfection of these constructs could rescue synaptic 
alterations observed in PS1 knock-out cells.   Transfection of wild type PS1 back 
into PS1 knock-out cells is expected to rescue the wild type control phenotype.  
Conversely, if γ-secretase is required for modulation of mEPSC frequency, 
transfection of catalytically inactive PS1 D385N-EGFP mutant constructs into PS1 
knock-out cells should not rescue the wild type phenotype.    Potentially, this 
approach also enables the pre and postsynaptic effects of presenilin overexpression 
to be assessed with targeted transfection in either pre or postsynaptic neurons.   
 
Unfortunately, I found that transient transfection of cDNA using calcium phosphate 
method did not generate successful expression.  At best, weak intracellular (possibly 
ER) EGFP signal was observed following post-hoc staining and signal amplification 
with an EGFP antibody (data not shown).  No significant EGFP fluorescence was 
observed in live cells.  The reasons for this are not entirely clear.  One possibility is 
that the half-life of γ-secretase complex is long.   Past studies have shown that 
exogenous full length PS is rapidly degraded with a half life of several hours.  
However, catalytically active N and C terminal PS fragments are more stable and 
have a half life of at least 24 hours in cultured cells (and possibly up to several days 
– personal correspondence from C. Kaether) (Dries and Yu, 2008; Kim et al., 1997; 
Podlisny et al., 1997; Ratovitski et al., 1997; Steiner et al., 1998; Thinakaran et al., 
1997).  This relatively long time frame poses problems for integration of exogenous 
PS protein into endogenous γ-secretase complexes in neurons with transient 
overexpression methods.   As the cellular levels of γ-secretase are tightly controlled 
and depend on the availability of co-factors; APH-1, PEN-2 and nicastrin 
(Thinakaran et al., 1997), it is understood that transient overexpression of 
unincorporated presenilin will remain within the ER and then get degraded by 
proteasome, caspase or cysteine protease activity (Steiner et al., 1998).  Potentially, a 
way around the long half life of endogenous γ-secretase is to overexpress the 
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construct for longer duration so that exogenous presenilin will have sufficient time to 
replace endogenous presenilin within the cellular γ-secretase complex.  However, the 
calcium phosphate transfection method can often render cells unhealthy, making 
long-lasting expression difficult, and so an alternative DNA delivery system such as 
the use of lentiviral vectors which enables prolonged expression of exogenous 
proteins should be investigated (see Pratt et al., 2009).  Another possibility for the 
lack of expression is that presenilin may be misfolded, or improperly inserted into 
membrane compartments such as the ER in neurons with transient transfection 
(Haass and De Strooper, 1999).   
 
Several attempts were also made to clarify the subcellular location of presenilin 1 in 
my hippocampal neuronal culture system using immunocytochemical techniques.  
As already mentioned several groups had investigated the expression of presenilin in 
neurons using in situ hybridisation and mRNA probes and found PS1 in the 
hippocampus, cerebellum and other tissues of humans and mice (Berezovska et al., 
1997; Kovacs et al., 1996; Lee et al., 1996).  Immunoblot analysis also found that 
PS1 and PS2 were expressed in cultured neurons and astrocytes (Lee et al., 1996).   
However, the subcellular localisation of endogenous PS1 in hippocampal neurons is 
still under debate.  One of the first studies to examine the subcellular localisation of 
PS1 using overexpression of exogenous Flag tagged PS1 and PS2 constructs in non 
neuronal cells showed that PS1 and 2 primarily localised in ER and Golgi regions 
(Kovacs et al., 1996).  However it was not shown whether these constructs 
incorporated into γ-secretase complexes.  A later report using a functional GFP 
tagged PS construct, which was able to incorporate into the γ-secretase complex, was 
found to be localised to the ER, Golgi, endosomes, lysosomes and plasma membrane 
(Kaether et al., 2002).  Other studies have also tried to investigate the localisation of 
endogenous PS1 in neuronal cultures.  Annaert et al., (1999) performed analysis of 
PS1 wild type neurons and showed that the uncleaved presenilin holoprotein was 
associated with the nuclear envelope whilst PS NTF and CTF fragments were 
associated with post ER membranes and the intermediate compartment but not in 
regions downstream of the cis-Golgi.  A recent immunofluorescence study showed 
that PS1 co-localised with synaptic markers, Homer and Bassoon suggesting that 
presenilin was present at pre and postsynaptic compartments of mature synapses 
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(Inoue et al., 2009).  One major drawback to most reports investigating the 
localisation of endogenous PS1 is the lack of a negative control, such as a PS1 
knockout.  One study of cortical neuronal cultures showed that endogenous PS1 
staining was associated with the soma and neuritic processes in wild type neurons 
and only diffuse somatic signal was seen with PS1 knock-out neurons (Parent et al., 
2005).  However, in my hands, the use of several anti-PS1 antibodies did not lead to 
clear-cut results regarding the subcellular localisation of PS1 in hippocampal 
neurons.  The main problem I experienced was the highly similar PS1 antibody 
associated signal in both wild type and PS1 knock-out cultured neurons, suggesting a 
high degree of non-specific staining with the antibodies I was using (data not 
shown).  Further examination with different PS1 antibodies in PS1 knock-out and 
wild type neurons will be necessary to fully determine the subcellular localisation of 
endogenous PS1 in hippocampal neurons.    
 
Studies have demonstrated that axon transport defects are also observed during early 
stages of AD pathogenesis (Morfini et al., 2002; Stokin et al., 2005; Stokin and 
Goldstein, 2006). Early observations examining the role of APP in neurons found 
that APP could be transported along axonal processes (Buxbaum et al., 1998c; Koo 
et al., 1990).  One study showed that APP could act as a receptor for kinesin-1, an 
axonal motor protein important for fast axonal transport of synaptic cargo (Kamal et 
al., 2000).  The same group also found that the three components required for Aβ 
generation: PS1, BACE1 and APP were closely associated within axonal vesicles, 
promoting the idea that Aβ generation and release could occur within axonal 
processes (Kamal et al., 2001).  However, a later report could not confirm these 
findings.  Lazarov and colleagues found that not only did APP and kinesin-1 not co-
fractionate or co-precipitate, transport of kinesin-1 in axons was not altered in APP 
knock-out mice suggesting that APP was not a necessary component of kinesin-1 
associated axonal transport (Lazarov et al., 2005).  Biochemical and 
immunolabelling analysis also showed that PS1, BACE1 and APP co-localisation 
was not observed in the axons of the sciatic nerve, suggesting that the proteolytic 
machinery for Aβ generation could not be cotransported with APP (Lazarov et al., 
2005).  The reasons for the discrepancies between these studies are currently unclear.  
Whilst the results of Lazarov and colleagues question whether APP is involved in 
kinesin-1 associated axonal transport, it remains to be determined whether APP and 
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PS1 are implicated in synaptic vesicle transport.  Reports have indicated that PS1 can 
co-localise with presynaptic vesicle proteins and that other γ-secretase components 
can also be found in synaptic vesicle membrane fractions (Beher et al., 1999; 
Frykman et al., 2010; Smith et al., 2000; Thinakaran and Parent, 2004).  However 
the functional relevance of this link remains to be determined.  The anterograde and 
retrograde axonal trafficking of synaptic vesicles between presynaptic boutons in 
mature cultures was previously characterised in the lab (Darcy et al., 2006; Staras et 
al., 2010).  The reason for inter-bouton movement of vesicles remains to be fully 
understood but may play a role in synaptogenesis, synapse refinement or synaptic 
plasticity (Darcy et al., 2006; Krueger et al., 2003).  As γ-secretase activity of 
presenilins may be implicated in regulation of synapse number (Chapter 5), I sought 
to investigate whether γ-secretase activity may also alter synaptic vesicle trafficking 
as a possible mechanism for regulation of synapse formation.  To address this 
question, timelapse imaging was used to estimate the rate of FM-labelled synaptic 
vesicle movement back into a bouton using a Fluorescence Recovery after 
Photobleaching (FRAP) assay.  Whilst this protocol mainly examines the recovery of 
FM labelled recycled synaptic vesicles into pre-existing synapses rather than being a 
direct measure of synaptogenesis, the rate of recovery of fluorescently labelled 
vesicles into a synapse may provide an insight into synaptic vesicle movement 
associated with formation of new synapses (Darcy et al., 2006; Krueger and 
Fitzsimonds, 2006; Krueger et al., 2003).  Due to the low number of cells, it is 
currently not possible to make strong conclusions about the role of presenilins in 
synaptic vesicle trafficking.    However, initial experiments suggest that there are no 
significant differences in the rate of fluorescence recovery between control and γ-
secretase inhibitor treated cells (data not shown).  This preliminary finding suggests 
that presenilin activity is potentially not implicated in the axonal transport of 
synaptic vesicles between presynaptic boutons and in agreement with the findings 
observed by Lazarov et al., (2005) who find that presenilin is not involved in axon 
transport.  Further studies will be required to determine if this initial finding holds.   
 
A recent Society for Neuroscience abstract also reported similar findings to the 
observations presented in this current project (Pratt et al., 2009).  Recordings from 
hippocampal dissociated autapic cultures from constitutive PS1 knock-out mice 
revealed a dramatic increase in mEPSC frequency (Pratt et al., 2009).  The authors 
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also reported that evoked AMPA or NMDA current amplitude or paired-pulse ratio 
was not altered in PS1 knock-out mice suggesting that loss of PS1 gene had a 
selective effect on spontaneous currents.  Additionally, the increase in mEPSC 
frequency could be blocked by intracellular application of calcium buffer, EGTA or 
rescued by exogenous expression of wild type PS1.  This study suggests that PS1 
gene elimination may cause an increase in mEPSC through an elevation of 
intracellular calcium.  Whilst our calcium imaging experiments from the soma of 
hippocampal neurons do not indicate a change in somatic calcium concentrations 
during basal or CICR, our data do not rule out an alteration in calcium homeostasis 
in axonal terminals and hence further studies will be required to address this 
question.  One possible experiment is to image calcium in functional axonal boutons 
identified by loading with FM dyes.  KCl application can then be used to do two 
things: induce FM dye destaining to confirm synaptic vesicle exocytosis and to 
simulate CICR in active synapses to examine calcium release from intracellular 
stores (Evans and Cousin, 2007).  This approach will enable calcium within 
functional boutons to be measured in response to KCl-stimulated CICR. 
 
Overall this project has provided further insights into the role of presenilin in 
modulating different aspects of synapse function in hippocampal neurons.  The data 
presented also shows that presenilin may have presynaptic and postsynaptic 
functions.  Whilst an increase in mEPSC frequency is often associated with a change 
in presynaptic function, the alteration in synapse number indicates that pre and /or 
postsynaptic changes can occur to enable formation of new synaptic puncta.  This is 
in line with studies which show that changes can occur to pre and postsynaptic sides 
of the synapse during Aβ peptide application to simulate pathological synaptic 
events associated with AD, in vitro (Calabrese et al., 2007; Wei et al., 2010).   
 
However, further investigations are necessary to establish the molecular mechanisms 
that underlie the synaptic changes observed following presenilin manipulations.  
Whilst different synaptic studies have proposed that loss of γ-secretase activity can 
alter the processing of different substrates of γ-secretase (see for example: APP 
(Kamenetz et al., 2003; Priller et al., 2006), DCC (Parent et al., 2005), Eph4 receptor 
(Inoue et al., 2009 but see Table 1.1) it is currently unclear how signalling pathways 
downstream of γ-secretase could modify synaptic function.  It is currently not known 
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if the synaptic effects reported in this thesis arise from disruption of one signalling 
pathway or if the changes are the result of the collective disruption of multiple γ-
secretase modulated pathways.  These questions will need to be addressed in future 
studies. 
  
 
 
 
 
8.2 Possible γ-secretase dependent and γ-
secretase independent action of presenilin at 
hippocampal synapses 
 
 
Many previous studies have used presenilin knock-out mice to investigate the 
cellular role of presenilin.  However, as discussed, one major drawback with this 
approach is the loss of both γ-secretase dependent and γ-secretase independent 
actions of presenilin.  Early studies indicated that presenilin is predominantly 
involved in γ-secretase dependent processes, as the catalytically inactive holoprotein 
form of presenilin has been believed to be rapidly degraded (Annaert et al., 1999; 
Podlisny et al., 1997; Xia et al., 1997).  However, more recent studies have shown 
that presenilin can modulate some cellular processes in a γ-secretase independent 
manner, including regulation of intracellular calcium by forming an ER calcium leak 
channel and regulating cellular β-catenin levels (Kang et al., 1999; Koo and Kopan, 
2004; Tu et al., 2006).  The exact percentage of presenilin which functions in a γ-
secretase dependent and a γ-secretase independent context is not currently known.   
 
Previously, it has been shown that γ-secretase independent action of presenilin is 
potentially involved in modulating intracellular calcium concentration.  A study 
conducted using presenilin double knock-out animals showed that intracellular 
calcium was decreased compared to wild type control cells upon KCl-induced CICR 
(Zhang et al., 2009).  However, in this thesis work, as γ-secretase inhibitors did not 
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alter intracellular calcium in hippocampal neurons under basal conditions or during 
KCl-induced CICR (chapter 6), it was concluded that γ-secretase activity was 
dispensable for presenilin associated regulation of intracellular calcium.  These 
experiments highlight the value of using a combinational approach of knock-out 
mice models and pharmacological inhibitors of presenilin catalytic activity to 
distinguish between γ-secretase dependent and γ-secretase independent actions of 
presenilin.  However, to clarify γ-secretase independent functions of presenilin, a 
rescue experiment should also be performed as suggested above, making use of the 
wild type and the catalytically inactive mutant presenilin, PS1 D385N.  Being able to 
determine which synaptic functions are regulated by γ-secretase dependent actions 
and which synaptic effects involve γ-secretase independent action of presenilin may 
provide further insights into the possible cellular mechanisms modulated by 
presenilin at hippocampal synapses.   
 
 
8.3 Neuronal activity, Aβ peptides and synaptic 
transmission  
 
As already mentioned, chronic β-secretase and γ-secretase treatment were both 
shown to increase mEPSC frequency.  One interpretation of this data is that loss of 
Aβ can elevate spontaneous synaptic transmission.  Several studies have shown that 
Aβ generation from neurons can occur in an activity dependent manner (Cirrito et 
al., 2005; Cirrito et al., 2008; Kamenetz et al., 2003).  Decreasing neuronal activity 
by application of tetrodotoxin (TTX), led to a decrease in Aβ generation, whereas 
application of picrotoxin, which blocked inhibitory GABAA receptors leading to an 
elevation of neuronal activity, was associated with an increase in Aβ; moreover, an 
increase in Aβ generation was associated with a decrease in evoked current 
amplitude and mEPSC frequency (Kamenetz et al., 2003).  This led to the proposal 
that Aβ was involved in a negative feedback mechanism, where increased neuronal 
activity enhanced Aβ production which subsequently decreased synaptic 
transmission to prevent excessive neuronal activity.  The same study also showed the 
opposite configuration where blocking endogenous Aβ production via chronic 
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treatment with γ-secretase inhibitor, L-685,458, could lead to an increase in synaptic 
activity (in line with results presented in chapter 3).  These findings suggest that a 
potential physiological role of Aβ is to bidirectionally regulate neuronal activity 
depending on the amount of Aβ secreted/produced.   
 
However, it is not entirely clear how neuronal activity could alter Aβ production.  
Kamenetz et al., (2003) present evidence that Aβ associated depression of synaptic 
currents is linked with an elevation of β-secretase activity caused by enhanced 
neuronal activity, as evidenced by elevated β-CTF generation under conditions that 
increased neuronal activity.  However, it was not shown whether β-secretase 
inhibitors could prevent this elevation in β-CTF generation.  Additionally, this 
experiment does not rule out the possibility that neuronal activity can also regulate 
(elevate) γ-secretase activity.  Indeed, if the negative feedback model proposed by 
Kamenetz is dependent on enhanced Aβ generation, then it is reasonable to assume 
that neuronal activity should enhance both β-secretase and γ-secretase activity.  The 
effects of β-secretase and γ-secretase inhibitors on the activity dependent production/ 
secretion of Aβ remain to be determined.   
 
 
8.4 Evaluating γ-secretase inhibitors as a 
possible therapeutic strategy for AD 
 
Early findings showing a crucial role for presenilin in Aβ generation also raised the 
possibility of γ-secretase as a therapeutic target for treatment of AD.  It was 
proposed that application of γ-secretase inhibitors may limit the speed and extent of 
Aβ plaque deposition and associated neuronal pathology, such as dystrophic 
neurites, calcium homeostasis dysregulation and spine loss and therefore slowing 
down the rate of disease progression (Dickson and Vickers, 2001; Hsieh et al., 2006; 
Knowles et al., 1999; Kuchibhotla et al., 2008; Spires-Jones et al., 2007; Wei et al., 
2010; Wu et al., 2010).  Indeed several rodent studies have shown that certain γ-
secretase inhibitors can limit the deposition of Aβ in vivo (Dovey et al., 2001; 
Schenk et al., 1999, but see Garcia-Alloza et al., 2009).  Clinical trials in humans 
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have also commenced with certain γ-secretase inhibitors.   One specific inhibitor, 
LY450139 showed a reduction in Aβ biosynthesis in a dose-dependent manner 
indicating that γ-secretase inhibitor treatment could also alter Aβ levels in humans 
(Bateman et al., 2009).  
 
However, studies have proposed that Aβ has other physiological functions at 
synapses, therefore blocking synthesis completely may lead to a disruption of these 
other putative functions of Aβ (see for review: Marcello et al., 2008).  This notion is 
also applicable to presenilin which is implicated in the cleavage of a wide range of 
cellular type 1 transmembrane proteins and regulating many different signalling 
pathways (see Table 1.1).  Whilst different inhibitors may have differential effects on 
γ-secretase processing of different substrates, the use of γ-secretase inhibitors for 
therapeutic purposes should be considered with caution, especially until the 
molecular mechanisms underlying the synaptic changes following chronic γ-
secretase treatment are better understood.  It is currently unclear how 48 hr treatment 
with γ-secretase inhibitors may alter functional and structural properties of 
hippocampal synapses.  As DAPT and L-685,458 are both cell permeable inhibitors, 
it is suspected that inhibition of γ-secretase enzymatic activity should be fairly rapid.  
However, acute treatment did not generate a change in electrophysiological 
properties (see chapter 3) and suggests that synaptic changes associated with 
prolonged inhibition of γ-secretase activity may be a result of more long term 
cellular adaptations.  As γ-secretase is implicated in many different intracellular 
signalling pathways (see Table 1.1), it is conceivable that inhibition of γ-secretase 
activity or function could alter nuclear signalling, gene transcription and protein 
synthesis which may take hours – days to be fully revealed in neurons.  
Alternatively, the synaptic changes following 48 hr γ-secretase inhibitor treatment 
may occur as a result of protein degradation.  It is possible that γ-secretase 
negatively regulates synapse number through an intermediate player e.g. a protein or 
cue that inhibits synapse formation and therefore when γ-secretase activity is 
blocked the interaction and function of this player is loss.  However the synaptic 
effects may only be observed once this protein/ cue has degraded.  Again this 
possible sequence of events may occur over longer time frames.  Further studies are 
required to evaluate these possibilities experimentally and also to determine likely 
mechanisms and candidate players.    Additionally, the results of the power 
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calculations suggest that further studies should be conducted to clarify the cellular 
effects of acute γ-secretase inhibition. 
 
As shown in chapter 3 and other studies (Kamenetz et al., 2003; Parent et al., 2005; 
Priller et al., 2006), γ-secretase inhibitor treatment was associated with an increase in 
the rate of spontaneous excitatory currents and synapse number.  While an increase 
in synapse number may seem advantageous when it comes to treating the synapse 
and neuronal loss that accompanies AD progression, an increase in mEPSC 
frequency in the absence of a change in mIPSC frequency may cause an overall shift 
in the excitatory and inhibitory network balance towards a more excited state.  The 
long term implications of this potential change in network activity are not clear.  It is 
also not known whether γ-secretase treatment could eventually cause changes in the 
intrinsic excitability of neurons.  However, elevated neuronal activity has previously 
been linked to excitotoxicity (Barten and Albright, 2008; Zoghbi et al., 2000).  
Whilst not directly examined, changes in neuronal activity and firing may potentially 
cause excitotoxicity and provide an alternative explanation for the reported temporal 
difference in synapse number following γ-secretase treatment.  Whilst 4-48 hr 
treatments typically led to an increase in synapse number (Chapter 5, Parent et al., 
2005), longer treatment was associated with a loss of postsynaptic spines (Bittner et 
al., 2009; Inoue et al., 2009).  These temporal changes in synapse number were also 
reflected by presenilin double knock-out studies where an increase in synapse 
number was seen in young animals and a decrease in synapse number (and 
eventually neurodegeneration) was observed in older animals when compared to 
control animals (Aoki et al., 2009; Saura et al., 2004).  Therefore acute or short term 
treatment with γ-secretase inhibitors may promote synaptogenesis whilst chronic or 
long term use may cause the opposite and enhance synapse loss.  It is possible that 
the enhanced synaptic transmission or neuronal activity associated with shorter term 
γ-secretase treatment could eventually lead to excitotoxicity in neurons which may 
then cause synapse loss.  Understanding the mechanisms relating to this temporal 
effect on synapse number will hopefully provide insights into how the balance 
between synapse loss and synapse gain could be tipped towards the latter for 
treatment of AD.  Identifying a therapeutic window for γ-secretase treatment may be 
sufficient to enhance synapse number and counteract synapse loss.   
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The use of γ-secretase modulators rather than inhibitors may prove to be a better 
therapeutic strategy.  Such modulators are designed to alter γ-secretase processing of 
specific substrates whilst leaving the processing of other substrates intact.  Currently, 
γ-secretase modulators are being developed which specifically target γ-secretase 
processing of APP whilst sparing Notch processing (Wolfe, 2009).  Studies have 
also identified that non-steroidal anti-inflammatory drugs (NSAIDs) alter PS1 
conformation and shift γ-secretase cleavage of APP to selectively reduce Aβ42 
production whilst enhancing Aβ40 production (Eriksen et al., 2003; Lleo et al., 2004; 
Weggen et al., 2001; Weggen et al., 2003).  NSAIDs treatment was also associated 
with a reduction in microglia activation (and inflammation) and amyloid plaque 
pathology in a mouse model of AD (Lim et al., 2000). Crucially Notch signalling 
was not impaired following treatment which makes NSAIDs an attractive therapeutic 
possibility (Weggen et al., 2001).  However, clinical trials have indicated that long 
term treatment with NSAID could inhibit cyclo-oxygenase (COX1) activity which 
could promote gastrointestinal dysregulation (see Bergmans and De Strooper, 2010).   
Recent developments of newer NSAID derivatives which can reduce Aβ deposition 
whilst bypassing gastrointestinal side-effects are promising options and further 
studies will determine whether they will be clinically useful (Imbimbo et al., 2009).   
 
8.5 Relation of current findings to AD 
 
This study mainly focuses on the role of presenilin under basal physiological 
conditions.  This and other studies have provided insights into the biology of 
presenilin at the synapse and also the role of γ-secretase activity in hippocampal 
neurons.  However, the experiments presented in this thesis, do not provide direct 
information about the effects of clinical mutations in presenilins on synapse function.  
Indeed, (conditional) presenilin knock-out animals are not strictly a model for AD as 
these animals lack Aβ plaques (Saura et al., 2004).  Though, these animals have been 
used to demonstrate that presenilin is important for cell survival, and is therefore 
regarded as a good model for neurodegenerative studies associated with AD (Saura 
et al., 2004).  However some observations outlined in this thesis are also observed in 
certain AD transgenic mouse models.  With regards to synapse number, studies from 
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mice models which give rise to amyloid pathology have revealed that estimates of 
alterations in synapse number can be variable between different AD models.  For 
example, Vesicular Acetyl Choline Transporter (VAChT) labelling revealed that 
cholinergic presynaptic bouton number was increased in APP (K670N, M671L) 
single mutant mice but not altered in PS1 (M146L) single mutant mice (Hu et al., 
2003; Wong et al., 1999).  Intriguingly, APP (K670N, M671L) and PS1 (M146L) 
double transgenic mice showed a reduction in VAChT labelling but an increase in 
synaptophysin positive puncta, suggesting that different synaptic proteins can be 
differentially affected even in the same mouse model (Hu et al., 2003; Wong et al., 
1999).  Interestingly, the extent of plaque deposition was also associated with 
differential observations in synapse number as an increase in presynaptic marker 
labelling was seen in the absence of plaques whilst a decrease in synapses was 
observed with the onset and development of plaques (Bell and Cuello, 2006).  
However, a study of young (4 months old) TgCRND8 mice, which expresses human 
APP695 gene with the K680M/N671L and V717F mutations and is a model of early 
onset AD, showed that VGLUT (presynaptic glutamate transporter) and VGAD 
(presynaptic GABA transporter) positive bouton number was increased in amyloid 
plaque free areas as well as in areas next to plaques when compared to non 
transgenic controls (Bell and Cuello, 2006).  Overall the temporal changes in 
synapse number in these AD mouse models reflected observations in γ-secretase 
treated cells and presenilin double knock-out cells.  However, it remains unclear if 
the signalling pathways involved in synaptic regulation in knock-out studies are the 
same as in AD mouse models.  It also remains to be fully determined whether 
different AD mice models exhibit the same defects in cell signalling which 
ultimately lead to neurodegeneration and amyloid accumulation in these animals. 
 
Studies of human PS1 (A246E) mutant transgenic mice revealed some differences in 
synaptic properties when compared to PS1 knock-out and γ-secretase treated 
cultures.  Priller et al., (2007) reported that PS1 (A246E) mutant mice autapic 
cultures showed a reduction in evoked NMDA and AMPA EPSC amplitude, mEPSC 
frequency and synapse density, essentially the opposite effects to that observed in 
PS1 knock-out mice (Priller et al., 2007).  However, a separate study performed in 
acute slices showed that NMDA field responses and NR1 and NR2B subunit 
expression was elevated in the same PS1 mutant mice (Dewachter et al., 2008).  It is 
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unclear why there is a difference in NMDA receptor responses between these two 
studies.  Consistent with the increase in NMDA receptor responses, Dewachter et al., 
(2008) also showed that LTP and activated nuclear c-fos expression was increased in 
PS1 (A246E) mutant animals (see also Parent et al., 1999).  Analysis of a transgenic 
mouse overexpressing an aggressive FAD PS1 (L286V) mutation showed some 
similar properties to PS1 (A246E) mutant mice (Auffret et al., 2009).  In young 4-5 
month animals, NMDA receptor field responses, LTP and spine density was 
increased, however this facilitation in synapse function disappears in older animals, 
as 13-14 month mice showed a decrease in the magnitude of LTP and NMDA 
receptor response, indicating an age-dependent effect on synapse function (Auffret et 
al., 2009).  However, similarly to PS1 knock-out mice, paired-pulse ratio and 
mEPSC amplitude were not altered in PS1 (A246E) or PS1 (L286V) mutant mice 
(Auffret et al., 2009; Dewachter et al., 2008; Priller et al., 2007), suggesting that 
most perturbations in presenilin function in general do not alter these synaptic 
parameters (but see Zhang et al., 2009).  Further studies of other presenilin mutant 
mice will be useful to help determine if there are further differences in synaptic 
properties between different FAD clinical mutations and also determine if there are 
further similarities between presenilin knock-out animals and FAD mutant mice.   
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8.7 Final remarks 
 
The cellular and molecular mechanisms underlying AD are still poorly understood.  
The role of presenilin in regulating different cellular processes during pathological 
conditions has received much attention in recent years.  The importance of presenilin 
in AD pathogenesis is exemplified by the findings that mutations in PSEN1 gene are 
strongly associated with the onset of the more aggressive FAD.  Presenilin is also 
implicated in AD pathology as it the enzyme complex that gives rise to Aβ peptides, 
the major constituents of Aβ plaques.  However, the role of presenilin in regulating 
different cellular processes under physiological conditions is relatively poorly 
defined.  The aim of this study was to gain a better insight into the potential role that 
presenilins play in regulating synapse function at hippocampal synapses.  The results 
presented in this thesis indicate that presenilin is important for modulating excitatory 
synapse structure and function and are in agreement with other PS1 knock-out and γ-
secretase pharmacological studies (Kamenetz et al., 2003; Parent et al., 2005; Priller 
et al., 2006).  The experiments performed during the course of this work also tried to 
examine the role of presenilin in some unexplored aspects of synapse function.  The 
results provide evidence that presenilin is not implicated in regulation of release 
probability and γ-secretase activity of presenilin is not involved in regulating somatic 
intracellular calcium.  Additionally, the findings suggest that β-secretase and γ-
secretase may have some differential synaptic functions and provide some insight 
into targeting β-secretase and γ-secretase inhibition as possible therapeutic options. 
Further studies are required to fully understand the molecular mechanism underlying 
these synaptic changes and determine whether similar observations are present in 
vivo.  Ultimately it will be important to extensively investigate whether these 
synaptic changes may be linked to the synapse dysfunction observed during the early 
stages of AD, with the aim that better alternative therapeutic strategies may be 
designed.
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Appendix  
Appendix I: Western blot of APP 
from rat dissociated neuronal cultures  
 
Key: 
1. Mock DMSO control 
2. β-secretase inhibitor IV 
3. γ–secretase inhibitor DAPT 
4. γ–secretase inhibitor L-685,458 
Western blot analysis of rat dissociated neurons treated with mock DMSO control 
(1), β-secretase inhibitor IV (2), γ-secretase inhibitor DAPT (3) or γ-secretase 
inhibitor L-685,458 (4).  Full length APP and APP C-terminal fragments (CTFs) 
were probed with an antibody (O443) recognizing the C-terminal fragments of APP.  
Bands corresponding to APP-CTFs accumulated in cells treated with γ-secretase 
inhibitors DAPT (3) and L-685,458 (4) but not in β-secretase inhibitor IV (2) or 
mock DMSO control cells.  This result indicates that γ-secretase inhibitors can 
efficiently prevent presenilin mediated intramembranous proteolysis of APP-CTF in 
rat dissociated neurons, suggesting that DAPT and L-685,458 are active and can 
inhibit γ-secretase activity of presenilin.  Based on bicinchoninic acid protein 
quantification, 60µg of protein was loaded in each lane.  Immunoblots were 
performed blind to treatment and repeated on 3 separate cultures.  Western blot 
experiments were performed by Dr Xulun Zhang from the laboratory of Professor 
Sangram Sisodia at the University of Chicago, USA.
 
 
 
 
APP-  
Full length
APP-CTF 
1 2 3 4
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